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Abstract 
Introduction 
Fenestrated Endovascular Aneurysm Repair (fEVAR) is one of a multitude of treatment 
options for repairing a juxtarenal aortic aneurysm. Alternative treatment options include 
open repair using a prosthetic graft and endovascular repair using a standard EVAR device 
outside the intended manufacturer’s indications for use (IFU). Although there is perceived 
benefit of fEVAR over open repair and assumed deleterious effects of using standard EVAR 
outside of IFU, it is not known which of these three treatment options would result in the 
best clinical outcome when treating an aneurysm that would be anatomically outside the 
IFU for standard EVAR. For simplicity, this type of aneurysm is referred to as a non-standard 
aneurysm.  
The hypothesis tested in this thesis is that fEVAR has the best clinical outcome as a 
treatment strategy for non-standard abdominal aortic aneurysms (AAAs) that are 
unruptured in whom aneurysm repair is deemed to be more beneficial than conservative 
management. “Best clinical outcome” relates to the clinical outcome measures: all-cause 
mortality, aneurysm related mortality and clinical success as defined by agreed reporting 
standards throughout all follow up time points. The outcome measures regarding mortality 
will be weighted equally to each other and clinical success will be weighted less than those 
pertaining to mortality. 
Method 
To test the hypothesis a retrospective concurrent cohort study was carried out assessing 
the clinical outcomes of three categories of patients: those treated by traditional open 
operation, fEVAR, and a standard EVAR performed outside of IFU for non-standard 
aneurysms. A non-standard aneurysm is defined as one that falls outside the instructions 
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for use for standard EVAR in relation to anatomical features of the aortic neck. Analysis of 
all patients who underwent aneurysm repair for a ‘non-standard aneurysm’ in the Cheshire 
and Merseyside region in the 24-month period 1st April 2006 – 31st March 2008 were to 
form the basis of data for this study. The preoperative computed tomography (CT) scan of 
each patient was scrutinised separately by two observers to assess if they met the inclusion 
criteria i.e. if the aneurysm was outside the IFU for standard EVAR. Patients were excluded 
from analysis if they had a previous surgical or endovascular repair of their aneurysm or if 
they exhibited an aneurysm that was anatomically within IFU. 
Hospital records were then scrutinised to obtain clinical outcome data for each patient 
according to a proforma. The primary outcome measures included: 30-day mortality/In-
hospital mortality, mid-term mortality and aneurysm related mortality, clinical success and 
technical success. 
Results 
80 patients were included in the final analysis from two centres performing aneurysm 
repair in the Cheshire and Merseyside region. 28 patients underwent treatment with 
standard EVAR (EVAR), 15 with fenestrated EVAR (fEVAR) and 37 patients underwent AAA 
repair as an open procedure (OR).  The median follow up for all patients was 10.7 years. 
The results of the primary outcome measures are as follows for EVAR, fEVAR and OR, 
respectively: In hospital mortality, 7.1%, 0%, and 5.4% – no significant difference. Overall 
survival at 5 years was ; 54%, 57% and 68% - no significant difference. For the whole cohort 
(22) 29% of patients survived to 10 years and were alive at the end of the study period. 
Aneurysm related mortality over length of follow up; 10.7%, 0%, 8.1% - no significant 
difference. Technical success; 75%, 87% and 97% - p=<0.001. Clinical failure over the course 
of the entire follow up was; 46%, 7% and 8% - p= <0.001. None of the secondary outcome 
measures. 
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Conclusion 
Patients who underwent standard EVAR had a significantly worse outcome after their 
aneurysm repair, attributable to technical success and clinical failure rates. It can therefore 
be recommended from this study that where possible placement of standard EVAR devices 
out with IFU should be avoided in preference for an advanced stent-graft technique or 
open repair. However, it is not possible to accept the hypothesis of this study that fEVAR 
provides the best clinical outcomes. Further study needs to ascertain the magnitude of any 
differences in clinical outcomes between OR and fEVAR. 
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CHAPTER 1 – Abdominal Aortic Aneurysm 
1.1. Aneurysm 
An aneurysm is defined as a localised dilatation of the wall of a part of the circulatory 
system. This may include arteries or veins. Aneurysms develop within the arterial 
circulation more commonly than in either the venous circulation.  Arterial aneurysms can 
be classified according to their type, morphology or location. 
1.1.1. Type 
Aneurysms can be classed as either true or false aneurysms. True aneurysms involve a 
dilatation of all three layers of the arterial wall (intima, media and adventitia) whereas false 
aneurysms do not (See figure 1.1). 
Figure 1.1 Diagrammatic Representation of True and False Aneurysms 
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1.1.2. Morphology 
Aneurysms can be termed either saccular, sac like projections from the main arterial 
conduit, or fusiform, spindle shaped. By definition, fusiform aneurysms are thickest in the 
middle and taper towards each end.  
1.1.3. Location 
Aneurysms can occur anywhere within the arterial tree, however, the commonest sites for 
their development are within the aorta, cerebral vessels and popliteal arteries. The most 
common form of cerebral aneurysm is a saccular aneurysm within the Circle of Willis. These 
are almost always due to a congenital weakening of the wall of the artery causing the 
aneurysm. Aortic and popliteal aneurysms, however, tend to be atherosclerotic in nature 
and are most commonly fusiform in shape. The aorta is the most common site for 
aneurysm development. Aortic aneurysms can develop within the aortic root, within the 
thoracic segment of the aorta, within the abdominal component of the artery (abdominal 
aortic aneurysm, AAA) or as thoracoabdominal aneurysms where the aneurysmal segment 
of aorta involves both intrathoracic and abdominal components of the artery. The most 
common site of aneurysm development in the aorta is within the abdominal aorta. 
When an aneurysm develops within the abdominal aorta it does so most commonly inferior 
to the renal arteries, termed an infrarenal AAA. However, an aneurysm can come close to, 
abut or even extend around and above the renal arteries and in this scenario the aneurysm 
would be termed a juxtarenal, pararenal or suprarenal aneurysm respectively. 
1.2. Abdominal Aortic Aneurysm (AAA) 
When a true aneurysm develops within the abdominal aorta it tends to enlarge over time. 
The majority remain asymptomatic. The problems that can arise from aneurysm 
enlargement include: pressure on surrounding structures which can result in pain, 
embolization of thrombus from within the aneurysm to the distal arterial tree, and the 
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most significant complication – rupture. Once an aneurysm ruptures it commonly results in 
rapid exsanguination and death. This fact has led to the desire for an adequate and 
efficacious prophylactic treatment of aneurysms before their rupture and driven further 
understanding of the disease and its treatment options. 
1.2.1. Epidemiology 
The incidence and prevalence of aortic aneurysms increase with age. In 2010 the global 
prevalence rate was approximately 2200 per 100,000 people and the incidence was 165 per 
100,000 people in those aged 75 – 79 years. [1] According to the Office for National 
Statistics there were 5886 deaths secondary to aortic aneurysm or dissection within 
England and Wales during 2013 making it the 15th leading cause of death that year. 
Male sex, age, hypertension, hyperlipidaemia, family history and smoking are all risk factors 
for the development of aortic aneurysms. Furthermore, patients with certain connective 
tissue disorders are more prone to developing aneurysms such as Marfan syndrome and 
Ehlers-Danlos syndrome. Cigarette smoking is associated with a five-fold increase for the 
presence of AAA and as such is felt to be the most important modifiable risk factor related 
to AAA development and progression. [2]  
1.2.2. Pathology 
The pathological processes involved in aneurysmal formation and progression are complex 
and incompletely understood. Transmural vascular inflammatory processes, extracellular 
matrix (ECM) degradation, and an imbalance in smooth muscle cell haemostasis are all 
thought to play a significant role in AAA development.[3] Traditionally AAA have been 
classified as either inflammatory or atherosclerotic however this delineation is somewhat 
misleading. Although a high proportion of patients with AAA exhibit atherosclerosis, 
atherosclerosis within the aorta is frequently seen without AAA development. Some 
aneurysms are described clinically as ‘inflammatory’ exhibiting a classic triad of thickened 
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aneurysmal wall, extensive perianeurysmal and retroperitoneal fibrosis and dense 
adhesions of adjacent abdominal organs as described by Walker et al in 1972[4]. However 
some investigators believe that there is no such clear distinction between ‘atherosclerotic’ 
and ‘inflammatory’ aneurysms and, pathologically, inflammation plays the key role in AAA 
development meaning that they are the same disease but differing only in their degree of 
inflammation. [5] 
Transmural vascular inflammatory processes seem to be mediated by a myriad of different 
cells such as neutrophils, T cells, B cells, macrophages, mast cells, NK cells. These infiltrating 
cells secrete various inflammatory factors including cytokines, chemokines, leukotrienes, 
reactive oxygen species and immunoglobulins. [3] This inflammatory responses promotes 
extracellular matrix degradation and as AAA progress an increase in activity of matrix 
metalloproteases (MMPs), as well as serine and cysteine proteases seem to augment this 
degradation.[6] 
More recently there has been increasing interest in the role genetic factors play in the 
development of the disease and a study considering AAA prevalence in monozygotic and 
dizygotic twins suggests a significant genetic contribution to AAA development. [7] 
1.2.3. Natural History 
Once AAA develops often the natural course is that it will continue to enlarge and 
eventually rupture resulting in high rates of mortality. The rate of enlargement is not 
constant and methods of predicting rupture are limited. The most widely used parameter 
to predict rupture rate is maximum aneurysm diameter as this is both easy to perform 
using simple imaging techniques (ultrasound scanning) and simple to understand, both for 
patient and physician. The rate of enlargement of AAA is not linear and Lederle et al found 
that larger initial aneurysm diameter is associated with an increased rate of expansion 
suggesting that as an aneurysm grows its rate of expansion also grows. The median rate of 
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aneurysm diameter increase was 0.32cm per year (IQR: 0.16 – 0.42 cm per year) in that 
study. [8] As well as the baseline aortic diameter at diagnosis, cigarette smoking appears to 
cause greater expansion of the aneurysm. Other studies have suggested that reduced 
forced expiratory volume in one second (FEV1) and hypertension promote quicker 
aneurysm expansion as well. Although aneurysms are less common in women they tend to 
expand more rapidly, rupture more frequently and rupture at smaller diameters than in 
men. It appears that the coexistence of diabetes mellitus and peripheral arterial disease 
limit the rate of expansion of AAA but the reasons for this are unclear. 
The reported rupture rates per year for given maximum aneurysm diameters are: <1% for 
AAA of 4 – 5.4cm, 9% for AAA of 5.5 – 5.9cm, 10% for AAA of 6 – 6.9cm, 32.5% for AAA 
>7cm. [8, 9] Randomised controlled trials corroborated these figures for patients with small 
aneurysms (<5.5cm) confirming that the risk of rupture remains low when the aneurysm is 
small. Furthermore, these trials showed no benefit in performing intervention on these 
patients compared to continued surveillance until they were 5.5cm. These findings suggest 
a rather benign natural history in the main for small aneurysms. Patients who do suffer a 
ruptured aneurysm have a high mortality rate at approximately 80%. Those that undergo 
surgical repair of a ruptured aneurysm having in-hospital mortality rate of approximately 
50%. [10] 
It is also important to note that the incidence of AAA and that of ruptured AAA is declining 
over time, although the reasons for this are not entirely understood it appears to be 
following the trend with a reduction in smoking prevalence in the adult population.  
The natural history for aneurysms >5.5cm is less well-known because this is the threshold 
for consideration of surgical repair and as such there are limited studies evaluating what 
happens to patients above this size. In one study for patients deemed unsuitable for AAA 
repair the following data was reported: 
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 5.1 – 6.0cm AAA – Median survival 44 months, 11% died of rupture 
 6.1 – 7.0cm AAA – Median survival 26 months, 20% died of rupture 
 >7cm AAA – Median survival 6 months, 43% died of rupture 
However, in those 72 patients, with AAA ranging from 5.3 to 12cm, 60% were alive at the 
end of the study period (2 years). The median survival for the cohort was 34 months and 
the 5-year survival was 4.2%. 
Noronen et al (The natural course of abdominal aortic aneurysms that Meet, 2013) also 
investigated the fate of patients deemed unsuitable for aneurysm repair. With a median 
follow up of 19 months after decision not to operate 36.4 % of patients had ruptured. The 
following data is from that study: 
 5.5 – 6.0cm AAA – Median survival 24 months, 42% died of rupture 
 6.1 – 7.0cm AAA – Median survival 14 months, 44% died of rupture 
 >7cm AAA – Median survival 11 months, 44% died of rupture 
For the whole cohort the median survival time was 14.8 months and 22.1% were alive at 
the end of follow up. 
The UK Endovascular Aneurysm Repair 2 (EVAR 2) trial randomised patients to either 
receive endovascular repair or no repair in patients considered unsuitable for open repair.  
In the cohort randomised to no intervention 9.2% had died after 6 months, 61% after 4 
years and only 8.5% were alive at 12 years. The mean survival was 4.2 years for the whole 
study population and was not different between the intervention and no intervention 
groups.  
These studies of course document the experience of patients who are considered unfit or 
turned down for aneurysm repair for one reason or another and the true natural history of 
any given aneurysm cannot be definitively stated from these studies. However, they 
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provide the only limited insight available to the natural history of aneurysm greater than 
5.5cm. What is clear is that in these comorbid and often elderly patients their risk of short-
term mortality from their aneurysm as well as other causes remains high. The overall 
mortality for the population of patients deemed suitable for operative intervention may be 
lower than seen in the above studies if they were not to undergo aneurysm repair. 
However, it is reasonable to suggest that their aneurysm related mortality, although may 
still be lower, would be similar and if this is the case then this would continue to support 
the rationale for operating on patients when their aneurysm reaches 5.5cm or other 
predefined criteria such as rapid expansion. The paucity of data for the natural history of 
abdominal aortic aneurysms also means that there is no information within the literature 
specifically about the natural history of different types if abdominal aortic aneurysm and 
whether infrarenal, juxtarenal or suprarenal aneurysms behave differently from each 
other. 
1.2.4. Screening 
Due to the high mortality of ruptured AAA there has been an argument for population 
screening in order to detect aneurysms before they rupture. The aim of screening is 
therefore to detect more aneurysms when they could feasibly be directed for elective 
treatment to reduce the mortality within the population from this disease. Several 
countries now have population screening for AAA underway including Sweden, U.S.A., and 
the United Kingdom. There have been four large randomised controlled trials (RCT) of 
population screening for AAA [11-14] and in 2007 a Cochrane meta-analysis of the four 
trials was conducted which revealed that for men between the ages of 65 – 79, an 
invitation to screening reduced the aneurysm related mortality by 40% at 3 – 5 years of 
follow up. A significant decrease in incidence of ruptured AAA was also seen in the group 
invited for screening. [15] Only one of the four trials included women and failed to show 
any benefit in terms of aneurysm related mortality for those screened. However, the 
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prevalence of AAA in women is much lower than that for men and there is therefore a lack 
of evidence to identify whether women should also be invited for screening or not. There is 
some evidence that suggests selective population screening for women, for example those 
that are current smokers, may be cost-effective and yield benefit [16] however there is 
currently no population based screening programme that includes women. 
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CHAPTER 2 – Management of AAA 
2.1. Introduction 
The primary aim in the management of AAA is to prevent death secondary to aneurysm 
rupture. The most important factor that predicts aneurysm rupture and therefore mortality 
for any patient with a given AAA size is the maximum diameter of the aneurysm. [17-19] 
Elective surgical repair of an abdominal aortic aneurysm is the most effective means of 
preventing rupture. There has, as yet, been no pharmacological agent found that halts 
progression or causes regression of abdominal aortic aneurysm once formed. Operative 
management carries an inherent mortality risk and the decision whether to treat an 
aneurysm with an operation should be based on the clinical judgement pre-operatively of 
whether the risk of death from operation is less than that if the aneurysm is not operated 
on. Historically there was debate at what size of aneurysm patients should undergo elective 
surgery, some authors would argue that all aneurysms once detected should be considered 
for elective repair of their aneurysm. However through the 1980’s and early 1990’s 
evidence began to accumulate that those patients with small aneurysms (<5cm) had a low 
risk of rupture in the intervening years and therefore should be offered close surveillance 
and monitoring of the size of their aneurysm with ultrasound. [18] The UK Small Aneurysm 
Trial (UKSAT) sought to answer the question by means of a randomised controlled trial 
whether those patients with an aneurysm of 4.5 - 5.5cm were better served by ‘early 
operation’ or continued surveillance and found that there was no survival benefit over the 
longer term for those patients operated on early. [20] Therefore the figure of 5.5cm 
maximum aneurysm diameter is used as the ‘threshold’ for when elective surgical repair 
should be considered. If an aneurysm is detected and is less than 5.5cm patients will often 
be treated conservatively and enter a surveillance programme with regular 
ultrasonography examinations to monitor the expansion of their aneurysm. [8] These 
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findings support the decision to observe aneurysms that are less than 5.5cms in size, this 
includes whether an aneurysm is operated on by endovascular means also. [21, 22] 
Once an unruptured aneurysm has been identified and if it is considered large enough to 
merit surgical repair the patient will be assessed and counselled regarding repair of their 
aneurysm. If the patient and physician decide to proceed with surgical repair of the 
aneurysm, then there are broadly two methods of repair available: open surgical repair or 
endovascular placement of a stent-graft. In all cases of repair the primary aim is to reduce 
the risk of death from aneurysm rupture at a later date by excluding the aneurysm from 
the circulation. Important in this decision making is the relative rupture risk of any given 
aneurysm and the risk of operative intervention, in whatever form, for any given patient. 
2.2. Rupture Risk of AAA 
As already stated, the aim in management of AAA is to prevent rupture and although 
baseline aortic diameter has the greatest role in predicting rupture of AAA there are other 
factors that may affect the natural history or rupture risk in an individual patient. 
Therefore, the diameter of 5.5cm as a threshold for operative management of AAA should 
not be absolute and the decision to operate or not should be based on multiple factors. 
As stated before aneurysm expansion occurs at a relatively predictable rate overall but 
individual aneurysms can expand at different rates. It has also been shown that larger 
aneurysms tend to expand at a faster rate meaning that their risk of rupture is not only 
higher to begin with but continues to increase more quickly than either a smaller aneurysm 
expanding at the same rate or a large aneurysm that is not expanding at all.[23] Rapid 
expansion of an aneurysm, defined as >5mm within six months or >10mm within one year, 
has also been determined to be an indication to undergo elective aneurysm repair. [24] It is 
difficult to ascertain whether expansion itself is a predictor of aneurysm rupture 
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independent of aneurysm diameter but theoretically a rapidly expanding aneurysm may 
represent instability of the aortic wall and be a sign of impending rupture. 
Cigarette smoking is associated with the expansion of AAA and an increased risk of rupture. 
[25-27] Smoking cessation therapy is also associated with a reduction in the need for 
aneurysm repair and eventual rupture. [28] A metanalysis of over 15,000 patients across 18 
studies found that smoking increased the growth rate of aneurysms by 0.35mm/year and 
rupture rates were twice that of non-smokers. [29] 
Although hypertension is often quoted as a significant risk factor for AAA growth the 
literature fails to consistently show a strong association between hypertension and 
aneurysm expansion. [25, 27, 30]From the ADAM study there was a positive statistically 
significant association between increase in diastolic blood pressure and AAA expansion rate 
correlating to 0.2mm/year increase per 10mmHg increase in diastolic blood pressure. [25] 
However in the UK small aneurysm trial there was no statistically significant association 
between blood pressure and aneurysm growth. [27]That study did however find that after 
3 years follow up there was an increased risk of rupture with increasing blood pressure. 
[30] 
Respiratory disease, primarily COPD, with an associated decrease in the forced expiratory 
volume in one second (FEV1), appears to be associated with an increased risk of aneurysm 
rupture. [30] 
The prevalence of AAA in women is lower than men but in women that do have an 
aneurysm multiple studies have shown that their aneurysms tend to grow faster, rupture 
more frequently and rupture at smaller AAA diameters. [30-32] This is true even when 
controlling for other factors known to influence rupture risk. Therefore, the presence of an 
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abdominal aortic aneurysm seems to be a more aggressive and lethal disease when it is 
present in a woman. 
Baseline maximum aneurysm diameter remains the most influential factor in predicting 
both aneurysm expansion and rupture risk, but rate of aneurysm expansion, tobacco use, 
hypertension, respiratory disease and female sex also play an important adjunctive role in 
determining rupture risk. Therefore, when assessing a patient to determine the most 
appropriate treatment option all these factors should be taken into consideration when 
trying to predict their risk of aneurysm rupture. There may also be a rationale given certain 
characteristics for determining that the threshold for aneurysm repair may be lowered or 
even raised for an individual patient. For example, a female patient who is a smoker may 
have a greater rupture risk for a 5cm aneurysm than a male non-smoker with a 5.5cm 
aneurysm. It would therefore be sensible to consider repair of her aneurysm at this ‘sub 
threshold’ size given these characteristics. This argument takes into consideration the small 
numbers of women enrolled into the major randomised controlled trials that overall 
showed no benefit for patients undergoing repair when their aneurysm is less than 5.5cm. 
2.3. Medical Management of AAA 
All patients with a diagnosis of abdominal aortic aneurysm should be referred to a vascular 
service where a decision about initial management strategy can be made. Important in this 
consultation is also the explanation to the patient of what an aneurysm is, its natural 
history and therefore the importance of surveillance (for small aneurysms) and ensuring 
the initiation of appropriate medical management. All patients diagnosed with an 
aneurysm should have the same care and attention to appropriate medical, non-operative, 
management regardless of aneurysm size. 
Smoking cessation therapy is an important part of the medical management for any smoker 
with an aneurysm. As stated above smokers have a higher rate of expansion and rupture. 
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One study that assessed the cost effectiveness of an intensive smoking cessation 
programme found that the intervention (8 week smoking cessation programme, adjuvant 
pharmacotherapy and annual revisits) was cost effective by reducing the need for AAA 
repair and rupture over a 10 year follow up. [28] Furthermore it has been shown that 
patients surgery who stop smoking have fewer post-operative pulmonary complications 
[33]. Active smoking cessation therapy should therefore be part of the treatment of anyone 
with an abdominal aortic aneurysm who smokes. 
There have been numerous animal and in vitro studies that have suggested possible 
pharmacological targets to inhibit AAA progression however, as yet, there are no agents 
that have been found to consistently prevent AAA expansion or rupture. A large 
multicentre study of 5362 patients found no association between commonly used 
cardiovascular mediations (statins, beta blockers, angiotensin-converting enzyme inhibitors 
and angiotensin II receptor blockers) and AAA progression. [34] 
In a randomised controlled trial assessing the effect of beta blocker versus placebo no 
overall difference was seen in the expansion rate of small AAA with no significant 
difference in the proportion of patients undergoing elective surgery. [35]In that study 
propranolol was the beta blocker of choice and was poorly tolerated with 42% of the 276 
patients randomised to receive propranolol stopping their medication early because of side 
effects. Interestingly when the authors analysed the results for those patients still taking 
propranolol, they found that fewer patients underwent aneurysm repair compared with 
placebo and although growth rates were not statistically different there were fewer people 
who had rapid expansion of their AAA. These results of course do not confirm that beta 
blockade is beneficial for patients with a small aneurysm but there is an important area for 
future research to see if a better tolerated beta blocker does provide some benefit. 
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Regarding ACE inhibitors and ARBs – there have been conflicting reports from studies in the 
literature to date about the role of these medications on aneurysm expansion. One large 
scale study that retrospectively evaluated prehospital use of ACE inhibitors found that 
patients taking ACE inhibitors were less likely to present with a ruptured aneurysm than 
those who weren’t taking them. [36]However the UK small aneurysm study found an 
increased risk of aneurysm expansion in those taking ACE inhibitors. [37] One randomised 
controlled trial that assigned patients to an ACE inhibitor, amlodipine or placebo found no 
difference in annual growth rates or in the proportion of those undergoing repair. [38] 
Therefore there is insufficient evidence to suggest that these agents provide any benefit for 
patients with small AAA. 
Statins have a theoretical impact on AAA development related to their known effect on the 
expression of MMPs. MMPs are thought to play a role in the degeneration of the arterial 
wall leading to the development of and progression of AAA.[39, 40] Some animal studies 
have suggested that statin therapy may slow progression of AAA as well. [39, 41-43] A 
meta-analysis comparing results of 11933 patients across 12 studies found that statin 
therapy had no significant effect on AAA expansion rate but did show a post-operative 
mortality benefit. [44]  This highlights what is probably the most important feature of 
statins - their protective cardiovascular effect from sequelae of atherosclerosis. Therefore, 
there is limited evidence that statins may limit the progression of AAA, but they provide a 
long-term survival benefit in those undergoing AAA repair and are generally a well-
tolerated medication. On this basis all patients with AAA and without contraindication 
should be prescribed statin. 
Antiplatelet therapy has not been convincingly shown to limit the rate of AAA expansion in 
multiple studies but like statin there are well documented protective effects of antiplatelet 
therapy in patients with cardiovascular disease.[37, 45, 46] Due to the strong association of 
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AAA with cerebrovascular atherosclerosis it is reasonable to treat these patients with 
antiplatelet medication to further modify their cardiovascular risk. Furthermore, a large 
study in the UK investigating the effect of statins, antiplatelet therapy and antihypertensive 
agents evaluated records of 12485 patients with a known diagnosis of AAA. This study 
showed that between 2000 and 2012 the proportion of patients receiving these 
medications increased and also demonstrated 5 year survival improved for patients taking 
these medications compared to those who did not.[47] 
Antibiotics have also been investigated for their role in limiting expansion of AAA. This was 
because there was an initial suggestion that infection may play a role in AAA formation as a 
study found that presence of Chalmydiae pneumoniae infection was associated with AAA 
expansion. [48]Further studies showed that antibiotics may limit AAA expansion rates there 
is no clear evidence that antimicrobial action provides benefit for the majority of AAA that 
are non-infected. [49] Tetracycline antibiotics are also known to inhibit MMPs and 
therefore their role in modifying aneurysm expansion has been investigated. To date no 
study has definitively shown that the use of tetracycline antibiotics affects the progression 
of AAA.  [50, 51] 
In summary, although multiple agents have been investigated there are none that can halt 
or cause regression of an aneurysm once formed. There is some suggestion that beta 
blockers and statins may modify AAA progression, but further study is needed to determine 
the true effect of these agents. All patients with a diagnosis of AAA should have active 
smoking cessation therapy, antiplatelet and statin therapy if there are no contraindications. 
Hypertension has been shown to increase rupture risk and it therefore seems sensible to 
advocate aggressive management of hypertension but there is no evidence to suggest one 
antihypertensive agent is better than any other for patients with small AAA.  
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This management strategy is also aimed at controlling associated risk factors and limiting 
their impact on the health of the patient. This is to improve the overall health of the 
patient and should the patient need an operation in the future they will benefit from 
having these conditions optimally medically managed before intervention for their 
aneurysm. Surveillance with regular ultrasound examination to monitor and document the 
size of their aneurysm should also be considered an important part of this management 
strategy as it will identify the point, if the patient does not die from another cause first, at 
which they should be considered for operative intervention in a timely manner which 
therefore will reduce the risk of aneurysm rupture. Of course, it may be decided that an 
aneurysm should not be surgically repaired and therefore patients may be “turned down” 
for aneurysm repair. The decision-making process will be individual for each patient but an 
assessment of risk versus benefit would be made and a patient may be turned down for 
aneurysm repair before it ruptures for elective repair, but still be considered for emergent 
repair or turned down altogether. 
2.3.1. Turndown for Repair 
There is a paucity of data recording the proportion of aneurysms that are turned down for 
operative intervention however a few studies have documented turndown rates between 
13% - 37%.[52-55] The most oft quoted reason for patients being turned down in these 
studies is the existence of significant medical comorbidity. Other reasons include anatomic 
unsuitability, and patient choice. The median survival for these cohorts of patients after 
decision not to operate ranged from 15 – 34 months. In all the studies less than 50% of the 
patients suffered a ruptured aneurysm highlighting the severe nature of comorbidities in 
this patient population. There were varying methods by which patients were investigated 
and risk stratified to determine whether to operate or not but in most of the studies no 
validated aneurysm risk scoring model was used. This suggests two things: given the high 
rate of early death from non-aneurysm related causes there is significant utility in the 
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clinical assessment of a patient to determine their likely outcome. Secondly with nearly a 
third of patients dying from rupture in most series the question remains about whether a 
proportion of these patients would have been better suited with aneurysm repair and how 
best to define and identify those patients. 
If it is decided that an aneurysm should be repaired then this can be done, broadly 
speaking, by two methods; open surgical repair or endovascular repair. These treatment 
strategies are detailed below. 
2.4. Open Surgical Repair of AAA  
The first successful surgical resection of an abdominal aortic aneurysm was performed by 
Dubost in Paris, 1951. [56] The aneurysm was replaced with cadaveric aortic homograft to 
restore circulation distally. Although modern techniques of open surgical repair utilise 
prosthetic material for arterial grafts the principles of the operation remain the same. 
Under general anaesthetic the abdominal aorta within the retroperitoneal space is 
accessed usually through laparotomy and the transperitoneal route, however as Dubost 
did, it can be accessed retroperitoneally via a thoracoabdominal incision on the flank. Once 
access is gained the aorta is clamped proximal and distal to the aneurysm (usually on the 
iliac vessels) to enable access to the lumen of the aorta without exsanguination. The 
aneurysm is incised and thrombus from within the aneurysm is removed. Any back-
bleeding vessels from within the aneurysm are suture ligated at this point including the 
inferior mesenteric artery, if necessary. A prosthetic surgical graft (which can be tubular or 
bifurcated as needed) is sutured to the rim of aortic tissue immediately proximal to the 
aneurysm, usually below the renal arteries. The distal portion is then sutured to either the 
distal aorta or iliac vessels. The clamps are removed and the circulation to the peripheries 
is restored. The aneurysm sac is sutured over the prosthetic graft to minimise risk of 
adhesions and aortoenteric fistula. 
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2.4.1. Complications of Open Surgical Repair of AAA 
The most devastating complication after aneurysm repair is death. Open surgical repair is a 
major intervention, due to the nature and epidemiology of the disease it is usually 
performed in elderly people with many co-existing medical conditions. This translates into 
a high immediate and peri-operative mortality rate for these patients. The estimated 30-
day mortality rate for patients undergoing elective open surgical repair of an infrarenal AAA 
is 4.7% [57].  
There have been many models developed to estimate which patients are at a higher risk of 
mortality after elective aneurysm repair and as such there have been many factors found 
to be associated with an increased risk of mortality. A study by Grant et al. [58] which 
assessed and compared five such risk prediction models found that in the two best 
performing models there were common characteristics associated with an increased risk of 
peri-operative mortality and these were: increasing age, female sex, renal disease and 
vascular disease. In addition, respiratory disease and cardiac disease were associated with 
higher mortality rates separately between the two models.  
2.4.2. Morbidity of Open Surgical Repair of AAA 
Open surgical repair is a significant intervention and therefore there is significant risk of 
complication after the operation. Complications can be either local (such as wound 
infection, atheroembolism, bleeding, graft infection, anastomotic pseudoaneurysm) or 
systemic (such as stroke, myocardial infarction, and renal failure) these complications can 
result in death, limb loss and/or long-term reduction in independence and quality of life. 
The reported rates, in a meta-analysis, of significant systemic complications after open 
repair in the post-operative period are as follows: Stroke (1.9%), Myocardial Infarction 
(9.2%), Renal Failure (10.4%). [57] 
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Late complications after open repair appear to be relatively rare with reported rates of 
long-term complications being low, such as anastomotic pseudoaneurysm (3%), graft 
thrombosis (2%) and aorto-enteric fistula (1.6%). These complications were observed to be 
a median of 4 – 6 years after initial repair. [59] Therefore with open surgical repair the 
most significant risk is loaded at the beginning meaning if patients survive their initial 
operation and post-operative period without a significant complication, they are generally 
free from complication or re-intervention after that. 
2.5. Endovascular Repair of AAA 
In endovascular aneurysm repair (EVAR) the risk of aneurysm rupture is attenuated by 
excluding the aneurysm from the circulation by means of placing a metallic stent covered 
with fabric (a stent-graft) across the aneurysm from within the circulation. Under general, 
regional or local anaesthetic access to the circulation is gained via the femoral arteries. A 
stent-graft is then inserted under fluoroscopic guidance to the aneurysm. Once deployed 
the metallic stent acts to provide radial force and fixation to the arteries above and below 
an aneurysm with the fabric preventing blood entering the aneurysm itself. By removing 
the aneurysm from the circulation in this way the aneurysm is no longer subject to the 
haemodynamic forces of the circulation and its risk of rupture decreases. Furthermore, if 
the aneurysm does rupture but is still excluded from the circulation then the rapid 
exsanguination and death seen from rupture in untreated aneurysms would not occur. The 
operation is completed by repair of the femoral arteries that acted as access sites. Juan 
Parodi and colleagues are credited with the first successful use of such a stent-graft to 
successfully achieve aneurysm exclusion in a patient in 1990. [60]  
The perceived advantage of this technique is that it removes the need for direct access to 
the aneurysm itself through a laparotomy or thoracoabdominal approach thereby limiting 
the surgical insult that occurs. Initially this advantage was used in patients who exhibited a 
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particularly high risk of death or complication from standard open surgical repair. Over 
time, however, the techniques and devices used have been refined and in fact it is the most 
common method of infrarenal aneurysm repair used today. EVAR accounted for 74% of the 
total number of AAA repairs performed in the United States in 2010 [61]. 
2.5.1. Special Considerations for Endovascular Repair – Fixation 
One of the key differences between open aneurysm repair and endovascular repair is the 
method by which the graft or stent-graft is fixed in place within the aorta. In open repair 
the graft is hand sutured by the surgeon to a circumferential ring of aortic tissue proximal 
to the aneurysm. In endovascular repair the stent-graft is placed within the lumen of the 
aorta from below (while its diameter is constrained within a delivery system). Once at the 
appropriate level it is expanded to a larger diameter. This happens as the delivery system is 
withdrawn, unsheathing the device itself. The majority of the expansion to a larger 
diameter is due to the self-expanding nature of the stent-graft which is intentionally 
manufactured this way but can also be aided by expanding an endovascular balloon within 
the lumen of the stent-graft to ‘push’ out the device. As such, there is no direct suturing of 
the stent-graft to the aorta. It relies on the radial force of the proximal stent-graft as well as 
additional components such as hooks and barbs (that ‘bite’ into the aortic tissue and 
engage with it) to provide ‘fixation’ of the device to the aortic wall so that it doesn’t move 
caudally, also known as migration. 
This fact means that open repair grafts do not migrate caudally due to the secure fixation 
whereas it is possible that a stent-graft may. Migration can lead to inadequate ‘seal’ at the 
proximal end of the stent-graft allowing blood to once again flow into the aneurysm 
exposing the patient to risk of rupture. Migration may also cause kinking of the distal 
portion of the stent-graft that may lead to disturbances or even cessation of the flow of 
blood into the iliac arteries. Much work has been done on the fixation forces of various 
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types of stent-grafts and the ‘distraction’ forces which they are exposed to using 
experimental bench top models with animal, human or artificial aortas and mathematical 
models (such as computational flow dynamics). In an analysis of over 4000 patients who 
underwent standard EVAR from the EUROSTAR registry it has been shown that patients 
with shorter and wider infrarenal necks are more likely to experience migration [62], 
confirming the opinion that the anatomy of an aneurysm, especially at the site of fixation, 
plays a significant role in outcome after endovascular repair. 
2.5.2. Special Considerations for Endovascular Repair – Seal 
To exclude the aneurysm from the circulation an endovascular device should be placed in a 
position to stop blood flow into the aneurysm. As stated above the fixation of the stent-
graft to the aorta is from within the lumen and not, as in open repair, a continuous suture 
around the circumference of the aorta. This means that there is a potential space between 
the fabric of the stent-graft and the aortic wall where blood could continue to flow into the 
aneurysm. Due to this, it is imperative that a good ‘seal’ is achieved above and below the 
aneurysm. These are termed the proximal and distal seal zones, respectively. To improve 
the seal between the stent-graft and aorta the device should have adequate radial force so 
that the fabric is in contact with the aortic wall, and consequently be of an adequate size to 
expand to the diameter of the aorta. It should also be deployed within a segment of artery 
that is relatively free from intraluminal disease that could distort the fabric and hence 
compromise the seal. The ‘seal zone’ must also be in a relatively straight sided portion of 
aorta that is long enough to achieve a good seal especially considering the possibility that a 
stent graft may move or migrate through its lifetime. 
The importance for good fixation and seal from an EVAR device has led to the development 
of specific ‘indications for use’ recommendations by the manufacturers of stent grafts. 
Indications for use are recommendations an aneurysm must exhibit for the device to 
37 
 
perform adequately to achieve aneurysm exclusion. Most these recommendations relate to 
anatomical features that may affect the fixation or seal that a device will deliver. 
2.5.3. Complications of EVAR 
Despite the less invasive nature of EVAR compared with open repair it is still a major 
intervention and as such there is an appreciable risk of death related to the procedure. The 
30-day mortality rate for EVAR reported in the literature is in the region of 1 - 2% [63, 64]. 
The complications for EVAR include most of those detailed for open surgical repair 
including local and systemic complications such as MI, stroke and renal failure.  
Specific complications to EVAR include; conversion to open repair either immediately or 
after a period, endoleak and graft migration. The term endoleak was first defined by White 
and colleagues in 1997[65] as “…the persistence of blood flow outside the lumen of the 
endoluminal graft but within an aneurysm sac…being treated by the graft. Endoleak is due 
to incomplete sealing or exclusion of the aneurysm sac…”. This phenomenon has been 
classified according to the site where the ‘leak’; originates from (See table 2.1): 
Table 2.1 Description of Types of Endoleak 
Endoleak Site of Endoleak 
Type I Failure of seal at the proximal (Ia) or distal (Ib) attachment sites 
Type II Blood flow into the aneurysm from side branch vessels such as lumbar or 
mesenteric arteries 
Type III Failure of the device causing blood flow into the aneurysm at a modular 
connection (IIIa) or a tear in the fabric of the device itself (IIIb) 
Type IV Flow through porous fabric (<30 days after device deployment) 
 
Compared with open repair EVAR is more prone to failure at a later stage. Late aneurysm 
rupture remains a problem that is significantly more common after EVAR compared with 
open repair. The proportion of patients experiencing late aneurysm rupture, as detailed in 
38 
 
a meta-analysis, were 2% (EVAR) and 0.3% (Open repair) [57] with the vast majority of 
ruptures after EVAR occurring within the first two years after initial operation. [66] 
Although late aneurysm rupture represents catastrophic failure of the device in EVAR this 
may be preceded by several differing modes of failure, such type Ia endoleak, type III 
endoleak, migration or a distorted endograft. These modes of failure are also risk factors 
for late conversion to open repair within the same analysis by the EUROSTAR collaborators. 
[66] Furthermore specific anatomic characteristics such as short neck length and significant 
neck angulation have been shown to be associated with higher incidences of type Ia 
endoleak, suggesting that specific anatomic characteristics may predispose to higher failure 
rates. [67, 68] 
2.5.4. Follow up after EVAR 
Due to the risk of late failure, and the fact that a device may exhibit a mode of failure 
before actual rupture of the aneurysm, it is necessary that patients undergo post-operative 
surveillance. Surveillance is aimed at trying to detect these modes of failure before they 
lead to rupture, primarily because there are treatment options that can rectify these 
failures ranging from conversion to open repair to endovascular methods of correcting 
endoleaks or improving fixation and seal. Patients can undergo surveillance to detect 
device failure via ultrasound imaging (To detect aneurysm expansion +/- endoleak), plain 
abdominal radiography (To detect migration and/or stent fracture) and computed 
tomography (CT) scanning (which can detect all the above). Patients will generally undergo 
imaging with a combination of ultrasound and plain abdominal radiography +/- CT scanning 
at regular intervals for the remainder of their life. Should a failure be detected the patient 
will be investigated and considered for secondary intervention if appropriate and 
necessary. 
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Secondary intervention after EVAR remains relatively common and may be necessary in up 
to 9% of patients at some point during their follow up. In those that do receive a secondary 
intervention the majority are performed because of endoleak and are endovascular 
reinterventions. [69]  
2.6. Randomised Controlled Trials of EVAR versus Open Repair 
To date there have been four randomised controlled trials (RCTs) comparing the clinical 
outcomes of standard EVAR and open repair (OR) for infrarenal AAA. The table below 
details the pertinent facts relating to these trials. (See table 2.1) 
 Table 2.1 Randomised Controlled Trials Comparing EVAR and OR 
Trial Years 
Recruited 
EVAR 
(n) 
Open 
Repair 
(n) 
Mean 
Follow 
Up 
(Years) 
In Hospital 
Mortality 
(EVAR) 
In Hospital 
Mortality 
(Open) 
UK EVAR 
Trial 1[70] 
1999 - 2004 626 626 6 1.8% 4.3% 
DREAM[71] 2000 - 2003 173 178 6.4 1.2% 4.6% 
OVER[72] 2002 - 2007 444 437 5.2 0.5% 3% 
ACE[73] 2003 - 2008 150 149 3 1.3% 0.6% 
Table 2.1 - ACE = Aneurysme de l’aorte abdominale:Chirurgie versus Endoprothese, DREAM = Dutch 
Randomized Endovascular Aneurysm Repair, OVER = Open Versus Endovascular Repair 
The French ACE trial did not find a statistically significant difference in the short-term 
mortality after operation. This trial specifically investigated those patients whom presented 
a low or intermediate risk for open operative intervention and differs from the other trials 
in that respect. The remaining three RCTs showed a significant survival advantage for 
patients undergoing EVAR in the short term. A review by the Cochrane Collaboration 
confirmed that when comparing all four RCTs there was a clear benefit in terms of short-
term mortality for EVAR (1.4% vs 4.2%, p=<0.0001)[74]. 
40 
 
In all trials the rates of all-cause mortality equalise over the follow up period with no 
significant difference between EVAR and OR over the longer term in terms of all-cause 
mortality. The UK EVAR Trial 1 describes the convergence of mortality rates at two years 
[70]. The DREAM Trial reported convergence of mortality rates at one year after 
operation.[75] The OVER trial reported a convergence of mortality rates at three years after 
the operation.[76] With a median follow up of 3 years the ACE trial did not find a difference 
in all-cause mortality at any follow up point to three years. [73] 
Aneurysm related mortality rates show that EVAR confers an early benefit, which in the 
three trials that did show benefit for EVAR, was due entirely to the early post-operative 
benefit of EVAR. The early advantage of EVAR in this regard was also lost throughout follow 
up, with convergence of survival curves. The trial investigators explained this convergence 
of aneurysm related mortality to be due in part to late endograft failures resulting in 
aneurysm rupture. [70] Another explanation was that in general “frail” patients who 
underwent open repair simply died while in hospital whereas those same frail patients who 
underwent EVAR survived their operation but then died soon after as a consequence of 
their general health and physiological status. [76] 
The review by the Cochrane collaboration found that between the four trials there were no 
significant differences in terms of the following major complications experienced by EVAR 
or OR groups: Myocardial complications, stroke, renal dysfunction (using surrogate markers 
such as creatinine and eGFR levels), and sexual dysfunction. The analysis however did 
identify a significant difference in terms of pulmonary complications and pulmonary related 
deaths, with EVAR performing better. [74] The comparison of reinterventions after the 
initial operation shows that the reintervention rate was significantly higher in the EVAR 
group (23.4%) compared with OR (13.1%) at long-term follow up. [74]  
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The most significant non-randomised study found in the literature search is a comparison 
of propensity matched cohorts of the Medicare population in the U.S.A. undergoing either 
EVAR or OR between 2001 and 2004. [77] There were 22, 830 matched patients in each 
cohort analysed. The perioperative mortality rate seen compares with the RCTs, with 1.2% 
for EVAR and 4.8% for OR. This analysis showed convergence of the survival curves at 
approximately three years from the initial operation. Reinterventions related to the 
aneurysm were found to be more common after EVAR in this analysis also (9% vs 1.7%). 
Interestingly the rates of major post-operative complications were significantly higher in 
the open repair group; namely myocardial infarction, pneumonia, renal failure, deep vein 
thrombosis or pulmonary embolism.  
Overall the published evidence comparing EVAR and OR is vast but consistently a survival 
benefit in the short term is seen after EVAR compared with OR. Over the longer term this 
survival benefit is lost somewhere between 1 and 3 years, with an increased number of 
deaths after the initial post-operative period in the EVAR group. It is uncertain whether 
aneurysm related deaths or miscellaneous causes of death account for this converging of 
survival rates from the published data. There is heterogeneity among trials concerning 
what reinterventions are reported and how they are classified but it seems clear that EVAR 
results in more reinterventions in the long term. 
2.7. Limitation of Standard EVAR 
As stated, the majority of aneurysms of the abdominal aorta are within the infrarenal 
portion and as such have a length of aorta that is above the aneurysm but below the renal 
arteries. The morphology of this length of aorta, termed the neck of the aneurysm, will vary 
from patient to patient, in terms of its length, diameter, angulation, presence of 
intraluminal disease such as thrombus or calcification and its shape (broadly speaking the 
neck is usually either parallel sided or conical becoming wider the closer to the aneurysm it 
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is). Unless the renal arteries are occluded it is desirable to place the upper most part of the 
fabric of the stent-graft below the renal arteries so that perfusion is maintained to these 
vital organs. There are therefore limitations of anatomy within which EVAR can be placed 
so that adequate fixation and seal are achieved for aneurysm exclusion while maintaining 
perfusion to the kidneys. These anatomical limitations are outlined in the manufacturers’ 
indications for use (IFU) and are specific to each model of stent-graft. Broadly speaking the 
manufacturers require a reasonable length of aortic neck (>10mm or >15mm), diameter of 
aortic neck (<32mm), angulation within the neck (<60° relative to the aneurysm), minimal 
intraluminal disease and a relatively parallel sided neck. The specific IFU for some devices is 
discussed in more detail in the Methods section. These anatomical limitations pertain to 
the neck but there are also limitations relating to the seal zones within the iliac arteries and 
the ‘access’ vessels; those vessels through which the device is passed to reach the 
aneurysm. 
Although it is possible to place an EVAR device within an aneurysm that does not exhibit 
favourable anatomical characteristics as outlined in the IFU there have been studies that 
have revealed worse outcomes in terms of Type Ia endoleaks and aneurysm related 
mortality for patients receiving EVAR in these ‘hostile’ anatomies compared to patients 
with more favourable anatomy. [78] When presented with hostile neck anatomy therefore 
alternative treatment options may be explored. These comprise open surgical repair or 
endovascular repair with advanced stent-graft technologies. Advanced endovascular 
techniques include: 
 Chimney technique – Where an endovascular stent-graft is deployed across 
one or both renal arteries in order to move the seal and fixation zones to a 
more desirable part of aorta. Perfusion is maintained to the renal arteries 
by a separate stent that runs alongside the main stent-graft in the sealing 
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portion in a downward direction that enters the renal vessel, thereby 
acting as a ‘chimney’ to allow blood flow to the kidneys. 
 Fenestrated EVAR – A stent-graft that is designed with holes (fenestrations) 
that align specifically to the ostia of the visceral vessels in a given patient is 
manufactured. This enables the stent-graft to be deployed more superiorly, 
extending the seal zone into a long, disease free part of the aorta but 
maintaining perfusion to the viscerae through fenestrations. Stents are 
then placed through the fenestrations to secure the stent-graft in place 
relative to these vessels. 
 Branched EVAR – This is usually reserved for true suprarenal aneurysms 
where the aneurysmal process extends around and above the renal 
arteries. A stent-graft is deployed within the visceral aorta with perfusion 
maintained to the visceral vessels by means of covered branches attached 
to the stent graft. Although similar this is a distinct device with distinct 
indications from that of fenestrated EVAR. 
Of these advanced endovascular techniques, the most commonly utilised method is that of 
fEVAR and is discussed further in Chapter 3. 
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CHAPTER 3 – Fenestrated Endovascular Aneurysm Repair 
3.1. Introduction 
 
Fenestrated endovascular aneurysm repair (fEVAR) describes a specific type of 
endovascular device and technique used for endovascular repair of AAA. The aim of fEVAR 
is to enable endovascular repair of juxtarenal aneurysms that would not be suitable for 
standard EVAR, specifically those with a short infrarenal neck.  The use of a fenestrated 
stent-graft was first described by Park and colleagues in 1996 [79] after successful 
introduction of a ‘home-made’ fenestrated device in two patients. The first commercially 
available fenestrated device, and still the most widely used, is manufactured by Cook 
Medical (Bloomington, Indiana, U.S.A.). The device is bespoke for each individual patient 
and is manufactured according to his or her unique anatomy. Anatomical information is 
derived from pre-operative non-invasive imaging techniques to accurately delineate the 
anatomy for each individual patient, in particular relating to the visceral segment of the 
aorta. The role of fEVAR is specifically to treat AAA that is out with the IFU for standard 
EVAR in relation to the neck of the aneurysm. It does this by moving the sealing and 
fixation zone proximally to within the visceral segment of the aorta. This allows aneurysms 
with necks considered unsuitable for EVAR, because of an inadequate sealing zone below 
the renal arteries, to be repaired by endovascular means. To maintain perfusion to the 
visceral vessels, fenestrations are manufactured into the proximal portion of the device 
that seals within the visceral aorta. The alignments of these vessels vary from patient to 
patient and hence the need for bespoke manufacture. During implantation the 
fenestrations are aligned with their corresponding visceral vessel, termed a target vessel, 
before the stent-graft is fully deployed. The stent-graft is preloaded onto an introduction 
system to allow delivery of the compressed stent-graft into the circulation before full 
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‘deployment’. The proximal fenestrated portion is loaded onto its introduction system with 
‘trigger wires’ that control the deployment of the stent-graft, as with standard EVAR. In 
fEVAR an additional trigger wire is in place that controls the release of ‘diameter-reducing’ 
ties on the proximal end of the stent-graft. During deployment, diameter-reducing ties 
continue to constrain the device to less than full expansion so that with partial deployment 
the device can continue to be manipulated and rotated to align the target vessels with the 
fenestrations. Once aligned the stent graft can be fully deployed removing the diameter 
reducing ties. Then additional stents are placed through the fenestrations into the target 
vessels to further secure the stent-graft in position and maintain vessel patency. These 
stents protrude from within the aortic lumen, through the fenestrations into the target 
vessel. The fenestrated device is a modular stent-graft that comprises the proximal, 
fenestrated portion, the distal bifurcated body, and the iliac limbs. Once the fenestrated 
portion is deployed the remaining modules of the stent-graft are then deployed in a similar 
fashion to standard EVAR.  
3.2. Fenestrated Stent-Graft Technology  
The fenestrated stent-graft manufactured by Cook is based on the Zenith® platform 
manufactured for use in standard EVAR. It is composed of three components: a fenestrated 
proximal body, a bifurcated distal body and an iliac leg. It is manufactured from woven 
polyester fabric, which is hand-sewn to self-expanding stainless-steel Cook-Z® stents. The 
area in which the IFU for fenestrated devices differs from that of standard endovascular 
stent-grafts pertains to the aneurysm neck reflecting the rationale that its intended use is 
to extend the applicability of endovascular repair for juxtarenal aneurysms. The IFU 
recommends there only need be a minimum of 4mm length of neck inferior to the renal 
arteries compared with 10-15mm for standard EVAR. However due to the increased 
complexity of the fenestrated component it does require that there is only a maximum of 
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45° angulation between the neck and the long axis of the aneurysm as opposed to 60° 
allowed in standard EVAR.  
3.2.1. Fenestrated Proximal Body 
This component intends to provide seal and fixation within the visceral segment of the 
aorta while providing continued perfusion to the visceral vessels. It can do this in one of 
two ways, a scallop at the uppermost portion of fabric or a fenestration (a hole) within the 
fabric. At the top of the proximal body there is a bare stent which contains barbs that 
confer additional fixation of the device in its intended position by engaging with the aortic 
wall, in much the same way as for the standard endovascular device. There are also 
radiopaque gold markers placed on the device to aid in the correct positioning under 
fluoroscopic control and to attain the desired alignment with the target vessels (TV). The 
following table details the options for target vessel protection available (See table 3.1): 
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Table 3.1 Description of Different Mechanisms for Protecting Target Vessels with 
fEVAR 
Vessel 
Protection 
Mechanism 
 
Description Image 
Scallop  Width 10mm 
 Height 6 – 12mm 
 Between struts of stent 
at proximal fabric edge  
 May be stented 
 
Small 
Fenestration 
 Width 6mm 
 Height 6-8mm 
 Fit between struts of 
stent within sealing zone 
 May be stented 
 
Large 
Fenestration 
 Diameter 8-12mm 
 Struts of stent may cross 
opening (‘Strut-free’ 
option may also be 
possible to manufacture) 
 Not designed to be 
stented if there are struts 
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The most common architecture for fenestrated devices used is one scallop to 
accommodate the superior mesenteric artery (SMA) and two small fenestrations, one for 
each renal artery. However, the devices can be manufactured in a myriad of ways, from 
providing just one scallop for the lower most renal artery, to four fenestrations for all four 
visceral vessels (both renal arteries, SMA and Coeliac axis). Small fenestrations are 
intended to be stented to provide additional fixation of the stent-graft to its deployed 
position by preventing movement in either a caudal/rostral direction or rotational. Without 
the additional protection stents provide there is the possibility that target vessels may be 
compromised, by complete coverage or ‘shuttering’ of part of the vessel origin by the 
fabric. 
3.2.2. Bifurcated Distal Body 
The distal bifurcated body comprises one long limb that engages in one iliac vessel and one 
short limb that will accommodate the separate iliac leg. The proximal portion of the graft is 
tubular and is similar to a standard endovascular device with the exception that there is no 
bare stent above the top of the fabric for added fixation. This is because barbs on the bare 
stent would engage with the fabric of the proximal fenestrated body and would tear and 
damage that portion of fabric. The intended deployment of the uppermost part of the 
bifurcated distal body is within the lower part of the proximal fenestrated portion, with at 
least a two-stent overlap. This ‘overlap zone’ and lack of active fixation at this site is 
intentional because if there were to be caudal migratory forces acting upon the whole 
system the intention is that the bifurcated distal body should be ‘free’ to move to 
accommodate this force. The bifurcated distal body would therefore move but the 
proximal fenestrated portion would not. Although this may result in component separation 
and resultant type III endoleak, this may be less disastrous and more easily treated than if 
the proximal body were to move and compromise the target vessels. 
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3.2.3. Iliac leg 
The iliac leg utilised in the fenestrated device is the same as used in the standard Zenith® 
platform. It is constructed from polyester fabric sutured to self-expanding stainless steel 
and nitinol Z-stents. It is delivered and deployed within the short iliac limb of the bifurcated 
distal body with at least one stent of overlap as recommended in the manufacturer’s 
instructions for use. It then seals within the corresponding iliac artery. 
3.3. Complications of Fenestrated EVAR 
The complications of fEVAR are the same as those for standard EVAR such as migration and 
endoleak. However, some complications should be given special consideration with fEVAR.  
3.3.1. Spinal Cord Ischaemia 
Spinal cord ischaemia can occur after any form of AAA repair. Its exact aetiology is poorly 
understood but is thought to be multifactorial. It is primarily related to an interruption in 
the blood supply to the spinal cord, which may be due to; prolonged aortic clamping, 
intraoperative hypotension, atheromatous embolization and/or interference with pelvic 
circulation. Spinal cord ischaemia is more common after thoracic aortic aneurysm repair 
than after AAA repair in part related to the fact that the anterior spinal artery usually, but 
not always, derives its main blood supply from the lower thoracic aorta.  
 
The rate of spinal cord ischaemia after endovascular repair of a thoracic aneurysm has 
been reported in up to 9% of patients, and length of aortic coverage has been shown to be 
a significant risk factor for the development of spinal cord ischaemia. [80] Although this 
complication is seen rarely in open infrarenal AAA repair (0.26%) and standard EVAR 
(0.21%) [81] at the outset of the application of fenestrated technology there has been 
concern that there may be an increased incidence of spinal cord ischaemia owing to the 
greater length of aortic coverage inherent in fEVAR. In a report from the GLOBALSTAR 
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collaborators, spinal cord ischaemia was seen in 5 patients out of 318 who underwent 
fEVAR (1.6%) [82], confirming that although this complication is more common after fEVAR 
it is still a relatively rare complication. If spinal cord ischaemia develops in the post-
operative period prompt recognition and treatment including insertion of a spinal drain and 
blood pressure manipulation may improve the neurological deficit either partially or totally. 
Therefore, although uncommon this devastating complication requires careful 
consideration for those undergoing fEVAR. 
3.3.2. Target Vessel Loss/Compromise 
Target vessels are at risk of occlusion or compromise both during the initial fEVAR 
procedure and during follow up. Target vessels may be compromised due to several factors 
such as: 
1) Deployment Error – If the graft is deployed inaccurately this may result in 
shuttering or complete coverage of target vessel ostia. Although in some cases of 
incomplete coverage it may be possible to ‘rescue’ the situation by placing a stent 
in the artery and moulding the area with a balloon. 
2) Embolisation – During manipulation of the stent-graft, target vessel cannulation 
and stenting it is possible that embolisation of disease present within the visceral 
aorta or within the target vessel itself may occur. This could result in end organ 
ischaemia or infarction with occlusion of a branch of the target vessel or the main 
vessel itself depending on the size of the embolus. 
3) Angulated neck – If the angulation between the aortic neck and aneurysm is high 
(>45°), this may lead to distortion of the anatomy in an unpredictable way between 
the preoperative CT and the anatomy encountered on the day of operation. This 
can be in part due to the fact the aorta will naturally straighten when the stiff 
endovascular system is introduced through the lumen, this may then alter the 
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positions of the target vessels relative to each other and make it impossible to 
deploy the device preserving all of them. 
4) Non-stenting – Target vessel loss was noted, particularly in the early days, of fEVAR 
when in certain circumstances a target vessel was left unstented. During follow up, 
rotational migration of the stent-graft would eventually cause shuttering or 
coverage of the target vessel in question causing it to occlude. The recognition of 
this complication prompted the recommendation that all renal artery fenestrations 
should be stented. [83] 
5) Stent-graft migration – Migration in a caudal direction can result in crushing or 
deformation of target vessel stents sometimes resulting in the need for secondary 
intervention to rectify the compromise to the vessel. There have been reports that 
this may lead to loss of the target vessel.[84] 
6) In stent stenosis – Stenosis within or at the junction of target vessel stent and 
native vessel may occur during follow up with potential for target vessel 
compromise or loss.  
Although the potential for target vessel compromise and loss is present, according to 
reports in the literature it is relatively rare. This is likely secondary to the fact that, since its 
introduction, the complexities of fEVAR are better understood - including the 
recommendation that all small fenestrations should be stented, and the importance of 
accurate planning and deployment. Furthermore, for those that do occlude the effects do 
not seem to be as disastrous as one might expect with a significant proportion having no 
discernible clinical effect whatsoever. [82, 84]  
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3.4. Follow up after fEVAR 
Follow up after fEVAR is important to detect late complications in the same way as for 
standard EVAR. Follow up is also designed to survey target vessels and identify if any 
potential compromise is present that may be amenable to secondary intervention. 
The Global Collaborators on Advanced Stent-Graft Techniques for Aneurysm Repair 
(GLOBALSTAR) project has been set up on behalf of the British Society for Endovascular 
Therapy (BSET) to act as a registry of all fenestrated stent-grafts implanted within the UK. 
In the absence of randomised controlled trials the aims of the project at the outset were to 
evaluate the technique in terms of primary and secondary endpoints, establish an archive 
of all pre-operative and follow up imaging, to aid detection of mechanisms of failure, and 
to provide an “early warning system” for complications specific to the technique.[85] In 
2012 the first results from the registry were published for fEVAR confirming the safety, 
efficacy and feasibility of this technique reporting on 318 patients who received fEVAR in 
the UK. [82] The database is maintained and populated with data by physicians performing 
the procedures from across the UK and is the only such registry for fEVAR worldwide. 
3.5. Treatment of juxtarenal aneurysms 
Although fEVAR has extended the applicability of endovascular repair to juxtarenal 
aneurysms its increased complexity inherently brings greater potential for devastating 
complications, such as visceral vessel loss, morbidity and mortality. It is however important 
to note the flaw in the comparison of the treatment of infrarenal aneurysms that receive 
standard EVAR with juxtarenal aneurysms that receive fEVAR, as these are two different 
technologies and arguably two distinct versions of the same disease. Juxtarenal aneurysms 
may be considered a distinct entity as the options for repair are distinct from those for a 
simple infrarenal aneurysm; in open repair of a juxtarenal aneurysm the aortic cross clamp 
would usually be placed above one or both renal arteries and sometimes higher, above the 
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SMA or coeliac axis. The level of clamp site has been shown to effect the outcome after 
open aneurysm repair confirming that juxtarenal aneurysms pose a greater risk, in terms of 
short term mortality, than their infrarenal counterparts when undergoing open repair. [86] 
This furthermore reinforces the need for anatomical distinction between these two 
entities.  
The term ‘juxtarenal’ aneurysm is defined within reporting standards from the society of 
vascular surgeons (SVS) in the United States as an aneurysm that has “no normal aorta 
between the upper extent of the aneurysm and the renal arteries”. [87] This definition has 
not changed since 1991 and the interpretation of its meaning is variable across the 
literature. There is discrepancy about whether it truly means “no normal aorta” or whether 
a very short length of “normal” aorta would qualify. Some interpret to mean that only 
those patients in whom an aortic cross clamp would not be placed below both renal 
arteries fit the definition. The reason for this is probably that until the endovascular era a 
precise definition of a juxtarenal aneurysm was not necessary. In any case the term 
juxtarenal aneurysm is delineated from an infrarenal aneurysm primarily in the length of 
aneurysm neck that is present below the renal arteries. It is reasonable to suggest a new 
definition of ‘juxtarenal’ aneurysm that is fit for the endovascular era. The suggestion is 
that the new definition should utilise the limits of IFU for standard EVAR to define a 
juxtarenal aneurysm, i.e. an aneurysm that is not suitable for standard EVAR (according to 
its IFU), this could be termed – a non-standard aneurysm. 
The utilisation of such a definition is clear-cut and easily applied to all aneurysms as the 
anatomical measurements can be made from a pre-operative CT scan. The treatment 
options for such an aneurysm would therefore be; open repair, standard EVAR (placed 
outside of IFU) or advanced stent graft techniques (such as fenestrated or chimney EVAR). 
Importantly however there have been no randomised controlled trials to investigate these 
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various options for treating a non-standard aneurysm and as such the clinical outcomes for 
each method are largely unknown with respect to each other. 
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CHAPTER 4 – Rationale and Design of Study 
4.1. Introduction 
Although there has been randomised clinical trials assessing the treatment options for 
standard infrarenal aneurysms [64, 72, 73, 88], namely standard endovascular repair versus 
open repair, there has been no such randomised controlled trial of the treatment options 
for juxtarenal aneurysms. The treatment options for these aneurysms include open repair 
and endovascular repair. The most commonly used method of endovascular repair 
specifically designed for treatment of juxtarenal aneurysms is fenestrated endovascular 
repair. The safety, feasibility, efficacy and mid to long term results of fEVAR have been well 
documented and show a technique that has acceptable rates of mortality and success in 
the short term as well as acceptable rates of complication and target vessel loss in the 
longer term. [82, 84, 89-92] There are alternative options of endovascular repair of 
juxtarenal aneurysms and one commonly used method is applying standard EVAR, used 
outside its indications for use (IFU) within anatomy that it is not designed to treat i.e. a 
juxtarenal or short neck infrarenal aneurysm. However, the data comparing fEVAR with this 
and other treatment strategies is scarce and requires further review. 
The aim of this study therefore was to investigate these treatment options for juxtarenal 
aneurysms and specifically compare the clinical outcomes of conventional open surgery, 
EVAR used outside IFU and fEVAR for juxtarenal aneurysms within a defined geographical 
region, in terms of perioperative mortality, mid to long term survival and clinical success (as 
defined in the reporting standards for endovascular repair[93]. The defined geographical 
region in question is the Cheshire and Merseyside region. 
For standard infrarenal aneurysms it is relatively well understood from the gathered 
evidence that EVAR confers a short-term benefit over open repair in terms of perioperative 
mortality, but this advantage appears to equalise over time. The compromise for this early 
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advantage is an increased risk of late failure and need for reintervention in the future. The 
decision-making process for individual patients is therefore relatively well understood and 
can be explained to them. For juxtarenal aneurysms however the differences in 
perioperative mortality (if there are any) are not as well understood and likewise the long 
term outcomes in terms of mortality, need for reintervention and rate of late failure i.e. the 
‘compromise’ of endovascular repair – in comparison to open repair is much less 
understood and therefore the weighing of advantages and disadvantages of any given 
treatment for a particular patient are less well understood. It is the desire to understand 
better these differences for juxtarenal aneurysms, and thereby improve the evidence base 
that informs the decision-making process for individual patients that provides the rationale 
for this research. In essence – for those patients that are out with the treatment of 
standard EVAR or infrarenal open repair (which is usually because of an unsuitable 
infrarenal neck – making them juxtarenal aneurysms) what are the advantages and 
disadvantages of the three most common treatment strategies? To investigate this 
question the following hypothesis and study were designed. 
4.2. Hypothesis: 
It is proposed that an endovascular solution to repair juxtarenal aneurysms would have 
superior outcomes in line with what is seen in the RCTs of standard EVAR. Furthermore, 
fenestrated EVAR is specifically designed to treat these types of aneurysms to ameliorate 
the risk of late failure whereas standard EVAR is not – it is therefore also proposed that 
fEVAR will have superior outcomes of the three treatments. The terminology of non-
standard aneurysm will be used to replace the term ‘juxtarenal’ to specifically define the 
anatomy that is related to. These proposals generated the following hypothesis: 
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Fenestrated Endovascular Aneurysm Repair (fEVAR) has superior clinical outcomes as a 
treatment strategy for non-standard AAAs that are unruptured in whom aneurysm repair is 
deemed to be more beneficial than conservative management.  
 
The term “superior clinical outcomes” is in relation to all cause and aneurysm related 
mortality at all time points both perioperatively and throughout follow up. For the 
purposes of the hypothesis these primary outcome measures carry an equal weighting 
towards the definition of “superior clinical outcomes” to reflect the need for aneurysm 
repair to prevent death both in the short and longer term. Aneurysm related, and all-cause 
mortality are equally weighted to reflect the desire for any given treatment option to be 
superior to its alternatives both in improving survival from the condition and in providing 
an overall benefit to any given patient. This is because, for an individual patient, mortality 
has the same devastating effect whether it is caused by the aneurysm or not. It remains 
important however to demonstrate (if possible) that a treatment reducing mortality from 
the condition it is treating regardless of all-cause mortality which inevitably is influenced by 
unrelated confounding factors. Other clinical outcome measures that will be considered to 
contribute to whether fEVAR is “superior” will be technical success and clinical success as 
defined by agreed reporting standards.[93] These outcome measures will inform the 
decision of whether the hypothesis is satisfied or not and to reflect the importance of 
continued clinical efficacy throughout follow up clinical success will have a greater 
weighting to technical success in making this decision but less of a weighting than the 
outcome measures related to mortality. This reflects the fact that each of these represents 
the ability of the method of repair to exclude the aneurysm from the circulation without 
demonstrable major consequences that potentially affect the patient’s quality of life in a 
measurable and quantifiable way.  
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4.3. Definition of non-standard aneurysm 
In order to examine the clinical outcomes of fEVAR and its alternative treatment options it 
is important to define the cohort of patients being studied so that similar anatomical 
characteristics apply for all patients regardless of the treatment they have undergone or 
are due to undergo. Essentially, as with any clinical research, an attempt to control for 
confounding factors is important to increase the applicability and validity of the results for 
the population as a whole. By its nature fenestrated endovascular repair is reserved for 
patients with an aneurysm that extends close to the renal arteries. It was specifically 
developed and designed for this purpose. Studies comparing standard EVAR stent grafts 
have shown that decreasing neck length between the renal arteries and the top of the 
aneurysm correlate to worse clinical outcomes in terms of higher perioperatively mortality 
[68], increased aneurysm related mortality over follow up [94], Increased perioperative 
type 1a endoleak rate [68, 95] and perioperative reintervention rate [96]. Therefore, when 
comparing treatment options, one should be careful to define and report the anatomy of 
the patients being studied as this seems to be an important confounding factor that affects 
relevant and commonly used clinical outcome measures. The desire to find efficacious and 
durable treatment for those patients with shorter necks culminated in the development 
and use of fenestrated (and other advanced endovascular) technology. The IFU for the 
Zenith fenestrated device is similar to that of the standard Zenith stent-graft with the 
notable exception that the fenestrated device can be used for aneurysms with an infrarenal 
neck length of 4mm or more compared to 15mm or more. In order to compare this 
technology with alternative treatment strategies one should therefore aim to compare like 
for like anatomy. Although this may sound a simple proposition in principle, in reality it is 
more complex. 
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The starting point therefore in the design of this study was to define the patient population 
being studied. The definition of juxtarenal is relatively loose and is used interchangeably 
with the definition pararenal. As stated earlier when reviewing the literature, the term 
juxtarenal can relate to a ‘short’ neck, no neck, a neck which requires suprarenal clamping 
and is therefore an imprecise term. For the purpose of this study it was important to 
develop a new term that specifically defines the anatomy of interest and the patient 
population being studied. The patient population of interest was patients that were not 
suitable for standard endovascular repair according to anatomical criteria pertaining to the 
infrarenal neck. The term non-standard aneurysm/non-standard anatomy was developed 
to describe any anatomy of the infrarenal neck that fell out with standard EVAR indications 
for use. 
Stent-graft devices used to treat infrarenal abdominal aortic aneurysm by EVAR have 
specific instructions for use that accompany each device. These are instructions from the 
manufacturer about various aspects of the use of each device. They generally include a 
description of the device, indications for its use, contraindications, specific warnings and 
precautions related to the implantation of the device, reported adverse events associated 
with its use, advice on patient selection and treatment and how to physically use or 
‘deploy’ the device. Included within the instructions for use are detailed indications for use 
(IFU). The IFU details specific pre-operative anatomical criteria that an aneurysm must 
adhere to in order that the device is used according to each manufacturer’s intention. The 
specific anatomical criteria include the diameter, angulation and length of the infrarenal 
neck along with other criteria. If an aneurysm possesses anatomy that violates any of these 
criteria and the device implanted anyway then this would be considered ‘off-label’ use of 
the device. The defined parameters for the indications for use were determined from 
preclinical engineering studies and clinical trial results for endovascular repair as a whole 
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and for specific devices. [97]  The term ‘instructions for use’ is often used in both everyday 
clinical practice and the wider literature when ‘indications for use’ is intended.  
As stated above the outcomes for patients treated by standard endovascular repair and 
open repair for infrarenal aneurysms are well known due to numerous randomised 
controlled trials in this area. For inclusion into the randomised controlled trials patients’ 
anatomy was assessed to determine whether it was suitable for endovascular repair with a 
standard device before the patient could be randomised to either EVAR or open repair. In 
the UK EVAR Trials [64] there was no specific anatomical cut off that was defined as making 
a patient suitable or not for EVAR. However, all aneurysms were assessed by a radiologist 
and specifically the question was asked whether the “aneurysm neck dimensions are 
suitable for EVAR?” taking into consideration, length, diameter, angulation and thrombus. 
The majority of devices implanted in that study were one of the following three – 51% 
Zenith (Cook, Copenhagen, Denmark), 33% Talent (Medtronic, Minneapolis, MN, USA), 7% 
Excluder (Gore, Flagstaff, AZ, USA). At the time of the EVAR trials IFU relating standard 
EVAR was specific to the device used but in general the infrarenal neck should be ≥10mm, 
with a diameter <28mm and angulation <60 degrees. It is not possible to state from the 
published articles on the UK EVAR trials exactly what the anatomies being treated was, but 
it is reasonable to assume the vast majority of patients treated fell within these IFU criteria. 
Therefore, the use of non-standard anatomy to define the anatomy of a patient population 
specifically defines those patients not treated within the RCTs and helps to answer the 
question posed by the hypothesis stated above.  
Therefore, in the design of this study it was decided that the anatomical criteria for 
inclusion were that patients should have an infrarenal neck that violates the IFU for 
standard EVAR, i.e. ‘non-standard aneurysms’. There are many different manufacturers of 
stent-grafts, each with their own similar but specific IFU and therefore to simply define 
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non-standard anatomy as that which is ‘outside IFU’ for standard EVAR is too simplistic and 
would create confusion but this is the essence of the definition.  
To define non-standard anatomy the IFU of three commonly used stent-grafts within the 
Cheshire and Merseyside region were identified and scrutinised. The anatomical criteria to 
define a non-standard aneurysm were drawn from these specific manufacturers IFU. The 
three stent-grafts in question were: the Endurant Stent Graft System (Medtronic, Inc. 
Minneapolis, Minnesota, U.S.A.), the Zenith Flex AAA Endovascular Graft (Cook Medical, 
Bloomington, Indiana, U.S.A.) and the Gore Excluder AAA Endoprosthesis (W.L. Gore 
&Associates, Inc. Flagstaff, Arizona, U.S.A.). 
Table 4.1 below details the manufacturers recommended IFU anatomical criteria that were 
present in the years of the study: 
Table 4.1 Stent-Graft IFU from Manufacturers 
Type of Device Endurant Zenith Flex Gore Excluder 
Infrarenal neck length (mm) ≥ 10 ≥ 15 ≥15 ≥15 
Infrarenal neck diameter (mm) 19 – 32 19 - 32 18 - 32 19 – 29* 
Suprarenal aortic angulation ≤45° ≤60° <45° NS 
Infrarenal aortic angulation ≤60° ≤75° <60° ≤60° 
Table 4.1 - Diameter is measured outer wall to outer wall unless otherwise stated. * = measured inner wall to 
inner wall, NS = Not stated 
The Endurant stent-graft is unique among the three in that the criteria for angulation are 
dependent on the neck length as can be seen from the table. If the neck length is 15mm or 
greater then a greater degree of aortic angulation can be treated ‘within IFU’. If the neck 
length is between 10 and 15 mm then the recommendations from the manufacturers is 
that less angulation should be present. It is important to note that the stent-graft remains 
the same design and manufacture, but it is simply the criteria for what is recommended as 
acceptable anatomy that changes. Suprarenal aortic angulation termed the alpha (α) 
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angulation is defined as an angle relative to the axis of the suprarenal aorta. Infrarenal 
aortic angulation, termed the beta (β) angle is defined as the angle relative to the long axis 
of the aneurysm. 
If an aneurysm was treated with a specific endovascular device and the anatomy was in 
breach of the IFU for that device in any way, then it was deemed non-standard. This would 
therefore capture all patients who were treated with a standard EVAR device ‘off – IFU’. If 
the patient did not receive a standard endovascular device then their anatomy would only 
be considered non-standard if none of the above devices could be placed within IFU. For 
example, in someone who has not had an endovascular repair a neck length of 9mm would 
qualify the aneurysm as non-standard but not, necessarily, a neck length of 11mm (because 
the Endurant device can be used in neck lengths ≥10mm, as long as angulation is 
acceptable). In order to exclude patients that possessed a thoracoabdominal aneurysm and 
one that would traditionally necessitate placement of a branched endovascular stent-graft 
if treated endovascularly it was deemed that if an aneurysm possessed a neck diameter of 
>36mm immediately below the level of the renal arteries then this would exclude it from 
the definition of a non-standard aneurysm and instead it would be defined as a 
thoracoabdominal aneurysm.  
In the design of a study one could propose to include all patients, treated by any method 
with a neck length of <10mm and exclude those with a neck length of >10mm. Although 
this would have the value of simplicity it may not include several patients with other 
adverse anatomical characteristics that would be relevant to this research. It would also 
ignore the important confounding factor of stent-graft device and its potential effect on 
outcome. Since different stent grafts have different anatomical thresholds set in their IFU a 
single cut off value could include some who were in IFU or exclude some who were out of 
IFU depending on the threshold set. As stated before if the threshold is set so that all stent 
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grafts included are out with the IFU for only one anatomical variable then this potentially 
excludes some who are out of IFU for another characteristic. Therefore, not including an 
important part of the population in whom fEVAR would be a realistic alternative treatment 
option. The premise of this research is to compare fEVAR with alternative treatment 
options and conversely to compare those alternative treatment options with fEVAR. In 
order to do this anatomical inclusion criteria must allow for the flexibility in differing IFUs 
between device manufacturers. This accepts and takes account of the fact that some 
patients included, who are out of IFU for a device implanted, could have been potentially 
treated within IFU by an alternative standard device. This considers the fact that stent-
grafts differ in their design and manufacture and accepts the supposition that for any given 
device there are assumed tolerances of anatomy that it can treat effectively. 
Utilising IFU as a threshold in itself, although more complex, does allow the inclusion of 
patients that may have been treated within IFU by a different device. Furthermore, the 
research will explore and investigate whether ‘IFU’ is a useful and valid indicator of 
anatomy and whether being inside or outside ‘IFU’ equates to better or poorer outcomes. 
This would be important for ongoing and future research because technology is continually 
evolving and the IFU evolves with it, using IFU as a bench mark will ensure that patients can 
be compared irrespective of what device was placed. It may be that this research shows 
that ‘IFU’ is not a useful marker for the thresholds of anatomy treatable, which would be 
useful information also both for manufacturers and clinicians. In order to make them both 
consider again why the anatomy thresholds in the IFU are what they are, and should they 
be any different.  
An alternative method would be to employ a stratification of anatomy either based on 
anatomical values or IFU criteria. Some studies [68, 98] have successfully employed both 
methods by investigating outcomes for necks <10mm, 10 – 15mm and >15mm in length. 
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And conservative, liberal and time dependant IFU, which essentially alters the number of 
patients who were definitely out of IFU included in the study population. What is notable 
about both these studies however is that they were large database studies analysing data 
from thousands of patients enabling meaningful conclusions to be drawn from stratification 
because each group still had a considerable number of patients within it. As in this study 
and most published studies the numbers are  relatively small and do not allow multiple 
groups to be created. 
In this study then the definition of non-standard aneurysm applies to any aneurysm that 
exhibits any one of the following criteria: 
1) Any aneurysm with an EVAR device placed outside IFU 
By deductive reasoning; 
2) A neck length of <10mm 
3) An alpha angle of > 60 degrees 
4) A beta angle of >75 degrees. 
5) Neck diameter >32mm (but ≤ 36mm) 
Moreover, if the neck length is 10 – 15mm AND one of the following apply then it is non-
standard: 
1) Alpha angle >45 degrees 
2) Beta angle >60 degrees. 
In summary the definition of a non-standard aneurysm is those that are out with the IFU 
for standard EVAR but within that for fenestrated EVAR.  Once the definition was decided 
the design of the study could begin.  
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4.4. Study Design 
The chief investigator was responsible for the design of the study. No expert 
methodological or statistical support was sought at the design stage of the study. There 
had been no prior pilot study performed either. The design of the study began in 2012, first 
with the hypothesis and then with the definition of non-standard aneurysm.  
In order to investigate the hypothesis, the study proposed contained four main parts: 
1. A Systematic Review of the Literature to investigate the outcomes for patients with 
non-standard aneurysms undergoing standard EVAR, open repair and fenestrated 
EVAR 
2. A retrospective single centre review of clinical outcomes following fEVAR 
3. A Multicentre retrospective concurrent cohort study of patients undergoing 
aneurysm repair with non-standard anatomy 
4. After initial analysis and review a decision was made to also include a retrospective 
analysis from a single centre of the clinical outcomes for patients undergoing 
standard EVAR or open repair for patients with standard anatomy. Primarily this 
study would act as a control group for the multicentre retrospective study of non-
standard aneurysms. 
The second part of the above four parts, the retrospective single centre review of fEVAR 
would identify patients from a departmental database and national registry and document 
clinical outcomes after fEVAR to provide a background of overall outcomes after fEVAR at 
the base site where the research was conducted. It is important to note that the specific 
anatomy of each fEVAR case would not be reviewed in the retrospective single centre 
review – this was for two primary reasons; firstly, the review is designed to investigate 
outcomes after fEVAR as a specific treatment rather than focus on anatomy alone. 
Secondly the use of fEVAR within the Royal Liverpool University Hospital (base site) goes 
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back to 2003 and it would have been practically impossible to obtain all CT scans for all 
those patients to review their anatomy. This aim of this study was to obtain results of a 
large number of fEVAR patients to understand better the short, mid-term and longer-term 
outcomes for patients undergoing fEVAR regardless of their anatomy. The study was 
therefore concerned with and centred around a specific treatment rather than a patient 
cohort.  
The multicentre retrospective concurrent cohort study of non-standard aneurysms would 
form the basis of the research and be the primary study. This study, unlike the single centre 
review of fEVAR patients, would aim to study patients with a specific anatomy rather than 
focussing on a treatment option. The idea was to identify all patients with non-standard 
anatomy that undergo operative intervention to treat their aneurysm and investigate the 
clinical outcomes. Therefore, the population of interest is defined by their anatomy as a 
starting point rather than anything else. Once the anatomy was defined all patients who 
fell within the definition of that anatomy (non-standard) would be considered for inclusion 
into the study. Ideally the study would have included all non-standard aneurysms that were 
considered for an operation whether eventually operated on or not however there was 
practically no way to identify these patients as no database of patients ‘turned down’ for 
aneurysm repair was kept at any of the hospitals included in the study. If these patients 
could have been identified and included, it would give a more complete picture of the 
outcomes of all patients with non-standard aneurysms and provided valuable data with 
regards to the natural history of this specific type of AAA. The study is designed to consider 
all patients from across the Cheshire and Merseyside area. This was for two reasons; to try 
and increase the number of patients for analysis to increase the validity of the results but 
also to include patients treated at different types of institutions. The reason it is important 
to include patients from a number of hospitals (small and large district general hospitals as 
well as large tertiary referral teaching hospitals) was to try and broaden the applicability of 
67 
 
the results to a general population of patients rather than including only those treated at 
the base site (a large tertiary referral centre) – if this is done inevitably there would be an 
element of selection bias inherent in the type of case seen and treated at such an 
institution. So, this decision in the design of the study was to try and reduce the effect of 
this confounding factor.  
 In designing this study consultant vascular surgeons at the Royal Liverpool University 
Hospital were asked about practices within their tertiary vascular unit for treatment of non-
standard aneurysms. This essentially identified that there would be three categories of 
patients: those treated by traditional open operation, fEVAR, and a standard EVAR 
performed outside of IFU. A preliminary literature search was conducted by the chief 
investigator but there was little evidence identified that could help determine the principal 
outcome effects for the different methods of repair. Therefore, no power calculations or 
sample size calculations were done due to a lack of reliable pilot data. There was no 
accurate record of the number of aneurysm repairs or the proportion that were non-
standard at the beginning of the study. Preliminary calculations based on activity at the 
Royal Liverpool University Hospital for fenestrated endovascular and standard 
endovascular aneurysm repair estimated that to identify approximately 150 – 200 patients 
with a non-standard aneurysm in total 500 – 600 aneurysm repair patients would need to 
be identified. In order to identify this many patients it was deemed necessary that patients 
would need to be identified over the entire Cheshire and Merseyside region and be from a 
two-year period of activity. The other advantage of conducting a multicentre study would 
be that the results of the study would be able to be generalised to a wider population 
primarily because the Royal Liverpool University Hospital (base site) was an expert tertiary 
referral centre. By including other hospitals in the region activity within district general 
hospitals would also be captured.   
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It was therefore decided that analysis of all patients who underwent aneurysm repair for a 
‘non-standard aneurysm’ in the Cheshire and Merseyside region in the 24-month period 1st 
April 2006 – 31st March 2008 were to form the basis of data for this study. The time period 
was chosen because the introduction of the electronic storage of radiological images on the 
picture archive and communication system (PACS) began in 2006 and it was envisaged that 
this would enable the chief investigator to perform core laboratory analysis of all CT scans 
of aneurysm repair patients as the images could be digitally transferred.  
There were seven centres within the Cheshire and Merseyside region that performed at 
least one of the three treatment methods during the study period. These included; the 
Royal Liverpool University Hospital, Aintree University Hospital, Southport Hospital, 
Warrington Hospital, Arrowe Park Hospital, Countess of Chester Hospital and Leighton 
Hospital. Therefore, during the design of the study, the lead consultant vascular surgeon at 
each site was contacted to consent for a retrospective analysis of patients at their site to be 
conducted and to act as a point of contact for the chief investigator at the site. It was 
envisaged that although the chief investigator would need to visit each site initially to 
identify patients and then once again to review clinical notes, the transfer of data could 
happen electronically and therefore there wouldn’t need to be a permanent researcher at 
each site. 
4.4.1. Inclusion criteria: 
Inclusion and exclusion criteria were defined during the design of the study as follows. 
Patients with a ‘non-standard aneurysm’ of their abdominal aorta who underwent repair 
within one of the centres listed above and within the above time period. Patients must 
have had a CTA of their abdominal aorta prior to the aneurysm repair that could be 
reviewed on a 3-dimensionsal workstation and be of satisfactory quality to allow for 
detailed anatomical measurements. 
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4.4.2. Exclusion criteria: 
All patients with previous surgical or endovascular repair of an abdominal aortic aneurysm 
were excluded. As well as any patients who were haemodynamically unstable or 
undergoing repair for a leaking or ruptured aneurysm. Patients who underwent ‘branched’ 
endograft technology as opposed to fenestrated EVAR were excluded as this method of 
treatment is recognised to be entirely distinct from fEVAR and EVAR. 
4.4.3. Identification of patients 
To try and identify the maximum number of patients for inclusion as possible multiple 
sources would be used to identify patients. Office of Population Censuses and Surveys 
(OPCS) codes would be used at every site to identify patients ‘coded’ as having some form 
of aneurysm repair within the specified time period. To identify further patients suitable for 
inclusion the intention was also to access theatre records of aneurysm repair, 
departmental databases and individual surgeon databases at each hospital.  
4.4.4. Study Protocol 
Before ethics approval could be gained a detailed protocol for what variables would be 
collected during the study and how this would be done was drawn up. Defined pre-
operative, intraoperative and anatomical variables would be collected. Furthermore, post-
operative clinical outcomes and follow up data from patient case notes, laboratory results, 
clinic letters and follow up medical imaging would be collected. A proforma was developed 
to assist with the data capture. Data points and information collected will be described in 
more detail in the methods section. The intraoperative details to be collected were derived 
after reviewing published reporting standards for endovascular repair [93, 99] 
4.4.5 Pre-operative Anatomical Characteristics of the Aneurysm 
One area of the study protocol that merits specific mention is the method by which 
anatomical measurements of an included aneurysm would be made. The measurement 
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protocol for anatomical measurements was designed after the chief investigator was 
trained in the use of software and aortic CT measurements. The chief investigator was 
trained by a consultant vascular and endovascular surgeon working at the Royal Liverpool 
University Hospital. The methods for measurement were used by that consultant in his 
routine clinical practice and where necessary those methods were standardised to provide 
a reliable and reproducible way of measuring the anatomy. Ten ‘test’ scans randomly 
chosen from the departmental database were measured by the chief investigator initially 
to identify potential pitfalls when measuring and to inform the development of the 
measurement protocol. There was no intention of using these ‘test’ measurements to 
validate a method of measuring, they were simply to aid the training of the chief 
investigator and to inform the development of the measurement protocol. At the time of 
the design of the measurement protocol (early 2012) no comprehensive, validated and 
agreed protocol was found to exist from a search of the literature. There were some 
reports and studies of isolated anatomical features but no comprehensive reports. The 
measurement protocol was set out at the beginning of the study and is described in detail 
in the methods section of the non-standard aneurysm study. 
4.4.6. Ethical Approval 
Ethical approval was not needed for the retrospective review of single centre data for 
fEVAR. However, to conduct the multicentre retrospective study of non-standard 
aneurysms ethical approval was needed. A detailed account of the process of ethical 
approval is included in the methods section for the relevant study later.  
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4.4.7. Outcome measures 
For the non-standard aneurysm study the primary and secondary outcomes were decided 
after review of the published reporting standards and literature review: 
Primary Outcome Measures: 
 30-day mortality/In-hospital mortality 
 Mid-term mortality and aneurysm related mortality 
 Technical success 
 Clinical Success 
Secondary outcomes: 
 Visceral vessel patency 
 Renal insufficiency and need for dialysis 
 Re-intervention rates, both surgical and endovascular 
 Conversion to open repair 
 Major complications 
 
4.5. Summary of Chapter 4 
This chapter details the design of the current study which the primary part of is the 
retrospective review of clinical outcomes for non-standard aneurysms treated by open 
repair, fEVAR or EVAR outside of IFU. More details regarding the methodology of that study 
are detailed later. To reiterate, in order to investigate the hypothesis, the study proposed 
contained four main parts: 
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1. A Systematic Review of the Literature to investigate the outcomes for patients with 
non-standard aneurysms undergoing standard EVAR, open repair and fenestrated 
EVAR  
2. A retrospective single centre review of clinical outcomes following fEVAR 
3. A Multicentre retrospective concurrent cohort study of patients undergoing 
aneurysm repair with non-standard anatomy 
4. After initial analysis and review a decision was made to also include a retrospective 
analysis from a single centre of the clinical outcomes for patients undergoing 
standard EVAR or open repair for patients with standard anatomy. Primarily this 
study would act as a control group for the multicentre retrospective study of non-
standard aneurysms. 
The analysis of clinical outcomes for standard aneurysm patients was conducted in the 
same way as that for non-standard patients with the exception that patients were only 
identified from one site, the base site (Royal Liverpool University Hospital). The remainder 
of the study protocol was carried out for those patients in exactly the same way including 
data capture and anatomical measurements. The intention is that this supplementary 
analysis would provide a control group for two of the interventions (EVAR and open repair), 
as by definition, fEVAR is not used in standard anatomy patients. It would also allow a 
deeper analysis of the outcomes for the patient population.   
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5. CHAPTER 5 – Systematic Review of Clinical Outcomes 
Following Placement of Standard EVAR stent Graft in Non-
Standard Anatomy 
 
5.1. Introduction 
The randomised controlled trials detailed above confirmed the benefit of endovascular 
repair compared with open repair, in the short term at least. By necessity the patients 
enrolled to these trials met had to be ‘anatomically suitable’ for endovascular repair. The 
definition of anatomic suitability has evolved since the inception of EVAR. Early in the use 
of EVAR, in the mid to late 1990s, ‘recommended guidelines’ [97] were used to define 
anatomic suitability. These guidelines were ‘derived from clinical experience, intuition, and 
mechanical and physical principles’ in the case of the development of the Cook Zenith 
bifurcated graft. Benchtop models and laboratory engineering testing provided insight to 
inform the guidelines to be applied to that particular device. [100]  With the approval of a 
number of endovascular stent graft devices in 1999 by the US Food and Drug 
Administration (FDA) device specific anatomical indications for use became clearly 
documented. Since then new and updated iterations of earlier stent graft designs have 
come to the market. With this technological evolution there has been expansion of the 
anatomy detailed in devices indications for use to allow treatment of a larger proportion of 
patients. 
The most common reason an aneurysm may not be suitable for endovascular repair is 
secondary to the aortic neck anatomy [101, 102]. Inevitably with additional experience with 
endovascular technology physicians expanded their treatment to include a proportion of 
patients who had anatomy outside the IFU for endovascular repair. With most of these 
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exhibiting features within the aortic neck considered to be less favourable to the 
performance of the standard endovascular stent graft. The advent of more complex 
endovascular technology and techniques such as fenestrated, branched and chimney 
endovascular repair were developed precisely to tackle the problem of patients who 
exhibited anatomy not suitable for standard endovascular aneurysm repair. They primarily 
achieve this by moving the seal and fixation zone of the ‘stent-graft complex’ more 
proximally, into the visceral segment of the aorta. This is to distance the proximal end of 
the stent graft away from ‘hostile’ anatomical features and into supposed healthy aorta – 
with the aim of providing a more durable proximal seal and fixation. The desire to achieve a 
durable seal and fixation proximally is because failure at this point of the interaction 
between ‘stent graft complex’ and native anatomy probably leads to the most dangerous 
sequalae, both in terms of clinical outcomes and for the resultant available treatment 
options available to solve the problem. The primary complication in this regard is type 1a 
endoleak which exposes the patient at significant increased risk of aneurysm rupture. 
However, there are significant disadvantages to advanced endovascular techniques 
including the need to ‘instrument’ and stent visceral vessels with potential serious 
complications from this. The use of custom made fenestrated or branched devices require 
several months to be manufactured and delivered. There is often a significant increase in 
cost with the use of these advanced devices and techniques. It is therefore understandable 
then that physicians would want to be able to place standard endovascular stent grafts 
even in anatomy that is considered outside the instructions for use as long as the resultant 
clinical outcomes are not deleteriously affected. During the evolution in practice of EVAR 
there has been debate at where the limit of anatomy is that can be successfully repaired 
with a standard EVAR stent graft. Therefore, it is important to understand what the risks 
and complication of using standard endovascular devices in patients with ‘hostile’ anatomy 
are to enable a full understanding of the treatment options available and whether the 
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shortcomings of standard EVAR used out of IFU result in more deleterious effects for the 
patient than advanced endovascular techniques or indeed open repair. 
EVAR used outside IFU has been associated with increased technical failure [103], type 1 
endoleaks [94, 104] and increased secondary interventions [67, 103] However some studies 
have reported equivalent rates of clinical outcomes both in the short and long term for 
patients treated when outside IFU compared to those treated within IFU [105, 106] There is 
therefore continuing debate about how far this technology can truly be pushed. Two 
systematic review and meta-analyses have been published in this area [78, 107] the most 
recent in 2013. The conclusions from those meta-analyses were that EVAR placed in 
unfavourable proximal neck anatomy leaded to an increase in the number of adjunctive 
procedures needed, 30-day morbidity, rate of type I endoleak development, secondary 
procedures needed and aneurysm related mortality within 1 year. However, their 
conclusions were not consistent across all these areas. There has been continued 
advancement of endovascular technology in the intervening years with publication of larger 
datasets since these systematic reviews and therefore the aim in this systematic review 
was to provide an updated synthesis of the available evidence and to use the larger 
number of studies published in this area to try and limit any potential bias or confounding 
factors that may have been present in earlier reviews. 
The question being addressed in this systematic review is to understand what the clinical 
outcomes are for patients undergoing Endovascular Aneurysm Repair using a standard 
stent-graft whom exhibit proximal aortic neck anatomy that is considered outside the 
indications for use for the implanted devices. The primary clinical outcome measures will 
include the following both perioperatively and throughout follow up; all-cause mortality, 
aneurysm related mortality, reintervention rates and graft related endoleaks. Secondary 
outcome measures will include: primary and primary assisted technical success, endograft 
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migration, visceral vessel patency, rates of conversion to open repair, rates of renal 
dysfunction, aneurysm expansion throughout follow up. The systematic review also aims to 
investigate by its narrative nature the question of whether investigation of specific 
anatomical values or “outside IFU” anatomy is a more valid and useful method of 
investigating clinical outcomes for patients with “hostile” anatomy. Specific anatomical 
values would relate to defined criteria such as a specific value for neck length or 
angulation, with the advantage that the criterion would be applicable to all aneurysms in 
the same way regardless of which EVAR device is placed. “Outside IFU” anatomy is a more 
abstract concept but potentially has the advantage of looking at anatomical criteria more 
holistically and using IFU as a benchmark for what constitutes “good” or “bad” anatomy. It 
may limit applicability of results to only the stent-grafts studied. 
Patients who undergo implantation of a standard stent-graft out of IFU with regards to 
proximal neck anatomy will be considered. In studies where there is also a comparator 
group of ‘in IFU’ patients receiving standard EVAR, their clinical outcomes will be assessed 
and used as a reference point for clinical outcomes. Through this report patients who have 
a standard stent graft placed in anatomy that is considered out of the IFU, “hostile” or 
“complicated” anatomy as per the inclusion criteria will be termed non-standard anatomy 
(NSA) patients. Those with anatomy conforming to IFU criteria will be termed standard 
anatomy patients (SA). It is expected that no randomised controlled trial will be identified 
and as such cohort and case series studies whether retrospective or prospective will be 
included. 
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5.2. Methods 
The systematic review followed reporting guidelines set out in the Preferred Reporting 
Items for Systematic Reviews and Meta-Analyses (PRISMA) document. [108] In line with 
these guidelines a protocol for the systematic review was established prior to the beginning 
of the literature search as follows. The protocol is reproduced here in its entirety.  
5.2.1. Protocol for Systematic Review, Including Eligibility 
Criteria 
With increased use of fenestrated endovascular aneurysm repair and the knowledge that 
clinical outcomes in terms of short- and long-term mortality are worse for fEVAR compared 
with standard endovascular aneurysm repair it is important to define the published 
outcomes for these patients and comparing these outcomes to valid alternative treatment 
strategies. Since aneurysms treated “on-label” with standard EVAR represent a distinct 
anatomical entity compared to those treated with fEVAR it is important to understand the 
outcomes for EVAR when used in anatomically similar patients – i.e. EVAR outside of IFU. 
This will help inform the debate about the best treatment option for non-standard 
aneurysms. 
A systematic review of the literature will be undertaken to examine the clinical outcomes 
for patients undergoing abdominal aortic aneurysm repair for non-standard aneurysms 
using standard EVAR. Non-standard aneurysms are defined as those in which the aortic 
neck anatomy is considered outside indications for use (IFU) criteria for standard infrarenal 
EVAR. Primarily this includes those aneurysms with a neck length of less than 10mm from 
the lowermost renal artery ostium to the top of the aneurysm, neck diameter of >32mm 
and or angulation of >90 degrees between the infrarenal neck and the aneurysm itself. An 
aneurysm would be considered non-standard if any of these criteria are present. 
Additionally, if a specific device was used and it is stated explicitly that the aneurysm 
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treated was outside the IFU for that particular device then this would also be considered 
“off-label” use of standard EVAR and these studies would be included in the systematic 
review. It is important to note that different devices from different manufacturers may 
have different anatomical criteria included in their IFU. Although the above anatomical 
characteristics encompass the restrictions set out in the IFU for most stent-grafts there are 
some in which their IFU does not exclude more extreme anatomies than that stated above. 
In that scenario the IFU for the stent graft being studied will be used to determine whether 
patients have had stent grafts placed in anatomy that is outside the IFU for the device used. 
The objective of the systematic review is to compare the published literature for all 
patients with non-standard aneurysms undergoing standard EVAR. It is expected that no 
randomised controlled trials would be identified and therefore non-randomised studies 
evaluating clinical outcomes for standard EVAR placed out of IFU would be included in the 
analysis.  
 
Inclusion criteria: 
 Aneurysm morphology - For a study to be included in the analysis, it should clearly 
state that the population had morphologic infrarenal neck characteristics that were 
not within the indications for use for standard EVAR. As already stated, the IFU for 
the specific device (or devices) used would be used to determine if the patients had 
a non-standard aneurysm or not i.e. the aneurysm being treated must have 
anatomy that is outside the indications for use for the device used. Statement that 
anatomy was outside the indications for use would be acceptable as definition of 
non-standard. If no such statement was present, potential studies should explicitly 
state anatomical features pertaining to the aneurysm neck, for most devices this 
79 
 
would mean: neck length <10mm, neck angulation of > 60 degrees (angle of 
intersection between lines of the long axis of the aneurysm and the long axis of the 
infrarenal neck), and/or neck diameter >32mm within 10mm from the lowest renal 
artery. Patients would be considered to have a non-standard aneurysm if one or 
more of the aforementioned criteria were present on preoperative computed 
tomography (CT) angiography scans. If neither a specific statement about either 
anatomical criteria or that the patients were “outside IFU” then that study would 
not be included. If the study combined outcomes for patients with standard and 
non-standard anatomy that study would only be included if it was possible to 
analyse the results separately for each study population. If they were grouped 
together with no specific outcomes reported for non-standard aneurysms, then the 
study would be excluded 
 There must be median (or mean) follow up of at least 1 year to enable meaningful 
results of short and mid-term data for the studied population 
 In order to reduce bias introduced from small case series studies must have at least 
50 patients with non-standard anatomy 
Exclusion Criteria: 
 Studies reporting solely on symptomatic or ruptured aneurysms. If a study includes 
symptomatic or ruptured aneurysms it is expected that the results for these 
patients will be identifiable and be able to be excluded from further analysis. If it is 
not possible to do so then an explicit statement as such will be made in the report 
to make it clear that this confounding variable exists in the identified study 
population. 
 Previous treatment for abdominal aortic aneurysm 
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 If the report solely presents on patients treated with an advanced endovascular 
technique or technology such as fenestrated or branched endovascular repair. 
 If the report solely presents treatment of aneurysms utilising the chimney 
endovascular repair technique or reports of aneurysm treated with endovascular 
aneurysm sealing technology (EVAS) 
 Patients in which adjunctive technology such as endoanchor fixation is used to 
complement the use of a standard infrarenal stent graft will be excluded 
 No statement of aneurysm morphology, either as “outside IFU” or specific 
anatomic criteria 
Eligibility Criteria 
 Publication dates within 20-year period (1998 – 2018) – to minimise the capturing 
of reports with physician made endograft devices and prior to widespread 
acceptance of indication for use anatomical criteria 
 English language only results considered 
 The population will include all adults with no age restriction 
The above protocol was referred to throughout the data identification and extraction phase 
to ensure it was adhered to. 
5.2.2. Definitions and Outcome Criteria.  
Outcome criteria and definitions were based on recommended reporting standards for 
EVAR, published by the Ad Hoc Committee for Standardized Reporting Practices in Vascular 
Surgery [24] and in line with the Pragmatic Minimum Reporting Standards produced for the 
British Society of Endovascular Therapy (BSET) [99]. Therefore, outcomes within the first 30 
days after the index procedure or occurring within the same hospital admission will be 
reported as perioperative outcomes, those occurring between 30 days and 1 year will be 
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termed ‘Early’, those between 1 and 5 years will be termed ‘Short’, 5 to 10 years will be 
considered ‘Midterm’ and > 10 years will be ‘Long-term’. Primary outcome measures 
included perioperative mortality from any cause, all-cause mortality, aneurysm related 
mortality, reintervention rates and graft related endoleak rates (All type I and III 
endoleaks). The secondary outcome measures are as follows: 
 Primary Technical success 
 Clinical success 
 Endograft migration 
 Visceral vessel patency 
 Conversion to open repair 
 Length of hospital stay 
 Rates of renal dysfunction throughout follow up (the definition used within the 
given study for renal dysfunction will be used) 
 Aneurysm growth throughout follow up (At all time points) 
 
5.2.3. Information Sources and Electronic Search Strategy 
An electronic search of the literature was undertaken. The search was applied to MEDLINE 
(database provider PubMed, from 1998 – 2018) and EMBASE (database provider Ovid, from 
1998 to 2018). The search was undertaken once in May 2018. A full record of the search 
strategy is included within Appendix 1. The full reference list of each full text study 
assessed was interrogated to identify any relevant articles missed in the original search. 
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5.2.4. Study Screening and Selection 
One reviewer (the chief investigator) reviewed all titles returned from the electronic search 
and identified those for abstract review. The same reviewer then screened all identified 
abstracts and excluded those in which the exclusion criteria were fulfilled, or it was clear 
that the study population did not meet the inclusion criteria. If there was any doubt at this 
stage the article was selected for full text review. All articles selected for full text review 
had their reference list cross checked against the initial search and if any were not present 
then they followed the same screening process as above. This identified a list of articles in 
which the full text was retrieved or attempted to be retrieved. After review of the full text 
and frequent reference to the study protocol it was decided whether a study should be 
included in the systematic review or not. The search strategy results and reasons for 
exclusion are listed in figure 5.1 below. 
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Figure 5.1. – Search strategy for Systematic Review of EVAR used outside IFU 
 
 
 
 
  
Figure 5.1 - Numbers represent articles. Arrows denote whether articles were excluded or included. 
 
Search of Electronic 
Databases 
672 
Screening of Selected 
Abstracts 
491 
Abstract not relevant 
361 
Title not relevant 
181 
Screening of Full Text 
Article 
132 
Studies Included 
21 
Relevant Studies Identified 
from Reference Lists 
2 
Full texts excluded and reasons 
(113) 
 Population <50: 30 
 No separation of NSA and SA 
outcomes: 28 
 Only standard anatomy: 26 
 Full text not available: 13 
 Study irrelevant: 8 
 FU <1 year: 5 
 Other: 3 
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5.2.5. Data collection 
A data extraction sheet was developed. As well as pertinent information relating to the 
publication (year of publication, journal etc.) the remaining collected variables were 
divided in three broad categories: (1) baseline clinical and demographic data, anatomic 
characteristics, and procedure related characteristics; (2) primary outcome data (3) 
secondary outcome data, as outlined previously. The methodological quality of the 
included studies was assessed according to previously described methods – the 
Methodological Index for Non-Randomized Studies (MINORS) tool was used to assess 
methodological quality of the included studies. MINORS was developed and designed 
specifically to assess the quality of non-randomised surgical studies whether comparative 
or non-comparative. It utilises a 12-item tool, with comparative studies requiring a score 
for all 12 items and non-comparative studies requiring a score for only the first 8. Each item 
is given a score for the interrogated study – 0 if it is not reported, 1 if it is reported but 
inadequate and 2 if it is reported and adequate. The maximum score for non-comparative 
studies being 16 and 24 for comparative studies. [109] 
5.3. Results 
Of the original 672 titles screened form database searching 21 studies were included in the 
final analysis. These comprised of 3 non-comparative studies (assessing only the outcomes 
from NSA) and 18 comparative studies. From all studies the number of patients with SA 
was 16053 (It was not possible to ascertain the number of SA patients from 3 studies). 
There were 8458 with NSA analysed across all the studies. The publication dates of the 
studies ranged from 2003- 2017 and the data collection periods within the studies ranged 
from 1996 – 2015. One study published in 2001 by Stanley et.al. from Australia [97] was not 
included but merits mention here. This was the earliest study identified through the search 
(with a publication limit set to 1998) that details outcomes for more than 50 patients with 
characteristics of the proximal aortic neck considered to be less than ideal for standard 
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EVAR. This paper details the early experience of the Australasian team in using the Zenith 
endovascular stent graft between 1994 - 1998. “Patient selection guidelines” were devised 
for application to patients during this time, in this region. In relation to the proximal aortic 
neck, they included: 
 Length: 20 mm if straight, 25 mm if angled > 15° from the longitudinal axis of the 
suprarenal aorta (either forward or lateral angulation); exclude if angle >30°. 
 Diameter: < 28 mm, uniform (cylindrical), and without filling defects indicating 
thrombus or soft atheroma; exclude if the diameter progressively increases 
between the renal arteries and the sac. 
These dimensions are like the recognised IFU criteria in use currently but would be 
considered to fall within IFU guidelines. It is for this reason that this historical report was 
excluded from further analysis. In fact when the Zenith device gained FDA approval in the 
U.S.A. in 2003 the IFU guidelines stated at that time were: Neck length ≥15mm, neck 
diameter 18 – 28mm and angulation of <60°. [98] However, the authors did show with their 
analysis of 238 patients of whom 128 fell outside their anatomic guidelines certain 
characteristics that increased the risk of complications during follow up. They showed that 
the risk of proximal endoleak increased with every millimetre decrease below the 20mm 
threshold, and that a change in the “contour” of the neck (>3mm) increased the risk of 
endoleak. They also showed that migration was positively correlated with a proximal neck 
diameter of >28mm. They also revealed that combining adverse neck features lead to an 
even greater risk of proximal neck complications in an additive manner. In the context of 
the wider literature this study suggested certain anatomical criteria that would be 
interrogated later by several studies for different stent grafts and provided important early 
evidence for adverse clinical outcomes for patients who exhibited more extreme proximal 
neck anatomy. It appears that these findings went on to influence other studies as the 
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principle of “contour change” or a localised “bulge” in the proximal aortic neck became a 
parameter to define hostile aortic neck anatomy in other studies.[110] A variety of stent 
grafts were investigated in the following studies, they are as follows: 
 Excluder and C3 (W. L. Gore & Associates, Flagstaff, AZ, USA) 
 Zenith Flex and Zenith Low Profile (Cook Medical, Bloomington, IN, USA) 
 Endurant I and II (Medtronic, Inc., Minneapolis, MN, USA) 
 AneuRx (Medtronic, Inc., Minneapolis, MN, USA) 
 Talent (Medtronic, Inc., Minneapolis, MN, USA) 
 Aorfix (Lombard Medical, Oxfordshire, UK) 
 Anaconda (Vascutek, Inchinnan, Scotland) 
 AFX endovascular system (Endologix, Inc., Irvine, CA, USA), 
 Powerlink (Endologix, Inc., Irvine, CA, USA), 
 Ancure (Guidant, Menlo Park, CA, USA) 
 Vanguard (Boston Scientific, Natick, MA, USA) 
 E-Vita (Jotec, Hechingen, Germany) 
 Lifepath (Lifesciences, Irvine, CA, USA) 
 Fortron (Cordis, Warren, NJ, USA) 
 EndoMed EndoFit (LeMaitre Vascular, Burlington, MA, USA) 
5.3.1. Review of methodology of studies 
Three non-comparative studies were identified and included 4640 patients with NSA.[98, 
111, 112] 18 comparative studies including 3818 patients with NSA were identified. [67, 68, 
94-96, 103, 106, 110, 113-122]The details of the studies are outlined in table 5.1. and 5.2. 
below. 
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Table 5.1. Details of non-comparative studies for NSA 
Study Years  No. 
SA 
pts 
No. 
NSA 
pts 
MINORS 
(Max = 16 
for NC) 
Type of study Definition of 
NSA 
Stent graft 
Pitoulias 
(NC), 
2017[111] 
2007 - 
2015 
88 73 9 Retrospective 
multicentre 
cohort study 
Utilised IFU of 
stent graft 
implanted 
Endurant 
Gallitto 
(NC), 
2016[112] 
2005 - 
2010 
- 60 8 Retrospective 
single centre 
cohort study 
Neck length 
<10mm 
Endurant, 
Zenith 
Schanzer 
(NC), 
2011[98] 
1999 - 
2008 
5721 4507 10 Retrospective 
cohort review 
from imaging 
repository 
Patients 
identified from 
imaging 
repository and 
stent grafts 
used not known 
for each patient 
– therefore IFU 
for available 
stent grafts on 
market at time 
of implantation 
used to define if 
patient had NSA 
NR 
Table 5.1 - NC = Non-comparative, C = Comparative, SA = standard anatomy, NSA = Non-Standard Anatomy, IFU 
= Indications for use, NR = Not reported 
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Table 5.2. Details of Comparative studies for NSA 
Study Years No. 
SA pts 
No. 
NSA 
pts 
MINORS 
(Max = 
24 for C) 
Type of study Definition of NSA Stent 
graft 
used 
Mateo (C), 
2016 [113] 
2000-
2014 
178 71 13 Retrospective 
single centre 
cohort study 
 Neck length <15 
mm 
 Neck angulation 
>60° 
 >50% 
circumferential 
proximal neck 
thrombus 
 >50% proximal 
neck calcification. 
Gore C3, 
Gore 
Excluder 
Cerini (C), 
2016 [95] 
2005-
2013 
94 115 11 Retrospective 
single centre 
cohort study 
“Hostile” neck: 
 Neck length <15 
mm 
 Neck angulation 
>60° 
 Neck diameter 
>28mm 
Zenith, 
Endurant
, E-Vita 
AbuRahma 
(C), 2016 
[96] 
2003-
2013 
251 275 15 Retrospective 
single centre 
cohort study 
“outside the IFU” 
 Neck length <10 
mm 
 Neck angle > 60° 
 >50% 
circumferential 
proximal neck 
thrombus (>2 mm 
thick) 
 >50% calcified 
proximal neck 
Gore 
Excluder, 
Zenith, 
AneuRx, 
Endologi
x, 
Endurant
, Talent 
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 Reverse taper 
 Neck diameter > 
31 mm 
Broos (C), 
2015 [114] 
2009 
- 
2011 
1114 104 16 Retrospective 
registry 
dataset 
(ENGAGE) 
Utilised IFU of stent 
graft used creating 
3 groups: REG 
(regular anatomy), 
INT (intermediate 
anatomy but still 
within IFU), CHA 
(challenging 
anatomy – outside 
of IFU) 
Endurant 
Walker (C), 
2015 [115] 
2000-
2010 
284 205 10 Retrospective 
multicentre 
cohort study 
Utilised IFU of stent 
graft implanted 
Zenith, 
Medtron
ic, 
AneuRx, 
Excluder, 
Talent, 
Guidant 
Ancure, 
Terumo 
Anacond
a 
Speziale 
(C), 2014 
[116] 
2010-
2011 
63 133 15 Retrospective 
multicentre 
cohort study 
‘‘off-L’’: 
Noncylindrical neck 
Neck angle >65° 
Neck length <15 
mm 
Neck diameter 
>28mm 
Endurant 
I, 
Endurant 
II, 
Excluder, 
Excluder 
C3, 
Zenith, 
Zenith 
Low 
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Profile 
Lee (C), 
2013 [117] 
2004-
2007 
143 75 16 Retrospective 
single centre 
cohort study 
Utilised IFU of stent 
graft implanted 
Zenith, 
Excluder, 
AneuRx 
Antoniou 
(C), 2013 
[118] 
NR 0a 60 12 Prospective 
double centre, 
non-
randomised 
study 
Utilised IFU of stent 
graft implanted 
Zenith, 
Endurant 
Stather (C), 
2012 [103] 
1999-
2010 
353 199 17 Retrospective 
single centre, 
data collected 
prospectively 
“Hostile neck 
anatomy”:  
 Neck diameter 
>28 mm 
 Neck angle >60° 
 Neck length <15 
mm 
 Neck flare 
 Neck thrombus. 
Zenith, 
Talent, 
Excluder, 
Endurant
, 
Edwards 
Lifepath, 
Endologi
x 
Powerlin
k, 
Lombard 
Aorfix, 
Jotec 
Hager (C), 
2012 [119] 
2002-
2009 
0a 84 13 Retrospective 
single centre 
cohort study 
 Neck <15mm 
 Patients excluded 
if neck angle >60° 
Excluder, 
Zenith 
Forbes (C), 
2010 [120] 
2003-
2008 
250 68 16 Retrospective 
single centre 
cohort study 
 Neck length 
<15mm 
 SA >15mm neck 
length even if 
other out of IFU 
features 
Zenith 
Chisci (C), 
2009 [121] 
2005-
2007 
0a 74 14 Retrospective 
multicentre 
 Neck diameter 
>28mm 
Talent, 
Zenith 
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cohort study  Neck angle >60° 
 Neck length 
<15mm 
 Significant 
thrombus: (>50% 
of the proximal 
neck 
circumference) 
 Reverse tapered 
 Neck bulge: focal 
neck enlargement 
>3 mm within 15 
mm 
Abbruzzese 
(C), 2008 
[94] 
1999 
- 
2005 
343 222 15 Retrospective 
single centre 
cohort study 
Utilised IFU of stent 
graft implanted 
Zenith, 
Gore, 
Aneurx 
Hobo (C), 
2007 [67] 
1996 
- 
2006 
4031 1152 16 Retrospective 
analysis of 
prospective 
registry data 
(EUROSTAR) 
 Neck angle >60° 
only criterion 
 All other anatomy 
SA 
Zenith, 
Talent, 
Excluder 
Choke (C), 
2006 [122] 
1997 
- 
2005 
87 60 16 Retrospective 
single centre 
cohort study 
“Hostile necks”: 
 Neck diameter 
>28mm 
 Neck angle >60° 
 Neck length 
<10mm 
 Significant 
thrombus: (>50% 
of the proximal 
neck 
circumference) 
 Reverse tapered 
 Neck bulge: focal 
Talent, 
Zenith, 
Excluder, 
AneuRx, 
Cordis 
Fortron, 
EndoMe
d 
EndoFit, 
Boston 
Scientific 
Vanguar
d, 
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neck enlargement 
>3 mm within 15 
mm  
 
Edwards 
Lifepath 
Leurs (C), 
2006 [68] 
1999-
2005 
2872 677 17 Retrospective 
analysis of 
prospective 
registry data 
(EUROSTAR) 
 3 groups 
analysed: 
 Neck length 
>15mm, 10-15, 
<10mm 
 All other 
anatomies 
considered SA 
Talent, 
Zenith 
Fairman 
(C),  2004 
[106] 
NR 66 153 10 Retrospective 
analysis of trial 
data 
“Complicated 
aortic necks”: 
 Neck length 
<15mm 
 Neck diameter 
>28mm 
 Neck angulation 
>45° 
 Calcified 
 Thrombus-lined 
Talent 
LPS 
Dillavou 
(C), 2003 
[110] 
1999 
- 
2002 
115 91 11 Retrospective 
single centre 
cohort study 
“Hostile neck 
anatomy” 
 Neck length 
<10mm 
 Neck diameter 
>26mm 
 Neck bulge - a 
focal enlargement 
of the aneurysm 
neck of at least 3 
mm 
 Reverse taper 
Ancure 
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 Neck angle >60° 
 Significant neck 
thrombus (>50%) 
 Table 5.1 - NC = Non-comparative, C = Comparative, SA = standard anatomy, NSA = Non-Standard Anatomy, 
IFU = Indications for use, NR = Not reported. a= Three studies are included in the comparative analysis as they 
were comparative in design and methodology but were comparing NSA patients with NSA patients. Anoniou 
et.al. were comparing the perfomrance of Zenith vs Endurant in NSA, Hager et.al. was comparing the 
perofmrnace of Zenith vs Excluder in NSA and Chisci et.al. were comparing OR, EVAR and fEVAR in NSA. 
All but one of the studies identified were retrospective in nature. Most commonly authors 
would retrospectively analyse data prospectively collected in a database from a single 
centre. The definition of NSA also varied quite widely between studies. One reason for this 
was the fact that the studies identified spanned a 20-year period and the indications for 
use commonly applicable to most stent-grafts has evolved along with technological 
advancement. As an example, the largest neck diameter that could be treated within IFU 
with an FDA approved device was 28mm until 2006. In 2006 Cook released a device in 
which the IFU stated a diameter of 32mm could be treated. As is the nature of competitive 
market forces, soon after this, other companies began selling devices with IFU stating a 
neck diameter of 32mm. By 2009 the most commonly used stent grafts were all able to 
treat a larger diameter. Therefore, earlier studies had used 28mm as a cut off with relation 
to neck diameter. However, two studies [95, 116] published later and even including 
patients after 2009 still used the 28mm neck diameter as a cut off for defining NSA. Most 
studies defined specific anatomic criteria to identify NSA whereas six studies [94, 111, 114, 
115, 117, 118] used the stent-graft IFU to define whether a patient met NSA criteria. In 
addition, one early study [110] used specific anatomical criteria but this essentially mapped 
directly to the IFU of the only device used within that cohort. Furthermore, with regards to 
anatomical criteria for inclusion; four studies chose to analyse only one specific anatomical 
variable [67, 68, 119, 120].Two of these studies were analyses of the large EUROSTAR 
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registry with the aim of identifying the specific role that certain neck characteristics play in 
the clinical outcomes for patients. In the study by Leurs et. al. comparing stent grafts with 
>15mm, 10 – 15mm and <10mm of neck length the primary aim was never to analyse all 
NSA and compare with all SA, it was simply to identify the role neck length plays in 
outcomes after standard endovascular repair, regardless of other features. In that study 
the group with neck length >15mm is considered the SA group for this and another 
systematic review [57] however it is important to note that in the SA group 23.1% had 
“severe aortic neck angulation”. This was significantly less than in the NSA group but is still 
a significant proportion. This should be borne in mind when analysing and interpreting any 
results with comparison between NSA and SA groups. For the other three Studies [67, 119, 
120] there was simply an unknown proportion of patients with other undesirable 
anatomical features that were included in the “SA” group (which essentially is the control 
group for these comparative studies). Therefore, there was this significant confounding 
factor in these studies that may affect their findings. It must be said that the study by Hager 
et. al. sought to minimise this somewhat by excluding all patients with severe neck 
angulation (>60°) from their analysis of patients with and without short necks. In essence 
there was significant heterogeneity found between studies with regards to definition of the 
primary defining characteristic of the study populations (NSA). This therefore limits the 
validity and applicability of any synthesis of results across the studies. 
 
In addition to the above there were other sources of significant heterogeneity within and 
between studies. The other striking source of heterogeneity is the number of different 
stent-graft used. This includes some stent-grafts that are no longer available on the market. 
This is understandable within a systematic review spanning 20 years, but it must also be 
mentioned that a number of the identified studies included many stent-grafts within the 
studied population (eight different stent-grafts in one study). In some cases only one 
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patient received one of the devices. Some reports did adjust and control for this by 
including only patients treated with one stent graft. And in the case of Leurs et.al., in their 
analysis of the EUROSTAR registry data, they elected to only include two devices - both 
with suprarenal fixation as part of their design in an attempt to control for device type as a 
confounding factor. 
 
In three comparative studies there was no comment on whether there were any conflicts 
of interest [96, 116, 122] whereas in four others [106, 110, 120, 121] there was clear 
documentation of conflicts of interest of involved authors. There appeared to be problems 
in two particular studies with obtaining preoperative imaging in order to perform their 
analysis meaning that 26% of patients couldn’t be included in one study [95] and 71% of 
the total EVAR cohort in another [115] this of course limits the conclusions that can be 
drawn from these studies as the studied population cannot be assumed to be 
representative of the population from which they came.  
 
The non-comparative studies identified were all retrospective in nature and scored 
adequately using the MINORS tool but consistently failed in similar areas. They all scored 
poorly in the item related to “prospective collection of data”, “unbiased assessment of 
study endpoint” and “prospective calculation of study size”. This is with the exception of 
the study by Schanzer et. al. in which the reviewers assessing the preoperative anatomy 
were blinded to the study outcomes. All studies consistently performed well in items 
relating to “Inclusion of consecutive patients”, “Endpoints appropriate to aim of study” and 
“Loss to follow up less than 5%”. The study by Schanzer et.al. provided the vast majority of 
patients within the non-comparative group and in fact were the largest group of patients 
contributing overall. 
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The comparative studies scored inconsistently using the MINORS tool. The mean score of 
all the included studies was 14 (Range 10 – 17). The maximum available score for a 
comparative study was 24. There were four areas in which studies consistently scored 
highly –“A clearly stated aim”, “Inclusion of consecutive patients”, “Loss to follow up <5%” 
and “Contemporary groups”. In fact, all the studies scored maximum for the latter. There 
were also two areas which consistently scored poorly – “Unbiased assessment of the study 
endpoint” and “Prospective calculation of the study size”. With the latter not achieving a 
single point across all the studies. On all the other criteria there were a range and mix of 
results. These results from using the MINORS tool highlights the relatively poor 
methodological quality of the body of evidence identified as outlined above. 
5.3.2. Demographic information 
Demographic information and that on co-morbidities was again inconsistently reported 
across the studies but some important points should be made about the heterogeneity 
within studies. See table 5.3.  
 
Table 5.3. Demographic information from included studies 
Study Length of 
FU 
(months) 
NSA age 
Mean years 
(+/- SD) 
Female 
NSA 
population
(%) 
ASA score Reporting on 
comorbidities 
Pitoulias 
(NC), 
2017[111] 
41 73.4 (8.6) 7.9% ASA III/IV 
- 100% 
Minimal 
Gallitto 
(NC), 
2016[112] 
51.4 74.9 (6.2) 12% ASA III/IV 
- 100% 
Minimal 
Schanzer 31 73.9 15.9% ASA III/IV NR 
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(NC), 
2011[98] 
- 100% 
Mateo 
(C), 2016 
[113] 
SA – 30.5 
NSA – 38  
 NR 4.2% NR Adequate, no 
differences 
Cerini (C), 
2016 [95] 
37 75.8 (6.8) 15.7% NR Adequate, no 
differences 
AbuRahm
a (C), 
2016 [96] 
30 73.5 20% NR NSA > proportion 
of CHF, CVA/TIA *  
Broos (C), 
2015 
[114] 
12  74 (7.7) 20.2%* ASA III/IV 
– 50% 
NSA > proportion 
of Cancer diagnosis 
and “GI 
complications”* 
Walker 
(C), 2015 
[115] 
36 74.6 (7)  14.6%* NR Adequate, no 
differences 
Speziale 
(C), 2014 
[116] 
24  NR 19.6% ASA III/IV 
- 85.7% 
Adequate, no 
differences 
Lee (C), 
2013 
[117] 
35  74.9 10.7% NR Adequate, no 
differences 
Antoniou 
(C), 2013 
[118] 
18 74* Difference 
between 
groups* 
ASA III/IV 
– 58% 
Adequate, 
difference in rate 
of previous CVA*  
Stather 
(C), 2012 
[103] 
SA – 48.8  
NSA – 
50.1   
73.9 (7.1) 6.5% ASA 
higher in 
NSA  
Adequate, no 
differences 
Hager (C), 
2012 
[119] 
18.6 IF 76.6 
SF 74.8 
No 
difference 
between 
groups 
NR Adequate, no 
differences 
Forbes 51.6 NR NR ASA III/IV Adequate, no 
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(C), 2010 
[120] 
– 96.6% differences 
Chisci (C), 
2009 
[121] 
19.5 77.5 (7.0)* 16% ASA III/IV 
88%* 
EVAR > proportion 
of renal 
insufficiency and 
CAD 
Abbruzzes
e (C), 
2008 [94] 
29.6 NR NR NR Adequate, no 
differences 
Hobo (C), 
2007 [67] 
19.9  72.1 (7.7)* 9.7%* ASA III/IV 
55.0%* 
NSA -more often 
“unfit for open AAA 
repair and GA”*  
Choke (C), 
2006 
[122] 
21.7 74.4 (1.0) 10% NR NR 
Leurs (C), 
2006 [68] 
12  73.5 No 
differences 
ASA > III 
61.5%* 
NSA > proportion 
of HTN, Renal 
impairment, 
Pulmonary disease, 
"unfit for open or 
GA"* 
Fairman 
(C),  2004 
[106] 
21 NR NR NR NR 
Dillavou 
(C), 2003 
[110] 
18 75.7 * 22%* NR Adequate, no 
differences 
Table5.3. -  NC = Non comparative, C = Comparative, SA = standard anatomy, NSA = Non-Standard Anatomy, 
IFU = Indications for use, NR = Not reported ASA - American Society of Anaesthesiology grading, CAD - 
coronary artery disease, CHF – Congestive Heart Failure, GA – General Anaesthesia, HTN – Hypertension, IF – 
Infrarenal fixation, SF – Suprarenal fixation, CVA – Cerbro vascular accident, TIA – Transient Ischaemic Attack. 
* - Denotes significant variable when compared with comparator group. Length of follow up is reported as in 
included study whether that be mean or median follow up. 
99 
 
 
Across all the studies the mean age of the patients was relatively similar with all reporting 
within the range of 72.1 – 77.5 years for NSA patients. The groups were also relatively 
homogenous within studies as only two [67, 110] found a statistical difference in the age 
between groups. One [110] found the NSA cohort were older and the other [67] found that 
the SA group were older. Antoniou et.al. reported a difference in the age of the two 
populations being studied but these were both NSA populations as that study was 
comparing two different types of stent graft. Similarly, Chisci et. al. found a difference in 
the age between their three NSA groups of OR, EVAR and fEVAR. In all cases the difference 
between the means was less than 3 years. With regards to gender within and across studies 
there is significant heterogeneity and it is not clear exactly why this may be the case. It is 
suggested that women tend to present with more severe anatomy of their AAA by nature 
[102] and this would explain heterogeneity within studies to an extent but there doesn’t 
appear to be a clear explanation why there should be such a large difference between 
studies. The proportion of women with NSA undergoing EVAR across the studies ranges 
from 4.2 – 22%. With regards to other medical conditions and co-morbidities the studies 
overall were reasonable at least in reporting the proportions of patients with basic vascular 
risk factors such as hypertension, coronary artery disease, diabetes etc. however studies 
often did not report the ASA grade. There were 10 studies in total not reporting ASA grade 
of patients. The ASA grade is simplistic and by no means a perfect assessment of a patient’s 
fitness for surgery but it is a standard preoperative variable usually readily available and 
therefore should be included in any report and indeed is recommended in the minimum 
reporting standards for endovascular repair as a necessary addition to any data set [99]. In 
those that did report ASA grade it was usually reported as a proportion of patients with 
ASA grade 3 or above, and this proportion ranged from 50 – 100% across the studies. 
Clearly there is significant heterogeneity between different studies with regards to ASA 
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grade. In three studies [67, 68, 103] patients with NSA were found to have a statistically 
significant higher ASA grade than their SA counterparts. In the EUROSTAR studies by Leurs 
et.al and Hobo et. al. patients were also noted to be more comorbid and “unfit for open 
repair or general anaesthesia” with an increased rate of renal and pulmonary pre-existing 
conditions. In another study by Broos et. al. the NSA group had a higher prevalence of 
cancer at baseline, and in AbuRahma et.al. study NSA patients were significantly more likely 
to suffer with congestive heart failure and previous stroke. This narrative analysis of 
demographics and reported comorbidities for included studies shows that there is 
significant heterogeneity between studies and within studies for important baseline 
characteristics and that the reporting of comorbidities is imperfect, and reporting of ASA 
grade is often non-existent. However, from the limited data available it does seem to 
suggest, that the NSA patients have a higher ASA score, more comorbidities and are less 
“fit” than their SA counterparts preoperatively. This is an important confounding factor for 
many of these studies with regards to the validity and applicability of clinical outcome 
results especially with regards to mortality and complication rates.  
One other important point of note is that the studies inconsistently dealt with varying 
presentation of AAA. Some explicitly stated that only elective patients were included in 
their cohort, others expressly stated that emergent or symptomatic patients were included 
[95, 114] and in others there was simply no mention.  
5.3.3. Anatomical data 
What was clear from the included studies’ reports was that anatomical characteristics are 
inconsistently reported. Often the pertinent anatomical characteristics (i.e. for the proximal 
aortic neck) were reported either as a mean value with standard deviation for the whole 
NSA group or proportions of patients violating a stated anatomical criterion were given (i.e. 
X% had a neck length <10mm). When only the mean values are reported this can often be 
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misleading as the mean value for any given characteristic is often well within IFU 
anatomical criteria due to the fact that patients vary in their nature in the breach of the IFU 
and therefore for any given single characteristic a large proportion of patients would be 
well within IFU criteria. If and when a mean anatomical variable fell outside the IFU criteria 
it was usually because that particular study was simply assessing one IFU criteria (e.g. neck 
length only). The pertinent anatomical characteristics reported for each study are detailed 
in the tables below. (see tables 5.4 – 5.7): Data are presented as mean (+/- S.D. or 
proportion) or Median (Range or IQR), when this information was available from the study 
Table 5.4. Anatomical data (AAA diameter) for included studies 
Study SA AAA Diameter 
mean  +/- S.D or 
median (IQR), 
(mm) 
NSA AAA Diameter 
mean  +/- S.D or 
median (IQR), 
(mm) 
Significant 
difference 
between groups 
Pitoulias (NC), 
2017[111]  
- NS - 
Gallitto (NC), 
2016[112]  
- 60.4 +/- 12.2 - 
Schanzer (NC), 
2011[98] 
- 54.8mm  
(59% <55mm) 
- 
Mateo (C), 2016 
[113] 
56 (34–112)  59 (40–100)  NS 
Cerini (C), 2016 
[95] 
59.9 +/- 1.2  62.4 +/- 0.9 NS 
AbuRahma (C), 
2016 [96] 
NR NR - 
Broos (C), 2015 
[114]a 
REG – 58 (53 – 64) CHA - 61 (55-73) <0.01 
Walker (C), 2015 
[115] 
5.7 +/- 0.9 60 +/- 12 <0.001 
Speziale (C), 2014 60.2 ± 12.7  61.9 ± 10.9  NS 
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[116] 
Lee (C), 2013 
[117] 
56.9 61.5 0.002 
Antoniou (C), 
2013 [118]b 
- ZEN - 67 +/- 11 
END - 63 +/- 15  
NS 
Stather (C), 2012 
[103] 
64.8 +/- 12.0  64.2 +/- 9.7 NS 
Hager (C), 2012 
[119]c 
- IF -  58 (34 - 80) 
SF - 49 (48 - 82) 
NS 
Forbes (C), 2010 
[120] 
NR NR - 
Chisci (C), 2009 
[121] 
- 62 (50 - 110) NS 
Abbruzzese (C), 
2008 [94] 
54.5 +/- 9.3 57.3 +/- 11.9 < .001 
Hobo (C), 2007 
[67] 
57.9 +/- 10.4 63.8 +/- 12.6 <0.0001 
Choke (C), 2006 
[122] 
62.7 +/- 1.1 65.3 +/- 2.0 NS 
Leurs (C), 2006 
[68]d 
A = 61.3 +/- 10.7  B =  62.2 +/- 11.3           
C = 62.9 +/- 11 
< 0.0314 
Fairman (C),  
2004 [106] 
NR NR  
Dillavou (C), 2003 
[110] 
53.8  54.8  NS 
Table 5.4. IQR – Interquartile range, SA – Standard Anatomy, NSA – Non-standard anatomy, AAA – 
Abdominal aortic aneurysm, NS – Not Significant, NR – Not reported  a - Broos et al. compared three groups 
of patients, REG vs INT vs CHA, they represent three 'levels' of anatomical complexity. CHA represents out of 
IFU for the device used and the other two represent in the IFU. Data presented are the comparison between 
the REG and CHA group. b – Antoniou et. al. compared two groups both with NSA – those receiving Zenith 
device (ZEN) and those receiving Endurant (END) device. C – Hager et.al. Compared two groups both with 
NSA – those receiving Excluder infrarenal fixation device (IF) and those receiving Zenith  suprarenal fixation 
device (SF). D – Leurs et.al. compared three groups with different neck lengths, (A) – >15mm, (B) – 10 – 
15mm, (C) - <10mm. 
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Across the studies twelve provide an average diameter for SA and twenty provide a 
diameter for NSA aneurysms. The median and range of these combined values are 58mm 
(53.8 – 64.8) for SA AAA. For NSA AAA it is 61.7mm (49 – 67). In three studies [98, 110, 119] 
the average AAA diameter in NSA was less than 55mm. In fact, across the studies there was 
a significant proportion of patients treated with aneurysms <55mm. The paper by Schanzer 
et.al. documents that 59% of the aneurysms treated in that large 10228 patient cohort had 
small AAA <55mm. In total across all the studies at least 6347 (25.9%) had aneurysms 
<55mm treated and included in the studies. The actual number is higher than this because 
some studies did not report the proportion of patients treated <55mm. There is therefore 
wide variation between studies with regard to the selection and size criteria for who 
undergoes AAA repair. Six of the 18 comparative studies found that the NSA patients had a 
significantly larger AAA preoperatively than their SA counterparts [67, 68, 94, 114, 115, 
117]. 
To continue the examination of the anatomical findings from the papers see table 5.5. 
below for details of the reported neck lengths from the various included studies. 
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Table 5.5. Anatomical data (Neck Length) for included studies 
Study SA Neck Length, 
mean  +/- S.D or 
median (IQR), 
(mm) 
NSA Neck Length, 
mean  +/- S.D or 
median (IQR), 
(mm) 
Significant difference 
between groups 
Pitoulias (NC), 
2017[111] 
- NR - 
Gallitto (NC), 
2016[112] 
- 8.4 +/- 1.6 - 
Schanzer (NC), 
2011[98] 
- 20.7 +/- 12.7 
(18% 10 - 15mm, 
24% <10mm) 
- 
Mateo (C), 2016 
[113] 
22 (12–65) 15 (10–40)  
(78.9% <15mm) 
< 0.001 
Cerini (C), 2016 
[95] 
27.3 (15 - 45) 10.2 (5 - 14)  
(34.4% <10mm) 
< 0.05 
AbuRahma (C), 
2016 [96] 
NR (13%  <10mm) - 
Broos (C), 2015 
[114]a 
29 +/- 11 22 +/- 15 < 0.01 
Walker (C), 
2015 [115] 
26.5 (20.7-35.0) 9.9 (6 - 13.9) < 0.001 
Speziale (C), 
2014 [116] 
24.9 ± 7.5  14.4 ± 6.7   < 0.001 
Lee (C), 2013 
[117] 
25 13 
(30.7% <10mm) 
< 0.001 
Antoniou (C), 
2013 [118]b 
- ZEN: 20 +/- 13  
(63% <15mm) 
END: 18 +/- 10 
(52% <15mm) 
NS 
Stather (C), 
2012 [103] 
NR NR NS 
Hager (C), 2012 - IF -  12 (7-14) NS 
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[119]c SF -  11 (5-14) 
Forbes (C), 2010 
[120] 
NR NR - 
Chisci (C), 2009 
[121] 
- 10 (8 - 12)  Significant difference 
between groups - 
significantly more <10mm 
necks in fEVAR 
Abbruzzese (C), 
2008 [94] 
27 +/- 10.7 22.2 +/- 11.9 
(39% oIFU) 
< 0.001 
Hobo (C), 2007 
[67] 
27.6 +/- 12.3 24.8 +/- 10.4 < 0.0001 
Choke (C), 2006 
[122] 
29.4 +/- 1.6 22.6 +/- 1.9 < 0.0075 
Leurs (C), 2006 
[68] 
NR NR    
Fairman (C),  
2004 [106] 
NR NR  
Dillavou (C), 
2003 [110] 
21.8  14.4 < 0.001 
Table 5.5. IQR – Interquartile range, SA – Standard Anatomy, NSA – Non-standard anatomy, AAA – 
Abdominal aortic aneurysm, NS – Not Significant, NR – Not reported  a - Broos et al. compared three groups 
of patients, REG vs INT vs CHA, they represent three 'levels' of anatomical complexity. CHA represents out of 
IFU for the device used and the other two represent in the IFU. Data presented are the comparison between 
the REG and CHA group. b – Antoniou et. al. compared two groups both with NSA – those receiving Zenith 
device (ZEN) and those receiving Endurant (END) device. C – Hager et.al. Compared two groups both with 
NSA – those receiving Excluder infrarenal fixation device (IF) and those receiving Zenith  suprarenal fixation 
device (SF) 
Unsurprisingly many studies report a statistically significant difference between NSA and SA 
patients for neck length given this is one of the primary neck characteristics that defines 
NSA. It is important to note however that in some studies [67, 94, 114] the neck lengths for 
the NSA groups fall well within IFU criteria (>20mm) and highlight the potential for 
misleading reporting if average values alone are used to define certain neck characteristics. 
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In fact, in the case of Abbruzzese et.al. all the primary neck characteristics are within IFU 
criteria when presented as means. Helpfully this report also documents the proportion of 
patients falling out with each IFU criteria to give a full understanding of the anatomy that is 
being investigated. For details on neck diameter in the included studies see table 5.6. 
below. 
 
Table 5.6. Anatomical data (Neck Diameter) for included studies 
Study SA Neck Diameter, 
mean  +/- S.D or 
median (IQR), (mm) 
NSA Neck Diameter, 
mean  +/- S.D or 
median (IQR), (mm) 
Significant 
difference 
between 
groups 
Pitoulias (NC), 2017[111] - NS  
Gallitto (NC), 2016[112] - 23.5 +/- 3  
Schanzer (NC), 2011[98] - 23.1 +/- 3.1  
(91% <28mm) 
 
Mateo (C), 2016 [113] 23.7 (18.5–31.5)  23 (18–29)  NS 
Cerini (C), 2016 [95] 24.3 +/- 1.2  25.6 +/- 0.8 NS 
AbuRahma (C), 2016 [96] - (6% >31mm)  - 
Broos (C), 2015 [114]a 24 +/- 4 24 +/- 4 NS 
Walker (C), 2015 [115] 24.5 (22.5-26.7)  23.5 (21.5-25.9)  < 0.01 
Speziale (C), 2014 [116] 22.5 ± 2.9  23.4 ± 2.5  0.0029 
Lee (C), 2013 [117] (>28 mm -  4.9%) (>28 mm -  12.0%) NS 
Antoniou (C), 2013 [118]b - ZEN 24 +/- 3 
END 26 +/- 4 
NS 
Stather (C), 2012 [103] NR NR NS 
Hager (C), 2012 [119]c NR NR - 
Forbes (C), 2010 [120] NR NR - 
Chisci (C), 2009 [121]  (>28mm - 74%) Significant 
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difference 
between 
groups – 
Larger 
diameter in 
EVAR and 
fEVAR vs OR 
Abbruzzese (C), 2008 [94] 22.7 +/- 2.3 23.7 +/- 2.7 
(18% oIFU) 
< 0.001 
Hobo (C), 2007 [67] 24.2 +/- 3.3 24.2 +/- 3.2 NS 
Choke (C), 2006 [122] 23.3 +/- 0.3  26.3 +/- 0.5  < 0.0001 
Leurs (C), 2006 [68] d A =  24.6 +/- 3.4 B = 24.8 +/- 3.3          
C = 25.7 +/- 3.6 
< 0.0004 
Fairman (C),  2004 [106] NR NR  
Dillavou (C), 2003 [110] NR NR but all <26  
Table 5.6 - IQR – Interquartile range, SA – Standard Anatomy, NSA – Non-standard anatomy, AAA – 
Abdominal aortic aneurysm, NS – Not Significant, NR – Not reported  a - Broos et al. compared three groups 
of patients, REG vs INT vs CHA, they represent three 'levels' of anatomical complexity. CHA represents out of 
IFU for the device used and the other two represent in the IFU. Data presented are the comparison between 
the REG and CHA group. b – Antoniou et. al. compared two groups both with NSA – those receiving Zenith 
device (ZEN) and those receiving Endurant (END) device. C – Hager et.al. Compared two groups both with 
NSA – those receiving Excluder infrarenal fixation device (IF) and those receiving Zenith  suprarenal fixation 
device (SF). D – Leurs et.al. compared three groups with different neck lengths, (A) – >15mm, (B) – 10 – 
15mm, (C) - <10mm. 
 
As stated earlier there were significant differences in the definition of what constituted a 
large diameter neck that defined NSA. Furthermore, there were often no details on exactly 
how the neck was measured on preoperative imaging and when there was - the method of 
measurement was inconsistent. Gallito et. al. report that the neck was measured from the 
most caudal renal artery to the beginning of the aneurysm from adventitia to adventitia for 
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every millimetre but no comment on how the final value of neck diameter was decided 
from these measurements. Gallitto et. al. comment that they only measured neck diameter 
at the level of the lowest renal artery. Therefore, there is significant disparity between 
studies as to how anatomical measurements are made. The table below details the results 
for neck angulation. 
Table 5.7. Anatomical data (Neck Angulation) for included studies 
Study SA Neck Angulation, 
mean  +/- S.D or 
median (IQR), (°) 
NSA Neck Angulation, 
mean  +/- S.D or 
median (IQR), (°) 
Significant 
difference 
between groups 
Pitoulias (NC), 
2017[111] 
- NS - 
Gallitto (NC), 2016[112] - Alpha angle >45° 10%, 
Beta angle >60° 33% 
A and B angle 10% 
- 
Schanzer (NC), 2011[98] - 36.9 (15.4)  
(8% >60°) 
- 
Mateo (C), 2016 [113] 29.7 41.8 
(23.9% >60°) 
0.04 
Cerini (C), 2016 [95] - 11.1% >60° - 
AbuRahma (C), 2016 
[96] 
- 18% >60° - 
Broos (C), 2015 [114]a Alpha – 15 +/- 14 
Beta – 24 +/- 18 
Alpha - 45+/-29 
Beta - 68+/-29 
< 0.01 
< 0.01 
Walker (C), 2015 [115] 35.5 (26.4-44.2)  43.3 (31.8-55.5)  < 0.001 
Speziale (C), 2014 [116]  22.1 ± 14.5  32 ± 19.8  < 0.001 
Lee (C), 2013 [117] >60°  - 0.7% >60°  - 68% < 0.001 
Antoniou (C), 2013 
[118]b 
- ZEN 56+/- 20 (59% 
>60°) 
END 61+/- 25 (67% 
>60°) 
NS 
Stather (C), 2012 [103] NR NR - 
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Hager (C), 2012 [119] NR NR - 
Forbes (C), 2010 [120] NR NR - 
Chisci (C), 2009 [121] - >60°: 53% - 
Abbruzzese (C), 2008 
[94] 
Alpha 16.3 +/-15.3  
 
Beta: 34.6 +/- 17.6  
Alpha - 29.2 +/- 21.8  
(26% oIFU) 
Beta: 46.7 +/- 20.7 
(14.7% oIFU) 
< 0.001                                      
 
 
< 0.001 
Hobo (C), 2007 [67] >60°: 0% >60°: 100%  
Choke (C), 2006 [122] 27.5 +/- 1.8  45.9 +/- 3.1 < 0.0001 
Leurs (C), 2006 [68]d A = 23.1% (>60°) B =  28.7% (>60°) 
C =  28.1% (>60°) 
0.0127 
Fairman (C),  2004 [106] NR NR    
Dillavou (C), 2003 [110]  22 40 < 0.001 
Table 5.7 - IQR – Interquartile range, SA – Standard Anatomy, NSA – Non-standard anatomy, AAA – 
Abdominal aortic aneurysm, NS – Not Significant, NR – Not reported  a - Broos et al. compared three groups 
of patients, REG vs INT vs CHA, they represent three 'levels' of anatomical complexity. CHA represents out of 
IFU for the device used and the other two represent in the IFU. Data presented are the comparison between 
the REG and CHA group. b – Antoniou et. al. compared two groups both with NSA – those receiving Zenith 
device (ZEN) and those receiving Endurant (END) device. C – Hager et.al. Compared two groups both with 
NSA – those receiving Excluder infra renal fixation device (IF) and those receiving Zenith  suprarenal fixation 
device (SF). D – Leurs et.al. compared three groups with different neck lengths, (A) – >15mm, (B) – 10 – 
15mm, (C) - <10mm. 
Again, there is significant discordance between the studies with how angulation is both 
reported and measured. Few studies comment on both alpha and beta angulation. Most 
concern their reports only with Beta angulation. The majority of studies do show a 
significant difference between SA and NSA groups in terms of neck angulation. With those 
in the NSA group exhibiting higher mean or median neck angulation. The values, however, 
were rarely outside the IFU for neck angulation (principally 60 degrees) with the notable 
exception of the study by Hobo et. al. in which neck angulation was the primary 
characteristic under scrutiny. 
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5.4. Primary Outcome Results 
The primary outcome data as stated in the protocol are: perioperative mortality from any 
cause, all-cause mortality, aneurysm related mortality, reintervention rates and graft 
related endoleak rates (All type I and III endoleaks). 
5.4.1. Perioperative Mortality 
The following table documents the perioperative mortality rates reported in the 
comparative studies. The three non-comparative studies could not be included in analysis 
of perioperative mortality for the following reasons: In one of the non-comparative studies 
mortality rate was given for the whole EVAR population and it was not possible to discern it 
for the NSA group. In the other two non-comparative studies the perioperative mortality 
was not reported. Those studies contributed 4640 patients to the total NSA cohort of 8458 
and 5809 patients to the total SA cohort of 16053. There were three comparative studies 
which did not report the perioperative mortality rate and have not been included in the 
following table [106, 115, 119] (Contributing 442 NSA patients and 350 SA patients). One 
study [120] only reported perioperative mortality for the entire EVAR cohort and didn’t 
define that of the NSA cohort and therefore were excluded from the following analysis 
(Contributing 68 NSA patients and 250 SA patients) Two further comparative studies that 
only examined patients with NSA having different treatment options were excluded from 
the below analysis  because there was no SA cohort for comparison, the perioperative 
mortality rate in those studies for NSA patients undergoing standard EVAR was 1.3% [121] 
and 4% [118] (Contributed 134 patients to NSA total).  
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Table 5.8. Perioperative mortality for SA and NSA patients 
Study N SA 
Perioperative  
Mortality, n (%) 
N NSA 
Perioperative  
Mortality, n (%) 
Significant 
difference 
between groups 
Mateo (C), 
2016 
178 0 71 0  
Cerini (C), 
2016 
94 0 
(6.3% - all 
emergency) 
115 0  
(7.8% - all 
emergency)  
NS 
AbuRahma 
(C), 2016  
251 1 (0.4%) 275 4 (1.5%) NS 
Broos (C), 
2015 a 
1114 13 (1.2%) 104 3 (2.9%) NS 
Speziale 
(C), 2014 
63 0 133 4 (3%) NS 
Lee (C), 
2013 
143 3 (2.1%)  75 0  NS 
Stather (C), 
2012 
353 4 (1.1%)  199 1 (0.5%) NS 
Abbruzzese 
(C), 2008 
343 6 (1.7%) 222 4 (1.8%) NS 
Hobo (C), 
2007 
4031 117 (2.9%) 1152  46 (4.0%) NS 
Choke (C), 
2006 
87 5 (6%)  60 2(3%)  NS 
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Leurs (C), 
2006 
A = Neck 
length 
>15mm 
B = Neck 
length 10-
15mm 
C = Neck 
length 
<10mm 
2872 A = 72 (2.6%)  677 B =  24 (5.0%)  
C=  8 (4.2%)  
B vs A SIG OR 
and CI 1.77 
(1.08–2.87) 
Dillavou 
(C), 2003 
115 0 91 1 (1.1%)  NS 
Total 9644  221 (2.3%) 3174 97 (3.1%)  
Table 5.8. SA – Standard Anatomy, NSA – Non-standard anatomy, AAA – Abdominal aortic aneurysm, NS – 
Not Significant, NR – Not reported. 
After exclusions of studies for the above reasons 9644 SA patients of a total of 16053 (60%) 
and 3174 of 8458 NSA patients (37.5%) were available to analyse perioperative mortality 
rates. It should be commented that in the study by Cerini et.al. their reported perioperative 
mortality rate included patients treated with a ruptured AAA. No patients treated electively 
in their series died perioperatively and therefore for the purposes of this analysis the 
perioperative mortality rate in that study was deemed to be 0%. Only one study reported a 
significant difference in perioperative mortality between the groups [68]. This was a large 
EUROSTAR registry study investigating the effect of neck length on clinical outcomes, they 
compared three groups of patients; Neck length >15mm (A), 10 – 15mm (B) and <10mm 
(C). Interestingly there was a significant difference in mortality rates when group B was 
compared with group A (5% vs 2.6% respectively, OR 1.7 95% CI 1.08 – 2.87) but, 
importantly not when group A was compared with the more severe <10mm neck length 
group C. The authors offered no explanation as to this disparity but on review of the 
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preoperative characteristics the groups were similar. In most cases group B had 
characteristics that were an intermediate between groups A and C as one would expect. 
Indeed, in the calculation of the odds ratio the authors “Adjusted for ASA class >3, 
hypertension, renal and pulmonary impairment, unfitness for open surgery or anaesthesia, 
maximal aneurysm diameter, infrarenal neck diameter, angulation, and team experience”. 
There were significantly more patients with significant beta angulation within group B 
compared to group C however – 28.7% vs 28.1% respectively. Whether this contributed to 
the outcomes seen is difficult to ascertain, though seems unlikely. The remaining studies 
showed no difference between SA and NSA for perioperative mortality rates with a range 
for SA patients from 0 – 6% with the combined total mortality rate being 2.3%. For NSA 
patients the range was 0 – 5% with a combined total rate of 3.1%.  
5.4.2. Aneurysm Related Mortality 
The aneurysm related mortality for the included studies where available is presented in the 
table below (See table 5.9.). One non comparative study [98] did not report aneurysm 
related mortality – with that study contributing 5721 SA patients (35.6% of total SA 
patients) and 4507 NSA patients (53.3% of total SA patients). That study was purely an 
imaging repository-based study and therefore could not comment on clinical outcomes 
such as mortality. It should therefore be highlighted that a large proportion of the 
populations being studied that have been published have no available clinical outcome 
data. Any interpretation of results presented within this review must bear this in mind. In 
addition to the above mentioned study there were 4 further, comparative, studies that did 
not report aneurysm related mortality over the long term follow up [96, 106, 110, 122] 
they contributed together 519 (3.2%) of SA patients and 579 (6.8%) of NSA patients. In one 
study [96] it was reported that only one patient died of aneurysm rupture during follow up 
of a total cohort of 526 patients treated but it does not report from which group this 
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patient was in and does not mention aneurysm related mortality. Therefore, it has been 
excluded from further analysis with respect to aneurysm related mortality. 
Table 5.9. Aneurysm Related Mortality for SA and NSA patients 
Study Length of 
FU, mean 
or median 
(Months) 
N SA 
Aneurysm 
Related 
Mortality, 
n(%) 
N NSA 
Aneurysm 
Related 
Mortality, 
n(%) 
Significant 
difference 
between 
groups 
Pitoulias 
(NC), 
2017[111] 
41 88 - 73 0 N/A 
Gallitto (NC), 
2016[112] 
51.4 - - 60 2 (3%) N/A 
Mateo (C), 
2016 [113] 
SA – 30.5 
NSA – 38 
178 0 71 0 NS 
Cerini (C), 
2016 [95] 
37 94 0 115 0 NS 
Broos (C), 
2015 [114] 
12 1114 15 (1.3%) 104 3 (2.9%) NS 
Walker (C), 
2015 [115] 
36 284 8 (2.8%) 205 2 (1%)  NS 
Speziale (C), 
2014 [116] 
24 63 0 133 0 NS 
Lee (C), 2013 
[117] 
35 143 1 (0.7%) 75 1 (1.3%) NS 
Antoniou (C), 
2013 [118] 
18 - - 60 1 (1.7%) NS 
Stather (C), 
2012 [103] 
SA – 48.8  
NSA – 50.1   
353 6 (1.7%) 199 4 (2.0%) NS 
Hager (C), 
2012 [119] 
18.6 - - 84 0 NS 
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Forbes (C), 
2010 [120] 
51.6 250 0 68 0 NS 
Chisci (C), 
2009 [121] 
19.5 0 - 74 3 (4.1%) NS 
Abbruzzese 
(C), 2008 
[94]a 
29.6 343 Freedom 
from ARM: 
1 year – 
100% 
5 years -  
100% 
222 Freedom 
from ARM: 
1 year – 
94% 
5 years -  
89% 
< 0.001 
Hobo (C), 
2007 [67] 
19.9 4031 190 (4.7%)  1152 78 (6.8%) NS 
Leurs (C), 
2006 [68] b 
12 2872 A = 15 
(2%) 
677 B = 4 
(1.9%) 
C = 0  
NS 
Table 5.9. SA – Standard Anatomy, NSA – Non-standard anatomy, AAA – Abdominal aortic aneurysm, NS – 
Not Significant, NR – Not reported, ARM – Aneurysm related mortality.  a - Freedom from aneurysm related 
mortality presented within study by Kaplan-Meier analysis. b – Leurs et.al. compared three groups with 
different neck lengths, (A) – >15mm, (B) – 10 – 15mm, (C) - <10mm. 
The length of follow up within studies ranged from 12 months to 51.6 months. Most 
commonly the median follow up time was reported but occasionally mean follow up time 
was documented. For the majority of studies, the number of aneurysm related deaths were 
reported, and this was simply reported as a proportion of the total patient population to 
give the above quoted figures for aneurysm related mortality across the follow up. In one 
study [94] as mentioned in the table above Kaplan Meier freedom from aneurysm related 
mortality was considered and compared between the groups. It was in this study where 
there was a significant difference both at 1 year and 5-year estimates of freedom from 
aneurysm related mortality. The difference was 100% freedom in SA patients at both time 
points and 94% and 89% at 1 and 5 years respectively for NSA patients. In total aneurysm 
related mortality was attributed to 14 deaths (2.5% of total population of 565). Ten of 
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these deaths occurred during the index hospital admission and 3 of the remaining four 
“late” deaths were secondary to aneurysm rupture. It should be noted that in this study no 
deaths in the SA group were reported as aneurysm related however there were 6 
perioperative deaths in the SA group and in line published reporting standards [24] [99] 
and other published studies these would normally be considered as aneurysm related 
mortality. This point highlights the disparity in the reporting of aneurysm related mortality 
figures within the literature. Taking his into account the aneurysm related mortality ranged 
from 0 to 4.7%, for SA patients, in the included studies. For NSA patients the aneurysm 
related mortality ranged from 0 to 6.8% for those included studies presenting figures as 
proportions of the total population. 
5.4.3. All-cause mortality 
There were six studies that did not report all-cause mortality through follow up. These 
include the previously mentioned large non-comparative study [98] and five comparative 
studies [94, 119-122]. Together they comprise 6401 SA patients (39.9% of total SA cohort 
and 5015 NSA patients (59.3% of total NSA cohort). Of the 15 studies with data available 
for analysis regarding all-cause mortality through the follow up 6 report an average follow 
up time of less than 2 years and 9 report more than 2 years follow up. These groups are 
presented together in the two tables below (Table 5.10. and 5.11.) 
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Table 5.10. – All cause mortality for studies reporting follow up <2 years 
Study Length of 
FU, mean 
or median 
(Months) 
N SA pts -  
All cause 
mortality 
over FU 
N NSA pts -  
All cause 
mortality 
over FU 
Significant 
difference 
between 
groups 
Broos (C), 
2015 [114] 
12  1114 7.2% 104 9.6% NS 
Antoniou (C), 
2013 [118] 
18 -  60 9 (15%) NS 
Hobo (C), 2007 
[67] 
19.9 4031 23.6% 1152 24.1% NS 
Leurs (C), 2006 
[68]a 
12 2872 A = 
19.2% 
677 B =  20.2% 
C = 34.0% 
NS 
Fairman (C),  
2004 [106] 
21 66 2 
yrs:81.7
% 
153 2 yrs.: 
84.3% 
NS 
Dillavou (C), 
2003 [110] 
18 115 5.2%  91 4.4% NS 
Table 5.10. . SA – Standard Anatomy, NSA – Non-standard anatomy, AAA – Abdominal aortic aneurysm, NS – 
Not Significant, NR – Not reported, ARM – Aneurysm related mortality. a – Leurs et.al. compared three 
groups with different neck lengths, (A) – >15mm, (B) – 10 – 15mm, (C) - <10mm. 
In the above studies with an average follow up period ranging from 12 – 21 months the all-
cause mortality at that follow up point ranged between 5.2 – 23.6% for SA patients and 4.4 
– 34% for NSA patients. In no instance was there a significant difference between SA and 
NSA groups at this follow up time point. The following table documents the outcomes in 
studies with a follow up period longer than 2 years (See table 5.11.) 
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Table 5.11. – All cause mortality for studies reporting follow up >2 years 
Study Length of 
FU, mean 
or median 
(Months) 
N SA pts -  
All cause 
mortality 
over FU 
N NSA pts -  All 
cause 
mortality 
over FU 
Significant 
difference 
between 
groups 
Pitoulias 
(NC), 
2017[111] 
41 88 - 73 21.1% N/A 
Gallitto 
(NC), 
2016[112] 
51.4 - - 60 1 year - 3% 
3 years - 13% 
5 years - 30% 
N/A 
Mateo 
(C), 2016 
[113] 
SA - 30.5 
NSA – 38 
178 2 years:  
7.7% 
71 2 years: 6.6% NS 
Cerini (C), 
2016 [95] 
37  94 22.8%   115 24.4% NS 
AbuRahm
a (C), 
2016 [96] 
30 251 6.3% 275 13.4% 0.008 
Walker 
(C), 2015 
[115] 
36 284 21.1% 205 21.5% NS 
Speziale 
(C), 2014 
[116] 
24 63 3.2% 133 5.4% NS 
Lee (C), 
2013 
[117] 
35 143 Survival: 
1 yr. 
90.7% 
2 yr. 
84.6% 
3 yr. 
79.9% 
75 Survival: 
1 yr. 92.5% 
2 yr. 86.3% 
3 yr. 71.5% 
NS 
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Stather 
(C), 2012 
[103] 
SA – 48.8  
NSA – 50.1 
353 5-year 
mortality: 
15.1% 
199 5 yr. 
mortality: 
14.6% 
NS 
Table 5.11. . SA – Standard Anatomy, NSA – Non-standard anatomy, AAA – Abdominal aortic aneurysm, NS – 
Not Significant, NR – Not reported, ARM – Aneurysm related mortality.  
As can be seen from the table above there was only one study where there was a 
significant difference in all-cause mortality between the two groups during long term 
follow up [96]. The authors comment that only one death was secondary to aneurysm 
rupture, but that study also found an increased rate of early reintervention, as well as early 
and late type 1 endoleak for NSA patients. There did not appear to be any other 
explanation for the higher mortality rate in the NSA group. There were two studies with 
sufficiently long enough follow up that survival rates could be commented on out to 5 years 
– in one [112] the five year survival rate was 70% (In NSA patients) and in the other [103] it 
was 85.4% (for NSA patients), and 84.9% for SA patients. 
5.4.4. Reintervention Rates 
Of all the included studies there were three that showed a statistically significant difference 
in reintervention rates. [67, 96, 103]. The first study by AbuRahma et.al. who investigated a 
relatively large cohort of patients – 526 in total, which make up 2.2% of the total 
population of included studies. In that study the authors found that the rate of 
reintervention within 30 days was statistically significant between groups with 10% of SA 
patients requiring a reintervention and 24% of NSA patients requiring a reintervention (p= 
<0.0001). The authors noted significantly more early (<30 day) type 1 endoleaks in the NSA 
group compared with the SA group. It should also be noted that there were a large number 
of type 1a endoleaks noted in the NSA group within 30 days compared to other studies. 
They report 18% of NSA patients had a type 1a endoleak within 30 days when the range 
from other studies was 0 – 10.9%. The authors define “early” endoleak as “a leak detected 
intraoperatively, or less than 30 days postoperatively”. They do not specify whether their 
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rate includes those patients in whom a type 1a endoleak was detected intraoperatively and 
sealed utilising an adjunctive manoeuvre. Unfortunately they do not report technical 
success rates, which in line with the reporting standards [24], would help the reader to 
determine whether the above point is true. Furthermore, the vast majority of all 
interventions performed within 30 days for both groups were either a proximal cuff 
extension or proximal aortic stent (97%). There were significantly more proximal cuff 
extensions in the NSA group vs SA group (16% vs 5% respectively, p = 0.0001), presumably 
secondary to the higher rate of type 1 endoleak primarily, again it is not defined within the 
study whether these were intraoperative adjunctive procedures or secondary procedures 
on another day from the index procedure. That study also found that through multivariate 
analysis beta angulation of > 60 degrees and neck length of <10mm were predictive factors 
for early intervention. The study found no significant difference in late reintervention rates 
or freedom from late reintervention.  
 
Stather et. al. investigated the outcomes for a total of 552 patients, making up 2.3% of the 
total population from included studies. In their study the rate of interventions less than 30 
days from the index procedure and over the long term was not significantly different 
between the SA and NSA groups however when they analysed the number of 
reinterventions (rather than number of patients undergoing reinterventions) they found 
that statistically significant more reinterventions were undertaken in the NSA vs SA group 
(37 (22.8%) vs 38 (11%), respectively, p = <0.01). In that study they had a mean follow up of 
4.1 years and although they found no difference in type 1 endoleaks less than 30 days from 
the index procedure they did find that significantly more patients in the NSA group 
developed a type 1 endoleak during follow up. Further analysis of reinterventions showed 
that significantly more reinterventions were undertaken for proximal type 1 endoleak in 
the NSA group vs SA group (5 (2.5%) vs 2 (0.6%), respectively, p = <0.05). They also found 
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more reintervention procedures performed for type 2 endoleak in the NSA group. Over the 
length of their follow up more patients in the NSA group suffered a ruptured aneurysm vs 
SA group (7 (3.5%) vs 4 (1.1%), respectively). However, this failed to reach statistical 
significance with a p value of 0.05. Furthermore, there was no significant difference in 
migration, sac expansion, <30-day mortality, >30-day mortality or aneurysm related 
mortality over follow up. Additionally, there was no difference found for the number of 
reinterventions performed for, type 1b endoleak, limb occlusion, migration, type 3 
endoleak or rupture.   
 
In the remaining study to show a significant difference in reintervention rates Hobo et.al. 
investigated outcomes for 5183 patients from the EUROSTAR registry (comprising 21% of 
the total population of included studies). They investigated the role of “severe neck 
angulation” (>60 degrees beta angulation) on clinical outcomes. They found that severe 
neck angulation played no role in early reintervention rates (<30 days from the index 
procedure) but did in ‘late’ reintervention rates, beyond 30 days. The reintervention rate 
over the follow up was 13.6% in the NSA group versus 10.8% in the SA group, with an 
adjusted hazard ratio of 1.29 (95% CI 1 – 1.67). In that population there was also 
significantly more type 1 endoleaks found in the NSA group over the follow up but no 
difference in migration, rupture or mortality rates. 
 
Of the remaining included studies, five did not compare reintervention rates between NSA 
and SA groups, three did not report on secondary interventions and 10 reported outcomes 
but did not show a significant difference between the NSA and SA groups. Interestingly, 
most showed an increase in proportion of secondary interventions over follow up in the 
NSA group versus the SA group, but it did not reach statistical significance. [68, 94, 113-
117]. Abbruzzese et.al. showed in their study that as the number of parameters of IFU 
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violation increased the freedom from reintervention over the follow up period decreased. 
They compared 18 patients with 3 or more IFU violations with 343 patients with SA and 
found that the 5-year freedom from reintervention rates were 21% vs 85% respectively (p = 
0.001). 
5.4.5. Graft related endoleak 
Two of the included studies did not report on any graft related endoleak at all [94, 98]. Of 
all the included studies that report on graft related endoleak no study found a significant 
difference between NSA and SA groups in terms of type 1b and type 3 endoleaks. There 
were three studies that specifically reported on type 1b endoleaks separately from type 1a 
endoleaks [68, 113, 122]. The range of type 1b endoleak beyond 30 days was 0.6% - 4% for 
SA patients and 4.2% - 7.2% for NSA patients. In three studies [103, 114, 119] “type 1” 
endoleaks are reported on but there is no definition as to whether this includes all type 1 
endoleaks or only proximal endoleaks. Seven studies report specifically and separately on 
the occurrence of type 3 endoleaks [68, 103, 113, 114, 116, 121, 122]. The range of type 3 
endoleaks reported beyond 30 days for SA and NSA patients respectively is 0 – 5.8% and 0 – 
1.5%. Again, no statistically significant differences were found when comparing type 3 
endoleaks over follow up. The following table details the reporting of type 1a endoleaks 
found before and after 30 days. Where possible the rates at standard time intervals is 
given, however often reports simply group endoleaks into <30 days and those found over 
the remainder of the follow up. (See table 5.12.) 
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Table 5.12. Reporting of type 1a endoleaks from included studies 
Study Length of 
FU, mean 
or median 
(Months) 
N SA pts -  Type 
1a Endoleak, 
n(%) (at 
varying time 
intervals) 
N NSA pts -  Type 
1a Endoleak, 
n(%) (at varying 
time intervals) 
Significant 
difference 
between 
groups 
Pitoulias 
(NC), 
2017[111] 
41 88 - 73 <30d: 4.1% 
1-5yr: 2.7% 
Freedom at 3yr 
- 94.2% 
N/A 
Gallitto 
(NC), 
2016[112] 
51.4 - - 60 <30d 3.3% 
1 – 5 yr.: 1.7% 
N/A 
Mateo 
(C), 2016 
[113] 
SA - 30.5 
NSA – 38 
178 0 71 <30d – 0 
5-10yr: 1.4% 
NS 
Cerini (C), 
2016 [95] 
37  94 <30d: 1.1% 
1 – 5 yr.: 1.1% 
115 8.8% 
All <30 d, all had 
neck length 
<10mm 
0.04 
AbuRahm
a (C), 
2016 [96] 
30 251 <30d: 7% 
>30d: 2% 
Freedom 
from type 1 
>30d 
1yr 99.5% 
2yr 99.5% 
3yr 98.4% 
275 <30d: 18% 
>30d: 6%  
Freedom from 
type 1 >30d: 
1yr 98.9% 
2yr 98.1% 
3yr 98.1% 
<30d: 
<0.0002 
>30d: 0.048 
KM analysis: 
0.049 
Broos (C), 
2015 
[114] 
12  1114 <30d: 0.7% 104 <30d: 7.4%  Significant 
Walker 
(C), 2015 
[115] 
36 284 Type 1 or 3 
during FU: 
3.5% 
205 Type 1 or 3 
during FU: 4.4% 
NS 
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Speziale 
(C), 2014 
[116] 
24 63 <30d: 0 
1-5yr: 1.6% 
133 <30d: 0 
1-5yr: 3% 
NS 
Lee (C), 
2013 
[117] 
35 143 >30d: 5.6%  75 >30d:5.3% NS 
Antoniou 
(C), 2013 
[118] 
18 -  60 1 (1.7%) N/A 
Stather 
(C), 2012 
[103] 
SA – 48.8  
NSA – 50.1 
353 <30d:  0.8%) 
>30d:  4.5% 
199 <30d:  2.5% 
>30d: 9.5% 
<30d NS 
>30d = 0.02 
Hager (C), 
2012 
[119] 
18.6 -  84 <30d: 7.1% N/A 
Forbes 
(C), 2010 
[120] 
51.6 250 <30d: 1.6% 68 <30d: 5.8% NS 
Chisci (C), 
2009 
[121] 
19.5 0  74 <30d: 4.1% 
>30d: 5.4% 
N/A 
Hobo (C), 
2007 [67] 
19.9 4031 <30d: 1.9%   
>30d: 3.2% 
1152 <30d: 4.9%   
>30d: 6.5% 
<30d 
=0.0001 
>30d 
=0.0016 
Choke (C), 
2006 
[122] 
21.7 87 <30d: 2% 
>30d: 1%) 
60 <30d: 3% 
>30d: 3% 
NS 
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Leurs (C), 
2006 [68]a 
12 2872 <30d:  
A=2.6% 
 
>30d:  
A=3.4% 
677 <30d:  
B= 3.5% 
C =10.9% 
>30d:  
B = 9.6% 
C = 11.3% 
 
<30d: C vs A, 
[OR 4.46 
(95% CI 2.61 
- 7.61)] 
>30d: B vs A, 
[OR1.98 
(1.16-3.38)] 
C vs A, [OR 
2.32 (1.17-
4.6)] 
 
Fairman 
(C),  2004 
[106] 
21 66 15.2% 153 10.5% NS 
Dillavou 
(C), 2003 
[110] 
18 115 <30d: 1.7% 
>30d:  0.8% 
91 <30d: 1.1% 
>30d: 2.1% 
NS 
Table 5.12 - SA – Standard Anatomy, NSA – Non-standard anatomy, AAA – Abdominal aortic aneurysm, NS – 
Not Significant, NR – Not reported, FU – Follow up,   a – Leurs et.al. compared three groups with different 
neck lengths, (A) – >15mm, (B) – 10 – 15mm, (C) - <10mm. 
 
The total cohort of SA patients is 16053 and NSA patients is 8458 across all included 
studies. However, when only considering those studies in which there is comparison 
between SA and NSA patients there are 10244 SA patients and 3600 NSA patients. Five 
studies showed that NSA patients have significantly more type1a endoleaks within 30 days 
from the procedure compared with SA patients. These studies comprise 8362 SA patients 
(81.6% of the SA patients where comparison with SA was being drawn) and 2323 NSA 
patients (64.5% of the total). Four studies show the same to be true over the course of 
follow up beyond 30 days and they comprise 7507 SA patients (73% of the total) and 1303 
NSA patients (36% of the total). The range of observed type 1a endoleaks is as follows: 
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 SA patients (<30 days) – 0 – 2.6% 
 NSA patients (<30 days) – 0 – 10.9% 
It should be noted that one study [96] included all intraoperative type 1a endoleaks 
whether treated successfully or not. The rate of type 1a endoleaks in that study for SA 
patients was 7% and NSA patients 18%.  
The range of observed type 1a endoleaks >30 days is as follows: 
 SA patients – 0.8 – 5.6% 
 NSA patients – 1.4 – 11.3% 
In one study, by Fairman et. Al. the reported endoleak rate for the SA group was 15.2% but 
this was for all endoleaks at all points and no distinction was made between perioperative 
endoleaks within 30 days and those found throughout follow up. 
5.5. Secondary Outcome Results 
According to published reporting standards [24], primary technical success is defined as 
“successful introduction and deployment of the (endovascular) device in the absence of; 
surgical conversion, mortality, type 1 or 3 endoleaks and graft limb obstruction.” The 
reporting standards also state that if unplanned endovascular or surgical procedures are 
necessary then the terms “assisted primary or secondary technical success, respectively, 
should be used.” For the purposes of this systematic review it is this definition that is used 
when determining rates of technical success. In general, across the literature authors 
poorly defined technical success in their report and in some instances were clearly contrary 
to the published reporting standards. It should be noted these accepted reporting 
standards were published in 2002, before all the included articles. Primary technical 
success was reported on or possible to gather from presented data in 11 of the included 
studies. Primary technical success for SA patients ranged from 89.7 – 99.7% [95, 107, 116, 
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120, 122]. In two cases where primary technical success was reported as 89.7% and 90.5% 
the assisted primary technical success rate was also reported and was 100% in both cases. 
For the NSA group 10 studies reported on primary technical success rates and they ranged 
from 80 – 98% [95, 103, 111-114, 116, 119, 121, 122]. The total combined primary technical 
success rate was 962 patients out of 1061 (90.7%). Five of these studies also documented 
additional unplanned endovascular procedures bringing their assisted primary technical 
success rate to 100%. [111-113, 116, 119]. One additional study reported an assisted 
primary technical success rate of 98%. [122]From these six studies it is possible to analyse 
the reasons for lack of technical success; in no study was there a statistically significant 
difference between the SA and NSA groups in terms of technical success but one study 
[113] did show a significant difference in the number of proximal cuffs placed for type 1a 
endoleak seen on completion angiogram; In the SA group 4 (2.2%) patients had an 
intraoperative extension cuff placed, compared to 7 (9.9%) NSA patients (OR 4.76, 95% CI 
1.3 to 16.8, p=0.014). From these six studies, comprising 328 SA patients and 481 NSA 
patients, there was a total of 19 unplanned adjunctive procedures performed for the SA 
group (5.8%) and 78 for the NSA group (16.2%). Of all the 97 adjunctive procedures, 75 
were for lack of proximal seal and 22 were for iliac issues. Of the 75 procedures for lack of 
proximal seal on completion angio; 34 were placement of an extension cuff, 16 were 
placement of a large palmaz stent, 2 were additional proximal balloon moulding, 1 was the 
placement of embolization coils and 22 procedures were not specified in the report.  
Although clinical success as per the reporting standards was defined as a secondary 
outcome measure at the beginning of the systematic review not a single included study 
reported clinical success rates as per the reporting standards. Due to the multiple 
requirements for clinical success to be achieved it was not possible to ascertain the true 
clinical success over the follow up for any given population in the included studies. 
Therefore, no further analysis can be made of it here. Similarly, the length of hospital stay 
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was very infrequently reported, and little can be made of further analysis in this systematic 
review. Rates of visceral vessel patency were rarely reported specifically. However, for 
completeness, the results of the 5 studies that commented on visceral vessel events are 
presented here [95, 106, 112, 117, 121]. There were 2 patients with renal artery occlusion 
in SA patients perioperatively (of 303 patients, 0.7%) compared with 10 NSA patients (of 
477, 2%). In only one study was there mention of visceral vessel events during follow up, 
the remainder pertained to perioperative events.  
Only one study showed a significant difference in terms of renal dysfunction between the 
SA and NSA groups [106]. That study focussed specifically on renal outcomes and a ‘renal 
event’ was defined as “renal artery occlusion, new parenchymal infarction visible on 
computed tomography (CT) scan, including segmental and small wedge-shaped infarcts; 
acute increase in serum creatinine concentration to greater than 2 mg/dL; and transient or 
new-onset uncontrolled hypertension.” They found that NSA was associated with an 
increased risk of any renal event at any time point (13.6% SA patients vs 27.5% of NSA 
patients, p= 0.04). The majority of events were a rise in creatinine with 100% of the SA 
patients and 74% of the NSA patients suffering this. Unfortunately, the study does not 
clarify what clinical sequalae, if any, these patients suffered from this increased rate of 
renal events. Of the remaining studies; one reported permanent deterioration in renal 
function rates as high as 8.1% [121] occurring perioperatively but noted no dialysis resulted 
from this. One other study [95] showed that 3 NSA patients (2.6%) went on to require 
dialysis after occlusion of a renal artery. 
5.5.1. Endograft Migration 
Most studies reported no or little stent graft migration both in the short term and 
throughout follow up (See table 5.13.) 
129 
 
Table 5.13. Rates of endograft migration reported in included studies 
Study Length of 
FU, mean 
or median 
(Months) 
N (SA 
patients) 
Migration 
reported 
through 
FU, % 
N (NSA 
patients) 
Migration 
reported 
through 
FU, % 
Significant 
difference 
between 
groups 
Pitoulias (NC), 
2017[111] 
41 88 - 73 0 N/A 
Gallitto (NC), 
2016[112] 
51.4 - - 60 0 N/A 
Mateo (C), 
2016 [113] 
SA - 30.5 
NSA – 38 
178 0 71 0 NS 
Cerini (C), 
2016 [95] 
37  94 0 115 0 NS 
Broos (C), 
2015 [114] 
12  1114 0 104 0 NS 
Speziale (C), 
2014 [116] 
24 63 0 133 6.4% NS 
Lee (C), 2013 
[117] 
35 143 2.1 % 75 2.7%  NS 
Antoniou (C), 
2013 [118] 
18 - - 60 0 N/A 
Stather (C), 
2012 [103] 
SA – 48.8  
NSA – 50.1 
353 2.5% 199 3.0% NS 
Hager (C), 
2012 [119] 
18.6 - - 84 0 N/A 
Chisci (C), 
2009 [121] 
19.5 - - 74 2.7% N/A 
Abbruzzese 
(C), 2008 [94] 
29.6 343 2.1%  222 1.4%  NS 
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Hobo (C), 2007 
[67] 
19.9 4031 <30d: 0.8% 
 >30d:4.3% 
1152 <30d: 1.6% 
>30d: 5.9% 
<30d = 
0.0105 
>30d - NS 
Leurs (C), 2006 
[68] 
12 2872 2.8% 677 1.2% NS 
Fairman (C),  
2004 [106] 
21 66 <30d: 0 
Free 
(2yrs): 
86.9% 
153 <30d: 0 
Free 
(2yrs): 
87% 
NS 
Dillavou (C), 
2003 [110] 
18 115 0 91 0 NS 
Table 5.12 - SA – Standard Anatomy, NSA – Non-standard anatomy, AAA – Abdominal aortic aneurysm, NS – 
Not Significant, NR – Not reported, FU – Follow up 
 
One study by Hobo et.al. found a significant difference between SA and NSA groups in 
terms of migration within the first 30 days. This study was a review of the large EUROSTAR 
registry investigating the effect of beta angle >60 degrees on outcome. Although this study 
found an increase in migration in the short term in NSA patients this difference was not 
sustained beyond 30 days. The authors offered no explanation for why this may be the 
case, but this may be due to the fact this was a registry-based study on a large number of 
patients and therefore resolution of individual patient data is inevitably less good in such a 
study. 
5.5.2. Conversion to Open Repair 
Of all the included studies, five of them did not report on conversion to open repair rates. 
[67, 96, 98, 115, 122] In some cases this may have been because there was no conversion 
to open repair, however without explicit statement of this it could not be assumed. The 
remaining 16 studies reported on conversion to open repair rates. Of 7935 patients (both 
SA and NSA) across those studies 93 cases of conversion to open repair were documented 
giving an overall rate of 1.2% across all time points. This included perioperative 
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conversions, within 30 days and beyond. Some studies did not clarify whether the 
conversions were in SA or NSA patients. In any studied that statistically analysed the 
difference between SA and SNA patients and the rate of open conversion there was no 
statistical difference. [68, 94, 106, 114] In 15 cases the reason for conversion was known 
but not mentioned in the remaining 78 cases. Reasons given for conversion included; 
 Access related failure during index procedure (2 patients) 
 Delivery system failure (device related failure) intraoperative (1 patient) 
 Bilateral renal artery coverage during index procedure (1 patient) 
 Infected endograft necessitating explantation (2 patient) 
 Proximal endoleak without rupture (4 patients) 
 Presentation with ruptured aneurysm (1 patient) 
 Presentation with proximal endoleak and ruptured aneurysm (4 patients) 
5.5.3. Aneurysm Growth 
Seven of the included studies did not report on aneurysm growth or reduction over time. 
Of the studies that did include it in their report there was significant variation in the 
reporting of changes in aneurysm dimensions. One reported rates of aneurysm 
enlargement using a definition of >8mm to define what constituted an enlarging aneurysm 
[68], another studied defined an enlarging aneurysm as growth >2mm [111]. In addition to 
this AbuRahma et.al. utilised Kaplan Meier analysis of freedom from “sac enlargement” 
while most other studies reported a proportion of patients with “sac enlargement”.  
Chisci et.al. who reported on outcomes of open repair, standard EVAR and fEVAR for NSA 
showed that in their study standard EVAR had a higher incidence of ‘late sac expansion’ 
compared with fEVAR (9 (12.2%) versus 1 (1.9%), p=0.036, respectively). Of note the largest 
study identified and included in the systematic review [98] identified a significant 
proportion of NSA patients with aneurysm enlargement over the course of follow up. In the 
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entire cohort of their studied population, including SA and NSA patients they found that 
the proportion of patients exhibiting aneurysm enlargement at 1, 3, and 5 years after EVAR 
were 3%, 17%, and 41% respectively. They also noted that 30% of patients did not 
demonstrate enlargement until 3 years after their index procedure. They also showed that 
aneurysm enlargement was more common in patients with NSA anatomy compared to SA 
anatomy. Interestingly they also found a correlation between year of endograft 
implantation and AAA enlargement over follow up, showing that those stent-grafts 
implanted after 2004 had a higher rate of expansion than those placed before this date. 
This study performed univariate and multiple variable analysis and determined the 
following predictors of AAA enlargement post EVAR; presence of endoleak on any post-
operative scan (HR 2.7, 95% CI 2.40 – 3.04), patient age >80 years, aortic neck diameter 
>28mm, beta angulation >60 degrees and anatomy outside IFU. 
5.2. Summary of results 
In summary; 21 studies were included in the final systematic review with a total population 
of 24511 patients. The number of patients with SA was 16053 and there were 8458 with 
NSA. The length of follow up within studies ranged from 12 months – 51.6 months. No 
significant difference was found between SA and NSA patients with regards to 
perioperative mortality with total rate of perioperative death being 2.3% in SA patients and 
3.1% in NSA patients. The rates of aneurysm related mortality throughout follow up were 
similar between the two groups also, with only one study revealing a significantly increased 
ARM in the NSA population, though the reporting of ARM was inconsistent within that 
study and when compared to other studies and published reporting standards. The rates of 
all-cause mortality throughout follow up were similar between the two groups also; the 
five-year survival rate was between 70 – 85% for NSA patients and approximately 85% for 
SA patients.  
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It appears from the collated results there may be an increased risk of secondary 
intervention during follow up (beyond 30 days) in NSA patients treated with standard 
EVAR. A large registry study (Hobo) found increased reintervention rates with a HR of 1.29 
(95% CI 1 – 1.67) for NSA patients. The remaining studies did not show a statistically 
significant difference, but all reported increased reintervention rates in the NSA group 
compared with SA patients. Often the increased reintervention was attributed to an 
increased number of procedures performed for the purposes of maintaining or achieving 
proximal seal. 
From the included studies it appears that type 1a endoleak rates are higher in patients with 
NSA treated with standard EVAR compared to SA patients. A maximum type 1a endoleak 
rate for NSA patients versus SA patients was 10.9% vs 2.6% respectively within 30 days. The 
difference beyond 30 days was 11.3% versus 5.6% for NSA and SA patients respectively.   
A large image repository-based study comprising the majority of included patients 
(schanzer) found that NSA anatomy seemed to predict aneurysm enlargement over the 
course of follow up (31 months in that study), as well as presence of endoleak and age >80 
years. 
5.3. Discussion 
Two previous systematic reviews and meta analyses have been done in this area, to 
investigate the differences between SA and NSA patients undergoing standard EVAR [57, 
78]. They were both published in 2013 with the most recent included article being from 
2012. Antoniou et.al. included 7 articles with a total of 1559 patients and the primary 
findings from that meta-analysis were that NSA patients require an increase in 
intraoperative adjunctive procedures, they have an increased 30-day morbidity from their 
procedure and the rate of type 1 endoleak and aneurysm related mortality are increased at 
1 year. The authors go on to conclude that insufficient high-level evidence exists and that 
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“EVAR should be used cautiously in patients with unfavourable aneurysm neck anatomy”. 
The other meta-analysis by Stather et al. included 16 articles with a total of 11959 patients. 
Their principle findings were that patients with NSA had an increased 30-day mortality rate, 
increased use of intraoperative adjunctive procedures and an increase in 30-day migration 
rates. They also found that the rate of both 30 day and “late” type 1 endoleaks were 
increased in NSA patients. The authors go on to conclude: “performing EVAR in patients 
with unfavourable neck anatomy results in poorer short-term outcomes. The higher rates of 
early and late type I endoleaks suggest that increased monitoring should be performed in 
this category of patient.” 
The current systematic review includes 10 papers published since 2012 and a total of 24511 
patients that makes it the largest systematic review in this area. No randomised controlled 
trials have been identified that investigated the differences between NSA and SA patients 
undergoing standard EVAR and all the included studies in this systematic review are 
observational non-randomised studies. The results from any synthesis of the literature 
therefore needs to be read with this in mind.  
This systematic review sought to define the study populations of NSA and SA based on 
manufacturers recommended instructions for use criteria. In fact, one important point to 
note is that there was significant heterogeneity across the included studies as to what was 
determined “hostile” or “bad” neck anatomy. This, in itself, therefore limits the validity and 
applicability of any synthesis of results across the studies. In fact the two meta analyses 
mentioned above [57, 78] differ on this exact point with one using the IFU definition for 
inclusion into their meta-analysis [78] and the other preferring set anatomical criteria [57]. 
Stather et. al. even goes on to criticise the meta-analysis by Antoniou et.al. in this regard 
stating that: 
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“A major limitation of Antoniou’s study is that the included studies defined hostile neck if a 
device-specific analysis had been conducted; otherwise, studies had to include neck length 
<15 mm and neck angulation >60°. Patients were thought to have HNA (Hostile neck 
anatomy) if one or more criteria were present. In addition, the lack of inclusion of patients 
with increased neck diameter limits the generalizability of these results. Our study, 
therefore, aimed to address these limitations by including any of the HNA criteria.” 
 
Stather et. Al. used specific set anatomical criteria to define whether anatomy was NSA or 
SA and included in their definition any proximal neck diameter of >28mm even though 
most stent-grafts at the time of their publication included neck diameters up to 32mm in 
their IFU. It is true that most of the included studies in their systematic review were 
published before 2008 and prior to this time most implanted stent-grafts had IFUs that 
would consider >28mm as a breach of that particular guideline. However, it does mean that 
some patients included in their study as having a “hostile” neck would have been treated 
by a clinician implanting a stent-graft within its IFU. If one was investigating the specific 
outcomes relating to specific anatomical parameters (e.g. neck diameter, or angulation or 
length) then a specific measurement value would be a valid defining criterion and analysis 
of the performance of different stent—grafts inside and outside that specified parameter 
would be an inherent and interesting part of the analysis. However, when the criteria of 
interest is “hostile” neck anatomy there is essentially a choice as to how one defines that – 
with specified anatomical values regardless of what stent-graft is implanted or anatomical 
criteria that vary depending on stent-graft implanted i.e. the IFU. If the former definition is 
applied this methodology would essentially ignore the fact that stent-grafts differ in their 
design and have been tested by the manufacturers against certain tolerances both ex vivo 
and in vivo. However, it potentially allows the analysis to define if there are finite limits to 
anatomy in which EVAR can be used. If utilising IFU for the definition of NSA then,  
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potentially less can be said about specific anatomical thresholds that may or may not 
impact on clinical outcomes.  
In endovascular surgery technological advancement is relatively rapid and evolution of the 
devices in question happens at a pace that outstrips the publication of clinical outcome 
data for a given device. This means that meaningful collation of large quantities of clinical 
outcome data, as in a systematic review, needs a way of handling the potential 
confounding factors of differing anatomy and stent-grafts used. Utilising IFU allows 
different stent-grafts to be compared using a common characteristic regardless of the 
anatomy being treated, i.e. inside or outside IFU. It is for these reasons that this author 
recommends that studies investigating this area should use IFU as the anatomical definition 
for “good” vs “bad” anatomy. At all points the IFU for each device being considered should 
be published to allow retrospective review to understand the characteristics considered 
“out of IFU” or that stent graft when it was implanted – as newer versions of the same 
stent graft may be released onto the market at a later date and it can be difficult to 
retrospectively source the IFU for a given time period from the manufacturer. Another 
comment to make about this is that there is no reason that specific IFU criteria (and 
therefore individual anatomical criteria such as angulation cannot be analysed within such 
a study) for example comparing less than 60 degrees of beta angulation with  greater than 
60 degrees but ensuring that all patients within the <60 degrees group are within IFU for all 
variables and that those within the >60 degree group are out of IFU for the stent graft 
used. It is the opinion of this author that populations should still be assessed and grouped 
whether they fulfil all IFU criteria or not. This does limit numbers of patients available for 
analysis but this ‘tool’ acts to control for the confounding factors of other anatomical 
features, which can affect outcomes.  
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The significant heterogeneity seen in the included studies was also evident in a number of 
areas. The methodological quality across the studies was relatively poor. Often studies 
would include patients treated as an emergency and not separate the data for those 
patients to allow separate analysis. Also, it was often not defined at all whether emergent 
patients were included or not. Definitions were reported in the main to follow published 
reporting standards however further analysis of the data revealed importantly that these 
definitions were sometimes inconsistently applied for example in the labelling of patients 
as having suffered aneurysm related mortality or not. Studies often did not state whether 
reviewers who analysed CT scan data were blinded to the clinical outcomes and studies 
consistently scored poorly in this domain when assessing their quality using the MINORS 
tool. Due to significant heterogeneity in the definitions and reporting of inclusion criteria, 
and outcome measures it was decided early in the process of performing this systematic 
review that a narrative account rather than a meta-analysis should be undertaken. In the 
meta-analysis by Antoniou et.al. mentioned earlier the authors found that only a limited 
number of studies (and patients) could be included for any given outcome measure they 
were investigating because of the disparities and inaccuracies in reporting in the wider 
literature. This limited the conclusions that could be drawn from that meta-analysis. 
Furthermore, Stather et.al. in their systematic review cited the fact that studies defined 
NSA differently introducing an important confounding factor into the systematic review 
and subsequent meta-analysis. They found that when they analysed only studies that 
included “all three” neck criteria of diameter, length and angulation, this reduced the 
number of studies analysed to 5 and with a patient cohort of 1995. They do state however 
that many of their principle findings were maintained when this analysis was done. 
Furthermore, the length of follow up was relatively short in the majority of studies with 10 
studies reporting a mean or median follow up of 2 years or less and 16 reporting 3 years or 
less. With reporting standards [99] defining follow up of between 1 and 5 years as “short 
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term” when EVAR is implanted electively it highlights the limited nature of this and other 
systematic reviews in determining outcomes over the longer term. 
From the included studies there were 4 more recent studies that detailed and showed a 
significant difference in the use of proximal aortic cuffs between the NSA and SA groups. 
[96, 113, 114, 117]. There were 2 other studies that failed to show a statistically significant 
difference and the rest did not report on the use of aortic cuff extensions. Of the four 
studies mentioned above they showed that 36 out of 1686 SA patients (2.1%) had a cuff 
placed wither intraoperatively or within 30 days of the original procedure. This compares to 
67 of 525 NSA patients (12.8%). It is reported by Broos et.al. that there were no significant 
differences in technical success rates and it appears that the majority of these extension 
cuffs were placed intraoperatively. This suggests that they were successful in most of the 
case to help achieve a proximal seal on the day of the index procedure. As noted earlier 
however there was a significantly higher type 1 endoleak rate within and beyond 30 days in 
the NSA group. What is difficult to ascertain is whether the higher endoleak rate within 30 
days is despite the extra use of proximal aortic cuffs or whether these extra cuffs are being 
placed to treat these extra type 1 endoleaks. However, because of the higher rate of 
endoleaks after 30 days it seems clear that whatever the scenario in perioperative phase, 
despite aggressive treatment of the proximal seal zone, these devices do continue to fail at 
a higher rate than their SA counterparts resulting in more type 1 endoleaks.  
It seems intuitive that if an aneurysm presents anatomy that fails a number of anatomical 
IFU criteria rather than just one it will have a greater risk of poor clinical outcomes. This 
supposition cannot be determined from the available literature. One study [116] did show 
significantly worse outcomes as the number of IFU violations were increased but the 
subsequent analysis included only small numbers of patients as the majority were out with 
139 
 
IFU on only 1 anatomical criterion. This is an important area for future research to 
determine truly what the additive effect of increasing IFU breaches is.  
There were several limitations within this systematic review. As stated previously there was 
significant heterogeneity within the literature in terms of the reporting of anatomical 
characteristics and between publications in terms of the focus of their analysis conducted 
(anatomical values vs in or out of IFU). To enable the inclusion of as many potentially 
relevant studies while trying to minimise the potential for confounding factors in terms of 
anatomical factors, inclusion criteria were drawn up to allow the inclusion of studies if they 
specifically reported anatomical values that were out with the IFU for the implanted device. 
In reality this lead to the inclusion of some studies, most notably the EUROSTAR series’ [67, 
68], that investigated individual anatomical factors (neck length and angulation) and 
included NSA patients in their “SA” group. To limit the inclusion to studies in which only SA 
patients were in the “SA” group would have significantly limited the number of patients 
included in the final analysis and thereby would have potentially ignored important results 
from these studies that are valuable and useful when analysed with this confounding factor 
in mind. Such as the findings of increased graft related endoleaks in those patients with 
short or angulated necks. This systematic review could also be criticised for the inclusion of 
the paper by Schanzer et.al. as this one paper contributed such a large proportion of the 
patients and was distinctly different in its methodology and patient capture than the 
others. This study utilised an imaging repository in the United States of America, to 
investigate anatomical features found pre and post EVAR in a large number of patients. 
Little is known about the clinical circumstances of the patients or even the type of 
endovascular device implanted. Therefore, there was only really one outcome measure 
analysed in this study – aneurysm growth over time. It was included because it indeed did 
meet the pre-specified inclusion criteria, but the value of its inclusion was very limited 
despite the number of patients it contributed. Without the inclusion of that study this 
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systematic review would have included 20 studies with 14283 patients (10332 SA patients 
and 3951 NSA patients). In addition to these criticisms the study by Schanzer et. al. 
included a large proportion of patients (59%) with AAA less than 55mm in diameter. Since 
the current indication for treatment is AAA >55mm electively the addition of these patients 
limits the applicability of the findings from that study to most patients treated today. 
This systematic review sought to analyse demographic and anatomical data in relation to 
NSA patients undergoing standard EVAR and also sought to compare outcomes for these 
patients with SA patients undergoing EVAR but arguably this is an irrelevant comparison. 
Most vascular surgeons would not argue that clinical outcomes after surgery are inferior 
when dealing with more complex anatomy, and this is especially true in aneurysm surgery. 
Reports within the first five years of EVAR use becoming widespread began to show this 
[97] and it has been continually confirmed by further reports detailed here in this 
systematic review and in other systematic reviews [57, 78]. Therefore, comparison of 
outcomes between SA and NSA patients undergoing standard EVAR provides value in 
knowing the magnitude of the deleterious effects of performing EVAR in this population 
and where if any thresholds of anatomy cannot be breached in any circumstances. If one 
accepts that NSA patients have inferior outcomes when treated by standard EVAR 
compared to SA patients the next question is whether those outcomes are inferior to the 
outcomes for alternative treatments for NSA patients. Therefore, comparison with the 
alternatives such as open repair, standard EVAR with auxiliary techniques and devices (e.g. 
endoanchors), advanced stent graft techniques (chimney EVAR, fEVAR and distinct 
technology such as endovascular aneurysm sealing is the important next step in research 
for these patients. 
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5.4. Conclusion 
In conclusion, there is limited high quality evidence to suggest what the magnitude of 
difference in outcomes there are between NSA and SA patients who undergo standard 
EVAR. It appears that there is a difference in outcomes when comparing the two groups. 
Primarily NSA patients experience an increased rate of type 1a endoleak both within 30 
days from the index procedure and beyond. They also experience an increased risk of 
secondary intervention, usually to maintain proximal seal. There is insufficient evidence to 
suggest whether these findings equate to significantly worse outcomes for NSA patients in 
terms of all cause or aneurysm related mortality beyond 30 days. The data on outcomes 
from these patients are currently only available for short term (up to 5 years post 
operatively) and therefore to better understand long term outcomes and risks in these 
patients further study and research is needed. This should analyse patients defined by 
anatomy relating to the IFU for the device implanted to allow comparisons of patients 
across a time period which has seen significant advances and evolution in technology. 
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6. CHAPTER 6 - Systematic Review of Clinical Outcomes 
Following Open Surgical Repair in Non-Standard Aneurysms 
6.1. Introduction 
As stated in the above systematic review it is important to compare outcomes for patients 
with NSA across different treatment options to understand what the shortcomings are of 
each treatment. The purpose of this research as a whole is to try and answer that question 
and specifically to investigate the clinical outcomes for three treatment options for patients 
with NSA: namely EVAR outside instructions for use, open surgical repair and fenestrated 
endovascular aneurysm repair. Open surgical repair has been performed on abdominal 
aortic aneurysms for many decades but gained prominence in the 1950’s with Dubost [56]. 
Since then it has been the mainstay of treatment for abdominal aortic aneurysms until the 
advent of endovascular techniques. By many open repair is still considered the gold 
standard and therefore it is important to understand the clinical outcomes for patients with 
NSA treated with open surgical repair to allow comparison with the other two treatment 
options described. The aim of this systematic review was to provide an updated synthesis 
of the available evidence from contemporaneous (20-year search limit) reports and 
previously conducted systematic reviews and meta-analyses investigating specifically the 
clinical outcomes for aneurysms that possess NSA. 
The question being addressed in this systematic review is to understand what the clinical 
outcomes are for patients undergoing open surgical repair whom exhibit proximal aortic 
neck anatomy that is considered outside the indications for use for standard EVAR. The 
primary clinical outcome measures will include the following both perioperatively and 
throughout follow up; all-cause mortality, aneurysm related mortality, and reintervention 
rates. Secondary outcome measures will include: visceral vessel patency (where reported), 
rates of renal dysfunction. The systematic review also aims to investigate by its narrative 
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nature the quality of reporting of anatomical detail with regard to the proximal aortic neck 
in the available literature to determine if current standard reporting within the published 
literature allows comparison between truly anatomically homogenous groups. This 
systematic review was conducted in a similar way to the above reported review looking 
into outcomes after standard EVAR used in NSA. 
6.2. Methods 
The systematic review followed reporting guidelines set out in the Preferred Reporting 
Items for Systematic Reviews and Meta-Analyses (PRISMA) document. [108] In line with 
these guidelines a protocol for the systematic review was established prior to the beginning 
of the literature search as follows. The protocol is reproduced here in its entirety.  
6.2.1. Protocol for Systematic Review, Including Eligibility 
Criteria 
A systematic review of the literature will be undertaken to examine the clinical outcomes 
for patients undergoing abdominal aortic aneurysm repair for non-standard aneurysms 
using open surgical repair. Non-standard aneurysms are defined as those in which the 
aortic neck anatomy is considered outside indications for use (IFU) criteria for standard 
infrarenal EVAR. Primarily this includes those aneurysms with a neck length of less than 
10mm from the lowermost renal artery ostium to the top of the aneurysm, neck diameter 
of >32mm and or angulation of >90 degrees between the infrarenal neck and the aneurysm 
itself. An aneurysm would be considered non-standard if any of these criteria are present. 
It is expected that within the published literature there may not be detailed anatomical 
criteria included in the reports and therefore it will be difficult to truly identify whether a 
study will include patients in whom the anatomy would have been suitable for standard 
endovascular repair. Therefore, the anatomical definitions used in a study will be 
scrutinised and if there is not enough clarity to ensure that the patients being studied truly 
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do have NSA then that study will be included. If a study includes patients in whom both 
NSA and SA are being investigated, then only if the results for patients with NSA can be 
ascertained from the published report then that study will be included. In the absence of 
reporting of specific anatomic criteria such as neck length, diameter or angulation a few 
other anatomic classifications will be accepted to reasonably suggest that NSA is being 
investigated. These will include the term “juxtarenal” and “pararenal” aneurysm as defined 
by the Ad Hoc Committee on Reporting Standards for the Society of Vascular Surgery [24]. 
This definition states that there is “no normal aorta between the upper extent of the 
aneurysm and the renal arteries”. Aneurysms defined as suprarenal will not be included as 
this description suggests the aneurysm involves the visceral segment of aorta and 
therefore, if treated endovascularly, would require branched endovascular technology, not 
fenestrated technology. Furthermore, aneurysm described as type IV thoracoabdominal 
aneurysms will not be included for the same reason. The caveat to this is if an aneurysm is 
defined as suprarenal but specific anatomic criteria are reported to clarify that actually 
fenestrated endovascular repair could be performed within its IFU. 
The objective of the systematic review is to compare the published literature for all 
patients with non-standard aneurysms undergoing open surgical repair. It is expected that 
no randomised controlled trials would be identified and therefore non-randomised studies 
evaluating clinical outcomes would be included in the analysis.  
Inclusion criteria: 
 Aneurysm morphology - For a study to be included in the analysis, it should clearly 
state that the population had morphologic infrarenal neck characteristics that were 
not within the indications for use for standard EVAR. As already stated above other 
definitions will be accepted in line with published reporting standards. 
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 There must be median (or mean) follow up of at least 1 year to enable meaningful 
results of short and mid-term data for the studied population 
 In order to reduce bias introduced from small case series studies must have at least 
50 patients with non-standard anatomy 
Exclusion Criteria: 
 Studies reporting solely on symptomatic or ruptured aneurysms. If a study includes 
symptomatic or ruptured aneurysms it is expected that the results for these 
patients will be identifiable and be able to be excluded from further analysis. If it is 
not possible to do so then an explicit statement as such will be made in the report 
to make it clear that this confounding variable exists in the identified study 
population. 
 Previous treatment for abdominal aortic aneurysm 
 If the report presents patients treated with a hybrid (endovascular combined with 
open surgical repair) technique. 
 Aneurysms repaired by laparoscopic means will be excluded from the analysis 
 No statement of aneurysm morphology, either as “outside IFU” or specific 
anatomic criteria 
Eligibility Criteria 
 Publication dates within 20-year period (1998 – 2018) 
 English language only results considered 
 The population will include all adults with no age restriction 
The above protocol was referred to throughout the data identification and extraction phase 
to ensure it was adhered to. 
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6.2.2. Definitions and Outcome Criteria.  
Outcome criteria and definitions were based on recommended reporting standards for 
EVAR, published by the Ad Hoc Committee for Standardized Reporting Practices in Vascular 
Surgery [24] which include details on reporting outcomes for open surgical repair also. The 
outcomes within the first 30 days after the index procedure or occurring within the same 
hospital admission will be reported as perioperative outcomes, those occurring between 30 
days and 1 year will be termed ‘Early’, those between 1 and 5 years will be termed ‘Short’, 
5 to 10 years will be considered ‘Midterm’ and > 10 years will be ‘Long-term’. This is in line 
with the pragmatic minimum reporting standards for endovascular aneurysm repair [99] 
Primary outcome measures included perioperative mortality from any cause, all-cause 
mortality, aneurysm related mortality and reintervention rates. The secondary outcome 
measures are as follows: 
 Primary Technical success 
 Clinical success 
 Visceral vessel patency 
 Length of hospital stay 
 Rates of renal dysfunction throughout follow up (the definition used within the 
given study for renal dysfunction will be used) 
6.2.3. Information Sources and Electronic Search Strategy 
An electronic search of the literature was undertaken. The search was applied to MEDLINE 
(database provider PubMed, from 1998 – 2018) and EMBASE (database provider Ovid, from 
1998 to 2018). The search was undertaken once in May 2018. A full record of the search 
strategy is included within Appendix 2. The full reference list of each full text study 
assessed was interrogated to identify any relevant articles missed in the original search. 
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6.2.4. Study Screening and Selection 
The study screening and selection strategy employed was exactly that as for the systematic 
review of clinical outcomes of non-standard aneurysms treated by EVAR (Chapter 5). The 
search strategy results and reasons for exclusion are listed in figure 6.1 below. 
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Figure 6.1. Search strategy for Systematic Review of Open Repair used outside IFU 
 
  
Figure 6.1 - Numbers represent articles. Arrows denote whether articles were excluded or included. 
 
Search of Electronic 
Databases 
315 
Screening of Selected 
Abstracts 
95 
Abstract not relevant 
45 
Title not relevant 
220 
Screening of Full Text 
Article 
50 
Studies Included 
8 
Full texts excluded and reasons (36) 
 Conference abstract or 
commentary: 16 
 Population <50: 2 
 Unclear definition of anatomy: 9 
 Only standard anatomy: 1 
 Full text not available: 4 
 FU <1 year: 4 
 Systematic review/meta-
analysis: 6 
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6.2.5. Data collection 
A data extraction sheet was developed. As well as pertinent information relating to the 
publication (year of publication, journal etc) the remaining collected variables were divided 
in three broad categories: (1) baseline clinical and demographic data, anatomic 
characteristics, and procedure related characteristics; (2) primary outcome data (3) 
secondary outcome data, as outlined previously. The methodologic quality of the included 
studies was assessed using the MINORS tool. [109] 
6.3. Results 
From the 315 results returned from the original search 8 studies were included within the 
final analysis after full text review. [123-130] Regarding the 8 original studies included; 
there were 5 non-comparative and 3 comparative studies. Two of the three comparative 
studies compared juxtarenal aneurysms with infrarenal aneurysms treated by open repair 
[129, 130] and one study compared open repair with standard EVAR for juxtarenal 
aneurysms [128]. The year of publication ranged from 2007 – 2018 and most studies were 
conducted in the U.S.A. Patients were treated between 1986  - 2013. No randomised 
controlled trials were identified, and all studies were retrospective single centre cohort 
studies with the exception of one which was a multicentre retrospective cohort study. 
There were two studies that did not report the total number of aneurysm patients treated 
during the study period. Of the remaining 6 studies there was a total of 6608 patients 
treated during the study periods. From these 6 studies 867 (13.1%) patients were defined 
in a variety of ways to possess juxta or pararenal aneurysms to satisfy the inclusion criteria 
of this systematic review. From all 8 included studies the total number of subjects deemed 
to have NSA was 1150. Details of the included studies are shown in the table below (see 
table 6.1) 
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Table 6.1. Details of included studies 
Study Years 
Recruited 
No. patients Comparative
/Non-
comparative 
MINORS 
score 
Definition of 
anatomy to 
include patient in 
“NSA” group 
Sugimoto, 
2018 
[123] 
2007 – 
2015 
108 Non 8 Clamp above at 
least one renal 
Kabbani, 
2014 
[124] 
1986 - 
2013 
127 Non 4 No infrarenal 
neck suitable for 
clamping 
Speziale, 
2010 
[125] 
2000 - 
2009 
92 Non 7 Aneurysm up to 
renal arteries and 
clamp above at 
least one renal 
Knott, 
2008[126] 
2001 - 
2006 
126 Non 8 Aneurysm up to 
renal arteries and 
clamp above at 
least one renal 
Pearce, 
2007 
[127] 
1996 - 
2006 
134 Non 10 Clamp above at 
least one renal 
Sultan, 
2011 
[128]a  
2001 - 
2009 
66 Comparative 15 Clamp above at 
least one renal 
Deery, 
2016 
[129]b 
2003 – 
2011 
340 Comparative 13 Clamp above at 
least one renal 
Jeyabalan
2011 
[130] c 
2000 - 
2007 
157 Comparative 15 Aneurysm up to 
renal arteries and 
clamp above at 
least one renal 
Table 6.1 – NSA – non-standard anatomy. A – Comparing open repair with EVAR, b – Comparing infrarenal 
and pararenal open aneurysm repair, c – Comparing infrarenal and “complex” open aneurysm repair 
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All of the included studies scored relatively poorly on the MINORS tool for assessing study 
quality suggesting they were all of poor methodological quality. Furthermore, all studies 
were retrospective in nature and carry the inherent disadvantages of any retrospective 
study. Although most of the studies defined the study population slightly differently there 
was generally a common theme. Some mentioned the SVS reporting guidelines [87] and 
clearly their definition was either directly from those guidelines or influenced by them. No 
study, however, gave detailed anatomical data or used precise anatomical data from pre-
operative imaging to define aneurysms with respect to their suitability for endovascular 
repair or not.  
6.3.1. Demographic information 
The table below details the pertinent demographic information for the included patients in 
the selected studies. (See table 6.2.) 
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Table 6.2 Demographic Information 
Study Age, 
years, 
mean +/- 
SD or 
Median 
(range) 
Male 
(%) 
ASA 
grade 
Pulmonary 
disease (%) 
Coronary 
artery 
disease 
(%) 
Preop 
CKD 
(%) 
Preop 
Aneurysm 
Diameter, 
mean 
(mm) 
Sugimoto, 
2018 
[123] 
72.1 +/-
6.1 
85.2 NR 13.9 NR 45.4 55.7 
Kabbani, 
2014 
[124] 
71 +/- 7.9 91 NR 37 42 56 66 
Speziale, 
2010 
[125] 
71.5 (53 – 
85) 
93.5 NR 25 41.3 39 53 
Knott, 
2008[126] 
73.6 78 NR 41 NR 17 62.5 
Pearce, 
2007 
[127] 
71 +/- 8 74 III – 
68% 
IV – 
28% 
33 64 27 59 
Sultan, 
2011 
[128]a  
70.8 +/- 
7.6 
77.3 NR NR 30.3 37.9 66 
Deery, 
2016 
[129]b 
71 +/- 8 67 NR 41 31 16 61.7 
Jeyabalan
2011 
[130] c 
73.2 66.8 NR NR 63 16.8 60 
Table 6.2 – ASA – American Society of Anaesthesiologists, COPD – Chronic Obstructive Pulmonary Disease, 
CAD – Coronary artery disease, CKD – Chronic Kidney disease, AAA – Abdominal aortic aneurysm. A – 
Comparing open repair with EVAR, b – Comparing infrarenal and pararenal open aneurysm repair, c – 
Comparing infrarenal and “complex” open aneurysm repair 
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There were inconsistencies across the studies about the nature of reporting demographic 
details. Only one study [127] reported ASA grades for patients and not all studies reported 
rates of pulmonary or coronary artery disease. Within the reported values there was 
significant heterogeneity in studied populations also. The proportion of patients who were 
male varied from 67% - 93.5% across the studies. Furthermore, the reported prevalence of 
pulmonary disease and coronary artery disease varied widely across the included studies 
ranging from 13.9 – 41% and 30.3 – 63%  respectively. Within the studies there was often 
little or no detail relating to how pulmonary disease and coronary artery disease were 
defined despite recommendations in published reporting standards [24]. This may account 
for the wide variation but is only speculation and again highlights important heterogeneity 
between the populations. All studies reported rates of chronic kidney disease within the 
studied populations and again there was relatively wide variation in the prevalence of 
chronic kidney disease preoperatively ranging between 16 and 56%. It should be noted that 
studies used a variety of means to define chronic kidney disease. Four studies [126, 127, 
129, 130] defined chronic kidney disease as anyone with preoperative creatinine levels of 
>1.5mg/dL. Two studies [123, 124] used CKD staging criteria with an eGFR of <60 
mL/min/1.73 m2 to define chronic kidney disease. One study [125] defined it as a serum 
creatinine clearance of <40ml/min and one other study [128] did not report how CKD was 
defined. The above snapshot of reported patient demographics from each of the included 
studies highlights the significant heterogeneity between study populations and it is 
important to bear this in mind when drawing conclusions from this systematic review. 
Most studies report preoperative aneurysm diameter to be in the region of 60mm however 
Speziale et.al. [125] report a mean diameter of 53mm in their study and comment that a 
32mm AAA was treated in their series with no explanation given as to why such a small 
aneurysm was treated. 
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6.3.2. Clamp position and timing 
The following table details the information given in each study regarding clamp positions 
and relative renal/visceral ischaemic times reported. In all cases the clamp position was 
above at least one renal artery in the studied population. (See table 6.3) 
Table 6.3. Clamp position and timing 
Study Clamp positions (%) Total reported Renal/Visceral 
Ischaemia time, mins (Mean) 
Sugimoto, 2018 
[123] 
Inter-renal 62.9% 
Suprarenal 31.5% 
Supracoeliac 5.6%  
NR 
Kabbani, 2014 [124] Inter-renal 13% 
Supracoeliac 39% 
NR 
Speziale, 2010 [125] Inter-renal 27.2%  
Suprarenal 72.8% 
26.7 
Knott, 2008[126] Inter-renal 35% 
Suprarenal 44% 
Supra SMA 17% 
Supracoeliac 4% 
22.5 
Pearce, 2007 [127] Inter-renal 43% 
Suprarenal 39% 
Supra SMA 13% 
Supracoeliac 5% 
30 (Median) 
Sultan, 2011 [128]a  Inter-renal 100% NR 
Deery, 2016 [129]b NR 24 
Jeyabalan2011 
[130] c 
Inter-renal 23.9% 
Suprarenal 55.4% 
Supra SMA 3% 
Supracoeliac 17.9% 
29.7 
Table 6.1 - A – Comparing open repair with EVAR, b – Comparing infrarenal and pararenal open aneurysm 
repair, c – Comparing infrarenal and “complex” open aneurysm repair 
There is again significant heterogeneity within the selected studies with regards to clamp 
position with proportion of supracoeliac clamping ranging from 0 – 39%. All studies report 
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a mean or median clamp time of 30 mins or under, but 3 studies did not report the 
ischaemia time at all. In one study [128] all the clamps were inter-renal, and in another 
[125] they were all below the SMA. In scrutinising these studies in more detail, it became 
apparent that strict inclusion criteria applied by the authors led to this finding rather than a 
specific strategy by the operating surgeons. This therefore indicates significant sampling 
bias in these studies at least. It appears that this is an attempt by the authors to try and 
select an anatomically homogenous group for analysis (i.e. to capture juxtarenal but not 
infrarenal aneurysms) but it is notable that the studies use clamp position as a surrogate 
marker for anatomy rather than using anatomy itself to define their patient population for 
study. For the remaining studies the decision at which level the clamp was placed at was 
driven by surgeon preference, whether this be in relation to specific anatomic features for 
a given operation or because of a specific strategy. There continues to be debate within the 
literature at large as to the most appropriate site for placement of an aortic cross clamp 
with some authors advocating routine supracoeliac clamping for juxta and pararenal 
aneurysms and others citing worse outcomes in terms of morbidity and mortality in this 
undergoing supracoeliac clamping. [131-133] Regardless, within the selected studies, 
Kabani et al and Knott et. al. investigated but did not find any significant association 
between clamp site and mortality, however numbers remain relatively small in each study. 
Two of the included studies did however find a significant association between clamp 
location and renal outcomes [127, 130] with higher clamp levels relating to higher levels of 
renal dysfunction in the short term. Again, numbers remain relatively small as with all 
studies in this systematic review 
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6.3.3. Perioperative Outcomes 
The following tables details pertinent perioperative outcomes reported in the included 
studies (See table 6.4) and perioperative rates of renal dysfunction (See table 6.5) 
Table 6.4. Perioperative Outcomes after Open Surgical Repair of NSA AAA 
Study Perioperative 
Mortality (%) 
Morbidity – as reported 
in individual studies 
Reintervention 
(perioperative) 
Sugimoto, 
2018 [123] 
0.9 NR NR 
Kabbani, 
2014 [124] 
3 Pulmonary 15% NR 
Speziale, 
2010 [125] 
1.1 "Major complications" 
24% 
NR 
Knott, 
2008[126] 
0.8 Cardiac 14% 
Pulmonary 11% 
Mesenteric ischaemia 
2% 
NR 
Pearce, 2007 
[127] 
3 Any morbidity 36% 
Major 23% 
Cardiac 15% 
Pulmonary 18% 
NR 
Sultan, 2011 
[128]a  
4.5 NR NR 
Deery, 2016 
[129]b 
2.7 CHF 7.2%*  
Pulmonary 19%* 
8.4% return to theatre 
Jeyabalan20
11 [130] c 
6 NR Bleeding req re-exploration 
4.3% (vs 0.4%) * 
Table 6.2 - * - Statistically significant result when compared with comparator group, NSA – Non-standard 
Anatomy, AAA –Abdominal aortic aneurysm, CHF – congestive heart failure, NR – not reported. A – 
Comparing open repair with EVAR, b – Comparing infrarenal and pararenal open aneurysm repair, c – 
Comparing infrarenal and “complex” open aneurysm repair.  
Perioperative mortality was reported in the majority of studies and ranged between 0.8 
and 6%. The total combined perioperative mortality for all studies was 37 patients out of 
1150 (3.2%). Due to small numbers of perioperative deaths in individual studies only one 
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[130] with the highest perioperative mortality rate of 6% (11 patients) could perform 
regression analysis to determine if there were any predictive factors for this outcome. They 
found that the presence of preoperative coronary artery disease, post-operative 
myocardial infarction and any post-operative pulmonary complications as a predictor of 
perioperative mortality. Of note, this was the case for the juxtarenal aneurysm population 
being studied as well as the infrarenal aneurysm comparator group. The presence of 
juxtarenal aneurysm, length of renal ischaemia time, left renal vein division or renal 
insufficiency preoperatively were not predictive of perioperative mortality in that group. 
Of the three comparative studies no study found a significant difference between the 
juxtarenal aneurysm population being studied and their comparator group with regards to 
perioperative mortality. However, Deery et. Al. did find a significant difference when 
comparing all “complex AAA” which included type IV thoracoabdominal and suprarenal 
aneurysms as well as juxta renal aneurysms which had a 30-day mortality rate of 3.6% 
compared to 1.2% for infrarenal AAA (p = 0.002). 
Post-operative complications or morbidity was inconsistently reported across studies, but 
most did report it to some degree. Relatively high rates of “major” morbidity were seen in 
two studies of 24 and 23% [125, 127]. Only two studies [129, 130] reported on 
reintervention rates in the immediate post-operative period as detailed in the table. 
Deery et. al. found significantly increased rates of congestive heart failure in the pararenal 
aneurysm group compared with their infrarenal open repair comparator group. That study 
also found a higher reintervention rate in the NSA group (8.4% vs 5.9%) but this didn’t 
reach statistical significance. Jeyabalan et.al. found in their study that there were a 
significantly greater proportion of patients requiring re-exploration for bleeding in the 
“complex”, NSA group compared with the infrarenal SA group. 
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Table 6.5. - Perioperative rates of renal dysfunction after Open Surgical Repair of 
NSA AAA 
Study Proportion of patients 
with perioperative 
Renal dysfunction (%) 
New permanent dialysis on discharge 
(%) 
Sugimoto, 2018 
[123] 
18.7% 0 
Kabbani, 2014 
[124] 
47% 1.5 
Speziale, 2010 
[125] 
11% 0 
Knott, 2008[126] 18%  1 
Pearce, 2007 
[127] 
12% NR 
Sultan, 2011 
[128]a  
15.2%* NR 
Deery, 2016 
[129]b 
20%* 1.1%* 
Jeyabalan2011 
[130] c 
32.1%* NR 
Table 6.3.  - * - Statistically significant result when compared with comparator group, NSA – Non-standard 
Anatomy, AAA –Abdominal aortic aneurysm, CHF – congestive heart failure, NR – not reported. A – 
Comparing open repair with EVAR, b – Comparing infrarenal and pararenal open aneurysm repair, c – 
Comparing infrarenal and “complex” open aneurysm repair.  
The rate of perioperative renal dysfunction varied between studies from 11 – 47%. Some 
studies clarified that the majority of perioperative renal dysfunction was temporary and 
had resolved by the team of discharge according to biochemical markers [123, 124, 126]. 
Rates of new permanent dialysis on discharge were low across the studies included with a 
maximum incidence of 1.5% [124]. 
The three comparative studies each independently showed a significant increase in post-
operative renal dysfunction in the juxtarenal aneurysm group compared with their 
endovascular (EVAR) counterparts [128] or infrarenal aneurysm repair comparators [129, 
130]. Again, Deery et. Al. also showed significant more rates of new dialysis at the time of 
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discharge compared to the infrarenal repair comparator group in that study (1.1% vs 0.5% 
respectively). 
6.3.4. Primary Outcome Measures 
The primary outcome measures for this systematic review were: perioperative mortality 
from any cause (discussed above), all-cause mortality, aneurysm related mortality and 
reintervention rates. The mean or median follow up was not reported within two studies 
[124, 129] and ranged between 12 – 54 months in the remaining studies. All-cause 
mortality over long term follow up was not reported in two of the studies [124, 130]. For 
the remaining studies 5-year survival rates were given in four of them [125-127, 129] and 
ranged from 64% - 88.6%. Knott et al. also noted that the 5-year survival rate by Kaplan 
Meier analysis of 64% did not differ when compared with a general age and gender 
matched population. Sultan et. Al. who compared open surgical repair with endovascular 
aneurysm repair did not find any statistically significant difference between the two groups 
in terms of survival over the longer term with a 3-year survival of 85% for open repair and 
57% for EVAR. Despite the disparity in the survival rates there wasn’t a statistically 
significant difference reflecting the limited numbers “at risk” beyond 2 years in that group 
(less than 20). Deery et al who compared “complex” AAA repair with infrarenal AAA repair 
also showed no significant difference in survival at 5 years.  
Three studies investigated predictors of long-term survival or mortality by regression 
analysis.  [124, 127, 129] As would be expected those studies found that patients with 
advanced age, pre-existing conditions such as COPD, coronary artery disease or worse 
preoperative renal function had worse survival outcomes. Kabani et. Al. who investigated 
outcomes for patients with juxta renal, suprarenal and type IV thoracoabdominal 
aneurysms did not find that proximal extent of the aneurysm predicted survival over the 
longer term.  
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Aneurysm related mortality was not explicitly stated or reported across most studies. 
Sultan et. Al. who compared 66 open repair patients with 52 patients treated 
endovascularly noted a statistically significant difference in aneurysm related survival after 
3 years with KM estimates of survival for open repair being 92.4% and EVAR 100% (p= 
0.045). Reintervention rates over follow up were similarly poorly reported in the included 
studies. One non comparative study recorded a rate of reintervention over a median follow 
up of 32 months as 10% after open repair [127]. No details were given as to the nature of 
the interventions or timing. Sultan et.al. who compared open and endovascular repair 
noted a non-significant difference in freedom from reintervention at 3 years: 95.5% for 
open repair and 83.4% for EVAR (p=0.301, 95% CI 0.47 to 9.87).  
6.3.5. Secondary Outcome Measures 
The secondary outcome measures are as follows: 
 Primary Technical success 
 Clinical success 
 Visceral vessel patency 
 Length of hospital stay 
 Rates of renal dysfunction throughout follow up 
Length of hospital stay ranged from 7 – 18.5 days (mean or median) for the included 
studies. None of the included studies specifically reported primary technical success or 
clinical success at any point. Similarly, no study reported rates of visceral vessel patency for 
the whole cohort. One study did comment that 11 out of 13 renal arteries that were 
revascularized at the time of the original operation were patent on follow up at a mean of 
717 days. This was from a total cohort of 126 patients. Perioperative renal dysfunction is 
detailed above and reported outcomes for renal function over the longer term are reported 
in the following table (See table 6.6.): 
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Table 6.6. – Reported rates of Renal Dysfunction after Open Repair for NSA AAA 
Study Median 
Follow up 
(months) 
Proportion of patients with 
new renal dysfunction 
during follow up 
Documentation of 
renal protective 
measures during 
surgery 
Sugimoto, 2018 
[123] 
34 15.9% N 
Kabbani, 2014 
[124] 
NR NR Y 
Speziale, 2010 
[125] 
54 NR Y 
Knott, 2008[126] 48 NR Y 
Pearce, 2007 
[127] 
32 24% N 
Sultan, 2011 
[128]a  
33 NR Y 
Deery, 2016 
[129]b 
NR NR Y 
Jeyabalan2011 
[130] c 
12 5.1% Y 
Table 4.6.  - NSA – Non-standard Anatomy, AAA –Abdominal aortic aneurysm, CHF – congestive heart failure, 
NR – not reported. A – Comparing open repair with EVAR, b – Comparing infrarenal and pararenal open 
aneurysm repair, c – Comparing infrarenal and “complex” open aneurysm repair.  
 
Although perioperative renal dysfunction was well reported in the included studies longer 
term renal function was not and varied widely between the three studies that did report it 
from 5.1% to 15.9%. Furthermore, these studies used varying definitions for what 
constituted renal dysfunction in the longer term. As such, conclusions about the rate of 
renal dysfunction after the perioperative period is difficult to make from review of the 
included studies. Sugimoto et.al. found that the only predictive risk factor for post-
operative chronic renal decline in their study was a pre-existing renal dysfunction 
characterised by stage 3 or 4 using eGFR criteria. Furthermore, they comment that left 
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renal vein division did not appear to have any causal relationship to renal function post 
operatively. 
6.4. Summary of Results 
In summary there were 8 studies included in the final systematic review with a total 
population of 1150 patients with NSA treated by open surgical repair. The studies were all 
retrospective in nature and cohort studies. Three were comparative and five non-
comparative. Overall the studies were of poor methodological quality in general and there 
was significant heterogeneity in study design, definitions (of both aneurysm anatomy and 
outcome measures), patient populations and operative technique (namely aortic cross 
clamp level).  
The reported perioperative mortality rate ranged from 0.8 – 6%. The 5-year survival rate 
across four studies which reported this outcome ranged from 64% - 88.6%. It was also 
noted by Knott et.al. that the 5-year survival rate by Kaplan Meier analysis of 64% did not 
differ when compared with a general age and gender matched population in the U.S.A. 
Aneurysm related mortality and reintervention rates were poorly reported across all 
studies and as such very limited conclusions can be drawn from these outcome measures. 
With regards to the secondary outcome measures investigated again technical and clinical 
success were not reported at all and rates of renal dysfunction during follow up were rarely 
reported with significant heterogeneity between studies as to what constituted renal 
dysfunction. The length of hospital stay ranged between 7 – 18.5 days.  
The rate of perioperative renal dysfunction varied between studies from 11 – 47%. For the 
most part it was noted that this renal dysfunction was transient and had resolved by the 
time of discharge and that although appreciable the rates of new permanent dialysis on 
discharge were low across the studies included with a maximum incidence of 1.5% [124]. 
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Of note the three comparative studies found that the rates of postoperative renal 
dysfunction were significantly higher in the juxtarenal aneurysm cohort compared to either 
the endovascular cohort [128] or the comparator infrarenal open repair cohort [129, 130]. 
6.5. Discussion 
This systematic review attempts to enlighten the discussion about what is considered the 
gold standard treatment for this particular condition. That is: Juxtarenal abdominal aortic 
aneurysm, to use the traditional definition reported in most of the literature regarding 
open repair, or AAA with NSA as proposed in this thesis. The search was limited to the 
preceding 20 years only primarily to exclude historical reports and include only a “modern” 
cohort of patients with the presumption that medical and surgical care continues to 
advance in general and therefore to include more historical reports would incur an 
important confounding factor. Furthermore, this time limit was chosen as it reflects, 
approximately, the time period in which endovascular aneurysm repair has become 
widespread and ultimately the aim is to enable comparison between open repair and 
endovascular repair of aneurysms with NSA. It was hypothesised before the beginning of 
the systematic review that more recent studies pertaining to open surgical repair would 
consider the reporting standards and norms within endovascular research when designing, 
conducting and disseminating research on open repair. So that certain outcome measures 
(such as aneurysm related mortality) and definitions (CT based precise anatomical 
definitions pertaining to the aneurysm neck) would be common in both open surgical and 
endovascular research and allow robust comparisons between the two. However, the 
included studies did not, in general, exhibit such an alignment with endovascular reporting 
standards and as such make comparisons difficult. As an example, the definition with 
regards to anatomy of the aneurysm was based either on clamp level intraoperatively on 
the SVS definition of juxtarenal aneurysm. There was no specific assessment of aortic neck 
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anatomy from the preoperative CT scan as would be expected in any report pertaining to 
endovascular repair. There is therefore inevitable heterogeneity in the anatomy of the 
populations being studied limiting comparisons that can be made. It is the 
recommendation of this author that future such studies whether comparative or not into 
open surgical repair of aneurysms should define anatomy precisely and based on 
preoperative CT analysis, which with the advent of computerised radiology software which 
is now commonplace in all hospitals in the United Kingdom and beyond, should be possible 
to achieve. Furthermore the use of reporting standards published for endovascular 
aneurysm repair but with comment on open repair [24] should be used to inform the 
method of reporting. 
None of the studies identified and analysed included ruptured aneurysms but three studies 
[126, 127, 129] commented that symptomatic/urgent aneurysms were included in their 
study cohort. The proportion was 9.5%, 11% and 11% in the three studies. The remaining 
studies did not make an explicit statement that symptomatic aneurysms were excluded 
but, in some cases, commented that only elective aneurysms were included.  
Sultan et.al. compared open aneurysm repair with patients treated by endovascular repair 
for NSA. In addition to the above reported outcomes they also interestingly comment that 
the number of patients discharged home rather than to another healthcare facility was 
significantly higher after EVAR than open repair (90% versus 70%, p=0.006). They also 
undertake cost effective analysis and find that in their study the mean cost per patient over 
a 3-year period is higher for open repair than for EVAR by approximately €3500. It appears 
the main source for this extra cost is in the extended length of stay in hospital and on ICU 
and longer operating time. It should be noted that these were standard endovascular grafts 
and if comparing with advanced endovascular techniques the extra cost of the 
165 
 
endovascular device may negate some or all of that cost burden from open repair in 
comparison. 
 Various renal protective strategies are commented upon in the included reports however 
there is little that can be said about their efficacy due to lack of comparator groups/analysis 
into their effectiveness. Strategies used include the use of N-acetylcysteine, mannitol, 
furosemide, bicarbonate and the use of cold renal perfusion during the operation. 
6.6. Conclusion 
Very limited information can be drawn from this systematic review due to the poor 
methodological quality of the studies and the heterogeneity evident between them. 
Nevertheless, it serves to provide data specifically about the rate of specific clinical 
outcome measures such as perioperative mortality, across the literature to enable some 
comment or comparison with other treatment options. This systematic review also 
highlights, importantly, the lack of standardised reporting for open aneurysm repair and 
though it is beyond the scope of the current work suggests an important area for future 
work – Combined open/endovascular reporting standards.  
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7. CHAPTER 7 - Systematic Review of Clinical outcomes 
Following Fenestrated Endovascular Aneurysm Repair 
7.1. Introduction 
In conjunction with the systematic reviews outlined above this final systematic review aims 
to provide an updated synthesis of the available evidence from previously conducted 
systematic reviews and meta-analyses and contemporaneous reports investigating 
specifically the clinical outcomes for aneurysms undergoing fenestrated endovascular 
aneurysm repair. 
From the previous systematic reviews, it became clear that there is a broad base of 
published literature regarding fenestrated endovascular repair and a plethora of systematic 
reviews and meta analyses published since the advent and widespread use of fEVAR. It was 
therefore decided to synthesise the available evidence across the available systematic 
reviews and meta-analyses published to date, and then perform a systematic review of 
articles published since the most recent systematic review. 
The question being addressed in this systematic review is to understand what the clinical 
outcomes are for patients undergoing fEVAR. The primary clinical outcome measures will 
include the following both perioperatively and throughout follow up; all-cause mortality, 
aneurysm related mortality, reintervention rates and graft related endoleaks. Secondary 
outcome measures will include: primary and primary assisted technical success, visceral 
vessel patency, rates of conversion to open repair, rates of renal dysfunction and aneurysm 
expansion throughout follow up. 
After Park et al. [79] first reported the use of a fenestrated endovascular stent-graft in 1996 
for repair of abdominal aortic aneurysm the principle of endovascular stenting while 
preserving blood flow to targeted visceral vessels was established. In 1999 two further 
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reports of experimental placement of fenestrated stent-grafts in canine subjects further 
proved the principle and paved the way for the use of this new technology. [134, 135] In 
2000 a case report describing the use of a fenestrated stent-graft in a female patient with a 
complex mycotic aneurysm within the visceral aorta was described. [136] 
In 2001 the first case series of 13 patients treated with customised stent-grafts based on 
the Zenith system was reported from Australia. [137] In this study procedural success was 
100%, with perfusion maintained to 33 target vessels at the end of the procedure and 0% 
perioperative mortality. The report describes in detail the construction of the endograft 
and the implantation procedure as well as recommending stenting through fenestrations of 
the target renal vessels to help maintain visceral vessel patency. 
After the above paper from Australia the literature records the uptake in use of fenestrated 
technology with multiple case series from around the world being reported with short term 
follow up data. This period also sees publication of papers relating to experimental models 
on fenestrated technology assessing forces needed to ‘pull-out’ or distract the stent grafts 
from their original position. One study details that the forces required to dislodge the 
fenestrated stent-graft are significantly greater than that for the standard infrarenal stent-
graft. [138] From the Cleveland clinic, U.S.A and the Netherlands two case series were 
reported during this period both documenting 100% procedural success for a combined 
population of 50 patients and 129 target vessels. [139, 140] Greenberg et al. reported one 
death (3%) within the perioperative procedure secondary to aspiration pneumonia. 
Verhoeven et al. reported one target vessel occlusion during the primary procedure, being 
the only one out of all 129 vessels from both studies. Both studies had a mean follow up of 
9 months and reported good outcomes to this time point with only a further two renal 
arteries noted to be occluded and 4 patients dead from non-aneurysm related causes. 
These initial case series further prove the feasibility and safety of the technique with good 
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short-term outcomes during the initial phase of use of fenestrated technology. A further 
case series from the Cleveland clinic expanding on the above study investigates the renal 
effects from fEVAR [141]; in this series of 72 patients 24% suffered a renal event; ranging 
from renal artery stenosis or occlusion to requirement of permanent dialysis (3%). It was 
found that most renal events occurred within the first month after fEVAR. This was the first 
study to fully document the concerns regarding renal outcomes after fEVAR.  
After the introduction and acceptance of a new technology there is an initial phase of 
investigation into feasibility and safety of that technology. Following this, clinical series 
begin to report on the short-term outcomes after use of the technology as documented 
above. The next inevitable stage is the expansion in use of the technology with reports on 
clinical outcomes over a longer follow up period and the publication of systematic reviews 
of the available evidence. The aim of this systematic review was to synthesise the available 
evidence by identifying all published systematic reviews on this subject and relevant 
published articles not included in the latest systematic review. 
7.2. Methods 
The systematic review followed reporting guidelines set out in the Preferred Reporting 
Items for Systematic Reviews and Meta-Analyses (PRISMA) document. [108] In line with 
these guidelines a protocol for the systematic review was established prior to the beginning 
of the literature search as follows. The protocol is reproduced here in its entirety.  
7.2.1. Protocol for Systematic Review, Including Eligibility 
Criteria 
A systematic review of the literature will be undertaken to examine the clinical outcomes 
for patients undergoing abdominal aortic aneurysm repair using fenestrated endovascular 
aneurysm repair. It is expected that there will be heterogeneity in the definition of 
anatomical extent of aneurysms being studied between the various published reviews. The 
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indications for use for fenestrated endovascular aneurysm repair using the Cook Zenith 
system (Cook Medical, Bloomington, Indiana, U.S.A.) specify that there must be 4mm of 
infrarenal neck available. Despite this fenestrated technology can be used to treat 
aneurysms extending up to and even above the renal arteries. Furthermore, branched 
endovascular technology is recommended for use in, and indeed is used, for aneurysm with 
this proximal extent also. There is therefore an overlap between fEVAR and bEVAR in terms 
of the anatomy that they are used to treat. It is expected that there will be heterogeneity 
and lack of precise definition of aneurysm extent within the published literature. The Ad 
Hoc Committee on Reporting Standards for the Society of Vascular Surgery [24]use the 
terms “juxtarenal” and “pararenal” to describe aneurysmal extent, and that the two terms 
can be used interchangeably. This definition states that there is “no normal aorta between 
the upper extent of the aneurysm and the renal arteries”. Those reporting standards make 
a distinction between juxtarenal/pararenal aneurysms and “suprarenal” aneurysms – the 
latter definition states that the aneurysm segment involves at least the renal arteries if not 
the splanchnic arteries also. Aneurysms that require branched endovascular technology by 
definition include suprarenal aneurysms, and aneurysms defined as suprarenal are by 
definition outside the instruction for use specified for Cook Zenith fenestrated platform. 
Therefore, aneurysms defined as suprarenal or in which branched endovascular technology 
is used will be excluded from this analysis. There may be reports that combine the data for 
branched and fenestrated repair and if so, they will only be included in this analysis if the 
outcomes can be separated and there is a specific comment that the aneurysms treated by 
fenestrated repair are juxtarenal or pararenal aneurysms. Ideally all reports would specify 
anatomic extent of aneurysms by reporting neck lengths and other anatomical features 
within study populations, however this is likely not to be the case. For practical purposes 
therefore, the statement that an aneurysm is juxtarenal or pararenal will be sufficient to 
include it in this analysis. Furthermore, aneurysms described as type IV thoracoabdominal 
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aneurysms will not be included. The caveat to this is if an aneurysm is defined as suprarenal 
but specific anatomic criteria are reported to clarify that actually fenestrated endovascular 
repair could be performed within its IFU. 
The objective of the systematic review is to compare the published literature for all 
patients with non-standard aneurysms undergoing fEVAR. It is expected that no 
randomised controlled trials would be identified and therefore all systematic reviews, 
meta-analyses and non-randomised studies published since the most recent systematic 
review will be included in the analysis.  
Inclusion criteria: 
 Aneurysm morphology - For a study to be included in the analysis, it should clearly 
state that the population had morphologic infrarenal neck characteristics that were 
not within the indications for use for standard EVAR but were within the IFU for 
fEVAR. As already stated above other definitions will be accepted in line with 
published reporting standards – such as juxtarenal or pararenal aneurysms as a 
definition. 
 There must be median (or mean) follow up of at least 1 year to enable meaningful 
results of short and mid-term data for the studied population 
 In order to reduce bias introduced from small case series studies must have at least 
50 patients undergoing fEVAR 
Exclusion Criteria: 
 Studies reporting solely on symptomatic or ruptured aneurysms. If a study includes 
symptomatic or ruptured aneurysms it is expected that the results for these 
patients will be identifiable and be able to be excluded from further analysis. If it is 
not possible to do so then an explicit statement as such will be made in the report 
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to make it clear that this confounding variable exists in the identified study 
population. 
 If the report presents patients treated with a hybrid (endovascular combined with 
open surgical repair) technique. 
 Aneurysms repaired by branched endovascular technology will be excluded from 
the analysis 
 No statement of aneurysm morphology 
Eligibility Criteria 
 Publication dates within 20-year period (1998 – 2018) 
 English language only results considered 
 The population will include all adults with no age restriction 
The above protocol was referred to throughout the data identification and extraction phase 
to ensure it was adhered to. 
7.2.2. Definitions and Outcome Criteria.  
Outcome criteria and definitions were based on recommended reporting standards for 
EVAR, published by the Ad Hoc Committee for Standardized Reporting Practices in Vascular 
Surgery [24]. The outcomes within the first 30 days after the index procedure or occurring 
within the same hospital admission will be reported as perioperative outcomes, those 
occurring between 30 days and 1 year will be termed ‘Early’, those between 1 and 5 years 
will be termed ‘Short’, 5 to 10 years will be considered ‘Midterm’ and > 10 years will be 
‘Long-term’. This is in line with the pragmatic minimum reporting standards for 
endovascular aneurysm repair [99]. Primary outcome measures included perioperative 
mortality from any cause, all-cause mortality, aneurysm related mortality, reintervention 
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rates and graft related endoleak rates (All type I and III endoleaks). The secondary outcome 
measures are as follows: 
 Primary Technical success 
 Visceral vessel patency 
 Conversion to open repair 
 Rates of renal dysfunction throughout follow up (the definition used within the 
given study for renal dysfunction will be used) 
 Rates of spinal cord ischaemia 
 Aneurysm growth throughout follow up (At all time points) 
7.2.3. Information Sources and Electronic Search Strategy 
An electronic search of the literature was undertaken. The search was applied to MEDLINE 
(database provider PubMed, from 1998 – 2018) and EMBASE (database provider Ovid, from 
1998 to 2018). The search was undertaken once in May 2018. A full record of the search 
strategy is included within Appendix 3. The full reference list of each full text study 
assessed was interrogated to identify any relevant articles missed in the original search. 
 
7.2.4. Study Screening and Selection 
The study screening and selection strategy employed was exactly that as for the systematic 
review of clinical outcomes of non-standard aneurysms treated by EVAR (Chapter 5). The 
search strategy results and reasons for exclusion are listed in figure 7.1 below.  
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Figure 7.1 - Search strategy for Systematic Review of fEVAR 
  
Figure 7.1 - Numbers represent articles. Arrows denote whether articles were excluded or included. 
 
Search of Electronic 
Databases 
947 
Screening of Selected 
Abstracts 
394 
Abstract not relevant 
372 
Title not relevant 
554 
Screening of Full Text 
Systematic Review 
22 
Systematic reviews 
Included 
11 
Full texts excluded and reasons (11) 
 Systematic review included 
different articles that included 
same population: 3 
 Review of In-situ fenestration: 1 
 Full text not available: 3 
 Review not including clinical 
outcomes: 3 
 Review of Thoracic aneurysm: 1 
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Following this the original list of retrieved articles was then searched again to identify all 
articles published after the most recent systematic review. The year of the most recent 
published article included in any systematic review was 2015. Then all published articles 
from 2015 onwards were screened again. As above the abstracts and then full texts (if 
appropriate) were reviewed to identify if they should be included in the review or not. 
After abstract review of all the articles 27 full texts were identified for further review and 
scrutiny. From this list of 27 articles 8 were included in the final review. The reasons for 
exclusion of the 19 articles were as follows: 6 articles didn’t separate differing anatomies or 
treatments to allow analysis of fEVAR, four articles did not investigate clinical outcomes of 
interest,  two articles had less than 50 patients undergoing fEVAR, three articles only 
reported 30 day clinical outcomes, two articles were early reports of a population that 
were updated in later articles (both updated articles were included), one article was a 
conference abstract only and was not able to obtain one article.  
7.2.5. Data collection 
A data extraction sheet was developed. As well as pertinent information relating to the 
publication (year of publication, journal etc) the remaining collected variables were divided 
in three broad categories: (1) baseline clinical and demographic data, anatomic 
characteristics, and procedure related characteristics; (2) primary outcome data (3) 
secondary outcome data, as outlined previously. 
7.3. Results of Systematic Reviews Identified 
After screening 11 systematic reviews were identified throughout the search. These 
systematic reviews were published between 2006 and 2018. The articles included within 
the systematic reviews were published between 2001 and 2015 and the number of fEVAR 
cases included in the systematic reviews ranged between 293 and 776. Five of the articles 
included a meta-analysis as part of the article and four reviews were comparative in nature 
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(three comparing with open repair and one with chimney EVAR). The following table 
outlines the details of the included studies (see table 7.1.) 
Table 7.1 Included systematic reviews of fEVAR 
Author, 
year 
Years of 
publication 
of included 
articles 
Number 
of 
included 
articles 
 
Comparative 
study (Y or 
N) 
Meta-
analysis 
(Y or N) 
N of 
cases 
Mean number 
of target 
vessels per 
patient (S.D.) 
Spanos, 
2018 [142] 
2001 - 2015 7 N Y 772 2.74 (0.77) 
Li, 2016 
[143] 
2005-2013 9 Y (chEVAR) N 542 2.73 (0.76)* 
Rao, 2015 
[144] 
2005 - 2012 14  Y (OR) Y 751 2.49 (0.82)* 
Ou, 2015 
[145] 
2006 - 2014 15 N N 763 2.59 (0.78)* 
Belczak, 
2014 [146] 
2006 - 2012 4 Y (OR) N 293 2.63 (0.64)* 
Di, 2013 
[92] 
2006 - 2011 12 N Y 776 2.52 (0.77)* 
Linsen, 
2012 [147] 
2006 - 2011 9 N Y 629 2.52 (0.77)* 
Donas, 
2012 [148] 
2001 - 2012 12 N N 631 2.52 (0.78)* 
Cross, 2012 
[149] 
2001 - 2011 11 N Y 660 2.52 (0.78)* 
Nordon, 
2009 [150] 
2001 - 2008 8 Y (OR) N 368 2.37 (0.82)* 
Sun, 2006 
[151] 
2001 - 2006 6 N N 317 2.37 (0.82)* 
Table 5.1. * - Not all studies in systematic review had sufficient information to calculate mean TV ratio and 
S.D, so result is calculated from studies where that information is present 
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As can be seen from the above table the mean target vessels per patient increased as time 
passed - from 2.37 in 2006 to 2.74 in 2015. This suggests that over the past two decades 
there has been increasing complexity of the fEVAR devices implanted and reported on, with 
more target vessels incorporated into the treatment. It should also be noted the vast 
majority of cases reported in the literature are regarding the Cook Zenith platform of 
fenestrated stent graft, though there are occasional reports of other manufacturers of 
fenestrated stent grafts. The primary other stent graft within the literature is the Anaconda 
stent graft.  
The four most recently published systematic reviews reports on 27 different studies 
between them with studies ranging in size from 8 cases of fEVAR to 318 and publication 
dates ranging from 2001 – 2015. One of these studies [142] present their results with the 
aim of presenting the “long term” outcomes of fEVAR. Two others compare fEVAR with 
open repair [144] and chimney EVAR techniques [143]. The following table details the 
baseline demographic and anatomical factors reported for those four systematic reviews: 
(See table 7.2) 
Table 7.2. Demographic Details from Four Most Recent Systematic Reviews 
Author, year Mean Age 
(years) 
Male patients 
(%) 
AAA diameter 
(mm), Mean 
Neck Length 
(mm), Mean 
Spanos, 2018 
[142] 
71.5 - 74 86.7% 60 – 65* NR 
Li, 2016 [143] 74 85.7% 64 6.7 (0-14mm)a 
Rao, 2015 
[144] 
73 86% 60 NR 
Ou, 2015 
[145] 
72 - 75.5 NR NR NR 
Table 7.2 - *- range of mean diameters, a – Mean neck length found in five of 15 studies, range of neck length 
in parentheses 
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Within the systematic reviews and all published literature, the vast majority of patients are 
male (approximately 85 – 87%) and the mean age is between 70 – 75. Mean aneurysm 
diameter is also relatively constant across the systematic reviews being between 60- and 
65-mm. Neck length is poorly reported in the literature and consequently the systematic 
reviews but Li et.al. report that in five of the fifteen studies included in their systematic 
review a comment about neck length was made. For these studies the combined mean 
neck length was 6.7mm (range 0 – 14mm).  
It should be noted that there is heterogeneity in the definitions used for comorbidities 
within the literature. Therefore, it is difficult to compare between studies the rates of any 
given comorbidity. Furthermore, a significant proportion of studies do not define what 
constitutes a certain comorbidity. They simply state the proportion of patients with chronic 
kidney disease (as an example). For the four systematic reviews mentioned above the rates 
of reported coronary artery disease/ischaemic heart disease range from 33.1% - 52.2%. 
Hypertension ranges from 67 – 76.8%, diabetes mellitus 15.4 – 17.4%, chronic kidney 
disease: 18.6 – 27% and respiratory disease: 33.7 – 36%. One study [143] comments that 
the use and reporting of ASA grading within the published literature is very sparse. The use 
of other comorbidity scoring systems is occasionally used [24] but again it is infrequently 
used.  
The studies included in the systematic reviews consistently reported high technical success 
rates of the procedures with successful introduction of the stent graft and high visceral 
vessel patency at the end of the procedure. The target vessel patency rates at completion 
angiogram were in the region of 90% [83] to 100% [152-154]. Semmens et al. [83] 
commented that one factor associated with target vessel loss in the short term was a lack 
of stenting through a fenestration for targeted renal vessels. One study also noted that 
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when target vessel occlusion did occur, they tended to be within the first year after the 
operation [155]. 
Significant heterogeneity was seen between the reporting practices of the systematic 
reviews pertaining to which clinical outcomes measures were included and in what form. 
The following table details the results across the systematic reviews for various important 
clinical outcome measures as reported within the systematic reviews. (see table 7.3) 
Table 7.3  Outcome Measures within systematic reviews of fEVAR 
Author, 
year 
Periop 
Mortality 
Range of 
Follow up 
periods for 
studies 
included 
,months 
All-Cause 
Mortality 
through 
FU 
TV 
Patency 
through 
FU 
Graft 
Related 
Endoleak 
through 
FU  
Reintervention 
Rate through 
FU 
Spanos, 
2018 
[142] 
2.5% 6 - 67 40% 86.8%  NR 24% 
Li, 2016 
[143] 
1.1% 12.8* (1 – 
65) 
5.4% 95.9% NR 10.7% 
Rao, 
2015 
[144] 
4.1% - 45% 95.8% 2.2% 12.7% 
Ou, 
2015 
[145] 
1.7% 11 - 67 20.1% 96.4% NR 30% 
Belczak, 
2014 
[146] 
0 -2% 21* (13- 
24) 
NR NR NR NR 
Di, 2013 
[92] 
2.5% 15 - 25 NR 94.5% NR 17.6% 
Linsen, 
2012 
2.1% 15 - 27 16% 93.2% NR 17.8% 
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[147] 
Donas, 
2012 
[148] 
1.2% - NR NR NR NR 
Cross, 
2012 
[149] 
2% 24* NR NR NR NR 
Nordon, 
2009 
[150] 
1.4% - NR NR NR NR 
Sun, 
2006 
[151] 
1.1% 6 – 25 8.3% 90% 9.4% NR 
Table 7.3. – FU – Follow up, TV – target vessel, NR – Not reported * - Mean follow up across all included 
studies  
Therefore, the perioperative mortality reported in the systematic reviews ranges from 0 – 
4.1%. With most reporting between 1 and 2% perioperative mortality rates. Th majority of 
studies within the literature report mean or median follow ups that are within 
approximately 2 years. It is difficult to compare long term mortality between studies and 
systematic reviews because of the differing reporting practices and follow up times 
between studies and reviews however one systematic review by Spanos et.al. attempts to 
present longer term dates. They report results from seven studies that all have follow up 
ranges that exceed 36 months. The details of pooled estimated mortality rates (with 95% CI 
in parentheses) over the longer term in their review is as follows: 
 12 months: 0.080 (0.060-0.106)  
 24 months: 0.129 (0.097- 0.169) 
 36 Months:  0.211 (0.158-0.277) 
 48 Months:  0.279 (0.193-0.386) 
 60 Months: 0.405 (0.303-0.517) 
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They have therefore, shown a mortality rate of approximately 40% at 5 years. Aneurysm 
related mortality over follow up is generally poorly reported in the literature. There is 
rarely as estimation of aneurysm mortality free survival by Kaplan Meier analysis reported 
which would be the most accurate way to present such data. Studies may report rates of 
aneurysm related mortality as a percentage of all patients included, all patients surviving 
beyond 30days or as a proportion of late follow up deaths. It is the opinion of this author 
that these methods are misleading and do not give a true representation of aneurysm 
mortality free survival. Nevertheless, the numbers of patients identified as having an 
“aneurysm related” mortality within the literature during longer term follow up remain 
small.  
The four most recent systematic reviews, detailed above, were interrogated to ascertain 
perioperative and longer-term rates of reintervention and graft related endoleak. For 
perioperative reintervention; Spanos et. al. reports a pooled estimated perioperative 
reintervention rate of 5.9% (4- 8.8%) within their systematic review. That same systematic 
review also reports the following reintervention rates as pooled estimates over the longer 
term: 
 12 months:  0.097 (0.066-0.140)  
 24 months:  0.131 (0.082-0.203) 
 36 Months: 0.281 (0.182-0.406) 
 48 Months: 0.244 (0.103-0.477) 
 
Li et. al. reports a combined reintervention rate over follow up in their systematic review of 
9 articles with a median follow up of 12.8 months as 10.7%.  Rao et. al. Also show a pooled 
estimated reintervention rate of 12.7% for their 14 included studies. 
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The rates of perioperative (either at completion angiography or within first 30 days) graft 
related endoleak are reported in three reviews for type 1 endoleak [142-144] and two 
reviews for type 3 endoleak [142, 144]: 
 Perioperative Type 1 endoleak rate – 3.7%, 5.8% and 5.8%. 
 Perioperative type 3 endoleak rate – 1.6% and 2.6%. 
Graft related endoleak was infrequently reported within the systematic reviews during 
longer term follow up primarily because of heterogeneity between included studies for 
their length of follow up and therefore cannot be commented on here. 
It should be noted that only one article that was frequently cited in the systematic reviews, 
Kristmundsson et al. [84], has a median follow up that could be classified as mid-term (>5 
years). In that paper, overall survival at 5 years was noted to be 60% with the majority of 
deaths secondary to non-aneurysm related causes. During follow up there were no 
conversions to open repair and only one patient died of aneurysm rupture secondary to 
component separation and endoleak. The primary target vessel patency at 5 years was 90% 
and primary assisted patency was 93%. Eight target vessels occluded throughout follow up 
(three SMAs and five renal arteries), only one of the renal artery patients suffered any 
clinical consequence from their occlusion – they became dialysis dependant. The reports on 
long term follow up after fEVAR are, at this point, relatively scarce, however they do appear 
to show continued efficacy of the technique in terms of avoiding aneurysm rupture without 
major adverse event in the long term.  
Since the proliferation of fEVAR there have always been concerns about the fate of target 
vessels and the outcomes for patients in terms of the incorporated visceral vessels. A 
report by Grimme et al. [156] has investigated this concern in 138 patients who received 
fEVAR over a ten-year period. There were 392 target vessels, 140 of which were protected 
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by a scallop and 252 with fenestrations. A variety of stents were placed in 254 target 
vessels. Overall patency rates for visceral artery stents was 88.6% at four years in that 
study. They noted that stent fractures and renal artery stenosis occurred more frequently 
in uncovered stents. This study confirms with the remaining body of evidence that 
outcomes after fEVAR for visceral vessels are good and that even when target vessel events 
do occur it does not necessarily lead to disastrous clinical consequences such as dialysis or 
frank bowel ischaemia resulting in death or need for operation.  
7.4. Results of Original Articles Identified from Systematic 
Review 
As stated above 8 articles were identified [157-164] using the inclusion and exclusion 
criteria from the literature from the beginning of 2015 onwards. Four of these articles [157-
160] were updates from centres that had previous published reports which were included 
in some of the systematic reviews reported above. The following table documents the 
studies included from this portion of the systematic review: (See table 7.4) 
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Table 7.4. Details of original studies investigating fEVAR published since 2015 
Author, year Years 
patients 
treated 
N Mean 
number of 
target vessels 
per patient 
(S.D) 
Type of study Follow up of 
study, mean or 
median with S.D. 
or range 
(months) 
Verhoeven, 
2016 [157] 
2010 - 
2014 
281 3.19 (0.48) Single centre, 
retrospective 
21 +/- 15.9 
Oikonomou, 
2017 [158] 
2006 - 
2014 
141 3.64* Single centre, 
retrospective 
33 +/-23 
Blankensteij
m, 2017 
[159] 
2011 - 
2015 
60 2.33 (0.73) Multi centre, 
retrospective 
16.4 (11.9 - 27.4) 
Roy, 2017 
[160] 
2003 - 
2015 
173 3.31 (0.77) Single centre, 
retrospective 
34 
deSouza, 
2017 [161] 
2005 - 
2012 
67 NR Matched 
cohort study 
from US 
multicentre 
trial 
32 
Caradu, 2017 
[162] 
2010 - 
2015 
90 2.2 (0.5) Single centre, 
retrospective 
19 (1 - 68) 
Wang, 2018 
[163] 
2012 - 
2017 
100 NR Single centre, 
retrospective 
20.4 
Colgan, 2018 
[164] 
2010 - 
2014 
101 3.08 (0.76) Multi centre, 
retrospective 
12 
Table 7.4. S.D. – Standard deviation, NR – Not reported- * Data not given to allow calculation of S.D. 
As can be seen the majority of these contemporaneous reports include more complex stent 
graft designs with a higher number of target vessels per patient (>3) when compared with 
the systematic reviews outlined above. All of these studies only included outcomes for 
fenestrated endovascular repair without combining results for branched endovascular 
repair in line with the inclusion and exclusion criteria for this systematic review. 
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Furthermore, three studies [157, 158, 160] specifically state that thoracoabdominal, or 
type 4 aneurysms were excluded from their analysis. This represents a shift compared to 
the previous period from when the systematic reviews were drawn where often reports 
may include these aneurysms or combine branched and fenestrated outcome data. The 
majority of the above studies report outcomes for the Cook Zenith fenestrated platform 
with the notable exception of two: Blakensteijn et.al. and Colgan et.al. document their 
centres’ experience with the use of the Anaconda stent-graft. 
The largest study found during the literature search was a report by Gupta et.al. [165] with 
535 patients. They used the American College of Surgeons National Surgical Quality 
Improvement Program (NSQIP) database to capture patients. This is essentially a large 
registry dataset from numerous hospitals across the United States that collects data 
prospectively. In that study they only examined 30-day outcomes and therefore it was 
excluded from this analysis, but it merits mention because of the large number of patients.  
7.4.1. Demographic Details 
The table below documents the demographic and anatomical details recorded in the 
included studies: (See table 7.5) 
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Table 7.5. – Demographic details within original studies investigating fEVAR 
published since 2015 
Author, year  Age, years 
mean or 
median 
(With S.D.)  
Male 
(%) 
AAA diameter, mm 
(mean or median 
with S.D. or range) 
Aneurysm neck length, 
mm (mean or median 
With S.D. or range) 
Verhoeven, 
2016 [157] 
72.1 87% 60.2 (45 - 110) 2 (0 - 10) 
Oikonomou, 
2017 [158] 
72 (7.6) 85% - NR 
Blankensteij
m, 2017 
[159] 
72 (7) 86.7% 64 (9) 6 (4) 
Roy, 2017 
[160] 
76 90% 63 NR 
deSouza, 
2017 [161] 
74 81% 60 NR 
Caradu, 2017 
[162] 
71.3 (6.6) 98% 58.3 (9.8) NR 
Wang, 2018 
[163] 
72.6 86% NR NR 
Colgan, 2018 
[164] 
76 85% 64 (45 - 106) 5 (1 - 13) 
Table 7.5. AAA – Abdominal aortic aneurysm, S.D. – Standard deviation, NR – Not reported- * Data not given 
to allow calculation of S.D. 
As with the systematic reviews reported above the age and gender of the population being 
studied is fairly similar. The reporting of specific anatomical characteristics such as neck 
length are more common place in these included studies and suggests a relatively 
heterogenous group of aneurysms being treated with a median neck length of 2mm in one 
study compared to 6mm in another. (Although there are still only three studies from 8 that 
do report the neck length) 
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Comorbidities were reported using varying definitions across the studies, so it is difficult to 
compare patient populations accurately across the studies but for completeness the 
reported rates are given here: (See table 7.6.) 
Table 7.6. - Comorbidities within original studies investigating fEVAR published 
since 2015 
Author, 
year 
published 
CAD 
(%) 
HTN 
(%) 
Resp 
Disease 
(%) 
CKD 
(%) 
Definition of 
CKD used 
Previous 
aneurysm 
repair (%) 
ASA grade 
(3 or more) 
(%) 
Verhoeven, 
2016 [157] 
59.8 78.3 48.8 44.5 Cr >100 
µmol/L 
16 39.1 
Oikonomou
, 2017 [158] 
70 95% 52 41 GFR <60 25 68 
Blankenstei
jm, 2017 
[159] 
55 65 26.7 28.3 NR - 63.3 
Roy, 2017 
[160] 
52.6 63.6 NR 57.8 NR 8.7 69.7 
deSouza, 
2017 [161] 
16 90 36 24 NR - - 
Caradu, 
2017 [162] 
43.3 80 26.7 14.4 NR 3.3 - 
Wang, 2018 
[163] 
50 89 36 16 Cr >1.5 
mg/dL 
12 - 
Colgan, 
2018 [164] 
52 71 NR 39 Stage 3 or 
more 
2 76 
Table 7.6. AAA – Abdominal aortic aneurysm, S.D. – Standard deviation, NR – Not reported, CAD – coronary 
artery disease, HTN – Hypertension, CKD – Chronic kidney disease, ASA – American society of 
anaesthesiologists, Cr – Creatinine. 
 
There was significant heterogeneity among the reported studies with regards to 
preoperative renal dysfunction as can be seen from the table above, but this is partially 
explained by the differing definitions used for CKD. The study by Verhoeven et.al. is notable 
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in that only 39.1% of patients had an ASA grade of 3 or more but the authors state in their 
study that they use fEVAR as a first line treatment for suitable patients and do not reserve 
it for those unfit or at “high risk” or open repair as stated in most other studies. Despite 
this however their patients still commonly exhibit coronary artery disease, chronic kidney 
disease, hypertension and respiratory disease. This probably reflects the fact that 
proportions of comorbidities seen in a population do not accurately reflect the “fitness” of 
a given population well. Nevertheless, these factors are commonly reported to allow 
comparisons between populations to be drawn. 
7.4.2. Perioperative Outcomes 
The perioperative technical success was reported in six studies. Four of these studies [157, 
158, 162, 163] report technical success rates of between 95.7 – 98%. This is in keeping with 
most previous reports for fenestrated repair. The other two studies report a technical 
success rate of 79.2% [160] and 85% [159]. Both these studies importantly however 
comment that this low rate is primarily secondary to intraoperative endoleaks that 
spontaneously sealed by the time of the first post-operative imaging. When adjusting for 
this Roy et.al. report a technical success rate of 95.4%.  
Perioperative mortality ranges from 0.7 – 5.2% in the included studies. The exceptionally 
low rate of 0.7% was seen in the study by Verhoeven et. al. mentioned above in which 
fEVAR was used as a first line treatment option. The highest rate of 5.2% was seen in the 
study by Roy et.al. where the authors offer the explanation of more complex graft design 
used in their study to account for the higher perioperative mortality rate. Of all the studies 
they did have the highest mean number of target vessel per patient in their study with 3.3. 
The pooled mortality rate for all the included studies was: 2.7%. Excluding the study by 
Verhoeven et. al. with the low mortality rate the perioperative mortality for the remaining 
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studies was 3.4%. Of note the perioperative mortality rate in the study mentioned above by 
Gupta et.al. of 535 patients, [165] which was not included in the final analysis, was 2.4%.  
Three studies reported proportions of type 1 endoleak at completion angiogram: 
- 11.7% - all resolved without intervention [159] 
- 2.2% [162] 
- 11% - 11 patients, 10 resolved without intervention, one required further angioplasty 
which resolved endoleak [164] 
The same three studies also reported type 3 endoleaks: 
- 3.3% - all resolved 
- 3.3% 
- 4% 
Perioperative open conversion was specifically reported in five studies, with 3 patients out 
of 756 (0.4%) suffering this complication. Presumably in the other studies it was not 
mentioned as it didn’t happen, and if this is true then the true rate of perioperative 
conversion in this systematic review is 0.3%.  
The following table documents the rates of renal insufficiency (as defined in each study), 
spinal cord ischaemia, and “complications” in the perioperative period. (See table7.7.) 
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Table 7.7. Perioperative outcomes from included studies 
Author, year 
published 
Renal Insufficiency Spinal cord 
Ischaemia 
Complications 
Verhoeven, 2016 
[157] 
5% AKI NR 12.1% 
Oikonomou, 2017 
[158] 
2.1% AKI 2.8% 12.1% 
Blankensteijm, 2017 
[159] 
30% Renal dysfunction NR 25% 
Roy, 2017 [160] 27.8% AKI 1.1%  27.2% 
deSouza, 2017 [161] 5% AKI NR NR 
Caradu, 2017 [162] 17.8% AKI NR NR 
Wang, 2018 [163] NR 1% 5%* 
Colgan, 2018 [164] 3% AKI 0% 16% 
Table 7.7. – AKI – acute kidney injury NR – Not reported,  * “cardiovascular” complications only. 
Spinal cord ischaemia was specifically mentioned in 4 studies as above. Seven patients 
(1.4%) suffered spinal cord ischaemia. It was noted to be transient in all with spinal 
protective measures (spinal cord drainage and blood pressure control) used in all cases, 
either prophylactically or as a reaction to the complication. In four cases a spinal drain was 
only placed after discovery of the symptoms, in two cases a spinal drain had been placed 
preoperatively but one developed symptoms after clamping of the drain and the other had 
symptoms related to hypotension which resolved after improving the blood pressure. In 
the other case the details are not mentioned in the report. 
The rate of post-operative complications ranged from 12 – 27%. In five studies a detailed 
breakdown of complications in the post-operative period was given to enable the following 
summary [157-160, 164]: 
Of 756 patients in those five studies 127 (16.8%) were documented as having had a “post-
operative complication”. The complications were as follows: 
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 Renal dysfunction 29 patients 
 Cardiac complications  21 patients 
 Respiratory 18 patients 
 Access related complications (Including bleeding needing return to theatre and 
conservatively managed seroma) 28 patients 
 Stroke 2 patients 
 Mesenteric ischaemia (Including operated and conservatively managed) 7 patients 
 Wound infection 10 patients 
 Other 12 patients 
Studies varied in their definition of complications however and some only reported those 
that “prolonged hospital stay” [160] whereas most did not specify what qualified as a post-
operative complication. 
7.4.3. Longer term Outcomes 
Overall survival was reported in the majority of the studies and is detailed in the table 
below for varying time points: (see table 7.8) 
Table 7.8 – Overall survival for fEVAR patients from Included Studies 
Author, year 
published 
Overall survival, 1 
year 
Overall survival, 3 
years 
Overall survival, 
5 years 
Verhoeven, 2016 
[157] 
94.7%  84.6% - 
Oikonomou, 2017 
[158] 
85.1% (79.1 - 91.1) 75.8% (68.2 - 83.5) - 
Blankensteijm, 2017 
[159] 
91.4% 86.3% - 
Roy, 2017 [160] - - 59.4% 
deSouza, 2017 [161] - - 92% 
Caradu, 2017 [162] 91.4% 82.1% (2 year) - 
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It is remarkable that deSouza et.al. report a 5 year overall survival rate of 92% which is 
conflicting with the one other report in this review which reports that outcome [160]. The 
study by DeSouza et.al. was comparing matched patients from the US Multicentre Trials of 
the Zenith Fenestrated Endovascular Graft (William A. Cook Australia PTY. Ltd., Brisbane, 
Australia) and the Zenith AAA Endovascular Graft (Cook Inc., Bloomington, IN, USA). There 
is no mention within the study how patients were selected for the fenestrated cohort and 
there is likely to be significant selection bias for such a study. 
Aneurysm related mortality is poorly reported across all studies. Seven patients are 
reported throughout follow up to have died secondary to aneurysm related causes in six 
studies that report it.  
The following table documents reintervention rates over longer term follow up for studies 
that analysed their reintervention rate with Kaplan Meier analysis: (See table 7.9) 
Table 7.9 – Long term Outcomes from Included Studies 
Author, 
year 
published 
Mean or median 
follow up within 
study, months 
(+/- S.D or range) 
Freedom from 
reintervention 
at 1 yr. 
Freedom from 
reintervention 
at 3 yr. 
Proportion of 
reinterventions 
that are 
Endovascular  
Verhoeven, 
2016 [157] 
21 +/- 15.9 96.1% 90% 73% 
Oikonomou
, 2017 [158] 
33 +/-23 90.6%  
(85.6 - 95.6) 
79.2  
(71 - 87.5) 
73% 
Roy, 2017 
[160] 
34 - 62.8% (5 
years) 
82% 
 
The reintervention rate is commonly reported as high after endovascular repair and 
remains in the region of 10 – 20% during follow up for the studies that report on it. In 
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addition to the studies in the table above Wang et al. reported an overall 20% 
reintervention rate over a mean follow up of 20 months. Blankensteijn et.al. reported a 
6.7% reintervention rate over 16 months follow up. Importantly the proportion of 
reinterventions that are purely endovascular also remains high with 75 – 80% 
approximately being endovascular from the included studies.  
The included studies detail that a relatively small but significant proportion of patients still 
exhibit graft related endoleak during follow up after fEVAR. Verhoeven et al report that 6 
patients from an initial cohort of 281 (2.1%) exhibited graft related endoleak at some point 
during follow up, this study had a mean follow up of 21 months. Oikonomou et. al. reports 
a rate of 4.2% over a median follow up of 33 months and Roy et al. report graft related 
endoleak prevalence of 10.4% over 34 months. This highlights the role of continued 
surveillance and a robust programme to detect and treat complications from endovascular 
aneurysm repair.  
Target vessel patency remains excellent throughout follow up with fenestrated 
endovascular repair. The range of target vessel patency within the included studies ranges 
from 95% [159] to 98.9% at 3 years [158]. Roy et al. report a rate of 90.1% target vessel 
patency at 5 years after initial operation. When details are reported the loss of target 
vessel is often silent or of little clinical consequence, that being said there is no evidence 
within the literature to suggests a conservative approach to target vessel threat is a safe 
strategy. This is particularly true when it comes to the SMA and coeliac axis as the majority 
of target vessel losses reported in the literature are renal arteries. Low rates of dialysis are 
seen throughout follow up in the studies that report renal outcomes. There is insufficient 
evidence within the published literature to suggest whether the endovascular repair has 
any aetiological role in the development of dialysis in these patients. Rates of renal 
dysfunction over the longer term are also reported in a heterogenous manner and it is 
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difficult to draw many conclusions from the literature regarding this, but the range of 
reported rates is 21 – 27% of patients develop chronic kidney disease over follow up [161, 
162]. Overall fEVAR is successful in the majority of patients at preventing aneurysm growth. 
Little data in individual studies is usually presented on this variable however and not much 
can be said about it here. For completeness the rates reported in the literature from three 
studies for aneurysm growth over whole of follow up are 8.3% [159], 9.2% [162], 21% 
[160]. 
7.5. fEVAR Compared with Alternative Treatment Options 
There have been no randomised controlled trials comparing fEVAR with the variety of 
alternative treatment options. In fact, there have been no prospective controlled trials of 
any sort comparing fEVAR with the alternative treatment options. The published studies 
are either retrospective reviews of patients treated with fEVAR versus a contemporaneous 
cohort of patients treated with an alternative option or systematic reviews attempting to 
synthesise results from published studies regarding fEVAR. An assessment published by the 
National Institute for Health Research Health Technology Assessment (HTA) programme 
reviewed the published literature widely and failed to find a single comparative study that 
met their inclusion criteria for assessment of fEVAR versus OR. [166] The studies that are 
published vary in their methodology and reporting of the outcomes after aneurysm repair 
making overall synthesis of this part of the literature base difficult.  
7.5.1. Comparison of fEVAR with Chimney EVAR 
One alternative to fEVAR is the use of the chimney technique. Briefly, this is an 
endovascular technique of repairing non-standard aneurysms utilising a standard EVAR 
stent-graft and separate covered stents to maintain blood flow to at least one visceral 
vessel.  Chimney EVAR tends to be used in patients with different anatomical 
characteristics to that of fEVAR. It is used generally when only one or two visceral vessels 
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are incorporated into the repair, in those that are unsuitable for fEVAR either because of 
anatomical constraints or if the presence of symptoms or rupture dictate the need for 
urgent repair and hence the manufacturing delays inherent in the use of fEVAR prohibit its 
use. The reports comparing these two techniques are heterogeneous in their indications 
for use of chimney or fEVAR and in the patients selected for either technique. Banno et al. 
[167] retrospectively compared fEVAR (80 patients) with chimney EVAR (38 patients) 
undertaken at their institution and explained that chimney EVAR was reserved for those 
patients in which it was not possible to place fEVAR and as such those that underwent 
chimney EVAR had larger aneurysms with longer infrarenal necks, incorporated less visceral 
vessels and were done in ruptured or symptomatic patients. Bearing these differences in 
mind, along with other studies, chimney EVAR has shown to have comparable 30-day 
mortality, complication and reintervention rates versus fEVAR. [148, 167-169] One study 
however does suggest there may be an increase in stroke rate following chimney EVAR, 
which seems plausible as unlike fEVAR, chimney EVAR usually utilises the left subclavian 
artery for access to deploy the side branch stent-grafts. [169] A more recent study by 
Caradu et.al. compares 90 fEVAR patients with 31 chimney EVAR patients and showed 
increased 30-day mortality in those patients receiving chimney EVAR. They conclude 
however that there was no difference in survival at 24 months and the apparent 
advantages of chimney EVAR should render the two methods as complentary options in the 
armamentarium of vascular surgeons, to be used in different scenarios. Similar results and 
sentiments were seen in a systematic review by Li et.al. comparing the two techniques. 
Rather than being compared as alternatives. As comparative studies the methodology in 
these published reports is flawed but these studies with short term follow up do seem to 
suggest relatively equivalent outcomes between fEVAR and chimney EVAR albeit for 
aneurysms that are anatomically distinct. 
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7.5.2. Comparison of fEVAR with OR 
Open repair is still considered by many to be the ‘gold standard’ for juxta or pararenal 
aortic aneurysm repair. Of those studies identified within the literature there were two 
retrospective comparative cohort studies from large international centres performing both 
OR and fEVAR for non-standard aneurysms, three systematic reviews and two retrospective 
comparative study utilising a national database. Tsilimparis et al. [91] utilised the American 
College of Surgeons National Surgical Quality Improvement Programme (ACS-NSQIP) 
database to collect information on over 1300 (1091 OR, 264 fEVAR) patients who 
underwent aneurysm repair over a five-year period in the U.S.A. They compared 30-day 
outcomes and found that patients who underwent fEVAR had a lower; mortality (0.8% vs 
5.4%), complication (19.3% vs 42%) and operative reintervention (4.5% vs 10.1%) rate, all 
of which were found to be statistically significant. The authors compared those with 
complex aneurysms undergoing OR and those undergoing fEVAR utilising procedure codes 
from this large national registry. Gupta et. al. performed a similar analysis using the same 
database but included 535 fEVAR patients and 1207 open repair patients. The 30-day 
mortality in that study was 2.4% for fEVAR patients compared with 4.7% for open repair 
patients. However, complex aneurysmal disease, as stated by the authors, could include 
type IV thoracoabdominal aneurysms which as stated previously represents a distinct 
anatomical entity to those patients suitable for fEVAR. There was no anatomical 
information relating to the aneurysms presented within the study and therefore it is 
difficult to comment on the true ability of this study to compare these two treatment 
options for similar populations. A single centre study from the U.K. [170] retrospectively 
compared patients undergoing fEVAR and OR and tried to address the issue highlighted 
above by excluding any OR patient with a thoracoabdominal aneurysm. Canavati et al. 
[170] compared 54 patients undergoing OR and 53 patients undergoing fEVAR and found 
reduced mortality and morbidity rates after fEVAR as well as reduced length of hospital 
196 
 
stay and critical care utilisation after the endovascular approach. The literature gives 
conflicting reports however on the outcome of fEVAR when compared with OR and one 
study comparing 42 patients undergoing fEVAR and 147 patients undergoing OR showed 
that fEVAR was associated with a significantly higher 30-day mortality rate (Odds ratio 5.1), 
with the crude mortality rates being 9.5% for fEVAR and 2% for OR. [171] This study does 
have its limitations however and compares patients undergoing fEVAR from an experienced 
centre in France with those undergoing OR from an experienced centre in the U.S.A. To try 
and create a relatively homogenous group of patients the authors performed propensity 
matching with preoperative physiological and anatomical factors. However, by the authors 
own admission, there were a number of anatomical characteristics that were simply not 
measured or taken into consideration. It is therefore impossible to truly comment on the 
complexity of the fEVAR cases included. This may have resulted in fEVAR patients that 
actually represent a high procedural risk and significant procedural complexity due to their 
anatomy rather than any physiological score being matched with OR patients of similar 
physiology. Complex anatomy will have a deleterious effect on the outcome of an 
operation more readily if that patient were to undergo fEVAR compared with OR. Mainly 
due to the precise attention to anatomical detail that is required and the small margin for 
error that exist when deploying fEVAR. 
A systematic review of the literature and meta-analysis was conducted and identified 35 
case series with data on 2326 patients. [144] Of the total, 1575 patients underwent OR and 
751 underwent fEVAR, only two of the included studies reported outcomes for both OR and 
fEVAR and the remaining were case series of either OR only or fEVAR only. The pooled 
perioperative mortality rate was 4.1% for both OR and fEVAR suggesting no apparent 
advantage in terms of short-term mortality. The meta-analysis suggested that more fEVAR 
patients developed renal insufficiency during follow up, but rates of permanent dialysis 
were not increased.  
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7.5.3. Comparison of fEVAR with OR and Standard EVAR 
There has been one published study comparing the outcomes of patients undergoing 
fEVAR, open repair and standard EVAR for aneurysms with ‘challenging’ infrarenal 
necks.[121] The study defines a ‘challenging’ neck as one that is large diameter (>28mm), 
short (<15mm), angulated (>60°) and/or thrombus lined. The study compared patients 
treated at two different centres, one in Italy and the other in Sweden. The three groups 
being compared consisted of 61 OR patients, 74 standard EVAR patients and 52 fEVAR 
patients. All the patients who underwent OR were treated at the Italian centre and all of 
those that underwent fEVAR were treated at the Swedish centre. The standard EVAR 
patients were treated at a mixture of the two centres. Those undergoing endovascular 
methods were older, had more comorbidities and in general a higher ASA grade. Overall 
the anatomical characteristics of the aneurysms were similar but those undergoing 
endovascular repair had shorter and wider infrarenal necks. In this study, there was no 
statistically significant difference between the three groups in terms of 30-day mortality, 
aneurysm related mortality during follow up, reintervention rate, renal impairment or need 
for dialysis during follow up. There was an increase in late aneurysm expansion in the group 
treated with standard EVAR compared with fEVAR but no other significant findings during 
the follow up. The mean follow up was almost 20 months. Although this study has 
limitations especially in terms of the geographic disparity, it appears to show no significant 
differences between the three treatment options in terms of short-term outcomes. 
7.6. Learning Curve with fEVAR 
Many publications from early on in the global experience of using fEVAR demonstrate a 
significant learning effect. As experience has grown and publications from high volume 
centres continue to report – less is said about learning curve in the recent literature, 
including those from the above systematic review. This is most probably due to the fact 
that the centres who continue to publish outcome data have previously demonstrated their 
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learning curve and are now expert in the deployment of fenestrated technology. Recent 
papers from 2015 [172] and 2016 [173] document learning curve effects for fEVAR. Starnes 
et.al. show that over the course of 136 fEVAR procedures performed by one surgeon 
perioperative mortality or complication rate, procedure length and fluoroscopy time all 
reduced. This was despite an increase in the complexity of stent-grafts as 53% of cases had 
2 or more fenestrations at the beginning of the study compared to 88% towards the end.  
Sveinsson et.al. document the experience at two expert centres (in Sweden and France). 
That study also showed an increase in graft complexity over the 10-year experience. Again, 
despite increasing complexity those groups found that fluoroscopy time and contrast use 
decreased as time progressed. They didn’t find a difference in clinical outcome measures 
however such a perioperative mortality, endoleaks or target vessel patency. The French 
Multicentre study from Haulon et.al. [174] similarly documents a study in which many 
operators were performing their first fEVAR cases and explains certain results are 
secondary to the learning curve such as extremes of operative time, fluoroscopy time and 
contrast use. 
Verhoeven et. al. [175] documents the learning curve in his analysis of a single centres 
outcome over 8 years and cites the fact that half of all target vessel occlusions within that 
study occurred early on and in non-stented fenestrations and scallops. He goes onto 
explain it was only after this experience that a policy of stenting all fenestrations was 
employed. The literature contains many incremental learning steps such as this for 
endovascular and fenestrated repair, specifically. Verhoeven et.al. also documents a few of 
the lessons learned through their experience, and technical advances that have made the 
operation easier for the surgeon: 
- The introduction and use of guiding sheaths for deployment of stents within target 
vessels 
- Separate puncture of valve leaves in the sheath to minimise blood loss 
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- The advent of diameter reducing ties 
- The use of a hybrid theatre with fully stocked ancillary equipment  
- The reinforcement of scallops/fenestrations to stop infolding of the fabric. 
There is no doubt there is a learning curve for fenestrated repair and most authors cite this 
and reasonably state that complex endovascular techniques should be reserved specialist 
high volume centres. This intuitively makes sense for these complex procedures, what is 
unknown however is the learning effect for a single surgeon within an experienced centre 
and what role the learning effect is experienced by each single operator or by the 
‘department’ as a whole. It is likely that accrued experience of a department and the 
development of highly tuned processes and team working within each department is 
maintained despite the introduction of a new surgeon, but this is conjecture. 
 
7.7. Discussion 
There is an increasing literature base concerning fenestrated endovascular repair available. 
However, there are no randomised controlled trials or prospectively conducted high quality 
trials. This makes comparison with other treatment options difficult. The patients selected 
for fenestrated endovascular aneurysm repair in the majority of studies are, by the authors 
own admission, unfit for open repair or “high risk” for open repair. This obviously presents 
a significant selection bias when comparing outcomes of fEVAR with open repair or other 
methods. One study is notable in its exception to this [157]. It is also interesting to note in 
that study by Verhoeven et.al. they report a significantly lower perioperative mortality at 
0.7% for fEVAR compared with the literature. Of course, this is a high-volume experienced 
centre with expert operators, but their series is of 281 patients with a mean target vessel 
ratio per patient of 3.2 vessels per patient. This adds credence to the argument that the 
true utility of endovascular repair and even fenestrated repair is for the “low risk” patient, 
not the high risk. Furthermore, reports that compare fEVAR with bEVAR or include these 
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two treatments together in analyses are comparing and mixing two distinct treatment 
options. The lack of consistent and robust anatomical criteria for reporting and selection of 
patients for either treatment is one reason for this problem. Although similar they remain 
distinct technologies intended for and used (in the majority) for different extents of 
aneurysms. The lack of clear guidelines on anatomical reporting of aneurysms has 
exacerbated this problem. The majority of studies that use anatomical definitions for 
aneurysms that are not considered simply “infrarenal” tend to cite the SVS guidelines on 
reporting of arterial aneurysms [87]. This document was published in 1991 and does not 
truly reflect either the information available to clinicians with readily available CT scans 
that can be reviewed using 3-dimensional software, or the current practice of endovascular 
repair. Juxtarenal and pararenal aneurysms are terms that are interchangeable in that 
document and are defined as aneurysms with “no normal aorta below the renal arteries”. 
This has led many authors to conclude that an acceptable definition of this type of 
aneurysm is anyone in which a clamp is placed above one renal artery during open repair. 
This does not consider the fact that a clamp may be placed above the renal arteries for 
other reasons than aneurysmal extent and that the necessity of a suprarenal clamp does 
not necessarily mean the anatomy of that particular aneurysm is comparable to one that a 
physician would undertake standard EVAR, fenestrated EVAR or branched EVAR. Simply put 
the use of loose anatomical terms such as juxtarenal/pararenal/suprarenal or clamp 
position does not allow for meaningful comparison and analysis. The recommendation is 
therefore that these terms should not be used and instead precise and specific anatomic 
criteria such as neck length, diameter and angulation should be used when reporting on 
treatments and their outcomes. This will allow comparisons across differing types of repair.  
The literature is also significantly heterogenous when it comes to reporting patient 
characteristics and outcomes such as renal failure. This made any comparison between 
studies difficult within this analysis. 
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There has been a progression over the years since the widespread use of fEVAR towards 
more complex grafts including more target vessels. Several studies have tried to quantify if 
there is any deleterious effect to the use of more complex grafts more recently. Two 
studies included in the above analysis (Roy, Oikonomau) analysed the outcomes of less 
complex graft design (2 or less fenestration) with more complex designs (3 or more 
fenestration). Neither showed significant differences in outcomes related to graft 
complexity but the numbers of patients in each group were small. Roy et.al. did show a 
trend toward higher in hospital mortality in those with more complex designs. 
This systematic review and the others in the chapters above deal with each treatment 
options separately. The following table attempts to synthesise the data for primary 
outcome measures for all three treatment options from these systematic reviews. Of 
course, such a comparison is limited due to the multiple potential confounding factors 
discussed in the above systematic reviews - such as study design, patient population, 
selection bias but it collates the above presented results together to allow a comparison 
from the identified literature. First the table presents the outcomes for non-standard 
aneurysms for the three treatment options (See table 7.10) 
Table 7.10 – Reported Outcomes for NS AAA from systematic Reviews 
Treatment Primary 
Technical 
Success 
Perioperative 
mortality 
5-year 
survival 
Aneurysm 
Related 
Mortality 
Renal 
Dysfunction 
fEVARa 95.6%* 2.7% 59.4 – 92% 0.8% 21 – 27% 
EVAR 90.7% 3.1% 70 – 85.4% 0 – 6.8% - 
Open Repair NR 3.2% 64 – 88.6% 1.3% 11.3% 
Table 7.10 – fEVAR – fenestrated endovascular aneurysm repair EVAR – Endovascular Aneurysm Repair. Renal 
dysfunction is the rate reported over long term follow up. A – The results for fEVAR are collated from the 
systematic review of 8 studies published since 2015. * - Adjusted Primary Technical success as reported by Roy 
et.al. 
The above table collates data for fEVAR from the most recently published data included in 
the systematic review of the 8 original studies.  
202 
 
Technical success was not reported in any of the open repair studies. For fEVAR two studies 
report a technical success rate of 79.2% [160] and 85% [159]. Both these studies 
importantly however comment that this low rate is primarily secondary to intraoperative 
endoleaks that spontaneously sealed by the time of the first post-operative imaging. When 
adjusting for this Roy et.al. report a technical success rate of 95.4%. The rate of 95.6% given 
in the table above uses the adjusted primary technical success rate given by Roy et.al. to 
calculate. 
Five-year survival was not commonly reported across many of the studies for the different 
treatment options, primarily due to length of follow up time. For EVAR it was only possible 
from 2 studies [103, 112]. For open repair it was only possible from 4 studies [125-127, 
129], for fEVAR – 2 studies [160, 161]. Therefore, only those studies that report 5-year 
survival using the Kaplan Meier method have been used to create the above table. Since it 
is not possible to amalgamate the outcomes for 5-year survival from KM method between 
studies a range is given 
It is important to note that the aneurysm related mortality rate for EVAR presented in the 
table were from studies with a wide range of FU times, so it is given as a range of results 
across all the studies. The range of mean or median follow up was 12 – 51.6 months in the 
studies. For open repair AAA related mortality was poorly and inconsistently reported. In 
those that did mention it there it was often difficult to extract the information. From 4 
studies that did mention it – 3 reported 0% and the other reported 5 deaths. The above 
value is a pooled value of these four studies. Aneurysm related mortality for fEVAR was 
from 6 of 8 studies, in general it was also poorly reported across the studies. Seven patients 
out of 845 are reported throughout follow up to have died secondary to aneurysm related 
over FU ranging 12 – 34 months 
203 
 
As stated in the above systematic reviews rates of renal dysfunction were poorly reported 
across all studies with differing definitions often for what constituted renal failure. For 
EVAR it was not possible to provide a value due to insufficient data. For open repair the 
value was collated from three studies and fEVAR 2 studies. 
It is disappointing that a more robust collation of the results cannot be made from the 
available and analysed literature for the above outcome measures, but primary technical 
success rates appear to be better for fEVAR when considering the definition of adjusted 
primary technical success used by Roy et. al. but similar when using the standard definition 
of technical success (92.3% for fEVAR). Furthermore, the above table highlights that 
perioperative mortality appears similar across all three treatment options which is 
surprising given the results of randomised controlled trials comparing open repair and 
infrarenal EVAR. However as stated there are many confounding factors across these 
studies and it is difficult to draw firm conclusions from the above presented results.  
For completeness the same information is presented for standard aneurysm patients from 
the literature. (See table 7.11) 
Table 7.11 -  Reported Outcomes for SA AAA from RCT 
Treatment Primary 
Technical 
Success 
Perioperative 
mortality 
4-year 
survival 
Aneurysm 
related 
Mortality 
Renal 
Dysfunction 
EVAR NR 1.4% 84.2% 2.9% - 
Open 
Repair 
NR 4.2% 83% 4.3% - 
Table 7.11 – EVAR – Endovascular Aneurysm Repair. 
 
The results from a cochrane review [74] of the four randomised controlled trials comparing 
open repair with EVAR provide the results for the above table. Primary technical success 
rates were not reported in that review or in the original studies. In the review there was no 
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statistically significant difference between the 4-year survival and aneurysm related 
mortality (also up to 4 years) outcome measures. Renal dysfunction was measured over the 
longer term in the EVAR 1 trial  [64] but reported as change in the eGFR rather than rates of 
renal dysfunction. The results from that trial showed “no significant change in the 
estimated glomerular filtration rate (eGFR) between groups, with a mean (SD) difference 
from baseline of -1.13 (1.43) and -1.00 (1.43) mL/min/1.73/year in the EVAR and OSR 
groups, respectively (P = 0.275)” 
7.8. Conclusion 
Fenestrated endovascular aneurysm repair has acceptable clinical outcomes both in the 
short and longer term as outlined above. There is heterogeneity between studies published 
and especially when concerning comparative studies making valid comparison difficult to 
draw. The safety, feasibility and efficacy is clear from the published literature. Further work 
is needed to compare this method of aneurysm repair with alternatives to ascertain its true 
utility in the context of treating aneurysmal disease. Furthermore, strict guidelines 
regarding the reporting of anatomical criteria of aneurysm treated should be adhered to 
within the vascular surgery community when publishing reports of endovascular repair. 
These guidelines should include details on aneurysm neck morphology, with reference to 
instructions for use, clamp position and reasons for choosing that position, as well as 
criteria for comorbidity reporting.  
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8. CHAPTER 8 - A Review of Clinical Outcomes at Royal 
Liverpool University Hospital after fEVAR 
8.1. Introduction 
Fenestrated endovascular aneurysm repair (fEVAR) has become an accepted and 
widespread technique for the treatment of complex abdominal aortic aneurysms in which 
the anatomy of the infrarenal neck precludes the placement of a standard endovascular 
device. It is estimated that to date more than 5000 fenestrated stent-grafts have been 
implanted worldwide.[176] Following this worldwide experience, many centres have now 
reported short to mid-term data on clinical outcomes after fEVAR with promising results. 
Meta-analyses show acceptable mortality, target vessel patency and long-term dialysis 
rates up to two years and beyond.[92] Whilst these early results support the use of fEVAR 
as a treatment for complex aneurysms, there remains a paucity of long-term data. This 
chapter reports the 10-year experience of fEVAR from the Royal Liverpool University 
Hospital (RLUH), the first hospital in the UK to adopt this technique. 
8.2. Methods 
This was a retrospective cohort study over 10 years of all patients within a single UK centre 
(RLUH) who had undergone a primary fEVAR procedure.  
8.2.1. Patients and Inclusion Criteria 
Data of all patients who underwent fEVAR were entered into the GLOBALSTAR registry. 
[85]This is a multi-centre collaborative online project developed within the University of 
Liverpool and includes the majority of UK fenestrated procedures at the time of writing. 
GLOBALSTAR is an online registry developed by physicians with data entry performed by 
physicians that perform the procedure. In the absence of randomised controlled trials, the 
aims of the GLOBALSTAR project at the outset were to evaluate the technique in terms of 
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primary and secondary endpoints, establish an archive of all pre-operative and follow up 
imaging, to aid detection of mechanisms of failure, and to provide an “early warning 
system” for complications specific to the technique. Retrospective analysis provided 
patient demographics, aneurysm characteristics, operative details and post-operative 
surveillance data. It should be noted that anatomical information for each aneurysm is not 
stored on the database nor are copies of the CT scans. Preoperative imaging was not 
reviewed as part of this study to ascertain specific anatomical criteria. This was primarily 
for two reasons; firstly, the review is designed to investigate outcomes after fEVAR as a 
specific treatment rather than focus on anatomy – to provide a background of the clinical 
outcomes for fEVAR over a long period of time. Not to compare clinical outcomes for 
patients with differing anatomy but to detail the mid – long term clinical outcomes for 
fEVAR. Secondly the use of fEVAR within the Royal Liverpool University Hospital goes back 
to 2003 and it would have been practically impossible to obtain all CT scans for all those 
patients to review their anatomy. All consecutive patients who underwent primary fEVAR 
within the RLUH between Feb 2003 and Feb 2013 were included in this analysis. The data 
for this study was collated prior to that for the retrospective multicentre study of non-
standard aneurysms and data collection for this study stopped in 2014 – four years earlier 
than the multicentre retrospective study.  
Patients who underwent a branched thoracoabdominal endovascular repair, a combined 
fenestrated and branched endovascular repair and a fenestrated cuff extension device 
were excluded. The primary endpoints included overall survival, freedom from target vessel 
loss, graft-related endoleak and secondary intervention. Definitions for success, 
complications and other events associated with endovascular repair were in accordance 
with accepted reporting standards.[93, 99] A target vessel is defined according to previous 
published reports on fEVAR, as “a vessel potentially covered by the stent-graft fabric if not 
for a deliberate mechanism of preservation, when the stent-graft is deployed as intended.”   
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8.2.2. Follow up Protocol 
There was a standardised post fEVAR surveillance protocol including plain abdominal 
radiograph (AXR) prior to discharge, one-month duplex ultrasound examination (DUS) and 
single arterial phase computed tomography angiography scan (CTA), and a six-week clinical 
review.  Six month and then annual AXR, DUS and CTA were undertaken. If complications or 
potential problems were identified patients were discussed at a multi-disciplinary team 
(MDT) meeting. Further imaging in the form of dual or triple phase CTA or contrast-
enhanced ultrasound (CEUS) were performed if deemed appropriate and secondary 
intervention was undertaken if clinically indicated. 
8.2.3. Statistics 
Continuous data are presented as a median with the range in parentheses. Overall survival, 
freedom from target vessel loss, graft-related endoleak and secondary intervention were 
all subject to Kaplan-Meier analysis. Median follow up length was determined using the 
reverse Kaplan-Meier technique. SPSS version 20.0 (SPSS Inc, Chicago, Ill; www.spss.com) 
was used for all statistical analyses. If the patient was known to be alive and still on the 
surveillance programme their last point of follow up was taken as the point of data 
collection. If the patient was followed up elsewhere and hence not in the local programme, 
then their last point of imaging was taken as the last follow up time point. 
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8.3. Results 
During the 10-year study period 115 patients underwent a branched and/or fenestrated 
procedure of which 107 underwent primary fEVAR. Eighty-nine per cent were male and the 
median age at operation was 75 years (53 – 88). Median pre-operative aneurysm size was 
64mm (55-92) and median post-operative follow up was 51 months (1 – 124). Patient co-
morbidities and American Society of Anesthesiologists (ASA) grading are detailed in table 
8.1 (See table 8.1). The median pre-operative creatinine level was 101 µmol/L (51 - 762), 
and the median BMI was 28 (19-41). There was information pertaining to pulmonary 
function testing in 87% of patients with a median forced expiratory volume in one second 
of 2.08 L (0.82 – 4.87). Pre-operative left ventricular ejection fraction was not recorded in 
48 patients (45%)  
Table 8.1 Patient Characteristics 
Comorbidity Percentage of patients 
Diabetes 14 
Ischaemic heart disease 50 
Congestive heart failure 8 
Hypertension 58 
Chronic kidney disease 20 
Previous vascular disease 14 
                     ASA Grade 
I 2 
II 22 
III 70 
IV 4 
Data missing 2 
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8.3.1. Operative Data 
All devices in the 107 patients were introduced successfully with no target vessel loss upon 
completion of the procedure. There were, however, 15 patients with a graft-related 
endoleak (type I or III) on completion angiography, giving a primary technical success of 
86% (92 patients). Thirteen of these fifteen endoleaks identified had resolved without 
intervention at the one-month surveillance imaging. 
There were 31 intraoperative adjunctive manoeuvres used in 28 patients. (See table 8.2) 
Table 8.2 Intraoperative Adjunctive Manoeuvres 
Adjunctive manoeuvre n 
Extra renal stent placed 4 
GTN for renal artery spasm 4 
Renal stent reinflated to correct endoleak 3 
Renal artery predilated (Pre-existing stenosis) 1 
Iliac angioplasty 5 
Adjunctive iliac limb stent because of kinking 4 
Femoro-femoral crossover 2 
Bilateral common femoral artery endarterectomy 1 
Iliac conduit 1 
Coda balloon to proximal main body to rectify endoleak 2 
‘Crossover technique’ as unable to cannulate contralateral stump 1 
 
The median operation time was five hours (3 hrs. 15mins – 11 hrs.), with data available in 
85% of patients. 
8.3.2. Stent-graft Configuration 
The most common stent-graft and target vessel configuration was a scallop for the superior 
mesenteric artery (SMA) and a small fenestration for each of the renal arteries (50%). (See 
table 8.3) 
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Table 8.3 Stent-Graft Configuration 
Number of Target vessels Configuration Number of patients 
4 Fen CA/SMA/LRA/RRA 5 
Sc CA, Fen SMA/LRA/RRA 21 
3 Fen CA/SMA/LRA 1 
Sc CA, Fen SMA/LRA 2 
Sc CA, Fen SMA/RRA 1 
Fen SMA/LRA/RRA 9 
Sc SMA, Fen RRA/LRA 53 
Sc SMA, Fen LRA, Sc RRA 1 
2 Fen CA/SMA 1a 
Fen SMA/RRA 1 
Sc SMA, Fen RRA  1 
Fen RRA/LRA 1 
Fen RRA, Sc LRA 2 
1 Sc RRA or LRA 8 
Table 8.3 - a - Patient with end-stage renal failure on dialysis. Fen = Fenestration, Sc=Scallop, CA = Coeliac 
axis, SMA = Superior mesenteric artery, LRA = Left renal artery, RRA = Right renal artery.  
Over the ten-year period studied there were an increasing proportion of stent-grafts 
incorporating four target vessels in the repair. (See figure 8.1) 
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Figure 8.1 Proportion of 3 and 4 Target Vessel Stent-Grafts Implanted Over Time 
 
8.3.3. Target Vessels 
There were 325 target vessels in 107 patients. Of these, 90 were preserved with a scallop 
and 235 with a fenestration (72%). It was routine practice to stent all fenestrations 
however this was not possible in four instances. One was due to an inability to cannulate 
the celiac axis, and in another a large fenestration with struts crossing the opening was 
manufactured and therefore the target vessel was not stented. There was no reason 
recorded for the lack of stenting in the other two. Furthermore, eight renal arteries that 
were protected with a scallop were stented in this series. In total 239 target vessels were 
stented with details on type of stent available for 225 (94%). Bare metal stents were used 
in 70 target vessels (Palmaz Genesis, Cordis Corp.= 53; AVE, Medtronic Inc. = 15; Racer RX, 
Medtronic Inc. = 1; Unspecified in 1). Covered stents were used in 155 target vessels 
(Advanta, Atrium Medical = 141; Jotec stent-graft, Abbott vascular = 14). 
All target vessels were patent at completion of the procedure. However, in four patients 
there was a compromise noted to a single renal artery. In one right renal artery the flow 
was noted to be reduced with no additional procedure undertaken. The patient suffered 
mild renal impairment without clinical sequelae. In another, occlusion of an intra-renal 
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artery was noted, most likely secondary to thromboembolisation. The patient suffered a 
degree of renal impairment not requiring dialysis. Another renal artery was dissected at the 
origin due to difficult cannulation however, the patient suffered no complications or 
change in renal function. In the last patient, there was loss of perfusion to the lower pole of 
one kidney secondary to a dissection beyond the renal stent. No additional procedure was 
undertaken, and the patient died three days later secondary to extensive systemic 
cholesterol embolisation and gut ischaemia. 
8.3.4. Perioperative Mortality and Complications 
Three patients (2.8%) died within 30 days of the original procedure and one further patient 
during their primary admission giving a total in hospital mortality of 3.7%. The cause of 
death for each patient is outlined below:  
1. The patient suffered systemic cholesterol embolisation and died from gut 
ischaemia three days after the operation. 
2. The patient died of myocardial infarction four days after operation.  
3. The primary procedure was prolonged, lasting ten hours and the patient developed 
bilateral acute-on-chronic lower limb ischaemia. Bilateral fasciotomies and femoro-
femoral crossover were performed but the patient died from multi-organ failure on 
day nine. 
4. The patient died after 47 days having suffered a myocardial infarction and 
developing cardiac failure. 
In the post-operative period, 32 patients (30%) suffered 41 complications, (See table 8.4) of 
whom eight required a secondary intervention prior to discharge. 
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Table 8.4 Post-Operative Complications 
Type of Complication Complication n 
Infection Chest infection 8 
Urinary tract infection 4 
Cardiac Atrial fibrillation 5 
Myocardial infarction 4 
Pulmonary oedema 2 
Groin issues Haematoma 2 
Pseudoaneurysm 1 
Post op bleeding 1 
Ischaemic Mesenteric ischaemia 2 
Lower limb neuropathy 1 
Lower limb ischaemia 1 
Gastrointestinal Peritonitis 1 
Upper GI bleed 1 
Other CVA/TIA 2 
Cholesterol embolism 2 
Sepsis 1 
Confusion 1 
Epistaxis 1 
HIT 1 
Table 8.4 - GI = Gastrointestinal, CVA = Cerebrovascular accident, TIA = Transient ischaemic attack, HIT = 
Heparin induced thrombocytopenia. 
8.3.5. Renal Function 
Post operatively 30 patients (28%) suffered a greater than 25% increase in their baseline 
serum creatinine level. Of these, six patients had an abnormal creatinine preoperatively 
(>130 µmol/L). Two patients with pre-existing renal dysfunction required temporary 
dialysis while an inpatient. No patient went on to require permanent dialysis after 
discharge. Data on contrast volume was unavailable for analysis. 
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8.3.6. Overall Survival 
At 1, 3- and 5-years’ overall survival was 91%, 76% and 53% respectively. Four patients died 
during their primary hospital admission and 36 died during follow up. None are known to 
be aneurysm related (See figure 8.2) 
Figure 6.2 K-M Estimated Overall Survival 
 
 
Months 12 24 36 48 60 72 84 96 108 120 
Cumulative events 8 15 21 27 34 35 35 39 40 40 
Number at risk 95 66 54 39 23 18 15 6 3 1 
8.3.7. Target vessels 
Freedom from target vessel (TV) loss was 100%, 97% and 89% at 1, 3 and 5 years 
respectively. (See figure 8.3) 
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Figure 8.3 K-M Estimated Freedom from Target Vessel Loss
 
Months 12 24 36 48 60 72 84 96 108 120 
Cumulative events 0 1 2 4 5 6 6 6 6 6 
Number at risk 80 55 43 31 19 13 9 4 2 1 
 
During follow up six target vessels occluded. All occurred after 12 months from the initial 
operation at a median of 20 months (13 – 48). In five patients, the target vessel was a renal 
artery and one was an SMA, all were stented through a small fenestration. Four of these 
target vessels received a Palmaz genesis stent and two had a Jotec stent-graft. The mode of 
failure was recorded in four patients: angulation between TV stent and main stent-graft 
body in three; and shuttering of a misplaced SMA stent in one. In three cases a problem 
was identified on surveillance imaging with the target vessel in question prior to the date of 
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occlusion. In the other three cases, there were no such heralding phenomena. No patient 
required permanent dialysis or further intervention following their target vessel occlusion.  
During post-operative surveillance, the patency of 51 target vessels (16%) in 34 patients 
was threatened. The mode of threat was as follows: in-stent stenosis (13 TV), native vessel 
stenosis (8 TV), angulation (10 TV), stent fracture (7 TV), shuttering (6 TV), stent dislocation 
(6 TV), and vessel dissection (1 TV). Secondary intervention for target vessel threat was 
carried out in nine patients: three stenoses were stented, one was stented then later 
underwent a surgical bypass, two target vessels with stent-fracture were re-stented, one 
shuttering was stented and two patients underwent a diagnostic angiogram revealing no 
demonstrable pressure gradient across the target vessel of interest therefore no further 
intervention was carried out. Secondary intervention for target vessel threat occurred at a 
median of 8 months (<1 – 42) post operatively. 
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8.3.8. Endoleak 
Freedom from graft related endoleak was 98%, 96% and 89% at 1, 3 and 5 years 
respectively. (See figure 8.4) 
Figure 8.4 K-M Estimated Freedom from Graft Related Endoleak 
 
Months 12 24 36 48 60 72 84 96 108 120 
Cumulative events 4 4 4 5 6 6 6 6 6 6 
Number at risk 77 54 43 30 17 12 9 4 2 1 
 
There were six graft related endoleaks found during the post-operative surveillance period. 
All were para-ostial endoleaks related to the connection between renal target vessel stents 
and the main stent-graft body. Three patients had a secondary intervention that abolished 
their endoleak, confirmed on subsequent CTA. One patient had a secondary intervention, 
which abolished the endoleak on completion of the procedure but recurred on surveillance 
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imaging. One patient remains under surveillance with a para-ostial endoleak and one 
patient was lost to follow up.  
During the follow up period, 39 patients (36%) had a type II endoleak. Two patients 
underwent a secondary procedure to treat their type II endoleak; both patients had an 
increase in aneurysm size of ≥ 5mm. One patient had a successful IMA embolization at 15 
months with subsequent regression of aneurysm size and no further endoleak on 
surveillance. The other patient had embolisation of a lumbar artery feeding a type II 
endoleak at 7 years. No further type II endoleak was seen but the patient remains on the 
surveillance programme with an increasing aneurysm and no endoleak identified on either 
CTA or CEUS. 
8.3.9. Secondary Intervention 
Freedom from secondary intervention was 83%, 78% and 65% at 1, 3 and 5 years 
respectively. (See Figure 8.5) 
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Figure 8.5 K-M Estimated Freedom from Secondary Intervention 
 
Months 12 24 36 48 60 72 84 96 108 120 
Cumulative events 17 20 21 23 26 26 26 26 26 26 
Number at risk 74 54 46 29 16 13 11 3 1 0 
 
Twenty-six patients underwent 34 secondary interventions during follow up. The most 
common indications for a secondary intervention were endoleak, pending loss of seal, and 
threatened target vessel patency. Five patients had two secondary interventions and one 
patient had four during the follow up period. The majority of all secondary interventions 
were endovascular procedures (82%). The secondary interventions are detailed below. (See 
table 8.5) 
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Table 8.5 All Secondary Interventions 
Time after 
operation 
Intervention Reason for intervention 
Within 30 days Left hemicolectomy Mesenteric fibromatosis leading to 
perforation 
Within 30 days Groin exploration Bleeding from groin 
Within 30 days Groin exploration Bleeding from groin 
Within 30 days Fem-fem crossover and 
fasciotomies 
Lower limb ischaemia 
Within 30 days Bilateral renal stent PTA Proximal endoleak 
Within 30 days Renal stent PTA Endoleak around renal stent 
Within 30 days Renal stent PTA Stenosis of stent 
Within 30 days Wallstent Kinked limb 
1 month SMA PTA Mesenteric ischaemia 
3 months EIA stent Dissection of EIA 
3 months Renal artery stent Endoleak around renal stent 
4 months IIA embolisation and 
extension into EIA 
Minimal seal 
4 months Groin exploration Bleeding from groin 
7 months SMA stent Stenosis in native vessel 
8 months Diagnostic angiogram ? Stenosis right renal stent (No stenosis 
found) 
8 months Renal artery stent Shuttering of renal artery 
8 months EIA to SMA bypass Mesenteric ischaemia 
10 months Diagnostic angiogram Increased velocity in SMA (No pressure 
gradient on angiography) 
12 months Renal stent PTA Endoleak around renal stent 
13 months Further SMA stent Fractured SMA stent 
14 months Renal stent PTA Endoleak around renal stent 
15 months IMA embolisation  Type II endoleak and enlarging 
aneurysm 
22 months Bilateral limb extension Poor engagement bilaterally 
2 years Further SMA stent Fractured SMA stent 
221 
 
3 years Diagnostic angiogram Angulated and fractured renal stent (No 
intervention as renal artery occluded) 
3 years SMA stent Stenosed SMA 
4 years Bridging stent Modular distraction 
4 years Wallstent Kinked limb 
4 years Bilateral Wallstents Bilateral Kinked limbs 
5 years Bridging stent Modular distraction 
6 years Wallstent Stenosis within limb 
7 years Relining with bifurcated 
stent-graft 
Modular distraction 
7 years Lumbar artery 
embolization 
Type II endoleak and enlarging 
aneurysm 
8 years Diagnostic angiogram Enlarging aneurysm 
Table 8.5 - PTA = percutaneous transluminal angioplasty, SMA = Superior mesenteric artery, EIA = External 
iliac artery, IIA = Internal iliac artery, IMA = Inferior mesenteric artery 
8.3.10. Aneurysm growth 
With regards to aneurysm growth during follow up, when comparing the pre-operative 
planning CTA and the most recent CTA; 57 patients (57%) had aneurysm shrinkage of ≥ 
5mm, 31 patients (31%) had between 5mm of aneurysm shrinkage and 5mm of aneurysm 
growth, and 12 patients (12%) had aneurysm growth of ≥ 5mm. Data were not available for 
7 patients. 
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8.4. Discussion 
Fenestrated endovascular aneurysm repair is an effective and safe method for treating 
aneurysms not suitable for standard endovascular repair in the short to medium term. In 
this cohort, there was an in-hospital mortality of 3.7%. This is in-line with other 
contemporary single and multi-centre studies. [82, 84] Meta-analyses have reported a 
pooled mortality rate of 2% [149] and 2.5% [92] within 30-days. Again, these results are 
equivalent to this analysis where the 30-day mortality was 2.8%. For comparison, 
systematic reviews of open repair of juxta or pararenal aneurysms show that the mortality 
rate and dialysis rates are comparable with endovascular repair in these aneurysms.[177, 
178] 
The main limitations in this analysis were its retrospective nature and the fact that 10 
patients did not have their long-term post-operative surveillance at RLUH. Seven of these 
patients had their initial fEVAR procedure prior to 2008 and three had it in 2009. After this 
point there was a conscious decision to continue long term post-operative surveillance 
within the unit conducting the initial fEVAR to ensure that the rigorous follow-up protocol 
was adhered to in all patients. Even though 10 patients were followed up elsewhere long-
term surveillance data were fed back to the initial operating centre thereby providing 
valuable data for analysis. For those 10 patients, the median length of follow up data that 
were available was 23 months (6 – 75). 
All stent-grafts were implanted successfully in this series; however, there was a primary 
technical success rate of 86%. This loss of primary technical success was due entirely to 
graft-related endoleak noted at completion angiogram in 15 patients. Twelve patients had 
resolution of their endoleaks, without intervention, by the first post-operative CTA and 
remained endoleak-free for the remainder of their surveillance. The details of the other 
three patients are detailed below: 
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 One patient, with a proximal type I endoleak at the end of the procedure, that had 
resolved by the time of the first post-operative CTA, developed a para-ostial 
endoleak at the left renal stent 53 months later. This was due to caudal migration 
of the stent graft ultimately leading to dislocation of the left renal stent. The 
endoleak was not communicating with the aneurysm and the patient remained on 
the follow up surveillance programme.  
 A further patient who had a type III endoleak between the target vessel stent and 
main body on completion angiogram had two secondary procedures; the first was 
an angioplasty to ‘re-lock’ the left renal stent to the fenestration prior to discharge 
and a second renal stent three months later which abolished the endoleak. 
However, 15 months after the primary procedure the endoleak was present on 
CEUS with a stable aneurysm size, this patient remained on the follow up 
surveillance programme.  
 The remaining patient died before discharge of multi-organ failure preceded by an 
acute myocardial infarction. 
 There has been apprehension relating to the possibility of type I endoleaks after fEVAR, as 
the presence of target vessel stents within the proximal seal zone makes it undesirable to 
use balloon moulding of this area to try and abolish the endoleak, an effective technique in 
standard EVAR. Two of the nine patients noted to have a proximal type I endoleak on 
completion angiogram underwent balloon moulding of the proximal seal zone, both 
unsuccessful at abolishing the endoleak. Neither patient required secondary intervention 
for their target vessels nor suffered target vessel occlusion. Due to the risk of disrupting the 
target vessels, it was not routine practice to undergo adjunctive balloon moulding of the 
proximal sealing zone at the time of the operation. It is important to note that in all nine of 
these patients the endoleak was not present on the first post-operative CTA at one month 
and was never seen again during their follow-up. This highlights that fears of early proximal 
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endoleaks in fEVAR leading to clinical failure may be exaggerated. It has now become 
standard practice at RLUH to manage conservatively small proximal endoleaks noted at 
completion angiogram.  
With this technology in the second decade of its application, it is now possible to analyse 
the longer–term outcomes to determine the true utility of this technique. One area of 
concern since the introduction of this technology is the potential for target vessel loss 
during the longer term with potentially catastrophic clinical consequences. Freedom from 
target vessel loss was 89% at 5 years in this series. The attrition rate of target vessels is 
therefore surprisingly low even in the long term, and none of the six target vessels that 
occluded resulted in serious clinical consequences for any patient. This is within the context 
of a robust surveillance programme that identifies and can act upon threats to target vessel 
patency. These results are in line with another long-term study with median follow up of 67 
months [84] confirming that target vessel loss does not appear to be a significant problem 
with fenestrated technology.  
Late re-intervention remains an important disadvantage of endovascular techniques and 
fEVAR is no exception. However, in our series secondary interventions performed after 
discharge were, in the main, endovascular procedures (82%). The frequency of re-
intervention confirms the necessity of continued robust surveillance. 
Since the UK EVAR trials have shown an advantage to endovascular repair in terms of 
mortality in the short term [64] it has been assumed this advantage is maintained when 
dealing with juxta-renal aneurysms and fEVAR. With the lack of a randomised controlled 
trial there has continued to be a desire to compare fEVAR with open surgical repair using 
the best available evidence to determine the true utility of the endovascular technique in 
this setting.  However, there have been few studies that compare the two strategies 
directly, which make it difficult to ascertain the true advantage of fEVAR. Furthermore, as 
225 
 
standard stent-graft technology and techniques have improved over the past 10 years the 
scope and range of aneurysms that are now suitable for standard endovascular repair is 
significantly larger than it was 10 years ago. This means that reports on open repair prior to 
this time for ‘juxtarenal’ aneurysms may include patients in whom their aneurysm would 
now be suitable for standard repair. This, again, makes it difficult to draw comparisons 
between historic reports for open repair and contemporary reports for fEVAR. It may 
therefore now be appropriate to move away from defining infrarenal aneurysms 
anatomically and towards an endovascular based delineation – ‘standard’ aneurysms; for 
those aneurysms that are suitable for standard EVAR and ‘non-standard’ aneurysms for 
those that are not. This would focus further study in this area to compare anatomically 
equivalent aneurysms undergoing the two treatment options. In a recent analysis of 
patients, from the RLUH, who underwent open repair for ‘non-standard’ aneurysms 
between 2006 and 2010 the perioperative mortality rate was 9.2% with an absolute risk 
reduction for fEVAR of 5.5% when compared with open repair. [170]Therefore, it was 
correct to assume the preservation of the short-term advantage seen in standard EVAR, in 
this centre at least. Along with this analysis showing the durability of fEVAR in the long 
term these results show fEVAR to be a feasible, safe and durable technique for repairing 
‘non-standard’ abdominal aortic aneurysms.  
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8.5. Conclusion 
This chapter details the experience from the first centre in the UK to adopt fEVAR. It 
highlights the excellent technical success, low perioperative mortality and high clinical 
success rates seen in the short and mid-term. Furthermore, it shows that initial successes 
as regards freedom from graft-related endoleak and target vessel patency are maintained 
in the long term. A robust surveillance programme along with significant experience of 
fenestrated endovascular repair and the various modes of failure is necessary in order to 
provide fEVAR as an option that is durable in the long-term.  
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9. CHAPTER 9 – A Multicentre Retrospective Concurrent 
Cohort Study of Clinical Outcomes following Non-Standard 
Aneurysm Repair 
 
9.1. Introduction 
The treatment options for patients with non-standard aneurysms is varied and multiple, 
especially as technology continues to advance. However, the three most commonly used 
methods to repair a non-standard aneurysm are still open surgical repair, standard EVAR 
and fenestrated EVAR. 
For standard infrarenal aneurysms it is relatively well understood from the gathered 
evidence that EVAR confers a short-term benefit over open repair in terms of perioperative 
mortality, but this advantage appears to equalise over time. The compromise for this early 
advantage is an increased risk of late failure and need for reintervention in the future. 
When EVAR is used outside its IFU it exhibits inferior clinical outcomes when compared to 
EVAR within IFU such as increased type 1 endoleaks, reintervention rates and there is a 
suggestion that mortality may be increased over the longer term. It is not clear however 
the exact magnitude of these deleterious effects and whether when compared to 
alternative treatment options for non-standard aneurysms they will remain inferior clinical 
outcomes. Open surgical repair for non-standard aneurysms has been shown to be possible 
with low mortality rates from the literature. However, this finding is certainly not 
consistent across all studies. In addition to this the heterogeneity within the published 
literature to date and the use of loose anatomical terms such as juxtarenal aneurysm 
makes the outcomes for specific cohorts of patients with defined anatomical characteristics 
uncertain.  
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Fenestrated EVAR has been shown to be safe and effective in the short and mid-term but 
more recently with increasing stent graft complexity a concern has arisen that the limits of 
this technology are being pushed too far and outcomes are worsening for patients with 
more complex anatomy and treatments.  
It seems intuitive and to some extent is backed up from the published literature that when 
endovascular repair is tested to the boundaries of anatomy that it is designed to treat 
outcomes tend to worsen and this seems to be true for standard EVAR and may well be 
true for fenestrated EVAR. With continuing enthusiasm for endovascular repair and 
technological advancements both standard EVAR and fenestrated EVAR are being pushed 
to the limits of anatomy that they can safely treat, i.e. they are both moving proximally. 
Since no randomised controlled trial or prospective trial has been conducted to assess the 
outcomes of non-standard aneurysms all the available evidence within the published 
literature is from cohorts of patients being treated more aggressively both with EVAR and 
fEVAR as the years proceed. Due to this there is a gap in the understanding of whether an 
EVAR placed outside of IFU confers better or worse clinical outcomes than a fEVAR placed 
well within its IFU with the minimum number of target vessels possible. This supposition 
provides the rationale for this research. In essence – for those patients that are out with 
the treatment of standard EVAR or infrarenal open repair (which is usually because of an 
unsuitable infrarenal neck – making them juxtarenal aneurysms) what are the advantages 
and disadvantages of the three most common treatment strategies? To investigate this 
question the following hypothesis and study were designed. 
  
234 
 
9.2. Hypothesis: 
Fenestrated Endovascular Aneurysm Repair (fEVAR) has superior clinical outcomes as a 
treatment strategy for non-standard AAAs that are unruptured in whom aneurysm repair is 
deemed to be more beneficial than conservative management. 
The term “superior clinical outcomes” is in relation to all cause and aneurysm related 
mortality at all time points both perioperatively and throughout follow up. For the 
purposes of the hypothesis these primary outcome measures carry an equal weighting 
towards the definition of “superior clinical outcomes” to reflect the need for aneurysm 
repair to prevent death both in the short and longer term. Aneurysm related, and all-cause 
mortality are equally weighted to reflect the desire for any given treatment option to be 
superior to its alternatives both in improving survival from the condition and in providing 
an overall benefit to any given patient. This is because, for an individual patient, mortality 
has the same devastating effect whether it is caused by the aneurysm or not. It remains 
important however to demonstrate (if possible) that a treatment reducing mortality from 
the condition it is treating regardless of all-cause mortality which inevitably is influenced by 
unrelated confounding factors. Other clinical outcome measures that will be considered to 
contribute to whether fEVAR is “superior” will be technical success and clinical success as 
defined by agreed reporting standards.[93] These outcome measures will inform the 
decision of whether the hypothesis is satisfied or not and to reflect the importance of 
continued clinical efficacy throughout follow up clinical success will have a greater 
weighting to technical success in making this decision but less of a weighting than the 
outcome measures related to mortality. This reflects the fact that each of these represents 
the ability of the method of repair to exclude the aneurysm from the circulation without 
demonstrable major consequences that potentially affect the patient’s quality of life in a 
measurable and quantifiable way.  
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9.3. Methods 
9.3.1. Definition of non-standard aneurysm 
The definition used within this study for non-standard aneurysm has already been set out 
in the chapter on study design but is reiterated here. For the purpose of this study it was 
important to develop a term that specifically defines the anatomy of interest and the 
patient population being studied. The patient population of interest was patients that were 
not suitable for standard endovascular repair according to anatomical criteria pertaining to 
the infrarenal neck. The term non-standard aneurysm/non-standard anatomy was 
developed to describe any anatomy of the infrarenal neck that fell out with standard EVAR 
indications for use. 
In this study the definition of non-standard aneurysm therefore applied to any aneurysm 
that exhibited any one of the following criteria: 
1) A neck length of <10mm 
2) An alpha angle of > 60 degrees 
3) A beta angle of >75 degrees. 
4) Neck diameter >32mm (but ≤ 36mm) 
Moreover, if the neck length was 10 – 15mm AND one of the following apply then it is non-
standard (in keeping with the IFU for the endurant stent graft: 
5) Alpha angle >45 degrees 
6) Beta angle >60 degrees. 
These anatomical characteristics define non-standard anatomy but there is an important 
caveat within the definition of non-standard anatomy that was used in this study: If an 
aneurysm was treated with a specific endovascular device and the anatomy was in breach 
of the IFU for that device in any way then it was deemed non-standard. In order to exclude 
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patients that possessed a thoracoabdominal aneurysm and one that would traditionally 
necessitate placement of a branched endovascular stent-graft if treated endovascularly it 
was deemed that if an aneurysm possessed a neck diameter of >36mm immediately below 
the level of the renal arteries then this would exclude it from the definition of a non-
standard aneurysm and instead it would be defined as a thoracoabdominal aneurysm.  
In summary the definition of a non-standard aneurysm is those that are out with the IFU 
for standard EVAR but within that for fenestrated EVAR. 
9.3.2. Geographical and Temporal Location: 
To test the hypothesis a retrospective concurrent cohort study was carried out assessing 
the clinical outcomes of three categories of patients: those treated by traditional open 
operation, fEVAR, and a standard EVAR performed outside of IFU. Analysis of all patients 
who underwent aneurysm repair for a ‘non-standard aneurysm’ in the Cheshire and 
Merseyside region in the 24-month period 1st April 2006 – 31st March 2008 were to form 
the basis of data for this study. There were seven centres within the Cheshire and 
Merseyside region that performed at least one of the three treatment methods during the 
study period. These included; the Royal Liverpool University Hospital, Aintree University 
Hospital, Southport Hospital, Warrington Hospital, Arrowe Park Hospital, Countess of 
Chester Hospital and Leighton Hospital. 
9.3.3. Ethical Approval 
Ethical approval for this trial was first granted from the research and development 
department at the base hospital, Royal Liverpool University Hospital, with the Royal 
Liverpool and Broadgreen University Hospitals NHS Trust acting as sponsor.  Ethical 
approval was then granted from the regional ethics committee (North West REC centre). 
Once ethical approval was granted from both organisations, it was necessary to seek 
approval from the National Information Governance Board (NIGB) to gain section 251 
approval under the NHS Act 2006. This would ensure that patient identifiable information 
237 
 
could lawfully be accessed and gathered for research purposes without explicit patient 
consent. It was not possible to seek patient consent due to the retrospective nature of the 
research. It would have been impossible to gain consent from all patients as a significant 
proportion would have either been lost to follow up or have died. Furthermore, in order to 
contact patients to gain consent for use of their information for research purposes their 
personal information would have to be accessed. This would have amounted to a breach of 
confidentiality in this ‘catch-22’ situation. The NIGB was a statutory body established to 
promote, improve and monitor information governance in health and adult social care. The 
Health Research Authority (HRA) and its Confidentiality Advisory Group (CAG) regarding 
section 251 applications have since absorbed its functions.  Section 251 of the NHS Act 
2006 “allows the Secretary of State for Health to make regulations to set aside the common 
law duty of confidentiality for defined medical purposes”, in this case for medical research. 
Therefore, Section 251 approval was necessary so that the research could begin and 
progress. Section 251 approval was granted on the 17th April 2013. 
9.3.4. Inclusion/Exclusion Criteria 
 
Inclusion criteria: 
Patients with a ‘non-standard aneurysm’ of their abdominal aorta who underwent repair 
within one of the centres listed above and within the above time period. Patients must 
have had a CTA of their abdominal aorta prior to the aneurysm repair that could be 
reviewed on a 3-dimensionsal workstation and be of satisfactory quality to allow for 
detailed anatomical measurements. 
Exclusion Criteria: 
All patients with previous surgical or endovascular repair of an abdominal aortic aneurysm 
were excluded. As well as any patients who were haemodynamically unstable or 
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undergoing repair for a leaking or ruptured aneurysm. Patients who underwent ‘branched’ 
endograft technology as opposed to fenestrated EVAR were excluded as this method of 
treatment is recognised to be entirely distinct from fEVAR and EVAR. 
9.3.5. Identification of patients 
Methods of patient identification were intentionally broad-based to maximise the 
likelihood of capturing all patients suitable for inclusion. Each hospital within the NHS 
records and documents procedures that patients undergo during an in-hospital stay; this 
information is used to support operational and strategic planning, resource utilisation, 
financial reimbursement and for research. In order to categorise and classify procedures 
that patients undergo a standardised classification system was developed in the 1980’s, 
being further updated in the 1990’s and then 2006. The classification was initially issued by 
the Office of Population Censuses and Surveys (OPCS). Every surgical procedure has a 
specific code attached to it termed the OPCS code.  
The clinical coding team at the Royal Liverpool University Hospital was contacted and 
advice taken regarding the most suitable method of obtaining the desired information.  
After discussion with senior members of the clinical coding team a list of relevant OPCS 
codes (L18 – L28.9, Inclusive) were used to identify patients who were classed as having 
had an aneurysm repair. This resulted in a list of patients who had been ‘coded’ as having 
some form of aneurysm repair within the specified period. To identify further patients 
suitable for inclusion the intention was also to access theatre records of aneurysm repair, 
departmental databases and individual surgeon databases at each hospital.  
Once patients were identified to be potentially suitable for inclusion their preoperative CT 
scan was reviewed to determine if their aneurysm was non-standard. Two reviewers 
independently reviewed the preoperative CT scan of each patient to assess the anatomical 
characteristics within the infrarenal neck. The CT scans were reviewed on a dedicated 
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workstation with software that enables 3-dimensional reconstruction of the CT scan which 
can be manipulated for close scrutiny (syngoMMWP; version: VE40A, Siemens, Munich, 
Germany). Each reviewer was experienced in the use of the workstation in reviewing CT 
scans, one was the chief-investigator (AM) and the other was the co-investigator (SRV). 
Each reviewer had the IFU for each stent-graft type available to refer to during scrutiny of 
each scan. The reviewer would be free to manipulate the images as they saw fit to perform 
the required measurements and come to a conclusion. If there was discordance between 
the opinions of the two reviewers regarding a specific patient, then that patients CT scan 
was reviewed again by both reviewers and an agreement would usually be reached. If no 
agreement was reached, then the patient was not included in the study. Once reviewed, if 
the aneurysm was deemed non-standard then this patient was flagged as suitable for 
inclusion into the study. 
Below is the identification process carried out for each vascular unit or hospital included in 
the research for non-standard aneurysm patients. 
Royal Liverpool Hospital: 
A list of 287 patients ‘coded’ as having had an aneurysm repair according to OPCS codes 
(L18 – L28.9) was retrieved from the hospital coding department. A further list of patients 
was retrieved from the hospital computerised theatre system that logs each operation 
done within the hospital. All vascular operations were retrieved from the 12-month period 
April 1st, 2007 - March 31st, 2008 returning 971 operation ‘episodes’. A prospectively 
maintained departmental database of all endovascular procedures carried out during the 
entire study period was also scrutinised. Individual surgeon records from the National 
Vascular Registry, a personal online registry of all index operations, were also reviewed. 
The data entered into this registry is the responsibility of each individual surgeon. These 
lists were then crosschecked with duplicates and irrelevant patients (not receiving an 
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aneurysm repair) removed. There were 3 additional patients that were potentially suitable 
for inclusion that weren’t captured in the initial search using OPCS codes, all from the 
theatre database. It was therefore decided that use of OPCS codes to identify patients was 
a reliable method of capturing most patients and this would be the primary method used at 
all other institutions, with theatre records scrutinised when possible to retrieve additional 
patients. A significant proportion of patients identified as potentially suitable for inclusion 
did not have a pre-operative CT scan available for review (65 patients). There were various 
reasons for this including; CT scan not performed, CT scan not available on computerised 
image review system (with hard copy of scan having been destroyed) and CT scan 
performed at another institution and therefore not available for review. For some cases 
where the CT scan was performed at another institution within the Cheshire and 
Merseyside region it was possible to transfer the CT images for review (6 patients) but in 
other cases the CT scan had been performed distant to the local region and images were 
not available for transfer. The remaining patients had their CT scan reviewed and were 
assessed to determine if they met the inclusion criteria. 
Aintree University Hospital: 
The coding department at Aintree University Hospital was contacted and a list of patients 
was retrieved using the same OPCS codes and dates as for the Royal Liverpool University 
Hospital (130 patients). Again, there were instances where it was not possible to review a 
pre-operative CT scan for the same reasons as stated above but where possible CT scans 
were transferred to the Royal Liverpool University Hospital for detailed review.  
Southport Hospital: 
The coding department at Southport hospital was contacted to supply a list of patients as in 
line with the above centres however a list could not be retrieved. There were difficulties in 
establishing lines of communication and this method of identifying patients was abandoned 
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from this hospital. Only two vascular surgeons were performing aneurysm repairs during 
the period specified. Therefore, each surgeon was contacted and provided a list of patients 
in whom they undertook elective aneurysm repair during the period specified. 
Endovascular aneurysm repair was not performed at Southport hospital. Relevant patients 
were identified for potential inclusion into the study (30 patients). A request was made to 
transfer the relevant preoperative CT scans for further review however hard copies of the 
films and digital records had been destroyed for the majority of the scans. This meant that 
only a small proportion of scans were transferred for further review (4 patients). 
Warrington Hospital: 
The coding department at Warrington hospital was contacted to supply a list of patients as 
in line with the above centres however a list could not be retrieved. There were difficulties 
in establishing lines of communication and this method of identifying patients from this 
hospital was abandoned. The clinical director of the vascular unit at Warrington hospital 
was contacted to provide a list of patients for the whole department. However, during the 
period of the data collection this vascular department was merged with another, meaning 
that there was no longer a permanent vascular surgery presence at this hospital. Lines of 
communication with the clinical director from this department also failed after the initial 
request for data and this method of identifying patients was abandoned from this hospital. 
An attempt was made to obtain a list of patients from the theatre database at this hospital, 
but the specified information was not available and therefore could not be transferred. It 
was therefore not possible to obtain a list of patients who underwent aneurysm repair 
from this institution, the process of trying to identify patients had taken greater than one 
year and it was decided due to time constraints that patient identification from this centre 
should be abandoned. 
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Arrowe Park Hospital 
The coding department at Arrowe Park hospital was contacted in the same manner as the 
above centres and a list of patients for the relevant time period was retrieved. The 
computerised reporting system was accessed at Arrowe Park Hospital, which contains 
written reports of scans and blood results. Using this system, relevant patients were 
identified for potential inclusion into the study. A request was made to transfer the 
relevant preoperative CT scans for further review however hard copies of the films and 
digital records had been destroyed for the majority of the scans. In the remaining cases, 
there was either delay in transferring the relevant scans or case notes were not available 
for review. This resulted in no patients being included in the final analysis from this centre. 
Countess of Chester Hospital 
The coding department at Countess of Chester hospital was contacted in the same manner 
as the above centres and a list of patients for the relevant period was retrieved. To request 
for transfer of the CT scans to the Royal Liverpool Hospital, date of CT scan and pertinent 
patient information is required. Countess of Chester vascular department was contacted to 
enable access to this information, but lines of communication broke down after initial 
contact. It was therefore not possible to transfer any scans for review from this hospital 
and it was decided that patient identification from this centre should be abandoned. 
Leighton Hospital 
The coding department at Leighton hospital was contacted in the same manner as the 
above centres and a list of patients for the relevant period was retrieved. During the period 
of study, the vascular unit at Leighton hospital had merged and centralised to another 
hospital meaning there was no permanent vascular presence at this site. This made 
retrieval of further information impossible as no lines of communication were open at this 
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hospital. Due to time pressures, it was decided that patient identification from this centre 
should be abandoned. 
9.3.6. Outcome Measures 
 
Primary Outcome Measures: 
 30-day mortality/In-hospital mortality 
 Mid-term mortality and aneurysm related mortality 
 Technical success 
 Clinical Success 
Secondary outcomes: 
 Visceral vessel patency 
 Renal insufficiency and need for dialysis 
 Re-intervention rates, both surgical and endovascular 
 Conversion to open repair 
 Major complications 
Of note, after the initial analysis, review and systematic review the outcome measure of 
clinical success was included as a primary outcome measure. In accordance with the 
reporting standards clinical success for endovascular repair is defined as successful 
deployment of the device without; 
 Death as a result of aneurysm treatment 
 Type I or III endoleak 
 Graft infection or thrombosis  
 Aneurysm expansion (diameter >5 mm, or volume >5%)  
 Aneurysm rupture 
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 Conversion to open repair 
The presence of stent-graft dilatation (≥20%), migration (≥ 5mm), or failure of device 
integrity will class a case as clinical failure. For open repair success is dependent on the 
absence of aneurysm related death, graft infection or thrombosis and failure of device 
integrity. [93] No additional data was needed and all the information relevant to whether a 
case was a clinical success or not was gathered as part of the original study design. As can 
be seen clinical success effectively describes continued clinical efficacy across a broad 
range of outcomes throughout follow up and it was therefore decided it was an important 
and valid clinical outcome measure. 
9.3.7. Variables Measured 
Defined pre-operative and intraoperative variables were collected as well as detailed 
anatomical information about the patient’s aneurysm. Information was collected from 
patient’s case notes, laboratory results on hospital computer systems, computerised 
discharge summaries and clinic letters. A proforma was developed to assist with the data 
capture, however it was never used as data was recorded directly onto an excel 
spreadsheet in every case. Some patients who underwent endovascular aneurysm repair 
were also prospectively entered into an institutional database and where possible further 
information was retrieved from that database. In some cases, information on patients’ 
whereabouts, date and cause of death were obtained by telephone contact with their last 
recorded general practitioner. Imaging studies and reports verified by radiologists were 
reviewed both pre-operatively and during follow up from the hospital computerised image 
review system. Pertinent data was recorded in a pseudoanonymised form, to comply with 
information governance principles and so that a reverse anonymisation process could be 
carried out later if further information was needed for a specific patient. All 
pseudoanonymised information was recorded in an excel spreadsheet. The data points that 
were recorded can be split into various categories as outlined below. 
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Demographic Variables: 
A variety of demographic information was collected for each patient included in the study. 
This information included the age and sex of the patient. If they were enrolled on an 
aneurysm surveillance programme prior to their aneurysm repair, the date of enrolment 
was also recorded. 
Pre-operative Anatomical Characteristics of the Aneurysm: 
To obtain this information pre-operative CT scans were reviewed on the 3-dimensional 
workstation mentioned earlier, and all CT scans were reviewed on a single workstation. The 
software allows the reviewer to manipulate the images so measurements can be made in a 
plane orthogonal to the direction of blood flow. The aorta was reviewed in its entirety first 
then specific measurements were taken. Every CT scan was reviewed with the same 
settings for window width (800) and window level (100). The following protocol for 
anatomical measurements was designed after the chief investigator was trained in the use 
of the software and aortic CT measurements. The chief investigator was trained by a 
consultant vascular and endovascular surgeon working at the Royal Liverpool University 
Hospital. The methods for measurement were used by that consultant in his routine clinical 
practice and where necessary those methods were standardised to provide a reliable and 
reproducible way of measuring the anatomy. At the time of the design of the measurement 
protocol (early 2012) no comprehensive, validated and agreed protocol was found to exist 
from a search of the literature. Validated techniques pertaining to single anatomical 
variables existed. Measurements were obtained along a manually constructed central 
luminal line, without stretched vessel view. This was intentionally done to maintain the 3D 
structure of the anatomy in view when measurements were being made. All measurements 
were reviewed in at least 2 planes perpendicular to each other along the central luminal 
line (CLL), approximating a coronal and sagittal view, for lengths and angulation. Where 
necessary an axial view perpendicular to the central luminal line was used for 
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measurements such as diameter and assessment of thrombus and or calcification. Often all 
3 views were interrogated for each parameter to ensure accuracy of measurement. All 
measurements were recorded on an excel spreadsheet. When any measurement herein 
refers to either the coronal or sagittal plane it most often was not a true anatomical 
coronal (or sagittal plane) as the image was manipulated to present what was felt to be the 
most accurate representation of the anatomy by studying the CT scan in numerous planes. 
Therefore, the image presented would be equivalent to an approximation of the coronal or 
sagittal planes not those actual planes in relation to standard anatomy teaching as they are 
offset to be orthogonal to the blood flow. 
The measurements that were obtained and recorded included:  
 Maximum aneurysm diameter – Measured at the widest point of the aneurysm 
from outer wall to outer wall. To obtain the measurement the aneurysm was 
inspected along the central luminal line in an orthogonal plane to the flow of 
blood. The axial sections were visually inspected to decide at which point was 
the widest and 2 measurements at 90 degrees to each other were taken from 
outer wall to outer wall. If there was significant discordance of these two 
measurements the process began again to ensure the image was as true as 
possible to the orthogonal plane as possible (an elliptical ‘slice’ of an aneurysm 
would give discordant values). This process was repeated at the investigator’s 
discretion at varying points if it was not immediately obvious where the largest 
diameter was. This was to ensure that the largest diameter was truly captured. 
If there continued to be discordance between two values because of an 
unusual shape of the aneurysm despite repeated measurements, an average of 
the two values was taken as the maximal diameter. 
247 
 
 Neck length – The lower border of the lowermost main renal artery to the top 
of the aneurysm was measured. If there was doubt about which point to take 
as the top of the aneurysm, for example when the neck is conical in shape, the 
point at which the aortic diameter increases by >10% compared with the 
diameter at the lower most renal artery was taken as the point at which the 
aneurysm began and the ‘neck’ ends. To determine the diameter for this 
purpose the neck was measured in the same way as described below for all 
neck diameter measurements. 
 Neck diameter – This was measured outer wall to outer wall immediately 
below the lower border of the lowermost main renal artery and at 5, 10 and 
15mm distal to this point. As with maximal aneurysm diameter two 
measurements were made at each level, 90 degrees to each other and 
intersecting the central luminal line. The 5, 10 and 15mm distance points were 
determined as the distance along the CLL from the lowermost renal artery. The 
“neck diameter” was taken as the largest measurement made at these 4 points 
unless any of the points were below the previously defined neck length (as 
defined above) and therefore the measurement was considered part of the 
aneurysm and not the neck.  
 Neck angulation – Both the suprarenal aortic angulation and infrarenal aortic 
angulation were measured, termed the alpha (α) and beta (β) angle 
respectively. A standardised method was developed to measure neck 
angulation as follows. Angulation was measured along the CLL. First the 
aneurysm was inspected, and the image rotated subjectively till the maximum 
angle for, first the alpha angle, then secondly the beta angle, was displayed in 
either the ‘sagittal’ or ‘coronal’ viewing box of the software. The image could 
be manipulated in any way to first identify the most angulated point and then 
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present it in either viewing box. The first point of angulation was determined 
visually by inspecting the visceral segment of the aorta in all 3 planes 
mentioned previously. These planes were manipulated in any way seen fit by 
the reviewer to determine where the first demonstrable angulation of the 
aorta occurred below the renal arteries. The vertex of the α angle was placed 
at this subjectively determined point. If there was no clear demonstrable 
angulated point between the lowermost renal artery and the start of the 
aneurysm (which was previously determined as outlined above in neck length 
measurement) then the visceral aorta between the renal arteries and SMA was 
interrogated to determine if there was an appreciable angulation point in that 
segment of aorta. If there was then that point would be taken as the point of 
angulation and therefore the vertex of the angle placed at that point. If there 
was no obvious point of angulation between the SMA and the top of the 
aneurysm, then the point immediately below the lowermost renal artery was 
taken as the vertex. The vertex was always placed along the CLL. The rays of 
the angle were then placed along the long axis of the suprarenal aorta and the 
infrarenal neck. The angle calculated from this method was then subtracted 
from 180° to give the suprarenal aortic angulation with reference to the CLL – 
termed the α angle. The vertex of the β angle is placed at the point of 
angulation immediately above the top of the aneurysm but below the vertex 
placed for the α angle. If there is no such point, then the top of the aneurysm 
as previously defined would be the point at which the vertex for the beta angle 
was placed. One ray of the angle was along the long axis of the infrarenal neck 
exactly as in the α angle and the second ray was along the long axis of 
aneurysm lumen, ultimately to the aortic bifurcation. The angle computed was 
again subtracted from 180° to give the β angle. (See Figure 7.1) Both angles 
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were measured in the ‘coronal’ and ‘sagittal’ planes. If either angle was outside 
of the IFU used for that patient, then they were considered to have a non-
standard aneurysm. 
Figure 9.1 Method of  Measuring α and β Angles 
 
 
 Calcification within infrarenal neck – A subjective assessment was made as to 
the amount of calcification within the infrarenal neck, between the lowermost 
renal artery and top of the aneurysm. Although this area was the prime focus 
of the assessment the visceral segment of aorta would be interrogated too and 
an assessment of calcification within this segment would be made also. The 
degree of calcification was recorded as an ordinal variable; none, minimal, 
moderate or severe. 
           Vertex of angle 
           Ray of angle 
            α or β angle Renal Artery 
Abdominal 
Aortic 
Aneurysm 
α angle  β angle 
250 
 
 Thrombus within infrarenal neck – Presence of thrombus was recorded within 
the infrarenal neck and where it was present a measurement was made as to 
the thickness of the largest burden of thrombus. The thickness of thrombus 
was measured from the inner aortic wall (intima) to the periphery of thrombus 
within the aortic lumen using the naked eye and subjective assessment. The 
circumference coverage of thrombus within the infrarenal neck was also 
estimated by subjective assessment.  
 Patency of the visceral vessels – Each visceral vessel was noted and recorded 
whether it was patent or occluded due to whether it was opacified at its origin 
and remained so till its first branch. Any accessory renal arteries were noted 
and recorded but essentially ignored for the purposes of all the above 
measurements that refer to “the lowermost renal artery”. 
 Expected clamp site – This was recorded as the site one would expect the aortic 
cross clamp to be placed if the patient were to hypothetically undergo open 
repair. For simplicity this was limited to infrarenal, suprarenal or supracoeliac. 
Pre-operative Status of Patient: 
The data points that were collected are in part derived from validated risk prediction 
models designed specifically for patients undergoing major vascular surgery, namely the V-
POSSUM. Details that were collected include; co-morbid conditions, ASA grade, objective 
tests for fitness for operation (Including spirometry, ECG and echocardiogram), subjective 
tests of fitness for operation (Including clinical examination of respiratory and 
cardiovascular systems) and blood tests (Including full blood count, urea and electrolytes). 
Intraoperative Details 
Intraoperative details collected were in part derived from recommendations for minimum 
reporting standards of endovascular aneurysm repair. These include length of operation, 
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blood loss, technical success, whether conversion to open repair took place, fluoroscopy 
time, total radiation dose and amount of contrast given. The use of planned or unplanned 
adjunctive procedures during the procedure was also recorded as well as patency of 
visceral vessels at end of operation. 
In Hospital Complications 
All significant complications and reinterventions (including open and endovascular 
reinterventions) taking place within the first 30 days after operation or the total inpatient 
stay were recorded with details of event and outcome recorded as well. Laboratory 
investigations of renal function and need for dialysis in the short term was recorded. 
Renal Function 
Hospital records and computerised results systems were interrogated to determine 
biochemical and clinical markers of renal function. This included serum creatinine levels, 
estimated glomerular function levels, documented urine output and the use of renal 
replacement therapy. Whenever available the estimated glomerular function calculated by 
the hospital laboratory was used for eGFR results. When there was no eGFR value 
calculated however the 2009 CKD-EPI creatinine equation was used to calculate the eGFR 
for a given creatinine value for individual patients. The equation is as follows: 2009 CKD-EPI 
creatinine equation: 141 min(SCr/k, 1)a max(SCr/k, 1)1.209 0.993Age [ 1.018 if female] [ 
1.159 if black], where SCr is serum creatinine (in mg/dl), k is 0.7 for females and 0.9 for 
males, a is 0.329 for females and 0.411 for males, min is the minimum of SCr/k or 1, and 
max is the maximum of SCr/k or 1. 
In determining acute renal dysfunction in the post-operative period, the Kidney Disease: 
Improving Global Outcomes (KDIGO) definition was used to define whether a patient 
suffered an acute kidney injury during their hospital stay. The KDIGO definition also has a 
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staging system to enable severity of the acute kidney injury to be staged. The following 
table outlines criteria for the various stages of acute kidney injury using this system: 
Table 9.2.  KDIGO staging of Acute Kidney Injury 
Stage Serum Creatinine Urine Output 
1 1.5–1.9 times baseline  
OR ≥ 0.3 mg/dl (≥26.5 mmol/l) increase 
< 0.5 ml/kg/h for 6–12 hours 
2 2.0–2.9 times baseline < 0.5 ml/kg/h for ≥ 12 hours 
3 3.0 times baseline  
OR Increase in serum creatinine to ≥ 4.0 mg/dl 
(≥ 353.6 mmol/l)  
OR Initiation of renal replacement therapy  
< 0.3 ml/kg/h for ≥ 24 hours  
OR Anuria for ≥ 12 hours 
 
With regards to chronic kidney disease the KDIGO definition of an abnormality of kidney 
structure or function which is present for > 3 months was used. The eGFR was used to 
define whether a patient had chronic kidney disease or not pre-operatively and during 
follow up after their operation. Chronic kidney disease was graded and categorised 
according to the system recommended by KDIGO. Patients with an eGFR of >60 were 
considered not to have chronic kidney disease. The CKD category for given eGFR values is 
as follows: eGFR 45 – 59 (category G3a), eGFR 30 – 44 (category G3b), eGFR 15 – 29 
(Category G4), eGFR <15 (Category G5). The use of these definitions for both acute kidney 
injury and chronic kidney disease are recommended by The Renal Association in the UK. 
Mid-term follow up 
All significant complications and reinterventions (Including open and endovascular 
reinterventions) beyond the initial hospital stay were recorded with details of event and 
outcome recorded as well. Laboratory investigations of renal function, and whether there 
was any need for dialysis in the midterm was recorded. 
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Surveillance follow up 
All patients who undergo endovascular aneurysm repair have surveillance using a variety of 
imaging techniques. The most commonly applied surveillance protocol in the Cheshire and 
Merseyside region for standard EVAR is a plain abdominal radiograph (AXR) prior to 
discharge, one-month duplex ultrasound examination (DUS) and single arterial phase 
computed tomography scan (CTA). Annual AXR and DUS are then undertaken. The 
surveillance protocol for patients undergoing fEVAR is similar with the addition of AXR, DUS 
and CTA 6 months post operatively and CTA in addition to AXR and DUS annually. Patients 
who undergo open aneurysm repair do not have imaging surveillance but will occasionally 
undergo abdominal CT scans for either suspected aneurysmal/vascular pathology or 
entirely unrelated pathology. For all patients the verified report of each scan or x-ray was 
recorded with specific attention to any problems identified during the scan. In selected 
cases, the actual imaging was also reviewed, usually to confirm the findings mentioned in 
the report. Routinely during surveillance, the maximum aneurysm diameter is measured 
and the measurement from the DUS was recorded. If a DUS had not been performed but a 
CTA had then measurement would be taken from that. Measurement of aneurysm 
diameter was never taken from AXR as this is unreliable and often not possible. DUS was 
used as the principal method of obtaining maximum aneurysm diameter as this was 
available for the majority of patients during the total length of surveillance follow up who 
underwent endovascular repair. By contrast CTA was generally only available for patients 
who underwent fEVAR for the entire length of surveillance. 
Mortality 
The date and cause of death was recorded where possible. Where there was no 
information relating to cause or date of death in the patient’s hospital records other 
methods were used to attempt to clarify this information. The general practitioner was 
contacted to ascertain whether any information was available from their records as to the 
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cause or date of death. If this did not yield more information, then a request was made 
from the General Register Office for the death certificate. 
9.3.8. Comparison of Non-Standard Patients with Standard Patients 
Undergoing EVAR or OR 
Above definitions, measurement protocol and type of variables measured was repeated for 
patients with a standard aneurysm undergoing EVAR or OR. This was designed to be a 
single centre retrospective study of all patients with standard aneurysm repair during the 
same study period defined above conducted at the base hospital the Royal Liverpool 
University Hospital and was intended to act as a control group for two of the treatment 
options OR and EVAR. From the retrospective multicentre study, a number of patients were 
identified as standard aneurysms. All of those that had their operation at RLUH were 
identified for inclusion into the single centre study. The method of patient identification 
used for the multicentre study was intentionally broad based to include all aneurysm 
repairs at any given centre and as such all patients identified as standard through that 
method reflect all standard patients operated on. To ensure full capture of all standard 
aneurysm patients happened with that method the local departmental database at the 
RLUH was cross checked again with the original list of patients identified as standard to 
ensure no patient was missed through the main search. That database is mentioned above 
and is a prospectively maintained database of all endovascular aneurysm repairs at the 
Royal Liverpool university Hospital. There is no such database for open aneurysm repairs 
and as such the identification of these patients was reliant on the above methodologies 
such as patients coded as having an aneurysm repair. The coding of aneurysm repair used 
in the above study would capture all aneurysm repairs regardless of their anatomy and 
therefore did not distinguish between standard and non-standard anatomy. 
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9.3.9. Comparison of Expected and Observed Mortality 
The British Aneurysm Repair (BAR) Score is a published, validated model that provides an 
estimate of the risk of in-hospital mortality, expressed as a percentage, for patients 
undergoing elective aneurysm repair. [179]It was developed and validated using national 
audit data from the National Vascular Registry (NVR). The model uses 11 variables to 
calculate estimated in-hospital mortality for patients. These include; basic demographic 
variables (age and gender), results of blood tests (serum creatinine, sodium and white cell 
count), estimate of overall ‘fitness’ of the patient (ASA grade), previous medical history 
which may impact on the outcome (history of cardiac disease, whether the ECG is normal 
or abnormal), the extent of the proposed operation (open repair or EVAR, any previous 
aortic surgery), and finally one anatomic variable (AAA diameter). The variable of operation 
type only includes either EVAR or open repair within the BAR model. There is no distinction 
for fenestrated EVAR or non-standard open repair of aneurysm. This model was developed 
from a cohort of standard anatomy patients and this fact must be borne in mind when 
interpreting analyses that utilise it for a population of non-standard aneurysm patients. 
The BAR score was used to compare the observed deaths with those that would be 
expected according to this model. Firstly, the BAR score was calculated for each patient. 
For those undergoing fEVAR the method of repair selected was ‘EVAR’. If there were any 
missing data, then the lowest value available was selected for that variable with the 
exception of ASA grade. If the ASA grade was missing for any patient, then the mode of ASA 
grade for the rest of the cohort was used instead. This is in line with the published 
methodology on the use of the BAR score. To obtain the expected number of deaths the 
mean BAR score for each patient group (OR, EVAR and fEVAR) was calculated and then 
multiplied by the number of patients in that group. To compare the observed with 
expected deaths the Chi-square test with one degree of freedom was used. This procedure 
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was then repeated but the method of repair was reversed. In patients who underwent OR 
their BAR score was calculated as if they had had EVAR and vice versa. 
9.3.10. Risk Prediction Model 
To reiterate; the aim of this study was to compare clinical outcomes of conventional 
surgery, EVAR outside IFU and fEVAR for non-standard aneurysms. This research aim was 
developed to try and answer the question that the physician often faces when a patient 
presents with a non-standard aneurysm – ‘Which method of repair would be the best 
choice for my patient?’ To try to answer this supplementary question it would be important 
to try to develop a way of predicting risk for significant clinical events for a particular 
patient if they were to undergo one of the three proposed methods of aneurysm repair. 
The decision to undertake the development of a risk prediction model specific to non-
standard aneurysms was made following the beginning of data collection. This was because 
understanding of the research question developed through the data collection process and 
a deeper understanding of the applicability of the potential results of this study to a clinical 
scenario evolved. It was therefore concluded that if the data could be secondarily used to 
aid a physician in the decision-making process of which method of repair to use for a given 
patient then that would be beneficial and add to the overall conclusion of the analysis. The 
data collection was not primarily designed with this purpose in mind. However, it was felt 
there was no specific reason as to why the data already collected could not be used for this 
secondary purpose. With the proviso that its results should be interpreted with caution and 
would likely not be a complete risk prediction model but act as a basis to give a deeper 
understanding of what would be needed to develop a risk prediction model in future 
research. 
In order to develop a risk prediction model univariate models were used to assess the 
relationship of different variables to survival time. The different variables assessed were; 
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age at operation, neck length, expected clamp site, ASA grade and method of repair 
undertaken. Further statistical modelling was used to assess the relationship between the 
variables mentioned above against primary technical success and clinical success. Initially it 
was intended to proceed with multivariate modelling however there was a limited number 
of significant clinical events recorded for each group and therefore this method of 
statistical analysis could not be undertaken as the results would have been unreliable. 
9.3.11. Statistics 
Sample Size 
There was no accurate record of the number of aneurysm repairs or the proportion that 
were non-standard at the beginning of the study. An estimate of 500 – 600 patients was 
made for the two-year period from 1st April 2006 – 31st March 2008. It was estimated that 
roughly 150-200 [180] of these patients had a non-standard aneurysm. No power 
calculations or sample size calculations were done due to a lack of reliable pilot data. 
Analysis 
Non-standard aneurysms were grouped according to type of operation; open repair, EVAR 
or fEVAR. Continuous data is presented as median with range in parentheses. Overall 
survival and freedom from secondary intervention were subject to Kaplan-Meier analysis. 
Median follow up length was determined using the reverse Kaplan-Meier technique. SPSS 
version 20.0 (SPSS Inc, Chicago, Ill; www.spss.com) was used for all statistical analyses. If 
the patient was known to be alive and still on the surveillance programme their last point 
of follow up was taken as the point of data collection. If the patient was followed up 
elsewhere and hence not in the local programme, then their last point of imaging was 
taken as the last follow up time point. 
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9.4. Results 
From an initial list of 494 patients, a total of 81 patients were confirmed to have a ‘non-
standard’ aneurysm treated and therefore were eligible for inclusion in the final analysis. 
The following flow diagram shows how these patients were identified (See figure 9.2). As 
mentioned previously patients from only three centres were included because patient data 
was not available from the other four. These three centres were the Royal Liverpool 
University Hospital, Aintree University Hospital and Southport Hospital.  
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Figure 9.2 Flow Diagram of Numbers of Patients 
 
Figure 9.2 - Numbers represent patients. Arrows denote whether patients were excluded or included. 
 
Identified from Coding 
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Patients were excluded from the final analysis for various reasons in accordance with the 
inclusion and exclusion criteria. The most common reasons a patient was excluded from 
further analysis were: presence of a ruptured aneurysm, a small (<55mm maximal 
aneurysm diameter) AAA was treated, the operation was given the incorrect OPCS code 
and in fact the patient never received an aneurysm repair, and the aneurysm was 
thoracoabdominal. Other less common reasons for exclusion were patients that had 
previously undergone an abdominal aortic aneurysm repair prior to the study period and 
patients with no clinical information retrievable.  It should be noted that a large proportion 
of exclusions were due to the fact that an adequate pre-operative CT scan was not 
available for review. 
In nine cases there was initial disagreement between the two reviewers as to whether the 
aneurysm was non-standard or not. After secondary review an agreement was reached in 
seven patients (six non-standard aneurysms and one standard aneurysm). This meant that 
two patients were excluded from further analysis as no inter-observer agreement could be 
reached. Cohen’s κ was run to determine the strength of agreement between the two 
reviewers as to whether an aneurysm was standard or non-standard, Cohen’s κ = 0.969 
(95% CI, 0.928 to 1), p<0.0001. The strength of agreement between the two reviewers’ 
judgements therefore was very good. [181]In fact the strength of agreement between the 
two reviewers remains very good even when only considering the first round of review, 
Cohens κ = 0.859 (95% CI, 0.770 to 0.948), p<0.0001. 
Descriptive statistics were computed for the entire study population. Continuous variables 
are presented as their medians and inter-quartile ranges (IQR).  Categorical variables are 
presented as counts and percentages. Comparison of continuous variables was carried out 
through a Kruskall-Wallis test (*). Categorical variables were compared using Fisher’s exact 
test or χ2 test, depending on the amount of data present in each entry. 
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A total of 81 patients were identified as being eligible for inclusion in the analysis. This 
included 37 patients that underwent open repair (OR), 15 patients who underwent 
fenestrated endovascular aneurysm repair (fEVAR) and 29 patients who underwent 
standard endovascular aneurysm repair (EVAR). Of the 29 patients who underwent 
standard EVAR 28 patients received a stent-graft from the Zenith Flex (Cook Inc. 
Bloomington, Indiana) platform and one patient received an Aorfix device (Lombard 
Medical Inc. Oxfordshire, UK). The Aorfix device does not have any suprarenal fixation and 
exhibits different characteristics and IFU criteria than the Zenith Flex device. All patients 
who underwent fEVAR received the Zenith Fenestrated (Cook Inc. Bloomington, Indiana) 
platform which is made by the same company and indeed the device itself is based on the 
Zenith platform in general. It was therefore decided that the one patient who was treated 
with the Aorfix device represented an outlier in terms of device used and was excluded 
from the final analysis. The original intention in the design of the study was to include all 
patients identified as non-standard irrespective of stent graft device used and thereby 
excluding this one patient raises the potential for statistical bias in the results and 
therefore this should be borne in mind when interpreting the following results.  
9.4.1. Pre-operative Variables 
 
 Demographics 
A total of 80 patients were included in the final analysis and their results are presented 
below. These patients underwent treatment of their abdominal aortic aneurysm between 
May 2006 and March 2008. A total of 28 patients underwent treatment with standard 
EVAR (EVAR), 15 with fenestrated EVAR (fEVAR) and 37 patients underwent abdominal 
aortic aneurysm repair as an open procedure (OR). The majority of patients were male 
(67.5%) and the median age was 75 (68 - 81). The following table details the demographics 
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for all the patients grouped according to the type of operation performed and as a total for 
the whole group. (See table 9.2) 
Table 9.3 Patient Demographics 
Variable 
EVAR  
(n=28) 
fEVAR  
(n=15) 
Open Repair 
(n=37) 
Total  
(n=80) 
p-
value 
Age at operation (years), 
median (IQR) 
79 (73,  
84 ) 
71 (65,  
81 ) 
74 (67,  78 ) 75 (68,  
81 ) 
0.052 
Sex, n (%)     0.053 
Male 21 (75.0) 13 (86.7) 20 (54.1) 54 (67.5)  
Female 7 (25.0) 2 (13.3) 17 (45.9) 26 (32.5)  
Previous Abdominal 
Surgery, n (%) 
    0.474 
Yes 5 (17.9) 5 (33.3) 7 (18.9) 17 (21.3)  
No 23 (82.1) 10 (66.7) 28 (75.7) 61 (76.3)  
Unknown 0 0 2 (5.4) 2 (2.5)  
IHD, n (%)     0.001 
No 15 (53.6) 2 (13.3) 24 (64.9) 41 (51.3)  
Yes 12 (42.9) 13 (86.7) 11 (29.7) 36 (45.0)  
Unknown 1 (3.6) 0 (0.0) 2 (5.4) 3 (3.8)  
COPD, n (%)     0.472 
No 22 (78.6) 10 (66.7) 28 (75.7) 60 (75.0)  
Yes 6 (21.4) 5 (33.3) 6 (16.2) 17 (21.3)  
Unknown 0 (0.0) 0 (0.0) 3 (8.1) 3 (3.8)  
CVA, n (%)     0.540 
No 24 (85.6) 12 (80.0) 32 (86.5) 68 (85.0)  
Yes 2 (7.1) 3 (20.0) 3 (8.1) 8 (10.0)  
Unknown 2 (7.1) 0 (0.0) 2 (5.4) 4 (5.0)  
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DM, n (%)     0.890 
No 25 (89.3) 13 (86.7) 32 (86.5) 70 (87.5)  
Yes 3 ( 10.7) 2 (13.3) 3 (8.1) 8 (10.0)  
Unknown 0 (0) 0 (0.0) 2 (5.4) 2 (2.5)  
PVD, n (%)     1.000 
No 23 (82.1) 12 (80.0) 29 (78.4) 64 (80.0)  
Yes 5 (17.9) 3 (20.0) 7 (18.9) 15 (18.8)  
Unknown 0 (0.0) 0 (0.0) 1 (2.7) 1 (1.3)  
Hypertension, n (%)     0.309 
No 7 (25.0) 6 (40.0) 7 (18.9) 20 (25.0)  
Yes 20 (71.4) 9 (60.0) 29 (78.4) 58 (72.5)  
Unknown 1 (3.6) 0 (0.0) 1 (2.7) 2 (2.5)  
ASA Grade, n (%)     0.038 
1 0 (0.0) 0 (0.0) 1 (2.7) 1 (1.3)  
2 5 (17.9) 3 (20.0) 16 (43.2) 24 (30.0)  
3 20 (71.4) 12 (80.0) 15 (40.5) 47 (58.8)  
4 3 (10.7) 0 (0.0) 1 (2.7) 4 (5.0)  
Unknown 0 (0.0) 0 (0.0) 4 (10.8) 4 (5.0)  
Table 9.3 - Comparison of continuous variables was carried out through a Kruskall-Wallis test (*). Categorical 
variables were compared using Fisher’s exact test or χ2 test, depending on the amount of data present in 
each entry. IHD = Ischaemic Heart Disease. COPD = Chronic Obstructive Pulmonary Disease. CVA = 
Cerebrovascular Accident. DM = Diabetes Mellitus. PVD = Peripheral Vascular Disease. ASA= American 
Society of Anesthesiologists Grade.  
Concerning pre-operative comorbidities, only the incidence of ischaemic heart disease was 
found to be significantly different between the three groups undergoing aneurysm repair. 
A significantly higher proportion of the patients who underwent fEVAR exhibited a history 
of ischaemic heart disease when compared with OR or EVAR. Only one patient (within the 
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OR group) had suffered an acute coronary syndrome within the 6 months prior to their 
aneurysm repair. That patient suffered no further acute coronary syndrome post 
operatively or at all during the follow up period. 
ASA (American Society of Anesthesiologists) grade was not statistically different across the 
three types of operation. A higher proportion of patients undergoing open repair, however 
were deemed to have a lower ASA grade (<3) pre-operatively (45.9%) compared with those 
undergoing EVAR (17.9%) and fEVAR (20%).   
In addition to the above preoperative variables information was also collected with regards 
to smoking status and medications prescribed (antiplatelet, statin, angiotensin converting 
enzyme (ACE) inhibitor, β-blocker and steroid). There was no statistical difference between 
the smoking statuses of the patients. There were also no statistically significant differences 
between the proportions of patients taking the above medications across the three types 
of operations. The majority of patients were prescribed an antiplatelet agent (66%) and a 
statin (69%). 
Pre-operative investigations 
Parameters derived from pre-operative investigations were also collected for each patient. 
No statistically significant differences were found between the three groups with regards to 
pre-operative renal function or pre-operative values obtained from spirometry testing (See 
table 9.4). No patient was noted to be on renal dialysis pre-operatively and chronic kidney 
disease, as defined as having an eGFR <60ml/min/1.73m2, was present in 45% of all 
patients. Only 15% of all patients were noted to have an abnormal creatinine pre-
operatively (>130 µmol/L).The distribution of patients with abnormal renal function by 
either abnormal creatinine or a presence of chronic kidney disease was not statistically 
significant across the three types of repair.    
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Table 9.4 Pre-operative Investigations 
Variable 
EVAR 
(n=28) 
fEVAR 
(n=15) 
Open Repair 
(n=37) 
Total 
(n=80) 
p-value 
Best FEV1, 
median (IQR) 
1.9 (1.5, 
2.2) 
2.3 (1.7, 2.6) 2.0 (1.5, 2.6) 1.9 (1.6, 2.6) 0.778 
Unknown (%) 
4 (14.3) 2 (13.3) 6 (16.2) 12 (15.0)  
FEV1/FVC Ratio, 
median (IQR) 
66.8 
(58.7,73.7) 
70.5 
(64.5,74.4) 
70.4 
(65.3,77.2) 
69.5 
(60.5,74.7) 
0.558 
Unknown (%) 
4 (14.3) 2 (13.3) 7 (18.9) 13 (16.3)  
Creatinine 
(µmol/L), Median 
(IQR) 
97.0 (87.0, 
118) 
88.0 (81.0, 
115) 
95.0 (78.0, 
108) 
94.0 (81.0, 
114) 
0.249 
eGFR 
(ml/min/1.73m2), 
median (IQR) 
59.2 
(46.3,72.7) 
72.8 
(49.6,81.7) 
63.4 
(47.7,72.7) 
63.2 
(48.4,75.7) 
0.341 
Chronic Kidney 
disease, eGFR 
<60  
     
None, eGFR ≥60 
(%) 
13 (46.4) 9 (60) 22 (59.5) 44 (55)  
Category 3a, 
eGFR  45 – 59 (%) 
8 (28.6) 3 (20) 9 (24.3) 20 (25)  
Category 3b, 
eGFR  30 – 45 (%) 
6 (21.4) 3 (20) 5 (13.5) 14 (17.5)  
Category 4, eGFR  
15 – 29 (%) 
1 (3.6) 0 (0) 1 (2.7) 2 (2.5)  
Table 9.4 - Comparison of continuous variables was carried out through a Kruskall-Wallis test (*). Categorical 
variables were compared using Fisher’s exact test or χ2 test, depending on the amount of data present in 
each entry. FEV1 = Forced expiratory volume in one second. FVC = Forced Vital Capacity. eGFR = Estimated 
Glomerular Filtration Rate. 
 
266 
 
Information was also collected about preoperative cardiac investigations. Patients were 
assessed on an individual basis and as such some had preoperative dynamic imaging of the 
heart, such as transthoracic echocardiogram, multi-gated acquisition scan (MUGA), 
dobutamine stress echocardiogram (DSE) or a myocardial perfusion scan (using methoxy-
isobutyl-isonitrile, MIBI), and some simply had no pre-operative imaging.  A significant 
proportion (41.3%) of patients had no assessment of their ejection fraction pre-operatively. 
47 patients had a documented assessment of their left ventricular function (LVF) 
preoperatively and the majority of those (27 patients, 57%) were patients undergoing open 
repair. Of eleven patients undergoing EVAR who had a documented LVF preoperatively, 1 
patient was found to have “significant” impairment of their LVF with the remainder being 
“normal”. Of nine fEVAR patients, one had “mild” impairment, one had “mild-moderate” 
impairment and the remainder were “normal. Of the 27 patients undergoing open repair 
three had “mild impairment” and the remainder were normal. Six patients were found to 
have mild valvular abnormalities, but no patient was found to have moderate or severe 
aortic valve stenosis or regurgitation. Most patients, 73 (91.3%), had an electrocardiograph 
(ECG) preoperatively, with 17 (23.3%) of those found to have an abnormality on their ECG. 
The following abnormalities were detected on the pre-operative ECG: atrial fibrillation (6 
patients), Sinus bradycardia (4 patients), Left axis deviation (2 patients), right bundle 
branch block (2 patients), type 1 atrioventricular block (1 patient), t-wave inversion (1 
patient) and q waves (1 patient).  
9.4.2. Primary Outcome Measures 
The primary outcome measures were: 
 In-hospital mortality 
 Mid-term overall survival 
 Mid-term aneurysm related mortality 
 Technical success 
267 
 
 Clinical success 
 
In Hospital Mortality 
Four patients died before being discharged from hospital (5% in hospital mortality). Two 
patients had standard EVAR (7.1% in hospital mortality) and two patients had OR (5.4% in 
hospital mortality) (p= 0.823). 
The first EVAR patient was a 91-year-old woman who underwent a lengthy EVAR 
procedure. There were no significant immediate complications, but she returned to theatre 
on day 8 because of a gastric perforation. She survived the operation but deteriorated after 
that and eventually died on the 14th post-operative day. Her cause of death was certified as 
sepsis secondary to gastric perforation (operated). The second EVAR patient was an 85-
year-old gentleman who was deemed to be ASA grade 4 with a significant cardiac history. 
He suffered significant blood loss during the operation (2500mls) and was 
haemodynamically unstable on the critical care unit postoperatively. He required multiple 
blood transfusions and cardiovascular support with infusion of inotropic medication. He 
developed gastrointestinal obstruction and was palliated on day 19 post operatively. He 
died on the 23rd post-operative day.  
The first OR patient who died during the index hospital admission was a 91-year-old man 
who had a prolonged operation with significant blood loss (3000mls), he required 2500mls 
of blood transfusion intraoperatively. On the first day after the operation, he had deranged 
clotting factors, ischaemic changes on his ECG and increasing inotropic requirement on the 
intensive care unit. He died later that day. The second OR patient was a 71-year-old man 
with a significant cardiac history who also suffered significant blood loss (2000mls). On the 
second postoperative day, he suffered a sudden myocardial infarction and cardiac arrest; 
the patient had return of spontaneous circulation for a short time but died later that day. 
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Overall Survival 
To determine the follow up time for the whole cohort the ‘reverse Kaplan-Meier’ 
methodology was used, [182]with the median follow up being 10.72 years (95% CI 9.74 – 
10.91). Separately for the three repair groups the median follow up (with 95% confidence 
intervals) in years is as follows: fEVAR 10.02 years (6.96 – NA), EVAR 10.88 (10.77 – NA), 
Open Repair 9.92 (8.76 – 10.91). A total of 57 patients died during the study period (25 
EVAR patients, 10 fEVAR patients and 22 OR patients). Kaplan-Meier survival curves were 
generated in order to have a graph that compares the survival functions between the three 
surgery types and also a table showing the number of patients at risk (see figure 9.3 
below). Overall survival at 5 years was ; 54% (15 out of 28 patients) for EVAR, 57% (8 out of 
14 patients) for fEVAR and 68% (25 out of 37 patients) for Open Repair. For the whole 
cohort 29% of patients (n=22) survived to 10 years. And 24% patients (n=19) were alive at 
the end of the study period. 
Event of interest was death. Patients that until last follow-up were alive were treated as 
censored. Patients with missing data for death date and last visit date were excluded (1 
patient). Total number of observations included: N=79  
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Figure 9.3: K-M survival estimates with failure events (deaths) indicated in 
brackets 
 
 
 
 
 
 
 
 
 
 
A log-rank test was performed in order to compare those independent groups of survival 
time. The log-rank test is a non-parametric method for testing the null hypothesis that the 
groups being compared are samples from the same population as regards survival 
experience. Table 9.5 indicates a non-statistically significant p-value (=0.283>0.017) at a 
statistically significance level α=1.67% (Bonferroni correction). In other words, there is no 
evidence to suggest a statistically significant difference between the survival experiences of 
patients amongst the three methods of repair. 
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Table 9.5: Shows the results of the log rank test comparing survival distributions 
by surgery type 
Surgery Type Events Observed Events expected 
Open repair 22 27.06 
EVAR 25 19.50 
fEVAR 10 10.44 
Total 57 57.00 
 Chi2(2) = 2.53  
 Pr>chi2 = 0.283  
 
Life tables reporting survival rates were also produced indicating that: 
80% of patients survived 3 years or more in the open repair group. The percentage of 
patients surviving 7 years and above was 60% (see table 9.6). 
In EVAR group (see table 9.7), 79% of patients survived 3 years or more while 42% survived 
7 years and above. 
In fEVAR group (see table 9.8), 87% of patients survived 3 years or more, while 50% of 
patients survived 7 and above years. 
Table 9.6.: Survival Rates for Open Repair (n1=36) 
Time Survival rate 95% Conf. Interval 
3 follow-up years 80% [63% to 90%] 
7 follow-up years 60% [42% to74 %] 
 
Table 9.7: Survival Rates for EVAR (n2=28) 
Time Survival rate 95% Conf. Interval 
3 follow-up years 79% [58% to 90%] 
7 follow-up years 42% [25% to 60%] 
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Table 9.8.: Survival Rates for fEVAR (n3=15) 
Time Survival rate 95% Conf. Interval 
3 follow-up years 87% [56% to 96%] 
7 follow-up years 50% [22% to 72%] 
 
Aneurysm Related Mortality 
The exact cause of death was not available for 16 patients. A meaningful analysis of 
aneurysm related mortality could therefore not be performed. In addition to the two in 
hospital deaths for each of the EVAR and OR groups there was a further one death during 
follow up in each group that was aneurysm related. The details of each case are outlined 
below: 
 EVAR patient: 
 15 months post EVAR – Caudal migration diagnosed on plain AXR, CTA 
organised 
 18 months post EVAR – Type 1a endoleak diagnosed, with complete loss of 
proximal seal, Conversion to open repair planned. 
 22 months post EVAR – Died secondary to a ruptured aneurysm before 
undergoing open repair 
 OR patient: 
 4 years post OR – Empyema of the gallbladder, subsequent 
cholecystectomy 
 5 years post OR – Multiple episodes of sepsis, prosthetic graft infection 
diagnosed, and long-term antibiotics started 
 6 years post OR – Presented with acute gastrointestinal bleeding secondary 
to an aortoenteric fistula. Died as a result of massive haemorrhage 
Technical Success 
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The following table demonstrates the proportions of patients that exhibited technical 
success. (See table 9.9) 
Table 9.9 Technical Success 
Variable 
EVAR  
(n=28) 
fEVAR  
(n=15) 
Open Repair 
(n=37) 
Total 
(n=80) 
P - value 
Technical 
Success, n (%) 
    <0.001 
No 7 (25.0) 2 (13.3) 1 (2.7) 10 (12.5)  
Yes 21 (75.0) 13 (86.7) 36 (97.3) 70 (87.5)  
Table 9.9 - Comparison categorical variables were compared using Fisher’s exact test or χ2 test, depending on 
the amount of data present in each entry 
When comparing the proportion of technical success, there was a statistically significant 
difference in the proportions of patients exhibiting technical success. There were seven 
cases of technical failure in the EVAR group for the following reasons: 
 Four cases of persistent type 1a endoleak at the end of the procedure 
 Three cases of unplanned endovascular procedures – two were patients with a limb 
kink necessitating placement of further stents within the iliac limb and one case of 
an unplanned palmaz cuff extension to treat a type 1a endoleak (successful). 
This means that assisted primary technical success was present for 24 (85.7%) patients in 
the EVAR group. If comparing this success rate for EVAR with the other two treatments, 
there was no longer a statistically significant difference. Of the four cases of persistent type 
1a endoleak: One patient had no further type 1a endoleak identified during the follow up 
and died approximately nine years postoperatively from non-aneurysm related cause. 
Three patients had a type 1a endoleak identified at some point during the follow up:  
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 One was only seen on the one-month surveillance scan and never again, patient 
died of unknown cause nearly five years after the original operation.  
 One patient had migration and further type 1a endoleak identified and successfully 
underwent a conversion to open repair within the first year after their index 
operation. The patient recovered well and remained alive for approximately 10 
years until their death of unknown cause. 
 The final patient had migration and type 1a endoleak noted but died from a 
ruptured aneurysm prior to conversion to open repair.  
Adjusting the assisted primary technical success to take further account of the two above 
patients in whom their type 1a endoleak did not persist and did not cause any 
demonstrable deleterious effects gave an “adjusted” rate of 92.9% for EVAR. 
There were two patients with technical failure in the fEVAR group, both secondary to a 
modular type 3 endoleak, between the connection of renal stent and main stent-graft body 
noted at the end of the procedure. Both patients were treated intraoperatively with 
balloon moulding of this connection zone, which reduced but did not abolish the endoleak. 
It was decided to treat these conservatively with close follow up in surveillance. Neither 
patient exhibited a graft related endoleak at any point during the rest of their follow up. 
One patient died from non-aneurysm related cause nearly five years after the original 
procedure and the other was alive at the last surveillance time point. 
The one case of technical failure within the open group was a patient who died within the 
first 24 hours post-operatively, in line with reporting standards this is deemed a technical 
failure. [93] 
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Clinical Success 
In accordance with the reporting standards clinical success for endovascular repair is 
defined as successful deployment of the device without; 
 Death as a result of aneurysm treatment 
 Type I or III endoleak 
 Graft infection or thrombosis  
 Aneurysm expansion (diameter >5 mm, or volume >5%)  
 Aneurysm rupture 
 Conversion to open repair 
The presence of stent-graft dilatation (≥20%), migration (≥ 5mm), or failure of device 
integrity will class a case as clinical failure. For open repair success is dependent on the 
absence of aneurysm related death, graft infection or thrombosis and failure of device 
integrity. [93] 
There were 17 (21.3%) cases of clinical failure; 13 in the EVAR group, one in the fEVAR 
group and 3 in the OR group. This difference reached statistical significance (p<0.001). 
In the EVAR group, the mode of failure was: 
 Migration (3 patients) 
 Open conversion (3 patients) 
 Migration and aneurysm expansion (2 patients) 
 Migration and type 1 endoleak (1 patient) 
 Expanding aneurysm (1 patient) 
 Type 1 endoleak (1 patient) 
 In hospital death (2 patients) 
In the fEVAR group, the mode of failure was: 
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 Expanding aneurysm (1 patient) 
In the OR group the mode of failure was:  
 Graft infection and aneurysm related mortality (1 patient) 
 In hospital death (2 patients) 
The following graph demonstrates freedom from clinical failure for the three treatment 
options over the course of follow up as analysed by the Kaplan Meier method (See 
figure 9.4.) 
Figure 9.4: K-M survival estimates with failure events (clinical failure)  
 
 
Of those patients with clinical failure the 3 OR patients died as a result of their clinical 
failure. The fEVAR patient had a recorded expansion of aneurysm 86 months after the 
initial procedure. The patient had expansion from 47mm to 53mm and a type 2 endoleak 
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After this no endoleak was noted and at last surveillance scan the aneurysm measured 
59mm without secondary intervention and without endoleak, the patient remains alive on 
the surveillance programme. Of the 13 EVAR patients; 6 either died as an inpatient, had an 
open conversion or suffered a ruptured aneurysm (1 patient). The remaining 7 patients are 
detailed below: 
 Type 1 endoleak (1 month, IFU violation: Conical, B angle 70 degrees) 
o Endoleak never seen again, no intervention and shrinking aneurysm 
without endoleak on last surveillance scan before death from other causes 
 Migration (15 months, IFU violation: Conical) 
o No intervention, shrinking aneurysm at last surveillance scan without 
endoleak. Patient died from non-aneurysm related causes. 
 Migration (25 months, IFU violation: Neck diameter 37mm, Conical, Thrombus) 
o Patient still alive on surveillance programme with shrinking aneurysm, no 
endoleak and no secondary intervention at last follow up. 
 Migration (26 months, IFU violation: Neck length 7mm) 
o Patient had migration noted at 26 months, on last surveillance scan patient 
had neck dilatation noted with very limited seal proximally but no 
identifiable endoleak. The patient was diagnosed with metastatic cancer 
within liver and bone from unknown primary 1 month after this scan and 
died secondary to the malignancy 2 months after that diagnosis. 
 Migration and Expanding Aneurysm (36 months, IFU violation: Conical, Thrombus) 
o Patient had migration noted at 36 months post op, then aneurysm was 
noted to be shrinking with no endoleak identified from 59mm to 50mm. 
Without endoleak the aneurysm then was noted to be 56mm classifying it 
as an expanding aneurysm. The measurement of 50mm was one isolated 
scan and raises the possibility of measurement error. Regardless the 
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patient continued to exhibit migration and on the final surveillance scan 
was noted to have a proximal endoleak that could not be defined as either 
type1 or 2. This was 3 years after the migration was first noted. The patient 
died of non-aneurysm related causes on review of clinical case notes 3 
months later. (Pneumonia and Myocardial infarction) 
 Migration and Expanding Aneurysm (57 months, IFU violation: thrombus alone) 
o This patient had a 77mm diameter AAA treated, the neck diameter was 
measured at 30mm immediately below the renal arteries but then was 27 
and 26mm at 5,10 and 15mm below the renal arteries. A 30mm diameter 
stent graft was placed in this 21mm long neck. Migration expanding 
aneurysm was noted with very little seal in proximal neck but no 
identifiable endoleak. The patient underwent a cuff extension 60 months 
from the original procedure with a chimney renal stent. The patient 
recovered well from the operation and the last surveillance scan revealed 
the aneurysm was continuing to expand and was now 110mm in size but 
with no identifiable endoleak on contrast enhanced ultrasound. The 
patient died from non-aneurysm related causes after this. 
 Expanding Aneurysm (73 Months, IFU violation: Alpha angle 47 deg, Beta angle 62 
degrees) 
o This aneurysm was noted to be shrinking with no concerns to 39mm up to 
73 months then expanded to 45mm, 53mm and 55mm on subsequent 
surveillance scans. No endoleak or loss of proximal seal was noted. No 
intervention was performed. The patient died from non-aneurysm related 
causes 3 years after aneurysm expansion was first noted. 
The above cases of clinical failure highlight a few things. Although the definition of clinical 
failure is appropriate to include all the above patients the difficulty of static definitions 
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applied to patients experiencing longitudinal surveillance is highlighted – for example the 
patient who exhibited an endoleak at the 1-month surveillance point and then never again 
was classed as clinical failure at that point and forever more. Despite the fact no 
identifiable sequelae came from this “clinical failure” identified at one surveillance time 
point. Furthermore, there were 2 patients in whom migration was noted and therefore 
classed as clinical failure but then stabilised and needed no intervention and had shrinking 
aneurysms throughout the remainder of their follow up. Although these three patients 
meet the definition of clinical failure, they do not clearly exhibit features that would be 
considered a clinical failure. The cases above also highlight that clinical failure may occur at 
any point throughout follow up even beyond 5 years, highlighting the importance of 
continued surveillance for these patients. Finally, the cases demonstrate that although 
clinical failure may occur it is not mandatory to treat the clinical failure at all costs because 
clearly these aneurysm patients have a high mortality rate from non-aneurysm related 
causes and interventions may not alter the clinical course for a given patient. The difficulty 
of course in this regard is that it is not clear which patients will go on to suffer aneurysm 
related mortality secondary to their clinical failure or not. This would be an important area 
for further research to determine if there are any predictive factors regarding clinical 
failure that can stratify patients into high or low risk.  
 
9.4.3. Secondary Outcome Measures 
The secondary outcome measures were: 
 Visceral vessel patency 
 Renal insufficiency and need for dialysis 
 Re-intervention rates, both surgical and endovascular 
 Conversion to open repair 
 Major complications 
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Visceral vessel patency 
Throughout the follow up period, only one visceral vessel was recognised to have occluded. 
One patient in the EVAR group suffered occlusion of their left renal artery secondary to 
maldeployment of the stent-graft during the procedure resulting in coverage of the renal 
artery. The patient suffered a temporary rise in their creatinine post-operatively exhibiting 
stage 1 acute kidney injury (AKI) but did not require dialysis. The patients renal function 
returned to their preoperative level prior to discharge. The patient died nine months later 
secondary to a sudden pulmonary embolism.  
No patient in the fEVAR group suffered visceral artery occlusion though seven patients 
were noted to have compromise to a target visceral vessel (renal artery in six cases and 
SMA in one other). In five cases stenosis/angulation with abnormal waveforms of a renal 
artery was seen on arterial duplex but no secondary intervention was performed for the 
target vessel. In one case of stenosis of a renal artery with abnormal waveforms, the 
patient had a secondary intervention 8 months post-operatively to place a second renal 
stent, this corrected the abnormal flow within the renal artery. No patient required dialysis 
because of compromise to his or her renal artery. The other case of stenosis in a superior 
mesenteric artery was identified on duplex 8 years postoperatively in a patient who had a 
fenestration for each renal artery and a scallop for the SMA. No intervention was 
undertaken, and the patient remains alive and on the surveillance programme 11 years 
after the original operation without signs or symptoms of mesenteric ischaemia. 
No visceral vessel occlusion was seen within the OR group; however, it should be noted 
that routine surveillance scanning did not take place in this group of patients and therefore 
it may be possible that occlusion could have occurred without being detected. 
Renal Insufficiency and Need for Dialysis 
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As stated above no patient required long-term dialysis throughout the follow up period, 
however one patient in the OR group did require temporary dialysis while an inpatient. 
In determining acute renal dysfunction in the post-operative period, the Kidney Disease: 
Improving Global Outcomes (KDIGO) definition was used to define whether a patient 
suffered an acute kidney injury during their hospital stay. The KDIGO definition also has a 
staging system to enable severity of the acute kidney injury to be staged. 
Regarding the post-operative in hospital period there was no significant difference in the 
maximum creatinine, the rate of AKI or the stage of AKI reached between the three groups 
(See table 9.10). 
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Table 9.10 Renal Function Post Operatively. 
Variable 
EVAR 
(n=28) 
fEVAR 
(n=15) 
Open Repair 
(n=37) 
Total 
(n=80) 
P - 
value 
Max Cr post 
op (in-
hospital), 
median 
(IQR) 
110 (94, 
150) 
110 (81, 
145) 
118 (84, 154) 115 (87, 151) 0.697 
Missing data 
(%) 
0 (0) 0 (0) 1 (2.7) 1 (1.3)  
AKI post-op 
(In Hospital), 
n (%) 
    0.258 
No 21 (75.0) 12 (80.0) 20 (54.1) 53 (66.3)  
Yes 7 (25.0) 3 (20.0) 16 (43.2) 26 (32.5)  
Missing 0 (0) 0 (0) 1 (2.7) 1 (1.3)  
AKI stage 
(In-Hospital), 
n (%) 
    1.000 
1 7 (25.0) 3 (20.0) 12 (32.4) 22 (27.5)  
2 1 (3.6) 0 (0) 3 (8.1) 4 (5.0)  
3 0 (0) 0 (0.0) 1 (2.7) 1 (1.3)  
No AKI 20 (71.4) 12 (80.0) 21 (56.8) 53 (66.3)  
Table 9.10 - Comparison of continuous variables was performed using one-way ANOVA when they were 
normally distributed and Kruskall-Wallis test (*) when not. 
During the in hospital stay the maximum creatinine for each patient was usually reached 
within 3 days of the operation (70% of patients). The median day for creatinine to peak for 
the whole cohort was day 2. (See figure 9.5) 
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Figure 9.5 Time to Reach Maximum Post-Operative Creatinine. 
 
With regards to chronic kidney disease the KDIGO definition of an abnormality of kidney 
structure or function which is present for > 3 months was used. The eGFR was used to 
define whether a patient had chronic kidney disease or not pre-operatively and during 
follow up after their operation. Chronic kidney disease was graded and categorised 
according to the system recommended by KDIGO. Patients with an eGFR of >60 were 
considered not to have chronic kidney disease. The CKD category for given eGFR values is 
as follows: eGFR 45 – 59 (category G3a), eGFR 30 – 44 (category G3b), eGFR 15 – 29 
(Category G4), eGFR <15 (Category G5). The use of these definitions for both acute kidney 
injury and chronic kidney disease are recommended by The Renal Association in the UK. 
Over the remainder of follow up there were no significant differences in the renal function 
between the three groups as measured by the last eGFR recorded during follow up or 
whether any patient had a deterioration of renal function sufficient enough to change their 
grade of CKD. Deterioration of renal function in this regard was defined as the eGFR 
dropping sufficiently so that a patients CKD grading would be altered, i.e. from an eGFR of 
61 to 59 would be classed as a deterioration in renal function, however it should be noted 
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that an eGFR dropping from 59 to 46 would not be classed (according to this definition) as a 
deterioration in renal function. (See table 9.11) 
Table 9.11 Renal Function during Follow up. 
Variable EVAR 
(n=28) 
fEVAR 
(n=15) 
Open Repair 
(n=37) 
Total 
(n=80) 
P - 
value 
Last eGFR 
during follow 
up(ml/min/1.
73m2), 
median (IQR) 
43 (35,  54) 55 (49,  64) 54 (36,  71) 49 (37,  66) 0.120 
Missing data 
(%) 
2 (7.1) 2 (13.3) 9 (24.3) 13 (16.3)  
Change in 
eGFR 
(ml/min/1.73
m2) (Last 
eGFR vs Pre-
op eGFR), 
Median (IQR) 
-10 (-22,-2) -3 (-16,5) -3 (-17,2) - 0.228 
Deterioration 
in renal 
function, n 
(%) 
     
No 12 (42.9) 11 (73.3) 19 (51.4) 42 (52.5) 0.057 
Yes 14 (50.0) 2 (13.3) 9 (24.3) 25 (31.3)  
Missing 2 (7.1) 2 (13.3) 9 (24.3) 13 (16.3)  
Deterioration 
by 2 or more 
CKD grades, n 
(%) 
     
No 9 (32.1) 2 (13.3) 6 (16.2) 17 (21.3) 1.000 
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Yes 5 (17.9) 1 (6.7) 4 (10.8) 10 (12.5)  
No 
deterioration 
/ Missing 
14 (50.0) 12 (80.0) 27 (73.0) 53 (66.3)  
Table 9.11 - Comparison of continuous variables was carried out through a Kruskall-Wallis test (*). Categorical 
variables were compared using Fisher’s exact test or χ2 test, depending on the amount of data present in 
each entry. eGFR = Estimated Glomerular Filtration Rate, CKD – chronic kidney disease 
As can be seen from the table there was no statistically significant difference in any of the 
variables measured, however those patients undergoing EVAR were, in this sample, more 
often exhibited a deterioration in their renal function as measured by CKD grades and 
change in eGFR. Of the fourteen patients that did have a deterioration in their renal 
function seven of them dropped their eGFR from >60 to 30 – 59. i.e. dropping from no 
chronic kidney disease to within stage 3a or 3b CKD. When comparing the last recorded 
eGFR during follow up with the preoperative value there was no statistically significant 
difference but the median eGFR change for EVAR patient was -10 compared with -3 for 
both other types. 
Reintervention Rates (In-hospital) 
No patients required an additional endovascular procedure while an inpatient however 
seven patients did return to theatre for an operative intervention while still an inpatient 
(See table 9.12). 
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Table 9.12 Re-Interventions (In Hospital). 
Variable 
EVAR 
(n=28) 
fEVAR 
(n=15) 
Open Repair 
(n=37) 
Total 
(n=80) 
P - value 
Return to theatre  
(In hospital), n (%) 
    0.288 
Yes 4 (13.8) 0 3 (8.1) 7 (8.6)  
No 23 (82.8) 15 (100) 34 (91.9) 73 (90.1)  
Unknown 1 (3.4) 0 0 1 (1.2)  
Table 9.12 - Comparison of continuous variables was carried out through a Kruskall-Wallis test (*). Categorical 
variables were compared using Fisher’s exact test or χ2 test, depending on the amount of data present in 
each entry. eGFR = Estimated Glomerular Filtration Rate, CKD – chronic kidney disease 
Four patients who initially underwent EVAR returned to theatre; three for incision and 
drainage of a groin haematoma and to ensure haemostasis was achieved (Day 0, 1 and 9). 
One further EVAR patient returned to theatre on the eighth post-operative day and 
underwent a laparotomy and over sewing of a gastric perforation.  
Three patients required return to theatre after open repair:  
 One patient was haemodynamically unstable and thought to be bleeding 
intraabdominally. They returned to theatre within the first post-operative day and 
bleeding from the aneurysm sac edge was found to be the cause for their 
instability. Haemostasis was subsequently achieved.  
 Another patient suffered left leg ischaemia on day 1 post operatively and returned 
to theatre for thromboembolectomy and fasciotomy. This restored perfusion to 
that leg and the patient subsequently made a good recovery.  
 The final patient underwent a prolonged operation (> 11 hours) with suprarenal 
clamp, there was an estimated 7000mls blood loss during the operation and post 
operatively the patient developed abdominal compartment syndrome and 
multiorgan failure. On day 2 post operatively, they returned to theatre for 
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abdominal decompression and placement of VAC dressing. They returned to 
theatre for numerous changes of abdominal VAC and required prolonged critical 
care stay. The patient was eventually discharged from the hospital and remains 
alive. 
Reintervention Rates (During Follow Up) 
There were 16 re-interventions in 12 patients during the follow up period, nine operative 
surgical interventions and seven radiological interventions. One patient in the EVAR group 
underwent 3 radiological re-interventions and two operative reinterventions for a groin 
lymphocele. The following table documents all the re-interventions performed during the 
follow up period (See table .7). 
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Table 9.13 Re-intervention procedures During Follow Up 
Repair 
Group 
Re-intervention Time from Initial 
Procedure 
Outcome 
EVAR Mesenteric angiogram 2 months No abnormality 
detected 
USS guided lymphocele drainagea 5 months Recurred 
USS guided lymphocele drainage and 
injection of alcohola 
6 months Recurred 
I+D Groin Lymphocelea 7 months Needed further 
debridement 
USS guided lymphocele drainage and 
injection of alcohol and tetracyclinea 
8 months Needed surgical 
debridement 
Debridement of Groin Wounda 9 months Prolonged 
convalescence 
but did fully 
heal 
Conversion to Open repair 13 months Successful 
Conversion to Open Repair 13 months Successful 
Conversion to Open Repair 37 months Successful 
Proximal extension cuff and right renal 
stent (Migration) 
66 months Successful 
Limb extension and embolisation of IIA 
to extend seal (Aneurysm expansion) 
96 months Successful 
fEVAR Right renal stent – Scallop to renal 
artery initially but shuttering noted with 
damped waveform 
8 months Renal artery 
waveform 
normalised 
after procedure 
Femoro-femoral Crossover graft 
(Occlusion of limb of bifurcated portion 
of stent graft) 
92 months Successful  
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Open 
Repair 
Femoro-femoral Crossover graft 
(Occlusion of limb of bifurcated graft) 
2 months Successful 
Anterior abdominal wall skin graft 3 months Successful 
Incisional hernia repair (open) 33 months Successful 
Table 9.13 - I+D=Incision and drainage, USS=Ultrasound scan, IIA=Internal Iliac artery. a=Same patient 
underwent numerous separate interventions 
The patient in the fEVAR group who underwent a fem-fem crossover 92 months after the 
index procedure was lost to follow up for a period of three years. Initially the patient had 
had 4 years of post-operative follow up with a standard protocol and no problems were 
identified. They were lost to follow up for 3 years then presented with an acutely ischaemic 
leg. CT angiogram on admission revealed an occluded limb but the rest of the fEVAR was 
patent with no issues. The patient underwent a successful femoro-femoral crossover graft 
but was found to have oesophageal cancer with metastatic disease and died 6 weeks later 
during the same admission. The only predisposing factor found to account for the 
thrombosed limb was the advanced malignancy. There was no significant difference found 
between the three groups for occurrence of surgical re-intervention, radiological 
reintervention or ‘any reintervention’ (See table 9.14).  
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Table 9.14 Re-Interventions (Follow up) 
Variable 
EVAR 
(n=28) 
fEVAR 
(n=15) 
Open Repair 
(n=37) 
Total 
(n=80) 
P - value 
Patients who 
returned to Theatre 
(Long term), n (%) 
    0.409 
No 20 (71.4) 13 (86.7) 30 (81.1) 62 (77.5)  
Yes 4 (14.3) 1 (6.7) 3 (8.1) 9 (11.3)  
Unknown 4 (14.3) 1 (6.7) 4 (10.8) 9 (11.3)  
Patients who 
returned to Radiology 
(Long term), n (%) 
    0.027 
No 20 (71.4) 13 (86.7) 33 ( 89.2) 66 (82.5)  
Yes 4 (14.3) 1 (6.7) 0 (0) 5 (6.3)  
Unknown 4 (14.3) 1 (6.7) 4 (10.8) 9 (11.3)  
Any secondary 
intervention (Long 
term), n (%) 
    0.167 
No 17 (60.7) 12 (80.0) 30 (81.1) 59 (73.8)  
Yes 7 (25.0) 2 (13.3) 3 (8.1) 12 (15.0)  
Unknown 4 (14.3) 1 (6.7) 4 (10.8) 9 (11.3)  
Table 9.14 - Comparison of continuous variables was carried out through a Kruskall-Wallis test (*). Categorical 
variables were compared using Fisher’s exact test or χ2 test, depending on the amount of data present in 
each entry. 
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Conversion to Open Repair 
There were three cases of conversion to open repair, all within the EVAR group. No patient 
that underwent fEVAR underwent open conversion though this difference between EVAR 
and fEVAR did not reach statistical significance (p=0.541). 
The cases of conversion to open repair are described below: 
 The first case was in a patient with an aneurysm that breached IFU on two counts; 
maximum neck diameter of 33mm, and presence of thrombus. An EVAR with a 
proximal body diameter of 36mm was implanted without complication. The patient 
made an excellent recovery and no complications were noted until at 36 months 
post-operatively significant migration was detected on surveillance scanning. The 
patient then underwent open conversion, recovered well and died of non-
aneurysm related cause 113 months after the original EVAR. 
 The second patient had an aneurysm that breached the IFU on five counts; neck 
length (5mm), conical, large diameter neck (34mm), β angle of 61⁰ and presence of 
thrombus. An EVAR stent-graft with a proximal body of 30mm was implanted and 
the patient made a full, uncomplicated recovery. 12 months post-operatively the 
patient was found to have migration of the stent-graft with only a short seal zone 
remaining. Conversion to open repair was undertaken at 13 months. 42 months 
post-operatively the patient died from an unknown cause. 
 The third patient had an aneurysm that breached the IFU on two counts; maximum 
neck diameter (38mm) and α angle of 47⁰. The EVAR was implanted successfully 
but a type 1a endoleak was noted at the end of the procedure. This was managed 
conservatively but one year post-operatively the endoleak was still present and 
migration was noted to have occurred. Conversion to open repair was therefore 
undertaken at 13 months. The patient recovered well with no further aneurysm 
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related problems through follow up. The patient died of an unknown cause 127 
months after the original EVAR. 
Major Complications (In hospital) 
There was a variety of post-operative complications recorded. Complications were 
classified according to published reporting standards[93]. This system of classification first 
recognises three groups or types of complication; deployment related complications, 
implant related complications and systemic complications. Implant related complications 
include features such as stent-graft migration and for the most part include complications 
that tend to only occur or be detected within the surveillance programme, after discharge 
from hospital. As such, there were no implant related complications within any of the three 
groups during their primary hospital stay. Within each group complications are then 
assigned a degree of severity; mild, moderate or severe. A mild complication indicates that 
the complication has occurred but resolved spontaneously without prolonging hospital stay 
or causing permanent impairment. A moderate complication indicates the need for 
significant intervention, prolongation of hospital stay and/or permanent disability, which 
does not preclude normal daily activity. A severe complication indicates the need for major 
surgical or medical intervention, which may be accompanied by prolonged convalescence, 
permanent disability and may result in death. There were 79 post-operative complications 
in 51 patients. The table below details these complications (See Table 9.15). 
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Table 9.15 Post-Operative Complications (In hospital) 
Type of 
Repair 
Complication 
Group 
Complication 
Complication 
severity 
Number of 
complications 
EVAR 
Deployment 
Related 
Access site 
Haematoma 
Mild 2 
Moderate 3 
Groin Lymphocele Mild 1 
Operative Blood 
Transfusion 
Moderate 1 
Peripheral 
Embolisation 
Severe 1 
Systemic 
Complications 
Gastrointestinal Severe 2 
Pulmonary Mild 3 
Renal Insufficiency Mild 1 
Urological Mild 1 
fEVAR 
Deployment 
Related 
Access site 
Haematoma 
Mild 1 
Operative Blood 
Transfusion 
Moderate 1 
Systemic 
Complications 
Cardiac Mild 2 
Pulmonary Mild 3 
Renal Insufficiency Mild 1 
Urological Mild 2 
Open 
Repair 
Deployment 
Related 
Operative Blood 
transfusion 
Mild 9 
Moderate 14 
Severe 2 
Peripheral 
Embolisation 
Mild 1 
Peripheral 
Ischaemia 
Moderate 1 
Systemic 
Complications 
Abdominal 
compartment 
Severe 1 
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syndrome 
Cardiac 
Mild 6 
Moderate 4 
Severe 1 
Cerebrovascular Moderate 2 
Coagulopathy Severe 1 
Gastrointestinal 
Mild 1 
Moderate 2 
Pulmonary 
Mild 3 
Moderate 3 
Severe 1 
Renal Moderate 1 
Urological Mild 1 
 
In line with the reporting standards [93] intraoperative blood transfusion is graded as a 
complication. If a patient receives < 2 units of autologous transfusion with no homologous 
transfusion it is considered a mild complication. If the patient receives >2 units autologous 
but < 3 units homologous then it is a moderate complication and if >3 units homologous 
blood transfusion, then it is a severe complication. Of note, in the open operation group 
there were 14 moderate and 2 severe complications related to intraoperative blood 
transfusion. This is in line with the reporting standards however; it should be borne in mind 
these reporting standards were developed primarily with endovascular repair in mind. As 
such, what would be considered an unusual and excessive intraoperative blood transfusion 
when carrying out endovascular repair may be considered routine and even ‘normal’ for an 
open operation.  
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An analysis of major complications between the three repair groups was undertaken 
including the definition of major complication from the reporting standards and applying it 
equally to all three groups. A complication was considered major if it fell into either the 
moderate or severe categories or minor if it fell into the mild category. There was a no 
statistically significant difference found between the three groups when comparing major 
complications as defined in the reporting standards. An analysis was also conducted 
excluding moderate intraoperative blood transfusion from the definition of major 
complication and only including severe. This analysis also revealed no statistically 
significant difference in the incidence of major complications between the three groups. 
(See table 9.16).  
Table 9.16 Patients Experiencing Major Complications (In-Hospital) 
Variable 
EVAR 
(n=28) 
fEVAR 
(n=15) 
Open Repair 
(n=37) 
Total 
(n=80) 
P - value 
Major Complicationsa 
(In hospital), n (%) 
    0.494 
No 24 (85.7) 14 (93.3) 17 (45.9) 55 (68.8)  
Yes 4 (14.3) 1 (6.7) 20 (54.1) 25 (31.3)  
Major Complicationsb 
(In hospital), n (%) 
    0.101 
No 24 (85.7) 15 (100) 26 (70.3) 65 (81.3)  
Yes 4 (14.3) 0 (0) 11 (29.7) 15 (18.7)  
Table 9.16 - Comparison of continuous variables was carried out through a Kruskall-Wallis test (*). Categorical 
variables were compared using Fisher’s exact test or χ2 test, depending on the amount of data present in 
each entry. 
. a = Major complications including moderate intraoperative blood loss as major complication. b=Excluding 
moderate blood loss as a major complication. 
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During the mid to long term follow up a further nine patients suffered nine complications 
related to their initial operation, not including issues related to stent-grafts (these are 
discussed separately). (See table 9.17) 
Table 9.17 Complications not Relating to the Stent-Graft (During Follow Up) 
Repair Type Complication Intervention 
EVAR Groin Lymphocele Incision and drainage 
EVAR Abdominal pain -? Mesenteric 
ischaemia 
Mesenteric angiogram – No 
vascular cause found 
Open Repair Retrograde Ejaculation No intervention 
Open Repair Infected Aortic Graft (5 years) – 
Source: empyema of the gallbladder 
Long term antibiotics 
Open Repair Right limb occlusion (2 months) Femoral-femoro crossover 
Open Repair Incisional hernia (12 months) Operative repair 
Open Repair Incisional hernia Conservative management 
Open Repair Incisional hernia Conservative management 
Open Repair Buttock Claudication Conservative management 
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9.4.4. Aneurysm Morphology 
Pre-operative CT scans were reviewed for all patients and various anatomical data were 
collected for each patient. The following table summarises these data. (See table 9.18) 
Table 9.18 Aneurysm Morphology 
Variable 
EVAR 
(n=28) 
fEVAR  
(n=15) 
Open Repair 
(n=37) 
Total 
(n=80) 
P - value 
Max Aneurysm 
Diameter (mm), 
Median (IQR) 
66.5 
(60.5,70.0) 
60.0 
(57.0,64.0) 
65.0 
(60.0,77.5) 
64.0 
(59.0,70.0) 
0.018 
Neck Length 
(mm), Median 
(IQR) 
20.0 
(15.0,23.5) 
4.0  
(0.0, 9.0) 
6.0  
(1.5,14.5) 
10.0 
(4.0,18.0) 
<0.001 
Neck Diameter 
(mm), Median 
(IQR) 
28.0 
(25.5,30.0) 
34.0 
(31.0,40.0) 
35.0 
(28.5,42.5) 
31.0 
(28.0,38.0) 
0.001 
α angle (⁰), 
Median (IQR) 
25.0 
(8.0,40.5) 
16.0 
(14.0,24.0) 
36.0 
(16.5,57.0) 
25.5 
(13.0,43.0) 
0.026 
β angle (⁰), 
Median (IQR) 
40.0 
(29.5,58.5) 
37.0 
(20.0,45.0) 
45.5 
(26.5,67.5) 
41.0 
(27.0,60.0) 
0.229 
Thrombus, n 
(%) 
    0.397 
No 14 (50.0) 10 (66.7) 23 (62.2) 47 (58.8)  
Yes 14 (50.0) 4 (26.7) 13 (35.1) 31 (38.8)  
Unknown 0 (0) 1 (6.7) 1 (2.7) 2 (2.5)  
Calcification, n 
(%) 
    0.827 
None 8 (28.6) 4 (26.7) 15 (40.5) 27 (33.8)  
Mild 13 (46.4) 6 (40.0) 15 (40.5) 34 (42.5)  
Moderate 6 (21.4) 3 (20.0) 4 (10.8) 13 (16.3)  
Severe 1 (3.6) 1 (6.7) 2 (5.4) 4 (5.0)  
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Unknown 0 (0) 1 (6.7) 1 (2.7) 2 (2.5)  
Number of IFU 
violations, n (%) 
     
1 12 (42.9) 1 (6.7) 6 (16.2) 19 (23.5)  
2 11 (39.3) 4 (26.7) 8 (21.6) 23 (28.4)  
3 4 (14.3) 8 (53.3) 10 (27) 23 (28.4)  
4 0 2 (13.3) 9 (24.3) 11 (13.6)  
5 1 (3.6) 0 3 (8.1) 4 (4.9)  
Unknown 0 0 1 (2.7) 1 (1.2)  
Number of IFU 
violations, 
median (IQR) 
2.0 (1.0, 
2.0) 
3.0 (2.0, 3.0) 3.0 (2.0, 4.0) 2.0 (2.0, 
3.0) 
0.001 
Expected clamp 
site, n (%) 
    0.061 
Infrarenal 24 (85.7) 9 (60.0) 22 (59.5) 55 (68.8)  
Suprarenal 0 (0) 2 (13.3) 7 (18.9) 9 (11.3)  
Supracoeliac 4 (14.3) 4 (26.7) 8 (21.6) 16 (20.0)  
Table 9.18 - Comparison of continuous variables was carried out through a Kruskall-Wallis test (*). Categorical 
variables were compared using Fisher’s exact test or χ2 test, depending on the amount of data present in 
each entry. 
All aneurysms were noted to be atherosclerotic in nature with the vast majority having a 
fusiform shape. Only four patients had an aneurysm with a non-fusiform shape. In each 
case, the shape would best be described as dumb-bell. The smallest aneurysm in the series 
was 55mm in maximal diameter and the largest was 110mm. The median aneurysm 
diameter was 64mm. Although not statistically significantly different those patients who 
underwent fEVAR had a smaller median aneurysm diameter of 60mm, compared with 
66.5mm for EVAR patients and 65mm for open repair patients. 
The neck length was significantly longer in patients who received standard EVAR. Only six 
patients (21.4%) in the EVAR group had a neck length outside the IFU, with the minimum 
298 
 
length treated being 5mm. This is perhaps unsurprising given the fact that neck length is 
one of the primary areas of scrutiny when deciding what type of repair a patient should 
have. 
There was no statistically significant difference between the groups when comparing neck 
diameter although there was a trend towards a smaller neck diameter in the EVAR group 
(28mm) when compared with the other two groups - open repair (35mm) and fEVAR 
(34mm). In fact, the median neck diameter in this group is within the IFU for standard EVAR 
(≤32mm) but larger in the other two groups. 
Again, there was no statistically significant difference between the groups in terms of 
median α or β angle. Though there was a trend towards a smaller alpha angle in fEVAR 
patients. The alpha angle represents angulation within the visceral segment of the aorta 
between the SMA and the beginning of the aneurysm below. This is precisely the segment 
where EVAR and fEVAR are placed to achieve a ‘seal’. Furthermore, in fEVAR, the fact that 
the device requires careful manipulation and placement to align the visceral vessels with 
the precisely manufactured fenestrations mean that angulation would be less well 
tolerated as it would distort the anatomy and make accurate placement of the device very 
difficult. In open repair, there are no such concerns and hence may be why patients with a 
significantly larger α angle were preferentially treated with open repair.  
There was no statistically significant difference found between the groups when comparing 
presence of thrombus or degree of calcification within the neck. In fact, when calcification 
was considered to be simply either present or not there was still no significant difference 
between the groups. This suggests that distribution of calcification was relatively 
homogenous between the three groups and did not significantly affect whether a patient 
had one type of operation or another. With regards to calcification, the IFU for the three 
standard stent-grafts that were consulted during the design of the study differ in their 
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consideration of calcification and whether its presence constitutes a breach of the IFU. In 
two cases, the IFU simply states that if ‘significant’ calcification is present then the 
aneurysm would be outside IFU. For the third device presence of calcification at 
‘implantation sites’ is considered to represent a breach of the IFU. There is no standard 
agreed definition as to what constitutes significant calcification. The presence of 
calcification and its degree were determined subjectively during the data collection. For 
these reasons the presence of calcification was not considered to represent an IFU 
violation and therefore further analysis took this into account. In no patient was presence 
of calcification the sole breach of IFU and therefore the sole reason for inclusion into the 
study.  
The median number of IFU violations for each of the groups approached but did not reach 
statistical significance. EVAR patients had a median of 2 IFU violations per patient and 
fEVAR and OR patients had 3. This is perhaps unsurprising given that standard EVAR is by 
definition not intended for use in patients with any IFU violation and is less likely to be the 
treatment choice selected when there are multiple factors violating its intended use. fEVAR 
on the other hand is specifically designed to be used in patients who exhibit violations to 
standard EVAR IFU. Furthermore, open repair is not limited by the same anatomical 
constraints and therefore in an era when most patients receive an endovascular solution to 
treat their aneurysm if suitable, the majority of the remaining patients who receive open 
repair will exhibit a higher preponderance for IFU violations. The most common reason for 
IFU violation in all three groups was conicality of the neck: 63 patients (78.8%).  The 
Reasons for IFU violations are explored in the table below (See table 9.19): 
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Table 9.19 IFU Violations 
IFU Violation EVAR (n=28) fEVAR  (n=15) Open Repair (n=37) Total (n=80) 
Neck Length, n (%) 6 (21.4) 13 (86.7) 22 (59.5) 42 (52.5) 
Neck Diameter, n (%) 5 (17.9) 9 (60) 20 (54.1) 35 (43.8) 
Conicality, n (%) 18 (64.3) 14 (93.3) 31 (83.8) 63 (78.8) 
α angle, n (%) 4 (14.3) 0 11 (29.7) 15 (18.8) 
β angle, n (%) 6 (21.4) 1 (6.7) 9 (24.3) 16 (20) 
Significant Thrombus, 
n (%) 
12 (42.9) 4 (26.7) 10 (27) 27 (33.8) 
Table 9.19 - Comparison of continuous variables was carried out through a Kruskall-Wallis test (*). Categorical 
variables were compared using Fisher’s exact test or χ2 test, depending on the amount of data present in 
each entry. IFU=Instructions for use. The number represents the number of patients that exhibited that 
feature outside of IFU. As patients can exhibit more than one IFU violation the percentages add up to more 
than 100%. 
Expected clamp site, as judged from the pre-operative CT scan, did not differ significantly 
between the three groups. The only group in which an actual clamp was placed is that of 
the open repair group. The following table shows the distribution of predicted clamp site 
with actual clamp site in the open repair group (See table 9.20) 
Table 9.20 Expected Versus Actual Clamp Site 
Expected Clamp 
Site, n 
Actual Clamp Site, n 
Infrarenal Suprarenal Supracoeliac 
Infrarenal 15 (75%) 4 (20%) 1 (5%) 
Suprarenal 3 (60%) 2 (40%) 0 
Supracoeliac 3 (50%) 3 (50%) 0 
 
In this cohort of patients if an Infrarenal clamp was predicted from the pre-operative CT 
scan, 75% of the time an infrarenal clamp was placed. However, when suprarenal or 
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supracoeliac clamp was predicted <20% of the time that clamp was placed intraoperative. 
Fisher’s exact test was applied in order to investigate the association of expected and 
actual clamp site in open repair patients. The results suggested that there is not a 
statistically significant relationship between the variables mentioned above (p=0.636). 
9.4.5. Operative data 
All patients underwent their procedure in the operating theatre under general anaesthetic. 
No patient died intraoperative and there were no immediate conversions to open repair in 
the endovascular group. For those that received endovascular repair the device was placed 
under fluoroscopic guidance using a mobile C-arm in theatre. There was a radiologist 
present in theatre (along with a surgeon) for all the fEVAR cases, all but five of the EVAR 
cases and none of the OR cases. 
The following table details information relating to intraoperative variables. (See table 9.21) 
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Table 9.21 Intraoperative Data 
Variable 
EVAR 
(n=28) 
fEVAR 
(n=15) 
Open Repair 
(n=37) 
Total 
(n=80) 
P - value 
Operation time 
(mins), Median 
(IQR) 
210 ( 165, 
240 ) 
315 ( 270, 
360 ) 
240 ( 173, 
300 ) 
240 ( 180, 
300 ) 
0.001 
Estimated blood 
loss (ml), median 
(IQR) 
800 ( 800, 
800 ) 
1000 
(1000,2000 
) 
1650 ( 
950,2000 ) 
1250 ( 
800,2000 ) 
0.314 
Missing data (%) 
23 ( 82.1% ) 12 ( 80.0% ) 17 ( 45.9% ) 52 ( 65.0% )  
Intraoperative 
Transfusion 
(mls), Median 
(IQR) 
0 (0,   0 ) 0 (0, 250 ) 500 ( 255, 
800 ) 
0 (0, 500 ) <0.001 
Persistent 
Intraoperative 
Graft related 
Endoleak (Type I 
or III), n (%) 
    0.290 
Yes 4 (14.3) 2 (13.3)    
No 24 (85.7) 13 (86.7)    
Table 9.21 - Comparison of continuous variables was carried out through a Kruskall-Wallis test (*). Categorical 
variables were compared using Fisher’s exact test or χ2 test, depending on the amount of data present in 
each entry. 
The operation time was longer with fEVAR compared with either open repair or EVAR, 
which given the increased complexity of the procedure necessitating multiple vessel 
cannulation and stenting is unsurprising, yet this failed to reach statistical significance. 
Again, somewhat unsurprising is that the estimated blood loss and volume of 
intraoperative blood transfusion is greater in open repair. 
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There were four cases of persistent intraoperative graft related endoleak (all type 1a) 
noted on completion angiogram in the EVAR group. In all cases a moulding balloon was 
used at the proximal attachment site which reduced the endoleak but did not abolish it. In 
each case it was decided to manage the endoleak expectantly with close surveillance on 
follow up as it was felt that the endoleaks were small and of low flow and would therefore 
seal spontaneously. The outcome for each patient is described above in the section on 
technical success and is repeated here for clarity. Of the four cases of persistent type 1a 
endoleak: One patient had no further type 1a endoleak identified during the follow up and 
died approximately nine years postoperatively from non-aneurysm related cause. Three 
patients had a type 1a endoleak identified at some point during the follow up:  
 One was only seen on the one-month surveillance scan and never again, patient 
died of unknown cause nearly five years after the original operation.  
 One patient had migration and further type 1a endoleak identified and successfully 
underwent a conversion to open repair within the first year after their index 
operation. The patient recovered well and remained alive for approximately 10 
years until their death of unknown cause. 
 The final patient had migration and type 1a endoleak noted but died from a 
ruptured aneurysm prior to conversion to open repair. 
There were two cases of graft related endoleak (both type 3) within the fEVAR group. They 
were both arising from the junction between the main fenestrated stent graft body and a 
renal artery stent. In both cases the renal stent was “re-locked” with an angioplasty balloon 
but the endoleak persisted. In both cases the endoleak was never seen on surveillance 
imaging during follow up. There was no significant difference seen in the proportion of 
patients undergoing unplanned adjunctive manoeuvres between the EVAR and fEVAR 
groups. The adjunctive manoeuvres performed were as follows: In the EVAR group; 
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 Iliac limb stenting/angioplasty (Five patients) 
 Moulding balloon use at top end (two patients) 
 Placement of a zenith cuff for type 1 endoleak (one patient) 
 Placement of Palmaz stent for type 1 endoleak (one patient) 
In the fEVAR group; 
 Extra TV stent due to maldeployment of first (two patients) 
 Balloon moulding of TV stent connection due to endoleak (two patients) 
 Iliac limb angioplasty (one patient) 
In the majority of patients undergoing a repair by endovascular means, the incision used 
was bilateral oblique groin incisions to gain access to the femoral arteries for subsequent 
cannulation. In two patients undergoing EVAR a different incision was used: in one patient 
in whom there was contralateral iliac occlusion and significant ipsilateral disease a 
Rutherford Morrison incision was used, and an ilio-femoral bypass procedure was 
performed to act as a conduit for deployment of an aorto-uni-iliac device. In the other case 
the patient had short common iliac arteries and standard endovascular repair would 
necessitate coverage of both internal iliac ostia. Instead, on one side a Rutherford Morrison 
incision was used to gain access and then a surgical internal iliac artery transposition to the 
distal external iliac artery was performed. This allowed deployment of the stent graft into 
both external iliac arteries while maintaining internal iliac perfusion from one side. All cases 
of fenestrated EVAR utilised bilateral oblique groin incisions only for access. In the OR 
group only two patients did not have a midline laparotomy incision. In each case, they had 
a rooftop incision to gain access. 
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One case utilised a surgical conduit for deployment of the endovascular stent-graft. This 
was planned beforehand and is described above. There were no cases of conversion to 
open repair within either endovascular group at the primary operation.  
There were six immediate complications after the primary operation, three in the EVAR 
group and three in the OR group. No immediate complications were seen in the fEVAR 
group; however, this difference did not reach statistical significance (p=0.651). The 
complications are detailed below (see table 9.22) 
Table 9.22 Immediate Complications 
Type of Repair Complication Action 
EVAR 
Bleeding from left groin – 
In recovery 
Taken to theatre and haemostasis 
achieved 
EVAR 
Inadvertent renal artery 
coverage 
Attempts to recanalise in theatre, 
unsuccessful. 
EVAR 
Cholesterol embolization 
left leg 
Managed on critical care unit with 
inotropic support 
Open Ischaemic leg 
Taken to theatre for popliteal 
embolectomy 
Open Bleeding intraabdominally 
Taken to theatre and haemostasis 
achieved 
Open No left femoral pulse 
Aortofemoral bypass undertaken 
immediately 
 
9.4.6. Stent Graft configuration 
In all cases of fenestrated EVAR the Zenith Fenestrated (Cook Inc. Bloomington, Indiana) 
platform was used. In the EVAR group all 28 patients received a stent-graft from the Zenith 
Flex (Cook Inc. Bloomington, Indiana) platform. One patient within the EVAR group 
received a custom-made Cook device that did not have suprarenal fixation as part of the 
implanted stent graft system. All the remaining patients treated by endovascular means 
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had suprarenal fixation. In all cases of fEVAR the distal main body was bifurcated. 
Regarding standard EVAR all but one were bifurcated main bodies. One case of aorto-uni-
iliac device was described earlier. 
The following graph presents the diameters of the proximal main body portion for all 
standard endovascular device utilised: (See Figure 9.6) 
Figure 9.6 Proximal Body Diameter in EVAR Cohort 
 
The following table documents stent-graft configuration with relation to target vessels for 
the fEVAR cohort (See table 9.23) 
Table 9.23 Stent-Graft Configuration for fEVAR 
Number of Target vessels Configuration Number of patients 
4 Sc CA/SMA (Conjoined origin), Fen 
LRA/RRA 
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There were 45 target vessels in total, mean of 3 target vessels per patient (Standard 
deviation 0.38). Fourteen target vessels were protected with a scallop, two with a large 
fenestration and 29 with small fenestrations. No target vessels protected with a scallop and 
one target vessel protected by a large fenestration received a stent. All target vessels 
protected with a small fenestration and one by a large fenestration, however, were 
stented. In total 31 target vessel stents were placed in 30 target vessels. One target vessel 
received two stents due to inadvertent distal deployment of the first stent. A second stent 
was required to complete the stenting and achieve a seal. Bare metal stents were used in 
15 target vessels (Palmaz Genesis, Cordis Corp.) and covered stents were used in the other 
fifteen (Advanta, Atrium Medical.). In four patients, a mix of stent types were used.  
9.4.7. Post-operative data 
There was a significant difference in length of stay both in a critical care environment post-
operatively and overall hospital stay between the three groups. The following table details 
the length of stay for the three groups (See Table 9.24) 
Table 9.24 Length of Stay 
Variable EVAR (n=28) 
fEVAR 
(n=15) 
Open Repair 
(n=37) 
Total 
(n=80) 
P - value 
Critical care stay 
(days), Median 
(IQR) 
0 (0, 0) 0 (0, 0) 1 (0, 2) 0 (0, 1) <0.001 
LOS (days), Median 
(IQR) 
7 (5, 9) 5 (4,   8 ) 13 (8,  20) 8 (6, 14) <0.001 
Table 9.24 - Comparison of continuous variables was carried out through a Kruskall-Wallis test (*). Categorical 
variables were compared using Fisher’s exact test or χ2 test, depending on the amount of data present in 
each entry. LOS=Length of stay. 
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When comparing complications specific to the endovascular technique, namely, conversion 
to open repair, presence of endoleak during follow up, aneurysm expansion, or migration, 
only migration revealed a statistically significant difference in the occurrence of migration 
at any point during the follow up. (See table 9.25) 
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Table 9.25 Complications Specific to the Endovascular Technique during Follow Up 
Variable EVAR (n=28) fEVAR (n=15) Total (n=43) P - value 
Open Conversion, n (%)    0.541 
No 25 (89.3) 15 (100.0) 40 (93)  
Yes 3 (10.7) 0 (0) 3 (7)  
Endoleak (Any), n (%)    0.734 
No 17 (60.7) 10 (66.7) 27 (62.8)  
Yes 10 (35.7) 4 (26.7) 14 (32.6)  
Unknown 1 (3.6) 1 (6.7) 2 (4.7)  
Endoleak (Graft Related), n 
(%) 
   0.539 
No 24 (85.7) 14 (93.3) 38 (88.4)  
Yes 3 (10.7) 0 (0) 3 (7)  
Unknown 1 (3.6) 1 (6.7) 2 (4.7)  
Aneurysm Expansion 
(≥5mm), n (%) 
   0.539 
No 24 (85.7) 14 (93.3) 38 (88.4)  
Yes 3 (10.7) 1 (6.7) 4 (9.3)  
Unknown 1 (3.6) 0 (0) 1 (2.3)  
Migration (≥ 5mm), n (%)    
 
No 18 (64.3) 14 (93.3)  0.017 
Yes 9 (32.1) 0 (0)   
Unknown 1 (3.6) 1 (6.7)   
Table 9.25 - Comparison of continuous variables was carried out through a Kruskall-Wallis test (*). Categorical 
variables were compared using Fisher’s exact test or χ2 test, depending on the amount of data present in 
each entry. LOS=Length of stay. 
The prevalence of type 2 endoleak during follow up for both EVAR and fEVAR groups was 
similar with no statistically significant difference identified. There were seven cases (25%) 
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within the EVAR group of type 2 endoleak noted during follow up. There were four cases 
(26.7%) of type 2 endoleak within the fEVAR group. No patient underwent a secondary 
intervention associated with their type 2 endoleak and two patients, one within the EVAR 
group and one within the fEVAR group, who had a type 2 endoleak noted during follow up 
had aneurysm expansion of ≥5mm. The EVAR patient had a type 2 endoleak noted on the 
first post-operative surveillance scan but it was never identified again on routine 
surveillance. Seven years after initial repair the patient was noted to have an increase in 
their aneurysm size of 5mm (from 39mm to 45mm maximal aneurysm diameter), there was 
tenuous seal within the common iliac artery at that point and the patient underwent an 
internal iliac artery embolization and stent graft extension into the external iliac artery. This 
procedure was done 92 months after the original EVAR and went without complication. 
The patient died 18 months later from non-aneurysm related cause. The fEVAR patient with 
a type 2 endoleak and expanding aneurysm had uneventful primary 3 vessel fEVAR and 
follow up until at 86 months follow up a type 2 endoleak was noted on surveillance and an 
aneurysm growth from 47 – 53mm. No intervention was undertaken, and the patient 
remains alive on the surveillance programme with an aneurysm that is 59mm on the most 
recent surveillance scan with no endoleak identified more than 11 years after the original 
operation.  
9.4.8 Comparison of Observed versus Expected In-hospital Mortality 
The British Aneurysm Repair (BAR) Score is a published, validated model that provides an 
estimate of the risk of in-hospital mortality, expressed as a percentage, for patients 
undergoing elective aneurysm repair. The BAR score was used to compare the observed 
deaths with those that would be expected according to this model. 
In the cohort of 80 patients there was at least one data point missing relating to the BAR 
score in nine patients. Four patients were in the EVAR cohort and in all cases there was no 
record of a pre-operative ECG, therefore in-line with BAR methodology these patients had 
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a score of ‘0’ given for the ECG component of the BAR calculation. The other five patients 
were in the OR group. Data missing in these cases included lack of information pertaining 
to previous cardiac history, no pre-operative ECG available and ASA grade. For all patients 
undergoing OR the mode of ASA was 2 and this was therefore used to calculate the BAR 
score for the four patients in which this data was missing. 
The following table details the comparison of observed versus expected mortality for the 
patients using the BAR score calculated according to the type of repair they had. (See table 
9.26) 
Table 9.26 Comparison of Observed Versus Expected Mortality using the BAR Score 
Variable 
EVAR 
(n=28) 
fEVAR 
(n=15) 
Open Repair 
(n=37) 
Total 
(n=80) 
Mean BAR score (%) 
1.70 1.15 5.42 3.32 
Expected number of deaths 
0.48 0.17 2.00 2.66 
Observed number of deaths 
2 0 2 4 
p-value 0.03 0.68 1.00 0.41 
Table 9.26 - Comparison of categorical variables was performed using χ2 test. 
For patients undergoing fEVAR or OR there was no statistically significant difference 
between the number of observed deaths in each group compared with the expected 
number as predicted by their BAR score. However, for patients that underwent EVAR more 
patients died than would have been expected according to their BAR score, this result was 
statistically significant. This is interesting, and it could represent that compared with what 
was expected of these patients (if they had standard anatomy) but everything else was 
equal a validated risk prediction model predicted 0.5 deaths for the EVAR cohort, but 2 
people actually died. With the only change from the data points inputted to the model 
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being that it was a non-standard aneurysm it may suggest that the anatomy play a part in 
the ‘increased’ mortality rate. 
The following table details the comparison of observed versus expected mortality when the 
BAR score was calculated using the opposite type of repair (i.e. those who underwent EVAR 
or fEVAR; had their BAR score calculated as if they underwent OR) (See table 9.27) 
Table 9.27 Comparison of Observed Versus Expected Mortality for the Opposite 
Type of Repair using the BAR Score 
Variable 
EVAR 
(n=29) 
fEVAR 
(n=15) 
Open Repair 
(n=37) 
Total 
(n=81) 
Mean BAR score (%) 8.01 5.61 1.14 4.38 
Expected number of deaths 2.24 0.84 0.42 3.5 
Observed number of deaths 2 0 2 4 
p-value 0.87 0.32 0.01 0.79 
Table 9.27 - Comparison of categorical variables was performed using χ2 test. 
For patients undergoing fEVAR or EVAR there was no statistically significant difference 
between the number of observed deaths in each group compared with the expected 
number as predicted by their BAR score (calculated as if they had undergone OR). However, 
for patients that underwent OR, more patients died than would have been expected 
according to their BAR score (calculated as if they underwent EVAR) this result was 
statistically significant. 
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9.4.8. Risk Prediction Models 
To try to develop a risk prediction model from the data gathered univariate modelling for 
the whole cohort was undertaken first, then for each repair group separately.  
Cox proportional hazards model (all cohort)- Univariate 
The tables below detail the results from fitting univariate Cox proportional hazards models 
to assess the relationship of different variables to survival over the follow up period. The 
different variables assessed were; age at operation, neck length, and expected clamp site. 
Proportional hazards assumption was checked and not violated in any of the cases below. 
The following table reports the outcome from fitting the Cox model for age and neck length 
(See table 9.28) 
Table 9.28 Relationship of Age and Neck Length with Survival Time Using Cox 
Proportional Hazards Model 
Variable Hazard Ratio 95% Confidence Interval p-value 
Age 1.03 [0.99 – 1.06] 0.11 
Neck Length (>15mm vs <15mm) 1.17 [0.69 – 1.97] 0.56 
 
More specifically, For every one-year increase in a patient’s age at operation, the hazard of 
dying is increased by 3%, although with 95% assurance this estimate could be between a 
1% decrease to a 6% increase. The result failed to reach statistical significance. Regarding 
neck length patients were split into two groups (≥15mm or <15mm). Patients with ≥15mm 
neck length have almost a 17%  increase in dying when compared to patients with smaller 
neck length, although with 95% assurance this estimate could be between 31% decrease  to 
97% increase. The result was not statistically significant. 
The Cox model was also fitted for expected clamp site (Suprarenal vs Infrarenal and 
Supracoeliac vs Infrarenal separately) this again gave no statistically significant results with 
wide confidence intervals in each case (p-values of 0.68 and 0.75 respectively). The hazard 
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ratio comparing Suprarenal vs Infrarenal expected clamp was 0.82 with 95% confidence 
interval between 0.32 and 2.09. This suggests that patients with an expected suprarenal 
clamp may be expected to have between a 68% decrease in the event and 2.09 times 
higher chance of the event. This is statistically insignificant at the 0.05 level. Similarly, for 
the comparison between Supracoeliac and Infrarenal expected clamp the hazard ratio was 
1.12 with a 95% confidence interval between 0.56 and 2.26. This was again not significant. 
Cox proportional hazards model (for each type of repair separately) - Univariate 
Cox proportional hazards models were also generated for each type of repair separately. 
Regarding neck length, it was not possible to split patients into two groups (≥15mm or 
<15mm), due to the low number of deaths observed. (see table 9.29) 
Table 9.29 Relationship of Age and Neck Length with Survival Time Using Cox 
Proportional Hazards Model for Each Type of Repair Separately 
Variable Hazard Ratio 95% Confidence Interval p-value 
Age – EVAR 1.01 [0.96 – 1.07] 0.664 
Age – fEVAR 1.03 [0.96 – 1.12] 0.377 
Age – OR 1.02 [0.96 – 1.08] 0.470 
Neck Length - EVAR 1.03 [0.98 – 1.09] 0.297 
Neck Length - fEVAR 0.93 [0.80 – 1.08] 0.340 
Neck Length - OR 1.008 [0.95 – 1.07] 0.806 
 
As can be seen from the table there were no statistically significant results. The association 
of ASA grade (4 levels) and expected clamp site (3 levels) with survival was not possible to 
be investigated for those two groups separately, once more due to the low number of 
events observed. 
Secondary analyses were also undertaken to determine the association between the 
factors above (age, neck length, ASA grade and expected clamp site) and whether a patient 
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achieved primary technical success and/or clinical success. For age at operation an 
independent samples t-test was used to compare the means of the normally distributed 
dependent variable (age) between the two primary technical success groups and separately 
between the two clinical success groups. Neither analysis reached statistical significance 
(p=0.247 for technical success and 0.0687 for clinical success). This suggests no association 
between age and whether the patients’ operation was primarily technical successful or not 
and whether it was clinically successful over the course of the entire follow up or not.  
In order to investigate the association of neck length (≥15mm or <15mm), ASA grade and 
expected clamp site, Fisher’s exact tests were generated. The results suggested that there 
is no statistically significant relationship between neck length (p = 1.000), ASA grade (p = 
0.454), expected clamp site (p = 0.190) and primary technical success. The same being true 
for clinical success with no statistically significant relationship for neck length (p = 0.069), 
ASA grade (p = 0.066), or expected clamp site (p = 0.433). 
The plan was then to undertake multivariate modelling in order to develop a robust and 
valid risk prediction model that could be applied to patients with non-standard aneurysms. 
However, the “rule of thumb” for Cox modelling suggests that a minimum of 10 outcome 
events (deaths in this case) per predictor variable should be present, therefore due to the 
low number of deaths observed it was not possible to generate multivariate models that 
would be valid or accurate. 
Alpha and Beta Angulation 
In order to investigate the role of angulation further logistic regression modelling was 
undertaken to determine if alpha or beta angulation played any statistically significant role 
in various outcome measures. The influence of angulation was first assessed with regards 
to primary technical success, in hospital mortality and reintervention within 30 days for the 
whole cohort. (see table 9.30) 
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 Table 9.30 - Univariate logistic model - Perioperative 
Outcome Measure Characteristic Odd’s Ratio (95% confidence 
interval) 
P-value 
Primary Technical 
Success 
α angulation 0.990 (0.962,1.018) 0.466 
β angulation 0.992 (0.959,1.027) 0.653 
Reintervention (<30 
days) 
α angulation 0.980 (0.939,1.022) 0.340 
β angulation 1.007 (0.969,1.046) 0.736 
In hospital mortality α angulation 1.012 (0.973,1.052) 0.549 
β angulation 1.007 (0.958,1.057) 0.794 
 
For the outcomes; primary technical success, reintervention within 30 days and in hospital 
mortality  the variable α angulation and β angulation have no statistical significance at the 
2.5% level (the significance level has been adjusted by Bonferroni). Next the influence of 
angulation with regards to clinical failure, reintervention over the longer term and 
mortality through follow up was assessed (see table 8.29) 
Table 9.31 - Univariate logistic model – During Follow up 
Outcome Measure Characteristic Odd’s Ratio (95% confidence 
interval) 
P-value 
Clinical Failure α angulation 0.982 (0.956,1.010) 0.202 
β angulation 1.002 (0.975,1.029) 0.992 
Reintervention (>30 
days) 
α angulation 0.990 (0.960,1.021) 0.510 
β angulation 1.018 (0.987,1.050) 0.251 
Mortality during 
follow up 
α angulation 0.981 (0.960,1.003) 0.085 
β angulation 0.992 (0.967,1.018) 0.562 
 
For the outcomes; clinical failure, reintervention during follow up and mortality during 
follow up the variable α angulation and β angulation have no statistical significance at the 
2.5% level (the significance level has been adjusted by Bonferroni). 
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Five- Year Survival Univariate Cox Proportional Hazards Model 
In the 5-year analysis there has been 32 events (deaths) out of 79 patients. The censoring 
time is 5-years survival and the cut-off point is 1826 days. Therefore, patients were either 
alive or dead at this point and were identified as such for the modelling. The following table 
depicts the results when fitting univariate Cox proportional hazards models to assess the 
relationship of different variables to 5-year survival. (see table 9.32) 
Table 9.32 5-Year Cox Proportional Hazards Model - Univariate 
Characteristics Sub-group 5-Year Survival 
Estimate (SE) Hazard Ratio (95% 
confidence interval) 
P-Value 
Type of repair (Baseline=EVAR)    
fEVAR -0.198 (0.494) 0.820 (0.312,2.159) 0.688 
Open -0.260 (0.392) 0.771 (0.357,1.663) 0.507 
Max aneurysm diameter 0.007 (0.014) 1.007 (0.979,1.036) 0.619 
Neck length 0.015 (0.019) 1.015 (0.978,1.054) 0.419 
α angulation -0.007 (0.008) 0.993 (0.978,1.009) 0.404 
β angulation -0.004 (0.009) 0.996 (0.979,1.014) 0.691 
Max neck diameter -0.017 (0.022) 0.983 (0.941,1.026) 0.432 
% Oversizing 0.002 (0.033) 1.002 (0.939,1.070) 0.953 
Number of IFU violations (Baseline=1)    
2 -1.094 (0.508) 0.335 (0.124,0.907) 0.031 
3 -0.544 (0.450) 0.580 (0.240,1.402) 0.227 
4 -0.693 (0.584) 0.500 (0.159,1.573) 0.236 
5 0.017 (0.771) 1.017 (0.225,4.609) 0.982 
Gender (Baseline=Female)    
Male 0.470 (0.409) 1.604 (0.719,3.565) 0.250 
Age 0.034 (0.024) 1.034 (0.987,1.084) 0.156 
Table 9.32 – IFU – Instructions for use, SE – Standard Error. 
At the 0.5% level (adjusted for Bonferroni correction) none of the variables are statistically 
significant. 
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Five- Year Survival Multivariate Cox Proportional Hazards Model 
As there are only 32 events (deaths) and using the general rule of thumb for cox modelling 
stating that for each variable adding to a multivariate model 10 events are needed 3 
variables were added for this data set. As none of the variables in the univariate model are 
significant those variables with the lowest 3 p-values were included in the multivariate 
model (see table 9.33). 
Table 9.33 - 5-Year Cox Proportional Hazards Model - Multivariate 
Characteristics Sub-group 5-Year Survival 
Estimate (SE) Hazard Ratio (95% 
confidence interval) 
P-Value 
Number of IFU violations (Baseline=1)    
2 -1.106 (0.509) 0.331 (0.122,0.897) 0.030 
3 -0.513 (0.452) 0.598 (0.247,1.452) 0.256 
4 -0.574 (0.593) 0.564 (0.176,1.802) 0.334 
5 0.127 (0.776) 1.136 (0.248,5.194) 0.870 
Gender (Baseline=Female)    
Male 0.046  (0.026) 1.047 (0.995,1.100) 0.075 
Age  0.786 (0.428) 2.194 (0.948,5.076) 0.067 
Table 9.33 -  IFU – Instructions for use, SE – Standard Error. 
At the 1.67% level (adjusted for Bonferroni correction) none of the variables are statistically 
significant. 
These results suggest that of the variables identified in the cox proportional hazards model, 
none of them play a significant impact on whether the patient is alive at the 5-year time 
point for the studied population. Therefore, from this data set it is not possible to generate 
a risk prediction model for patients with non-standard aneurysms to determine the risk of 
death over follow up or at the 5-year time point.  
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9.4.9. Comparison of Outcomes for Patients with a Standard 
Aneurysm 
During the time period of the study (2006 – 2008) 232 patients were identified as having an 
aneurysm repair at the Royal Liverpool University Hospital. Of those patients 69 were non-
standard and are included in the study above. In 2 patients there was disagreement 
between reviewers as to whether they were non-standard or standard and were therefore 
excluded. 65 patients had no preoperative scan available and therefore it is impossible to 
state whether they were standard or not. 11 patients identified suffered a ruptured 
aneurysm and therefore were excluded in line with the study methodology. 8 patients 
were treated for an aneurysm less than 55mm in diameter and again were excluded. For 31 
other patients there were various reasons for exclusion – including previous aneurysm 
repair. This left 46 patients in whom there was an adequate preoperative CT scan that 
underwent repair of a standard aneurysm at the Royal Liverpool University Hospital. 39 
patients underwent standard EVAR and 7 underwent open repair. Of the 39 patients who 
underwent standard EVAR 34 did so with a Zenith stent graft and in line with the above 
study these patients were included for further analysis along with the 7 open repair 
patients. The rest were excluded. 
Demographics of Standard Aneurysm Patients 
The majority of patients were male (87.8%) compared with 67.5% male patients in the non-
standard group. The median age of the cohort was 73 (67 – 78), similar to the median age 
of 75 in the non-standard cohort. The following table details the demographics for all the 
patients grouped according to the type of operation performed and as a total for the whole 
group. (See table 9.34) 
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Table 9.34 Patient Demographics for Standard Aneurysm 
Variable 
EVAR  
(n=34) 
Open Repair 
(n=7) 
Total  
(n=41) 
p-value 
Age at operation (years), 
median (IQR) 
75 (70,79) 65(62.5,68.5) 73(67,78) 0.005 
Sex, n (%)    1.000 
Male 30 (88.2) 6 (85.7) 36 (87.8)  
Female 4 (11.8) 1 (14.3) 5 (12.2)  
Previous Abdominal 
Surgery, n (%) 
   
0.309 
Yes 8 (23.5) 0 8 (19.5)  
No 25 (73.5) 7  (100) 31 (75.6)  
Unknown 1 (2.9) 0 1 (2.4)  
IHD, n (%)    0.031 
No 7 (20.6) 4 (57.1) 11 (26.8)   
Yes 24 (70.6) 3 (42.9) 27 (65.9)  
COPD, n (%)    0.584 
No 28 (82.4) 5 (71.4) 33 (80.5)  
Yes 5 (14.7) 2 (28.6) 7 (17.1)  
Unknown 1 (2.9) 0 1 (2.4)  
CVA, n (%)    0.552 
No 30 (88.2) 6 (85.7) 36 (87.8)  
Yes 3 (8.8) 1 (14.3) 4 (9.8)  
Unknown 1 (2.9) 0 1 (2.4)  
DM, n (%)    0.656 
No 24 (70.6) 6 (85.7) 30 (73.2)  
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Yes 9 (26.5) 1 (14.3) 10 (24.4)  
Unknown 1 (2.9) 0 1 (2.4)  
PVD, n (%)    1.000 
No 31 (91.2) 7 (100) 38 (92.7)  
Yes 2 (5.9) 0 2 (4.9)  
Unknown 1 (2.9) 0 1 (2.4)  
Hypertension, n (%)    
1.000 
No 8 (23.5) 1 (14.3) 9 (22)  
Yes 25 (73.5) 6 (85.7) 31 (75.6)  
Unknown 1 (2.9) 0 1 (2.4)  
ASA Grade, n (%)    1.000 
1 0 0 0  
2 4 (11.8) 1 (14.3) 5 (12.2)  
3 29 (85.3) 6 (85.7) 35 (85.4)  
4 0 0 0  
Unknown 1 (2.9) 0 1 (2.4)  
Table 9.34 - Comparison of continuous variables was carried out through a Kruskall-Wallis test (*). Categorical 
variables were compared using Fisher’s exact test or χ2 test, depending on the amount of data present in 
each entry. IHD = Ischaemic Heart Disease. COPD = Chronic Obstructive Pulmonary Disease. CVA = 
Cerebrovascular Accident. DM = Diabetes Mellitus. PVD = Peripheral Vascular Disease. ASA= American 
Society of Anesthesiologists Grade.  
The majority of patients were ASA grade 3 (85.4%). It is striking that there was a 10-year 
difference in the median ages between EVAR patients (75 years) and OR patients (65 years) 
with a statistically significant difference in this regard. Also 86% of standard patients were 
male compared to 67% of non-standard patients. Furthermore, significantly more patients 
who underwent EVAR had a history of ischaemic heart disease when compared with open 
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repair patients in the standard anatomy group. When comparing the difference between 
NSA and SA groups there was a statistically significant difference for the presence of IHD; 
65.9% in SA patients, 45% in NSA patients (p= 0.0019). 
Pre-operative investigations 
Parameters derived from pre-operative investigations were also collected for each patient. 
No patient was noted to be on renal dialysis pre-operatively and chronic kidney disease, as 
defined as having an eGFR <60ml/min/1.73m2, was present in 44% of all patients. (See 
table 9.35). 
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Table 9.35 Pre-operative Investigations 
Variable 
EVAR 
(n=34) 
Open Repair 
(n=7) 
Total 
(n=41) 
p-value 
Best FEV1, 
median (IQR) 
2.4(1.9,2.8) 2.5 (2.4,3.8) 2.5 (2.1,2.8) 0.257 
Creatinine 
(µmol/L), Median 
(IQR) 
101 
(85.3,112.3)  
86 (70,108) 101 
(82.5,111.5) 
0.182 
eGFR 
(ml/min/1.73m2), 
median (IQR) 
62 (51.8-
72.8) 
82 (59,97) 62 (54,80) 0.127 
Chronic Kidney 
disease, eGFR 
<60  
   
 
None, eGFR ≥60 
(%) 
18 (52.9) 5 (71.4) 23 (56.1) 
 
Category 3a, 
eGFR  45 – 59 (%) 
10 (29.4) 1 (14.3) 11 (26.8)  
Category 3b, 
eGFR  30 – 45 (%) 
6 (25) 1 (14.3) 7 (17.1)  
Category 4, eGFR  
15 – 29 (%) 
0 0  0  
Table 9.35 - Comparison of continuous variables was carried out through a Kruskall-Wallis test (*). Categorical 
variables were compared using Fisher’s exact test or χ2 test, depending on the amount of data present in 
each entry. FEV1 = Forced expiratory volume in one second. FVC = Forced Vital Capacity. eGFR = Estimated 
Glomerular Filtration Rate. 
When comparing the above values with those from the preoperative variables of non-
standard patients – preoperative creatinine and eGFR levels were not statistically 
significantly different between the two anatomical groups. The mean best fEV1 measured 
preoperatively was however significantly worse in NSA patients compared with SA patients 
(2.06 vs 2.43, p = 0.0156). Pre-operative CT scans were reviewed for all patients and various 
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anatomical data were collected for each patient. The following table summarises these 
data. (See table 9.36) 
Table 9.36 Aneurysm Morphology for Standard Patients 
Variable 
EVAR 
(n=34) 
Open Repair 
(n=7) 
Total 
(n=41) 
P – value 
Max Aneurysm 
Diameter (mm), 
Median (IQR) 
62.5 
(59.3,70) 
57 (56,81) 62 (57,72) 0.768 
Neck Length 
(mm), Median 
(IQR) 
29 
(23,38.5) 
25 (15,30) 28 
(22.5,37.5) 
0.152 
Neck Diameter 
(mm), Median 
(IQR) 
23 (21,27) 26 (24,27) 24(21.3,27) 0.199 
α angle (⁰), 
Median (IQR) 
17 
(10.3,23.8) 
16 (5,29) 17 (10,25) 0.831 
β angle (⁰), 
Median (IQR) 
32 
(17,47.5) 
32 (20,40) 32 (17,46) 0.813 
Expected clamp 
site, n (%) 
   
NA 
Infrarenal 34 (100) 7 (100) 41 (100)  
Suprarenal 0 0 0  
Supracoeliac 0 0 0  
Table 9.36 - Comparison of continuous variables was carried out through a Kruskall-Wallis test (*). Categorical 
variables were compared using Fisher’s exact test or χ2 test, depending on the amount of data present in 
each entry. 
The smallest aneurysm in the series was 55mm in maximal diameter and the largest was 
96mm. The median aneurysm diameter was 62mm, similar to that for the non-standard 
aneurysm cohort of 64mm. As would be expected the mean neck length, neck diameter , 
alpha angle and beta angle was different between the NSA and SA cohorts: 
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 Neck length – NSA 11.9 vs 29.2 SA (p = <0.001) 
 Neck diameter – NSA 33 vs 23.4 SA (p = <0.001) 
 Alpha angle – NSA 31.5 vs 18.3 SA (p = 0.005) 
 Beta angle – NSA 43.1 vs 32.6 SA (p = 0.0104) 
Maximum AAA diameter however was similar between the two anatomical cohorts with no 
statistically significant difference. Expected clamp site, as judged from the pre-operative CT 
scan, was infrarenal for all patients. Indeed all 7 open repair patients only had an infrarenal 
clamp placed as predicted. 
All patients underwent their procedure in the operating theatre under general anaesthetic. 
No patient died intraoperative and there were no immediate conversions to open repair in 
the endovascular group. For those that received endovascular repair the device was placed 
under fluoroscopic guidance using a mobile C-arm in theatre. These variables were the 
same for non-standard and standard patients with the same equipment used. 
Comparison of Standard with Non-Standard Aneurysms 
For the principal outcome measures In hospital mortality, mid-term survival, aneurysm 
related mortality, technical success and clinical success statistical advice was sought to 
compare patients between types of repair (EVAR, Open repair) and type of aneurysm (non-
standard and standard) to ascertain if there were any differences in these primary 
outcomes measures that could be attributed to either the intervention alone or the type of 
repair alone. 
To do this the patients who had fEVAR from the non-standard aneurysm were removed 
from the dataset, so that this dataset can be compared with the standard dataset. The 
analysis therefore included 65 patients who had non-standard aneurysms (Open=37 and 
EVAR=28) and 41 patients who had standard aneurysms (Open=7 and EVAR=34). The two 
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datasets were merged into one. The outcomes of overall survival and clinical success 
cannot be calculated using a linear model as the outcome is not binary. The following table 
details the comparison for in hospital mortality (See table 9.37)  
Table 9.37 – Comparison of In hospital Morality 
Characteristic Subgroup In-hospital mortality 
Alive at discharge 
(N=102) 
Died in hospital 
(N=4) 
Type of aneurysm, n 
(%) 
Non-standard 61 (59.8%) 4 (100.0%) 
Standard 41 (40.2%) 0 (0.0%) 
Type of repair, n (%) Open 42 (41.2%) 2 (50.0%) 
EVAR 60 (58.8%) 2 (50.0%) 
 
A generalised linear model was then fitted to the data, using the outcome of in-hospital 
mortality. Due to the number of events (deaths in hospital) being less than 10, the outcome 
is not robust, and a multivariate model is not appropriate. The type of aneurysm is used in 
the model, to see if there is a difference in in-hospital mortality over the 2 types. 
Table 9.38. - Univariate logistic regression model for the outcome in-hospital 
mortality 
Characteristic Subgroup Odd’s Ratio 
(95% confidence interval) 
P-value 
Type of aneurysm (Baseline=Non-
Standard) 
  
Standard 0.00 (0.00, ∞) 0.995 
 
As can be seen from Table 9.38, the results are non-informative because there are no 
patients who died in hospital with standard aneurysms and overall there was less than 10 
events. When comparing in hospital mortality the type of aneurysm does not play a 
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statistically significant role in whether a patient had a perioperative death or not within this 
cohort. 
Mid-term mortality outcome 
Mid-term mortality was calculated for patients who die between 5 and 10 years post-
operatively. These patients who die are given the indicator = 1 and all other patients are 
given the indicator = 0. If patients are given indicator = 0, this does not mean they are alive, 
it just means they did not die in the timeframe stated. (See table 9.39) 
Table 9.39. – Comparison of Mid Term Mortality 
Characteristics Subgroup Mid-term mortality 
Didn’t die between 
5-10 years post-op 
(N=67) 
Died between 5-10 
years post-op 
 (N=39) 
Type of aneurysm, n (%) Non-standard 45 (67.2%) 20 (51.3%) 
Standard 22 (32.8%) 19 (48.7%) 
Type of repair, n (%) Open 31 (46.3%) 13 (33.3%) 
EVAR 36 (53.7%) 26 (66.7%) 
 
A generalised linear model was then fitted to the data, using the outcome of mid-term 
morality. The type of aneurysm is used in the model, to see if there is a difference in mid-
term mortality over the 2 types. (See table9.40) 
Table 9.40 - Univariate logistic regression model for the outcome mid-term 
mortality 
Characteristic Subgroup Odd’s Ratio 
(95% confidence interval) 
P-value 
Type of aneurysm (Baseline=Non-
Standard) 
  
Standard 1.94 (0.87,4.36) 0.107 
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This analysis therefore reveals that the type of aneurysm is not statistically significant in 
predicting whether a patient died between 5 and 10 years. A multivariate model was 
produced to see the effects of type of repair. This included an interaction term. (See table 
9.41) 
Table 9.41 - Multivariate logistic regression model for the outcome mid-term 
mortality 
Characteristic Subgroup Odd’s Ratio 
(95% confidence 
interval) 
P-value 
Type of aneurysm (Baseline=Non-
Standard) 
  
Standard 1.22 (0.44,3.37) 0.701 
Type of repair (Baseline=EVAR)   
Open 0.50 (0.17,1.44) 0.199 
Type of aneurysm *Type of repair  3.40 (0.48,24.12) 0.221 
 
From Table 9.41, none of the variables are statistically significant to the outcome mid-term 
mortality, at the 5% level.  
Primary technical success outcome 
The following table investigates whether the type of repair or the type of aneurysm plays a 
significant role in technical success (See table 9.42) 
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Table 9.42 – Comparison of Primary Technical Success 
Characteristics Subgroup Primary technical success 
No 
(N=13) 
Yes 
(N=93) 
Type of aneurysm, n (%) Non-standard 8 (61.5%) 57 (61.3%) 
Standard 5 (38.5%) 36 (38.7%) 
Type of repair, n (%) Open 2 (15.4%) 42 (45.2%) 
EVAR 11 (84.6%) 51 (54.8%) 
 
Again, a generalised linear model (logistic) was fitted to the data, using the outcome of 
Primary technical success. Type of aneurysm is used in the model, to see if there is a 
difference in primary technical success over the 2 types. (See table 9.43) 
Table 9.43 - Univariate logistic regression model for the outcome primary 
technical success 
Characteristic Subgroup Odd’s Ratio 
(95% confidence interval) 
P-value 
Type of aneurysm (Baseline=Non-
Standard) 
  
 Standard 1.01 (0.31,3.33) 0.986 
 
The above table reveals that the type of aneurysm is not statistically significant at the 5% 
level for technical success. A multivariate model was produced to see the effects of type of 
repair. This included an interaction term. (See table 9.44) 
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Table 9.44. - Multivariate logistic regression model for the outcome primary 
technical success  
Characteristic Subgroup Odd’s Ratio 
(95% confidence interval) 
P-value 
Type of aneurysm (Baseline=Non-Standard)   
Standard 2.50 (0.65,9.64) 0.183 
Type of repair (Baseline=EVAR)   
Open 12.00 (1.38,104.40) 0.024 
Type of aneurysm 
*Type of repair 
 0.07 (0.00,1.64) 0.097 
 
The above table reveals that the type of repair is statistically significant for the outcome 
primary technical success, at the 5% level. This means from the odds ratio, patients who 
have an open repair are 12 times more likely to experience primary technical success. This 
is not dependent on what type of aneurysm they have, as can be seen from the interaction 
term being not statistically significant. 
Comparison of Renal Function 
Renal function changes over the longer term was also compared between standard and 
non-standard aneurysms to investigate this important secondary outcome measure in 
more detail. For standard aneurysm patients; the median eGFR change comparing 
preoperative eGFR with the last recorded eGFR was -18 (-24, -6) for open repair patients 
and was -13 (-21,3) for EVAR patients. This was not statistically significant with a p-value of 
0.300. The following table documents the comparison of median change in eGFR between 
standard and non-standard aneurysms (See table 9.45) 
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Table 9.45 - Comparison between the median change in eGFR (Last eGFR-Pre-op 
eGFR) for non-standard and standard aneurysms 
 
The table shows that although the median eGFR reduction is greater for standard aneurysm 
patients this difference is not statistically significant 
Change in eGFR was compared for EVAR and open repair patients separately for non-
standard patients and standard patients. (See table 9.46) 
Table 9.46 - Comparison between the median change in eGFR (Last eGFR-Pre-op 
eGFR) for non-standard and standard aneurysms 
 Non-standard Standard P-value 
Open Repair 
Change from baseline in eGFR, median 
(IQR) 
-3 (-17,2) -18 (-24,-6) 0.091 
EVAR 
Change from baseline in eGFR, median 
(IQR) 
-10 (-22,-2) -13 (-21,3) 0.810 
 
As can be seen from the above table there is no statistically significant difference between 
either open repair or EVAR when comparing standard with non-standard aneurysms.  
  
 Non-standard aneurysm Standard aneurysm P-Value 
Change from baseline in 
eGFR, median (IQR) 
-6 (-18,1) -13 (-22,-1) 0.222 
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9.5. Summary of Results 
The following tables summarise the principal outcomes for non-standard and standard 
patients from the above study and from the literature reported earlier. (See tables 9.34 and 
9.47) 
Table 9.47 – Reported Outcomes for NSA AAA from multicentre retrospective cohort 
study and Literature 
Treatment Primary 
Technical 
Success (n) 
Perioperative 
mortality (n) 
5-year 
survival 
(n) 
Aneurysm 
Related 
Mortality (n) 
Renal 
Dysfunction (n) 
Multicentre Retrospective Cohort Study 
fEVAR 100%* (15) 0% 57% (8) 0% 13.3% (2) 
EVAR 
82%* (23) 
7.1% (2) 54% 
(15) 
10.7% (3) 50% (14) 
Open Repair 97.3% (36) 5.4% (2) 68% 
(25) 
8.1% (3) 24.3% (9) 
Total 92.5% (74) 5% (4) 61% 
(48) 
7.5% (6) 31.3% (25) 
Literature 
fEVARa 95.6%* 2.7% 59.4 – 
92% 
0.8% 21 – 27% 
EVAR 90.7% 3.1% 70 – 
85.4% 
0 – 6.8% - 
Open Repair NR 3.2% 64 – 
88.6% 
1.3% 11.3% 
Table 9.47 – fEVAR – fenestrated endovascular aneurysm repair EVAR – Endovascular Aneurysm Repair. Renal 
dysfunction is the rate reported over long term follow up. A – The results for fEVAR are collated from the 
systematic review of 8 studies published since 2015. * - Adjusted Primary Technical success as reported by Roy 
et.al. 
The table collates principle outcome measures for the three treatment options from the 
study and the literature. The adjusted primary technical success rate as described by Roy 
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et.al. accounting for those patients with a graft related endoleak on completion angiogram 
that spontaneously seals without clinical sequelae is reported in the above table. In all 
cases a value is given for aneurysm related mortality but, as stated above, there were a 
number of patients in the retrospective study in which limited information meant that the 
true value of aneurysm related mortality was not known. However, the above reported 
values are the minimum possible true value for aneurysm related mortality (i.e. the 6 
deaths for the cohort are definitely aneurysm related). The results for aneurysm related 
mortality from the literature were inconsistently reported and similarly a limited conclusion 
can be drawn from these numbers. The definition of renal dysfunction varied between 
studies and the primary definition of a drop in CKD grade as described above was used to 
calculate the values in the above table. With all that being said the results for fEVAR 
between this study and the literature are fairly similar on all counts. For EVAR the values 
reported within the study appear to be worse on all counts compared with the literature, 
suggesting significant heterogeneity between the population being studied and the wider 
literature. IT is not clear exactly where this may be from. With regards to open repair the 
results appear worse for aneurysm related mortality and renal dysfunction in the study 
compared with the literature but similar in terms of perioperative and long-term mortality. 
The following table documents similar findings for standard aneurysms from both the study 
and the literature (See table 9.48) 
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Table 9.48 -  Reported Outcomes for SA AAA from multicentre retrospective cohort 
study and Literature 
Treatment Primary 
Technical 
Success (n) 
Perioperative 
mortality (n) 
4-year 
survival 
(n) 
Aneurysm 
Related 
Mortality (n) 
Renal 
Dysfunction (n) 
Single Centre Retrospective Cohort Study 
EVAR 88% (30) 0% 71% (24) 0% 53% (18) 
Open 
Repair 
86% (6) 0% 100% (7) 0% 43% (3) 
Total 88% (36) 0% 76% (31) 0% 51% (21) 
Literature 
EVAR NR 1.4% 84.2% 2.9% - 
Open 
Repair 
NR 4.2% 83% 4.3% - 
Table 9.48. EVAR – Endovascular Aneurysm Repair 
Little can be said about the comparisons between open repair and EVAR for the single 
centre retrospective study and in comparison, to the literature, primarily because the 
numbers of patients undergoing open repair especially were so small. However, of note the 
4-year survival (4 year chosen because this is what was represented in the literature) for 
EVAR for standard aneurysm patients was lower than that reported in the literature and 
was actually in line with the 5-year survival for NSA patients undergoing EVAR. The small 
sample size may play a role in this finding but 88% of the population of EVAR patients with 
SA were ASA grade 3. For all studies in the systematic review investigating outcomes after 
standard EVAR the proportion of patients with ASA grade 3 or 4 ranged between 50 – 100% 
with their SA counterparts at least the same if not “fitter” than this. Therefore, the increase 
in long term mortality may be related to this cohort of patients with a seemingly higher 
ASA grade at the outset. 
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10. CHAPTER 10 – Discussion of Retrospective Multicentre and 
Single Centre Cohort Studies 
The aim of this study was to compare outcomes of conventional surgery, EVAR outside IFU 
and fEVAR for non-standard aneurysms within a defined geographical region, in terms of 
risk-adjusted perioperative mortality, major perioperative complications, clinical success 
and mid-term survival. This was to test the hypothesis, which was: Fenestrated 
Endovascular Aneurysm Repair (fEVAR) has the best clinical outcome as a treatment 
strategy for non-standard AAAs that are unruptured in whom aneurysm repair is deemed 
to be more beneficial than conservative management. 
10.1. Primary and Secondary Outcome Measures 
The primary outcome measures were: in-hospital mortality, longer term overall survival, 
longer term aneurysm related mortality, technical success and clinical success. The 
secondary outcome measures were: Visceral vessel patency, renal insufficiency and need 
for dialysis, re-intervention rates (including conversion to open repair) and major 
complications. The following table demonstrates the results for these outcome measures 
alone comparing the three treatment options: (See Table 10.1) 
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Table 10.1 Primary and Secondary Outcome Measures 
Outcome measure EVAR 
(n=28) 
fEVAR 
(n=15) 
Open Repair 
(n=37) 
Statistically 
significant 
difference 
In hospital mortality 7.1% 0% 5.4%  
Overall Survival (at 5 
years) 
54% 57% 68%  
Aneurysm Related 
mortality 
10% + 0% 8% +  
Technical success 75% 87% 97% P <0.001 
Clinical Failure 46% 7% 8% P <0.001 
Visceral vessel occlusion 4% 0% 0%  
Renal insufficiency, AKI 
In-Hospital 
25% 20% 43%  
Renal Insufficiency, 
Change of CKD grade 
50% 13.3% 24.3%  
Dialysis 0% 0% 0%  
Reintervention rates 
(in-hospital) 
14% 0% 8%  
Reintervention rates 
(long term) 
25% 13.3% 8%  
Conversion to open 
repair 
11% 0%   
Major complications 
(in hospital) 
14% 7% 54%  
 
As can be seen from the table patients who underwent fEVAR, within this cohort, had the 
best clinical outcomes, as defined by the primary and secondary outcome measures, when 
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compared with the other two treatment methods. However, it must be noted that this 
apparent ‘advantage’ of fEVAR did not reach statistical significance when comparing it 
against the other two treatment methods in any outcome measure. The apparent 
‘disadvantage’ of the other treatment methods was only recorded as statistically significant 
for two outcomes: technical success and clinical failure – with EVAR performing the worst 
of the three, especially in clinical failure 
Despite the limited numbers in this study, especially of fEVAR patients, it is still the method 
of repair with the most favourable clinical outcomes in this cohort. Also, the lack of 
numbers acts to minimise potential statistically significant differences between the groups: 
in hospital mortality, aneurysm related mortality, reintervention rates and conversion to 
open repair. It seems plausible if a larger cohort of fEVAR patients were to exhibit similar 
outcomes then statistical significance would be reached. Chapter 8 detailed the clinical 
outcomes for patients who underwent fEVAR at the Royal Liverpool University Hospital 
over a longer period than the current study. The following table compares the primary and 
secondary outcome measures between the larger cohort detailed in chapter 8 with the 
patients that underwent fEVAR in the current study. It should be noted that all 15 patients 
in the current study were also included in the larger study also. (See table 10.2)  
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Table 10.2 Primary and Secondary Outcome Measures for fEVAR patients from the 
Current Study and Larger fEVAR study at the Same Institution 
Outcome measure 
fEVAR  
(current study, n = 15) 
fEVAR  
(larger study, n = 
107) 
In hospital mortality 0% 3.7% 
Overall Survival (at 5 years) 57% 53% 
Aneurysm Related mortality 0% 0% 
Technical success 87% 86% 
Clinical Failure 7% - 
Visceral vessel occlusion 0% 6% 
Renal insufficiency, Change of CKD 
grade over FU 
13% - 
Dialysis 0% 0% 
Reintervention rates (in-hospital) 0% 7% 
Reintervention rates (long term) 7% 24% 
Conversion to open repair 0% 0% 
Major complications (in hospital) 7% - 
Major complications (Long term) 0% - 
 
 The results, as detailed in chapter 8, show that: in-hospital mortality after fEVAR was 3.7%, 
still less than both standard EVAR and OR in the current study. Aneurysm related mortality 
was still 0% with a median follow up of 51 months (Range: 1 - 124). Conversion to open 
repair amongst 107 fEVAR patients was 0% and 7% of patients underwent in-hospital 
reintervention, in line with the results from the current study. This therefore suggests that 
the difference seen in absolute values would be unlikely to differ much for these 
parameters if more fEVAR patients were included in the current study. 
Regarding the hypothesis of this study - there are many facets of what would constitute the 
‘best clinical outcome’ and therefore it is important to interrogate these areas in more 
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detail individually to build up a picture of and be able to synthesise an answer to the 
question posed. 
10.1.1. In Hospital Mortality 
Patients who underwent fEVAR had a 0% in hospital mortality rate within this study. 
Although this apparent advantage of fEVAR compared with OR and EVAR did not reach 
statistical significance this is still a striking result. There are limited numbers within this 
study, especially of fEVAR patients, so this finding may be due to chance. The reduction in 
perioperative mortality is one of the central advantages of endovascular repair compared 
with OR. This has been shown in numerous randomised controlled trials and studies 
comparing standard EVAR (within IFU) with OR [71, 72, 77, 183-185] and one study that 
compares fEVAR with OR [170]. Another study by Chisci et. al. showed no significant 
difference in perioperative mortality in patients undergoing fEVAR compared with OR.[121] 
There is therefore a paucity of data comparing EVAR, fEVAR and OR for non-standard 
aneurysms, and in the one study in the literature (above) and the current study, no 
significant differences in perioperative mortality have been found and the results for those 
two cohorts of patients were at odds with each other, suggesting that neither study has 
adequately determined the true risk of perioperative mortality in these patient groups. 
The systematic review of the recent literature detailing outcomes from fEVAR reported 
above in Chapter 7 reported perioperative mortality ranges from 0.7 – 5.2% in the included 
studies. The pooled mortality rate for all the included studies was: 2.7%. One study by 
Verhoeven et.al. [157] included fEVAR as a “first-line” treatment and admits to treating a 
large number of “low risk” patients with fEVAR. The perioperative mortality rate in that 
study is 0.7%. The authors comment that fEVAR is used as a first line treatment options 
rather than specifically being selective of low risk patients, though this is essentially what it 
amounts to in the final analysis. That study shows that, albeit in expert hands, fEVAR can be 
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performed with an exceedingly low risk of perioperative mortality. AN important finding 
when comparing patients with those undergoing open repair which, when outcomes are 
reported for all patients from any given centre, tend to be those patients who are deemed 
to be “fitter” preoperatively.  
Although the results presented show open repair had a higher perioperative mortality rate 
compared with fEVAR the published literature does detail that OR can be performed safely 
with a lower rate of perioperative death than seen in the current study. The perioperative 
mortality rate reported in the systematic review above (Chapter 6) investigating the 
outcomes of NSA patients undergoing open repair details rates between 0.8 and 6%. The 
total combined perioperative mortality for all studies was 37 patients out of 1150 (3.2%). 
The results also showed a higher perioperative mortality rate for patients undergoing EVAR 
however the literature shows that patients who undergo standard EVAR in compromised 
anatomy perioperative mortality does not tend to be sacrificed but other clinical outcomes 
are. The literature documents the danger of placing standard EVAR within a less than ideal 
infrarenal neck; increased angulation and decreased neck length being associated with 
increased incidence of proximal type 1 endoleaks, increased need for intraoperative 
adjunctive manoeuvres, and a reduction in initial technical and midterm clinical success 
[67, 68, 122, 186], one of these studies by Leurs et.al. [68] does show a significantly 
increased perioperative mortality rate in those with a neck length <15mm compared with 
those >15mm, however there are limitations to this study in determining the outcome of 
those patients who are outside of IFU as neck length was the only determinant of selection 
for one group or another patients may have other factors that place them outside IFU in 
the >15mm neck length group, thereby limiting the conclusions that can be drawn from the 
analysis. However, it would be reasonable to suggest that if all patients who were out of 
IFU were excluded from the >15mm neck length group then the mortality of that group 
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would, at least, be no worse. This remains the stand-alone study that shows a difference in 
perioperative mortality however. 
The literature and the current study therefore fail to show convincing evidence to suggest 
the improvement in perioperative mortality associated with endovascular repair seen with 
standard aneurysms is applicable for non-standard aneurysms. There is also little evidence 
to suggest that perioperative mortality is significantly higher in those undergoing OR for 
these complex non-standard aneurysms. However, as stated, there is a lack of direct 
comparative studies of sufficient calibre and with sufficient numbers of patients to 
conclude that there is no benefit whatsoever. 
What was not clear during this retrospective study were the reasons why the physicians 
elected to place a standard EVAR device as opposed to fEVAR as each patient, by definition, 
was a less than ideal candidate for standard EVAR. One reason may be that these were 
grossly enlarged or symptomatic aneurysms that would be better served by a timely repair 
rather than incurring a delay of up to three months to wait for manufacture and delivery of 
the bespoke fenestrated device. However, all aneurysms in this study were asymptomatic 
and any patients in whom there was a suggestion from the clinical case notes that 
aneurysm related symptoms were present were excluded from the study, so this seems 
unlikely. Furthermore, although it was true that aneurysms within the EVAR cohort were 
larger overall compared with fEVAR patients, the difference was not so great to account for 
the preference of EVAR in most cases; the median aneurysm diameters were 66mm for 
EVAR and 60mm and fEVAR patients. There were only seven patients (24%) in the EVAR 
group who had an aneurysm diameter of >70mm and only two >80mm. What is apparent 
from the results is that the aneurysms within the EVAR group had simpler anatomy than 
that of the fEVAR group (Longer, narrower necks, less number of IFU violations for each 
case) and it is likely that the physicians assessing these cases simply did not ascribe these 
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characteristics that are outside of IFU but ‘not too bad’ a significant level of importance to 
warrant placing a more complex fenestrated device, especially with the additional costs 
and constraints placing such a device has. To clarify, during the time period studied these 
devices were funded only on an individual case by case basis and as such more delays and 
difficulties were present from an organisational level in using them. Therefore, it is not 
obvious that the increased mortality rate with EVAR seen in this study compared with 
fEVAR was simply due to more ‘acute’ aneurysms being treated quickly to prevent rupture. 
It is also unknown whether there were any patients that died as a result of the inherent 
delay incurred in the decision to treat with fEVAR secondary to rupture of their aneurysm. 
Although this effect is likely to be small if present at all it would be important to quantify 
and analyse this in any future research. The aim of this study is based on trying to answer 
the question of which type of repair should be offered to a patient who presents with an 
unruptured aneurysm. There would be no point in recommending fEVAR over everything 
else if once the decision is made in the outpatient department to treat by fEVAR a 
significant proportion of patients die while waiting 3 months for their repair. Future 
research would ideally be a prospective study following up all patients who present with 
such aneurysms from the pre-operative time-point. This would therefore help clarify 
whether rupture in the intervening period between initial assessment and operation is a 
disadvantage with selecting this method of repair. 
In terms of perioperative mortality there was no advantage in performing fEVAR over 
either other method of repair. This also seems confirmed by the published literature failing 
to consistently show a significant advantage in performing fEVAR or disadvantage in 
performing EVAR or OR for non-standard aneurysms, with regards to perioperative 
mortality. There remains a lack of direct comparative evidence however to state this 
definitively. 
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10.1.2. Overall Survival 
Of 80 patients, there was only one in whom it was not possible to identify if they were still 
alive or not. That patient underwent a successful fEVAR operation with no significant 
complications during their inpatient stay or up to one-year post operatively. The patient 
attended for their one-year post-operative surveillance which did not identify any problems 
but subsequently emigrated after that. It was not possible to contact the patient as no 
forward address or telephone number was available. That patient was considered alive at 
their last follow up time point and censored after that. In every other case it was possible 
to identify from a variety of sources whether the patient was still alive and if not the date 
of death was obtained. There were a handful of cases that were not local to the region in 
which they were treated, and, in each case, their general practitioner was contacted to 
confirm if they were still alive or not. With a median follow up of 10 years there was no 
statistically significant difference in the survival experience of the patients over the follow 
up period. The overall survival at 5 years was between 54 and 68% depending on the type 
of repair received. Although this value seems low it is in line with other published results of 
aneurysm repair patients with a similarly long follow up time. [77, 84, 175, 187] The fact is 
that patients with advanced aneurysmal disease represent a patient cohort at the severe 
end of the spectrum of cardiovascular disease. These patients often have coexisting 
medical conditions, such as ischaemic heart disease, chronic obstructive pulmonary 
disease, cerebrovascular disease, hypertension, and exhibit advanced age at presentation. 
According to the office for national statistics the current life expectancy in the UK for males 
aged 65 years is 18.3 years and for females aged 65 it is 20.8 years. [188] Considering that 
these statistics from the ONS include all people within the population at 65 years and the 
cohort of patients within this study are 75 years old on average and represent a specific 
cohort of unhealthy individuals it should be unsurprising that after 5 years roughly half of 
these patients are dead. 
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Although a significant difference was not seen in this study there was a trend towards 
worse overall survival in the EVAR cohort of patients. The patients undergoing 
endovascular repair in this study were less fit than their counterparts undergoing OR, with 
a higher ASA grade and this may in part explain the trend to worse overall survival in these 
patients. Interestingly however fEVAR patients had a significantly greater incidence of 
ischaemic heart disease but despite this they did not show a significantly increased chance 
of suffering post-operative complications of any type and specifically of a cardiac nature as 
one may have expected, especially when compared with their endovascular counterparts 
undergoing standard EVAR. Although no firm conclusions can be drawn from this data due 
to the limitations of this study these results do suggest that with reference to long term 
survival there does not appear to be an advantage of any one type of repair over another. 
Therefore, the traditional viewpoint that younger, fitter patients should undergo open 
repair as the upfront risk of increased perioperative mortality is offset by the longevity of 
the repair is not borne out by this data.  
The survival experiences of patients did not significantly differ within this study and 
therefore the decision of which type of operation a patient with a non-standard aneurysm 
should have should not be based upon an expectation of advantage in long term survival 
with one method of repair compared with another.  
10.1.3. Aneurysm Related Mortality 
Unfortunately, it was not possible to garner the cause of death for every patient within this 
cohort. There were 57 deaths during the study period, four were in hospital mortalities and 
a further two were aneurysm related deaths as detailed in the results section. Where a 
death certificate had been issued and was available the cause of death cited on the 
certificate was taken as the patient’s cause of death (19 patients). If there was evidence 
that a post mortem examination was carried out then the results of this, where available, 
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were taken into consideration when deciding the cause of death (2 patient). If either of 
these sources were not available, the clinical case notes were scrutinised and if the 
patient’s death was within hospital then an assumption of whether the cause of death was 
aneurysm related or not was made based upon the clinical details for that period of care 
leading up to the patient’s death (12 patients). If the death was not in hospital and the 
clinical case notes did not reveal the cause of death the GP was contacted to try and 
ascertain the cause. However, this did not give any more information pertaining to the 
cause of death in any case. There were therefore 18 cases where the cause of death was 
unknown. In all cases of fEVAR the cause of death was known. 
Since not all patients had a known cause of death it was not appropriate to analyse 
aneurysm related mortality further. However, it can be seen that there was no aneurysm 
related mortality in the fEVAR group and at least 10% of patients in the EVAR group and at 
least 8% in the OR group suffered an aneurysm related mortality. It is true that the majority 
of aneurysm related deaths were in hospital deaths after the primary procedure but in one 
case in the EVAR group a patient suffered a ruptured aneurysm after failure of the device 
occurred in the form of migration and type 1 endoleak. In the case of OR there was one 
patient that died nearly 6 years after his operation following massive gastrointestinal 
haemorrhage from an aortoenteric fistula secondary to an infected prosthetic aortic graft. 
It should be noted that this complication is not necessarily specific to OR and in fact has 
been seen with endovascular prostheses too. [189]  
The apparent advantage of fEVAR in relation to aneurysm related mortality seen in this 
study therefore appears to derive again from its lower perioperative mortality rate more 
than anything else. The case of the EVAR patient who exhibited migration further 
reinforces the idea that an endovascular device placed outside IFU may be prone to device 
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failure and this case is a potent reminder of the catastrophic consequences that can result 
from such a failure.  
The fact that no migration was seen within the fEVAR cohort compared with nine patients 
in the EVAR cohort (p= 0.017) reiterates the potential for device failure when EVAR is 
placed outside of the IFU. 
Aneurysm related mortality was poorly and inconsistently reported in the literature with 
some studies simply reporting deaths during follow up that were aneurysm related. Other 
studies reported deaths that were aneurysm related as a proportion of the whole patient 
cohort, the patient cohort surviving their index admission and a variety of other methods. It 
was this authors inclination to adopt the reporting standards definition of aneurysm 
related mortality and include any death within the index hospital admission or after any 
reintervention for aneurysm related issues as aneurysm related mortality, including those 
patients who were clarified as having ruptured. One way to report aneurysm related 
mortality would be Kaplan-Meier analysis of freedom from aneurysm related mortality with 
the above definitions and although not done in this study is recommended by this report as 
a more robust and consistent way of documenting the rates of aneurysm related mortality.  
10.1.4. Technical Success 
Although the rate of technical success, as defined by the reporting standards [93], was less 
in the group who received EVAR and the difference across the three groups was found to 
be significantly different, the rate was similar to that of technical success in the fEVAR 
group. The patients who underwent OR enjoyed a very high technical success rate of 97%. 
However, when scrutinising the reporting standards, it is apparent that the definition of 
technical success used is different for endovascular repair compared with open repair. This 
is because the method of repair and therefore potential failure mechanisms during the 
immediate phase after aneurysm exclusion are inherently different. Also, the reporting 
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standards are specifically designed for endovascular aneurysm repair and define the 
qualifying details for technical failure for OR more out of completeness rather than a desire 
to accurately compare the two treatment methods. Technical success for endovascular 
repair requires “successful introduction and deployment of the device in the absence of 
surgical conversion or mortality, type I or III endoleaks, or graft limb obstruction” 
furthermore if unplanned endovascular procedures are undertaken then this disqualifies 
the use of the term primary technical success. [93] Technical success for open repair 
requires “replacement or bypass of the aneurysmal segment with a prosthetic graft in the 
absence of mortality or graft thrombosis either during surgery or during the initial 24-hour 
postoperative period” and if an unplanned surgical procedure is performed then this 
disqualifies the use of the term primary technical success[93]. The main difference 
between the two definitions of technical success therefore is the requirement of 
endovascular repair to be performed without a type I or III (graft-related) endoleak at the 
end of the operation. A graft-related endoleak is one where there is continued perfusion of 
the aneurysm either by: a persistent “perigraft channel of blood flow due to inadequate or 
ineffective seal at the (proximal or distal) graft end” (type I endoleak) or, “at the midgraft 
region due to leakage through a defect in the graft fabric or between segments of a 
modular…graft” (type III endoleak)[190]. It is known that Type I endoleaks in general are 
associated with increased sac pressure and aneurysm expansion, and have been shown to 
be a significant risk factor for late aneurysm rupture and open conversion[66, 191]. This 
data relates to type I endoleaks in general, i.e. those that develop after aneurysm repair, 
and it is because of this data and a consensus that type I endoleaks will not seal 
spontaneously [192] that they have been considered a potentially fatal complication of 
endovascular repair if noted during the operation, hence the importance placed upon them 
in determining if a case is technically successful or not. The significance of type I endoleaks 
at the end of an endovascular procedure however has been questioned with literature 
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suggesting that the majority of patients with a type I endoleak at the end of an EVAR 
operation will spontaneously seal their endoleak. [193] Indeed in this cohort of patients; 
the two patients who exhibited technical failure in the fEVAR group were because of a type 
I/III endoleak at the end of the operation. In both cases the endoleak spontaneously sealed 
without adverse event or secondary intervention.  In the EVAR group, four patients had a 
type I endoleak at the end of their operation and two of these patients spontaneously 
sealed their endoleak without reintervention or adverse event. Roy et.al. [160] and the 
registry data report from the GLOBALSTAR collaborators [82] utilise the term adjusted 
primary technical success rate to allow for those patients with an endoleak that 
spontaneously seal without consequence and when utilising this definition for the above 
study technical success rates of 92.9% and 100% for EVAR and fEVAR respectively were 
reached. The use of primary technical success with the qualifier of adjusted technical 
success is a sensible and useful one primarily because it appears that those patients who 
have a small endoleak on the day of surgery that then seals within days or weeks progress 
(in terms of aneurysm relate outcome events) the same as patients who never had an 
identifiable endoleak. Furthermore, as imaging equipment and resolution of viewing 
screens improves the ability for clinicians to identify small, low flow endoleaks today is 
much improved compared to when fEVAR became widespread in its use (2001 – 2008). It is 
also probable that within the literature there are reports that chose to define primary 
technical success in the same way the above study has defined adjusted primary technical 
success but without explicitly mentioning it. The only way that we can be certain that these 
low flow, self-resolving endoleaks truly are as benign as they seem is for the entire 
community to report their presence.  
In addition, although technical success is important to record and report for any operation 
it may not be wise to use it to compare treatment methods with differing definitions of 
technical success. It can be seen that in patients with non-standard aneurysms each of the 
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three treatment options can be performed with high rates of successful completion of the 
operation without significant immediate sequelae. 
10.1.5. Clinical Success 
There was a statistically significant difference in terms of clinical failure across the three 
groups with standard EVAR showing significantly worse outcomes in terms of clinical 
success/failure. The measurement of clinical success, as defined within the reporting 
standards [93] gives an overall picture of the longitudinal experiences of each patient 
cohort with regards to clinically relevant events. The striking feature seen in this analysis is 
the sharp downward trend that continues throughout the follow up for patients within the 
EVAR group, but it should be noted that clinically relevant events such as migration of the 
stent graft >5mm is included in the definition of clinical failure. Although this is relevant 
and important as it can herald the onset of a significant graft-related endoleak which could 
ultimately lead to aneurysm rupture and therefore catastrophic failure of the stent-graft it 
is by no means certain that this will happen. Indeed, within the EVAR cohort of patients 
there were three patients classified as clinical failures because of migration; one was alive 
at the last follow up time point with a shrinking aneurysm, one more died of non-aneurysm 
related causes and had a shrinking aneurysm at last follow up surveillance scan, both didn’t 
demonstrate an endoleak throughout their follow up (9 and 5 years after migration first 
noted). The other patient had migration first noted 2 years after the index procedure and 
then over the next 2 years demonstrated progressive loss of seal with neck dilatation but 
no proximal endoleak. The patient died secondary to malignant disease at that point. 
 These cases demonstrate that it is quite difficult to define exactly what constitutes a 
clinical failure or continued clinical success. One method to counter this issue would be to 
analyse clinical failure in a hierarchical fashion by assigning certain methods of failure such 
as aneurysm related mortality an increased level of importance compared to migration 
alone. That would allow a certain amount of adjustment for those that represent 
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undeniable clinical failure (aneurysm related death, open conversion) with those that only 
represent a risk of undeniable clinical failure (graft related endoleak, migration). This 
however would need further research and statistical input to determine whether this was a 
valid and useful way of monitoring clinical success, which is beyond the scope of the 
current work.  
There are two facets to the measurement of clinical failure of aneurysm repair in the sense 
that it can be treatment centred or patient centred. Treatment centred would describe 
clinical failure in any patient who is considered to have failure of the treatment by 
predefined failure mechanisms as described in the published reporting standards. Patient 
centred clinical failure would take account of the initial aim of the treatment (to reduce the 
risk of the aneurysm rupturing) and secondary aims (to do so without causing death or 
disability) so that only events which have an impact on the patient are considered. The 
advantage of treatment centred measurement of clinical failure is that it can give a more 
accurate picture of the performance of a given treatment to allow the generalizability of 
how that specific treatment is expected to perform in any given population. The 
disadvantage is that it may class certain cases as clinical failure in which there potentially 
will be no consequences of the said ‘failure’ what so ever. Therefore, the main difference is 
that treatment centred will tend to over-report clinical failure whereas patient centred will 
tend to under report it. When the clinical failure in question is death or ‘risk of death’ it 
may be wiser to choose the method which over-reports its occurrence. Although the 
methods for measuring clinical failure are not perfect, they provide a reasonable 
assessment of how each method of repair performs within a patient cohort longitudinally 
and these results have shown clear inferiority with standard EVAR in this regard.  
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10.1.6. Visceral vessel occlusion 
Fenestrated stent-graft technology is unique from the other methods of repair in one 
respect – the incorporation of visceral vessels (Renal, superior mesenteric and coeliac 
arteries) into the repair. Both OR and standard EVAR have only indirect effects on the 
visceral vasculature whereas fEVAR, by its nature, demands endovascular access and 
stenting of visceral (target) vessels. Furthermore, the stents are an inherent part of the 
repair and as such remain in place for the life of the repair. It is true that in some 
circumstances the visceral vasculature would be incorporated into open repair by either 
bypass or reimplantation of the vessels during the initial repair, this however is usually only 
necessary when the aneurysm extends around and above the renal arteries in what would 
therefore constitute a type 4 thoracoabdominal aneurysm. This type of aneurysm was 
excluded from this study because it represents a distinct aneurysmal entity that, if repaired 
by endovascular means, would require entirely different technology, namely branched 
endograft technology. On occasion a pararenal or juxtarenal open aneurysm repair may 
require that a renal artery is reimplanted during the procedure because of complication or 
specific anatomical anomalies, however this was not true for any patient in this cohort. 
Since the introduction of fEVAR the increased exposure to a potential risk of target vessel 
loss has been an area of concern and perceived disadvantage of this method of repair. 
However, this potentially catastrophic complication has not been reported commonly in 
patients undergoing fEVAR with target vessel patency rates of 95% at 3 years in one large 
series. [82] In fact in the current study there were no target vessel losses noted at any point 
in the fEVAR group. There were also none recorded in the open repair group either, but it 
should be noted that this group of patients do not routinely undergo follow up scanning 
which could determine whether any visceral vessels had occluded during follow up. Target 
vessel loss with fEVAR is therefore relatively rare and even when it does occur it does not 
seem to have catastrophic consequences. In this study, there was also one patient who 
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suffered occlusion of a renal artery after standard EVAR highlighting that the risk of this 
particular complication is not solely experienced by those who undergo fEVAR. 
With regards to visceral vessel patency there is therefore no advantage, but importantly 
also, no disadvantage with fEVAR compared with the other repair options, as seen from the 
results in this study and from the wider published literature. 
10.1.7. Renal Insufficiency (Long term) 
Although no patients suffered renal dysfunction to a degree where long term dialysis was 
required patients who underwent EVAR did demonstrate worse renal function over the 
long term. There was also no significant difference in terms of the occurrence of acute 
kidney injury between the three repair types during the in hopsital stay though open repair 
patients suffered it more often (43% vs 20 and 25%). Despite this it was the EVAR cohort of 
patients that demonstrated the largest occurrence of deterioration in renal function as 
measured by CKD stage deterioration and change in eGFR; 50% of EVAR patients had a 
deterioration in their CKD stage at some point during follow up (compared with 13% of 
fEVAR and 24% of OR patients). This didn’t reach statistical significance however. The 
minimum eGFR postoperatively was reached at a median of four years from the operation 
(Range; 3 months – 6 years). The definition used in this study of deterioration of CKD stage 
seems sensible but may not be the most clinically relevant. As discussed above a patient 
would be classed as renal insufficiency over the long term by this definition if their eGFR 
dropped from 61 to 59, which may not be clinically relevant. It may be argued that this 
excess of renal insufficiency in EVAR patients was simply due to this ‘low-level’ renal 
deterioration. However when analysing if a patient dropped two stages (representing a 
drop from 61 to 44) EVAR patients still more commonly suffered this (18% of patients vs 7% 
for fEVAR and 11% for OR). Again this didn’t reach statistical significance it should be noted. 
The fact that EVAR patients demonstrate worse renal function over the longer term is 
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interesting and somewhat surprising as this is the group that, theoretically, has the least 
invasive intervention in terms of potential or actual disruption to the renal vasculature. 
fEVAR involves direct cannulation and stenting of the renal arteries and a significant 
proportion of patients undergoing OR (30%) had a clamp placed above at least one of the 
renal arteries. There was no significant difference between the three groups in terms of; 
pre-operative renal function, presence of hypertension or diabetic disease, which could 
have accounted for deterioration in renal function. There was also no significant difference 
in terms of in-hospital renal function, and in fact OR performed worse in this regard, 
suggesting that the deterioration in renal function seen in the EVAR group is attributable to 
events after the primary operation and hospital admission. One explanation for the 
deterioration in renal function may be that patients who underwent EVAR had more 
reinterventions over the longer term. The increased burden of secondary procedures and 
their potential detrimental effect on renal function is a plausible reason for the decrease 
seen in renal function especially since three patients underwent conversion to open repair 
and one further patient underwent an anterior resection and left nephrectomy, which was 
unrelated to the EVAR procedure and had been planned before the aneurysm repair. 
Furthermore, patients who underwent EVAR had a higher burden of thrombus within the 
infrarenal neck compared with the other two groups. This however did not reach a 
statistical difference. It is possible that microembolisation of thrombus within the 
infrarenal neck to the kidneys could have occurred causing renal dysfunction. However, if 
this was the case one would expect to see a significant rise in the creatinine for this 
complication within the first few days to week (i.e. the in hospital stay) after the operation. 
As already stated, this was not the case in any of the groups. Another explanation could be 
that stenting of the renal arteries in the fEVAR group provides some protection to renal 
blood flow over the long term and therefore some protection and preservation of renal 
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function. There is little evidence to support this theory however especially considering that 
OR patients exhibited maintenance of their renal function without renal stenting. 
It is unfortunate that there was no data available relating to the amount of iodinated 
contrast used either during the primary or secondary procedures as it would be important 
to assess whether there was any relationship between the use of contrast and 
deterioration in renal function. It is however unlikely that this in itself would be an 
explanation for the worse renal function seen in the EVAR group, for two reasons: Firstly, 
fEVAR utilises contrast media also but the procedures tend to be more prolonged and with 
the additional complexities of target vessel cannulation and stenting there is often larger 
volumes of contrast medium used in these cases. Secondly, as stated, the deterioration in 
renal function occurred long after the initial procedure making a causal link unlikely. In 
addition, the increased contrast burden of surveillance scans is experienced mainly by 
fEVAR patients as they routinely underwent annual CTA as part of their surveillance and the 
EVAR patients only underwent selective CTA. 
These findings do not suggest superiority of fEVAR but rather inferiority of standard EVAR 
for the treatment of non-standard aneurysms. It is true that no patient went on to require 
dialysis as a result of their renal dysfunction but the detrimental effects of chronic kidney 
disease should not be underestimated either as patients with chronic kidney disease have 
an elevated risk of death, cardiovascular events and hospitalisation compared with those 
with normal renal function [194, 195]. 
10.1.8. Reintervention Rates 
There was no statistically significant difference across the three groups in terms of the 
number of patients requiring in-hospital reinterventions or any reintervention post 
discharge. 
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When comparing methods of aneurysm repair secondary intervention is an important 
outcome to assess, particularly as an oft quoted disadvantage of endovascular repair is the 
increased need for reintervention. In this study there was no significant difference in the 
proportion of patients needing a reintervention at any time with 25% of EVAR patients, 
13% of fEVAR patients and 8% of OR patients requiring at least one reintervention over the 
longer term. As can be seen the reintervention rate after EVAR is higher than fEVAR or OR, 
but in line with other reported studies, especially for NSA patients. The issue is of course 
more complicated than that. Although reintervention rates and freedom from 
reintervention is often quoted in the literature it doesn’t really give a true story of the 
relative experiences of the patients. The need for any reintervention is, of course, 
undesirable however there is a substantial difference between someone undergoing a 
conversion to open repair after EVAR when compared with a diagnostic mesenteric 
angiogram performed under local anaesthetic as a day case, for example. If a criterion were 
that only patients requiring or prolonging their initial hospital stay of >24 hours were 
considered to have a ‘significant’ reintervention then in this study; 28% of EVAR patients, 
0% of fEVAR patients and 8% of OR patients required a ‘significant’ reintervention. 
(p=0.021). It would be important in any future study of outcomes of endovascular (or open) 
repair of abdominal aortic aneurysms to assess the rate of ‘significant’ reintervention as 
well as all reintervention, to give a richer picture of the experiences of patients undergoing 
the operation so that judgements can be made regarding the true magnitude of the 
detrimental effect of reintervention. 
Those undergoing standard EVAR will experience the need for more reinterventions and 
specifically more ‘significant’ reinterventions than those undergoing fEVAR or OR. 
However, there is no clear evidence that fEVAR confers the greatest advantage of all the 
repair types in terms of reintervention rates. 
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10.1.9. Conversion to Open Repair 
There was no statistically significant difference between the fEVAR and EVAR groups in 
terms of the number of patients requiring conversion to open repair. Three patients 
required conversion during follow up in the EVAR group and no patient experienced this 
particular complication in the fEVAR group. Common to all patients that required open 
conversion was that the maximum neck diameter in each case was greater than 32mm. 
Although it is difficult to draw firm conclusions from this small number of patients this may 
highlight this as a potentially ‘more important’ area of IFU violation than some others. 
There were only six patients in total that breached the IFU for neck diameter in the EVAR 
group meaning that half of all the standard stent-grafts implanted within a neck greater 
than 32mm required conversion to open repair. 
10.1.10. Major Complications 
As discussed within the results section major complications seen during the primary 
hospital admission were not significantly different across the three treatment groups. 
However, what is striking is that a significant proportion (49%) of major complications seen 
in the OR group were related to intraoperative blood transfusion alone. This was also the 
category of complication with the largest single contribution to the overall total of major 
complications in any repair group. The reporting standards used to define the threshold for 
what determines a major complication in terms of intraoperative blood transfusion are 
primarily reporting standards for endovascular repair, although there are definitions 
relating to open repair contained within them also. It is reasonable to compare 
intraoperative blood transfusion in a like-for-like manner between endovascular and open 
repair as the physiological insult derived as a result of the need for blood transfusion and 
the blood transfusion itself remains the same. The fact that endovascular repair usually 
requires less blood transfusion intraoperative than OR is a testament to the less invasive 
nature of the procedure and one of a set of parameters that have helped to define the 
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theoretical advantage of the endovascular approach. However, the term major 
complication implies a clinically significant event that results in a risk of death for the 
patient or at least a prolonged disability of some sort. In fact, the reporting standards 
define a major complication as one that “indicates the need for significant intervention, 
prolongation of hospitalization more than 24 hours, and at most, minor permanent 
disability that does not preclude normal daily activity” at its least severe and “necessitates 
major surgical or medical intervention, may be associated with prolonged convalescence, is 
usually accompanied by prolonged or permanent disability, and may result in death” at its 
most. The reporting standards go on to give specific instructions as to how intraoperative 
blood transfusion should be assessed in terms of whether it is a mild, moderate or severe 
complication. The concern is that the threshold that is set for moderate or severe 
intraoperative blood transfusion is actually quite low. Any patient receiving the levels of 
blood transfusion intraoperatively as described for a moderate complication (>2 units 
autologous but < 3 units homologous) would almost certainly not result in a prolonged 
disability. Although the data collected and presented cannot answer the question of 
whether intraoperative blood transfusion prolongs hospital stay it seems unlikely that 
someone who receives 2-3 units of blood transfusion would be significantly impaired as to 
delay their discharge from hospital after an open aneurysm repair. In fact there was no 
significant difference in length of stay when comparing those patients who had a moderate 
or severe complication relating to intraoperative blood transfusion during OR with those 
who had no or mild complications relating to blood transfusion (p = 0.556, t test) 
Therefore, although it is not unreasonable to record intraoperative blood transfusion as a 
complication, and it is not unfair to compare OR and endovascular methods directly in this 
regard, what is not reasonable is the thresholds that have been set by the reporting 
standards. Any future research into this area should carefully scrutinise reporting standards 
with regard to what would constitute a major complication before commencement of the 
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data collection. Particular attention should be paid to the comparison between 
endovascular and open repair to give an accurate reflection of clinical consequences from 
this complication. 
The recording and reporting of major complications gives an important insight into any 
medical treatment. It is not only important, so the patient understands what can 
potentially go wrong and therefore give truly informed consent but also, so the physician 
and patient can come to an ‘educated’ decision together as to what is the ‘best’ treatment 
option for them. To fully understand the ‘risk profile’ of the three treatment options 
however it is not adequate to consider only major complications on its own. As well as 
major complications, clinical failure (as defined within the reporting standards[93]), 
maintenance of device integrity and re-interventions are considered together below and 
collectively termed adverse clinical events (ACE). This is because any one of these may 
promote re-intervention, re-hospitalisation and/or death and by considering these 
together a deeper insight into how the three treatment options perform will be gained. It is 
important to still consider these elements separately as was done in the results section but 
to give a more patient centred and holistic view of the outcomes this type of interrogation 
is necessary. It is likely that patients consider ‘problems’ that are related to an operation 
together and do not in fact delineate between a major complication and a failure of the 
device but rather they will view all such things as ‘problems’ arising from the operation. It 
should be noted that they will however categorise and grade these ‘problems’ and assign 
different levels of importance depending on the individual ‘problem’ and its consequences 
for the individual patient. For simplicity however, the collective ACE are described here 
(excluding ‘moderate’ blood transfusion intraoperative as described above). For the EVAR 
group 16 patients suffered 29 ACE. In the fEVAR group 1 patient suffered 1 ACE and in the 
OR group, 15 patients suffered 26 ACE. The difference in the number of patients 
experiencing ACE reached statistical significance across all three repair groups (p= 0.007, χ2 
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test). In fact, fEVAR patients suffered significantly less ACE when compared with EVAR or 
OR groups independently (p= 0.002 and 0.015 respectively, χ2 test). Therefore, when 
looking at combined adverse clinical events fEVAR does confer an advantage over the other 
repair options. 
10.1.11. Summary of Primary and Secondary Outcome 
Measures Discussion 
With regards to the primary and secondary outcome measures there does not appear to be 
any advantage in performing fEVAR over all other types of repair and therefore the null 
hypothesis (fEVAR has the same clinical outcome as EVAR and OR for non-standard AAAs) 
cannot be rejected. The analysis does however reveal that there appears to be a 
disadvantage in performing standard EVAR in this group of patients. Namely that patients 
who received EVAR had a lower rate of primary technical success and importantly, an 
increased rate of clinical failure. Therefore, concerning the stated primary and secondary 
outcome measures EVAR appears to be the most inferior type of repair. Although not an 
outcome measure stated within the study the analysis of ACE provides an interesting 
insight into the overall experience of patients undergoing the three types of repair. This 
analysis suggests there is a specific advantage in performing fEVAR, however it would need 
further study with ACE as a specific outcome measure before this could be definitively 
stated. 
10.2. Aneurysm Morphology 
10.2.1. Measurement of Aneurysm Morphology 
Prior to deciding on the measurement protocol used the chief investigator searched the 
literature and did not find a comprehensive protocol to describe validated measuring 
techniques across a range of anatomical variables. There were some reports and studies of 
isolated anatomical features but no comprehensive reports at the time when the study was 
designed (early 2012). Since then there has been a published report by Ghatwary et.al. 
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[196] in which a comprehensive measuring protocol is proposed - the St George’s Vascular 
Institute Protocol. This was reviewed and in comparison to the protocol described in the 
methods section used in this study there are some important differences and also some 
similarities. It should be noted that the fact the measurement protocol used in the above 
study was not validated and do differ from those in the validated St Georges protocol (and 
other validated techniques for single anatomical measurements) there is limited 
application of the results of the above study because of this. The fact that the protocol 
used was not validated does not automatically and necessarily mean it was inaccurate or 
inferior but just that the results should be interpreted with this in mind. The first difference 
noted between the St George’s protocol and the protocol used in this study are that 
Ghatwary et.al. propose the use of an automated central luminal line (CLL) and stretched 
vessel view for all measurements. Whereas in the protocol utilised in this study the CLL was 
manually imagined and created without automatic help from the software at all and 
stretched vessel view was not used. In both these instances it was specifically intended that 
way in order to preserve the 3-dimensional anatomy when making measurements and 
assessments. This is so the reviewer could continually utilise all the anatomical information 
available when making measurement-based decisions. Also, to the knowledge of the 
author, there has never been a comparison between the use of an automated or semi-
automated CLL and a manually imagined one. Therefore, it is not known which method 
produces more accurate and reliable measures. The next prime difference was that the St 
Georges protocol was more substantial and expansive for both the aneurysm as a whole 
and the neck of the aneurysm itself. There were 13 different measurements for the 
proximal aortic neck alone in the St Georges protocol. This included volume and area 
measurements as well which was not included in this study. The parameters measured in 
this study were not designed to give an accurate overall assessment of the anatomy of each 
aneurysm but to determine whether it was ‘inside’ or ‘outside’ IFU and since the IFU used 
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doesn’t include these other values there was no reason to include them. Although full 
anatomical assessment is important and useful for clinical decision making and research it 
was not the primary aim in this study.  That protocol also measured neck diameter at 1mm 
intervals rather than 5mm intervals as was done in this study. 
The St Georges protocol does not define where the top of the aneurysm begins and is 
inferior in this regard. Ghatwary et. al. show that: “Better reproducibility in length 
measurements was achieved when using predefined anatomical landmarks, such as ‘‘the 
lowest renal artery to the aortic bifurcation’’ (RC 5 2.5%–4.2%), as opposed to more poorly 
defined areas such as ‘‘the beginning of the aneurysm sac’’ (RC 5 7.5%–9%).” 
This has been previously shown in other studies also [197]. The measurement technique 
applied in the St George’s protocol for angulation was adapted from that published 
previously [198]. It describes a specific method to interrogate a 3 – dimensional model of 
the aneurysm to determine the maximum angulation for both the alpha and beta angles. 
The prescriptive nature of the description on how to do this would undoubtedly increase 
reliability and repeatability of such a measuring technique, as demonstrated by Van Keulen 
et. al. themselves. However, it is interesting that the ST George’s team, when applying this 
method found the inter and intraobsever variability was less favourable than reported by 
the original Van Keulen study. Ghatwary et. al. also cite that they included more patients in 
their analysis lending more weight to their conclusion than Van Keulen et.al. Therefore, 
although the prescriptive nature of the measurement technique seems attractive it isn’t 
necessarily the most repeatable way of measuring angulation. In reality it is difficult to find 
a practical and robust way of measuring angulation due to its complex 3-dimensional 
nature in an aneurysm. In this study this problem was mitigated by being prescriptive about 
the placement of where the vertex of the angle should be along the CLL. Something which 
Van Keulen et al. were not as prescriptive about. However, the potential limitations of the 
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method of angulation used in this study include the fact that angulation was measured 
along an imagined central luminal line rather than one created by the software. This would 
potentially increase the risk of measurement area for this particular measurement 
compared with other techniques. Also, it was not specifically stated to observe the area of 
interest rotated around 360 degrees though this was the intention. Without being 
prescriptive about this in the measurement protocol it is possible this was not always done 
and again may have led to inaccurate recording of an angulation that was less than the 
maximal actually present in the aneurysm being measured. Future methodologies for 
angulation measurement should be prescriptive as Van Keulen was about observing the 
aneurysm through a full 360-degree rotation using 3D software before deciding which view 
produced the maximum angulation. One addition to this though is that the protocol in th9is 
study required the reviewer to measure the angulation in 2 different planes which could 
potentially increase the accuracy of angulation measurement compared to the 
measurement of one angle. Of course, further research would be needed to clarify that but 
future methodologies for angulation measurement could include 2 separate measurements 
at least to ensure maximal angulation was recorded. Inevitably with both methods (Van 
Keulen and that presented in this study) there was an element of subjectivity but 
potentially a better way to reduce this even further would be to combine both methods. 
This would be an area for further and ongoing research.  
Therefore, with regards to the measurement protocol the results of this study certainly do 
need to be analysed with the fact that a validated protocol was not used. This does limit 
the applicability and validity of the results however in the absence of a robust and 
continually well performing protocol the one used seems reasonable and at least was 
practical and relatively quick to apply. The design of the measurement protocol was in 
small part influenced by the desire to create a protocol which was not too time consuming 
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to apply, both in order to reduce the amount of time spent on it during the research but 
also with an eye on it potentially being applied in the clinical setting. 
Two reviewers independently assessed aneurysm morphology to decide whether patients 
met the inclusion criteria and therefore could be classified as non-standard aneurysms or 
not. Regarding the agreement as to whether a patient exhibited a non-standard aneurysm 
or not the strength of agreement between the two reviewers was judged to be ‘very good’ 
as measured by Cohen’s κ (0.969 (95% CI, 0.928 to 1), p<0.0001). This method of 
identification of patients will reduce potential bias compared to one reviewer assessing 
each scan on their own, however it is true there is still the potential for error to be made in 
the decision as to whether a patient had a non-standard aneurysm or not. Using defined 
anatomical criteria for the inclusion of patients along with a prescriptive method of 
measuring certain anatomical characteristics such as the alpha and beta angles was 
invoked to try to reduce this potential bias further. It would have been possible to carry out 
a parallel study to ascertain the inter and intra-observer variance to identify the degree to 
which the measurements produced by the two reviewers varied but it was deemed not 
necessary to carry out such an analysis. Firstly, when considering if patients were to be 
included or not it did not matter whether the measurements observed were different and 
to what degree, what mattered was the final decision whether they were non-standard or 
not. Secondly there is previously published data on inter and intra-observer variance 
relating to measurements from CTA and it was felt not necessary to repeat this. That study 
showed a minimal and acceptable rate of variance.[199] 
Once a patient was included in the study the pre-operative CT scan was reviewed again to 
document measurements of anatomical criteria by the chief investigator. Here there is 
again potential for measurement error. The use of prescriptive methods of measuring each 
anatomical criterion, ensuring that all the CT scans were reviewed using the same 
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workstation and reconstruction software and that when viewing the images, they were all 
pre-set to defined window width (800) and window level (100) helped to reduce potential 
measurement error.  
10.2.2. Consideration of Patients with Complex Iliac Anatomy 
When assessing patients for inclusion into the study only anatomical characteristics 
pertaining to the neck of the aneurysm were used to define whether an aneurysm was 
‘non-standard’ or not. This is despite the fact that all manufacturers of stent-grafts have 
similarly strict criteria, set out in the indications for use, pertaining to the iliac vessels. This 
was a deliberate choice for three main reasons. 
1. It was important to capture patients that best represent the clinical dilemma that a 
surgeon faces that is at the heart of this study: for patients with aneurysms that are 
not suitable for standard EVAR, what is the best method of repair in terms of 
clinical outcomes? The most common reason that a patient is not suitable for 
standard EVAR is anatomical characteristics that pertain to the aneurysm 
neck.[117, 200]. Aneurysms that violate the IFU because of anatomical 
characteristics pertaining to the iliac vessels present a distinct and different 
problem, that can be overcome using different techniques other than fenestrated 
technology. In fact, with hindsight, the hypothesis could have been more 
prescriptive in its wording to help define the intended patient cohort as non-
standard aneurysms in which fEVAR would be a valid alternative treatment option 
to standard EVAR or OR. Rather than simply all patients who are not suitable for 
standard EVAR. 
2. Breach of IFU from an iliac anatomy point of view alone does not influence 
whether fenestrated stent-graft technology needs to be used to seal more 
proximally. Therefore, if patients were included in the study based on being outside 
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IFU concerning iliac anatomy then there would potentially have been a subset of 
patients that had ‘standard’ necks being compared to other patients with a ‘non-
standard’ neck. Specifically, complications secondary to failure mechanisms that 
are related to device failure at the proximal neck would have been compared for 
one group treated inside the IFU and one outside the IFU. This would have resulted 
in a small group of patients – ‘inside IFU neck, outside IFU iliacs’ and if included in 
the ‘standard EVAR’ group could have potentially biased the results for that group. 
However, it is possible that patients who were outside IFU for the iliac segment 
were included in the study but not identified as such as no measurements of the 
iliac segment were recorded. What is not known is whether these patients were 
preferentially selected for one type of repair over another and it is feasible and 
possible that a proportion of patients that underwent open repair as opposed to 
endovascular repair did so primarily based on their iliac anatomy. This again could 
have potentially influenced outcomes of patients, as being outside IFU for iliac 
anatomy implies more challenging anatomy overall, and the corollary of this is a 
more difficult operation, whatever the method of repair chosen.   
3. The construction of a fenestrated stent-graft differs from that of a standard 
endovascular stent-graft primarily at the ‘top end’ of the device, that which seals in 
the neck. Challenging neck anatomy was the primary reason for development of 
fenestrated technology in the first place. This was so that the seal zone could be 
moved proximally, away from disease or unsuitable necks. The configuration of the 
device that seals in the iliac vessels is the same in both devices.  
Therefore, there is a potential confounding factor (complex iliac anatomy) that is present 
but unmeasured in the study population. As stated, it is unusual for an aneurysm to be 
deemed unsuitable for standard EVAR because of iliac anatomy alone and therefore any 
unmeasured bias in this regard is likely to be have a limited effect on the results. In future 
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study however, it would be important to address this issue by measuring iliac anatomy so 
its effects on the outcomes of aneurysm repair could be analysed and taken into 
consideration. 
10.2.3. Consideration of Thrombus and Calcification within the 
Neck 
Regarding specific anatomical characteristics measured on the pre-operative CT scan there 
were broadly two types of anatomical characteristics that were measured: Firstly, objective 
measurements were made of neck length, neck diameter (both at the maximum diameter 
and how the diameter changed over the length of the neck for 15mm), the α and β angles 
and the maximum aneurysm diameter. The amount of thrombus within the aneurysm neck 
was also measured. The second type of measurement made was a more subjective 
measurement of the amount of calcification within the aneurysm neck.  The IFU 
recommendations for the three manufacturers used to design this study vary regarding 
thrombus: 
 Endurant Stent Graft System (Medtronic, Inc. Minneapolis, Minnesota, U.S.A.)  - no 
mention of thrombus within the IFU 
 Gore Excluder AAA Endoprosthesis (W.L. Gore &Associates, Inc. Flagstaff, Arizona, 
U.S.A.) - IFU comments that the device should not be placed where there is 
‘significant thrombus’ but gives no definition as to what would constitute 
significant. 
 Zenith Flex AAA Endovascular Graft (Cook Medical, Bloomington, Indiana, U.S.A.) - 
IFU states that significant thrombus, as defined as >2mm in thickness or covering ≥ 
25% circumference of the aneurysm neck would be considered outside of the 
indications for use.  
367 
 
To enable the most objective assessment as possible of thrombus within the aneurysm 
neck the definition within the Zenith IFU was used when measuring thrombus within the 
neck for all aneurysms to ascertain if they fell outside the IFU or not. As it so happens in all 
of the standard EVAR the Zenith platform stent-graft was implanted.  
Calcification was graded as; not present, mild, moderate or severe for each aneurysm 
studied. Although there is inherent subjectivity in this method of measuring and recording 
calcification there was no simple or reliable way that the extent of calcification could be 
measured objectively. This is in part due to the fact that although thrombus tends to form 
in a crescent shape along the inner surface of the aneurysm neck calcification is much more 
sporadic and varied with ‘lumps’ of calcification present at different points along the neck 
and round the circumference of the neck. In addition, thrombus is an intraluminal entity 
whereas calcification is present within the wall of the artery. This means that although two 
patients may have a similar burden of calcification in terms of volume, they may not 
deform the circumferential shape of the neck to the same degree. This circumferential 
deformity probably causes the most deleterious effects on the sealing of any endovascular 
repair within the neck. Therefore, the grading of calcification was in fact grading of the 
severity of deformation of the neck secondary to calcification, rather than volume of 
calcification alone. When the presence or absence of calcification was compared across all 
three groups there was no statistically significant difference found. In addition, not one 
case was included in the study solely due to the presence of calcification. This suggests that 
either calcification was not present to a significant degree in the population studied or that 
it had little bearing as to which type of repair they were selected for. These facts, along 
with the subjective nature of its measurement, dictated the decision not to consider the 
presence of calcification as a violation of IFU for the purposes of the further analysis. 
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There were no statistically significant differences in the amount of thrombus or calcification 
observed in patients across the three groups. However, the results show that those 
patients undergoing EVAR exhibited more infrarenal thrombus than either the fEVAR or OR 
groups. This finding is hard to explain but may be an indicator as to the general arterial 
health of the population selected for EVAR rather than a specific choice to treat these 
patients preferentially with EVAR. Thrombus within the infrarenal neck would generally be 
present in those with arteries of inferior quality and if this is a surrogate marker for the 
general health of the patient then might explain why these patients underwent 
endovascular repair as opposed to OR. However, when comparing both those with 
significant thrombus who underwent EVAR and those without there is no apparent 
differences in the pre-operative history to suggest that these patients are less fit. The 
median ASA grade in both groups was 3, the number of patients who had previous 
myocardial infarction or symptomatic ischaemic heart disease were higher in the no 
thrombus group (24% vs 17%). It is therefore difficult to explain this difference in presence 
of thrombus across the three repair groups. In light of the worse long-term outcomes after 
EVAR regarding renal function it would be important to investigate this area further in any 
future study as increased thrombus burden within the neck could potentially shed light on 
the aetiology of this complication due to the potential for thromboembolism into the renal 
arteries during aneurysm repair. 
10.2.4. Aneurysm Diameter 
The maximum aneurysm diameter was smaller, but not significantly so, in the group that 
received fEVAR (Median 60mm, Range 57 – 64). The reasons for this are unclear but the 
result could be a type I error, due to the small number of patients in the fEVAR group. In 
fact, the larger study of 107 patients who underwent fEVAR (detailed in chapter 8) showed 
the maximum aneurysm diameter to be closer to that of both the EVAR and OR groups in 
this study (Median 64mm, Range 55 - 92). It is unlikely that patients who had smaller 
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aneurysms were preferentially selected for fEVAR. What is possible however, and more 
likely, is that patients with very large aneurysms were preferentially selected for either 
standard EVAR or OR. This is because there is a delay of between 8-12 weeks present with 
fEVAR from the time of decision to operate to operation date that is not present with the 
other repair options. This time delay is to allow manufacture and delivery of the bespoke 
device to take place. It is feasible that a surgeon faced with a very large aneurysm at 
significant risk of rupture would not wish to burden the patient with an extra 3 month wait 
during which time they would be exposed to a risk of rupture when there is no delay (in 
theory) if another repair method is chosen. In fact, there was only one aneurysm (7%) with 
a maximum diameter of 70mm or more repaired in the fEVAR group whereas there were 
seven (24%) in the EVAR group and 13 (35%) in the OR group. 
10.2.5. Neck Length 
The aneurysm neck was significantly different between the groups. They were longer for 
patients who received EVAR compared with the other two repair groups. This is perhaps 
unsurprising as neck length would be the primary and most obvious determinant of 
whether a patient would be ‘suitable’ for standard EVAR or not. Of all the anatomical 
measurements made when assessing what type of repair a patient can be offered safely 
neck length is one of the simplest and most obvious measurements to make. It is also one 
of the anatomical measurements in which there is a significant amount of data from the 
literature to suggest inferior results in standard EVAR when placed outside the IFU for neck 
length [68, 104]. It is therefore unsurprising that neck length is significantly longer in this 
group with only seven (24%) patients exhibiting a neck length outside IFU for standard 
EVAR. When comparing the group with a neck length outside the IFU for standard EVAR (< 
15mm) with those that were within the IFU there were no significant differences seen in 
the rates of complications as outlined below: 
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Table 10.3 Comparing those Within and Outside IFU for Neck Length in EVAR Group 
Complication 
Short neck (<15mm) 
(n=6) 
Long neck (≥ 15mm) 
(n=22) 
Major Complications (In 
hospital), n (%) 
  
Yes 0 4 (18) 
No 6 (100) 18 (82) 
Migration (≥ 5mm), n (%)   
Yes 3 (50) 6 (27) 
No 43(50) 16 (73) 
Neck Effacement, n (%)   
Yes 2 (33) 1 (5) 
No 4 (67) 21 (95) 
Endoleak (Any), n (%)   
Yes 4 (67) 6 (27) 
No 2 (33) 16 (73) 
Endoleak (Graft Related), n 
(%) 
  
Yes 1 (17) 2 (9) 
No 5 (83) 20 (91) 
Open Conversion, n (%)   
Yes 1 (17) 2 (9) 
No 5 (83) 20 (91) 
Major Complications (Long 
term), n (%) 
  
Yes 3 (50) 10 (45) 
No 3 (50) 12 (55) 
Clinical Failure, n (%)   
Yes  3 (50) 8 (36) 
No 3 (50) 14 (64) 
Table 10.3 - Comparison of categorical variables was performed using Fisher’s exact test (†).  
Neck effacement is a term that describes progressive cephalad progression of the 
aneurysmal process following endovascular repair. It acts to reduce the length of seal 
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within the decreasing aneurysm neck even if there is no migration of the stent-graft. Its 
aetiology is probably of continued aneurysmal progression rather than secondary to the 
repair itself but there is no study in this area. It is important to note in this situation 
specifically as effacement in a neck that is already short in which a standard EVAR is placed 
outside of IFU could quickly result in complete loss of seal, type 1a endoleak and 
consequently repressurise the aneurysm. In both patients who exhibited neck effacement 
with short necks no graft related endoleak was seen during the follow up and their 
aneurysms were noted to be shrinking. In the one patient with a long neck (22mm) their 
aneurysm was noted to be expanding with migration of the stent graft during follow up but 
no endoleak was seen on any surveillance imaging. With small numbers of patients 
exhibiting effacement it is difficult to ascertain the consequence or importance of this 
particular complication in this study but what is suggested by these results is that a long 
neck pre-operatively doesn’t necessarily protect against effacement occurring. 
The neck diameter was also less in the group who underwent standard EVAR. This would be 
expected given the findings relating to neck length. In both the fEVAR and OR groups there 
were a significant proportion of patients recorded as having no infrarenal neck whatsoever, 
five (33%) in the fEVAR group and eight (22%) in the OR group. This means that the 
aneurysm was present immediately below the renal arteries and therefore by definition, in 
these patients, there was a larger neck diameter below the renal arteries where the 
measurements were made.  
10.2.6. Angulation 
The α angle was significantly greater in patients who received OR compared with those that 
underwent fEVAR, however there were no statistically significant difference between the 
two endovascular methods of repair. This may highlight that when a surgeon is faced with 
an aneurysm with significant angulation within the visceral aorta, they would be less 
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inclined to use an endovascular method of repair. This is unsurprising given that angulation 
may preclude or render endovascular repair more challenging whereas angulation would 
be of less concern when carrying out OR, and certainly wouldn’t compromise the end result 
of the repair per se, in the same way.  
The value of angulation as a predictor of clinical outcome was not seen in this study. By 
univariate logistic modelling alpha and beta angulation were assessed against the 
outcomes of technical success, reintervention (both perioperative and through FU), 
mortality (both perioperative and through FU) and clinical failure. These outcomes were 
interrogated and no statistically significant association was found. The literature examined 
did not shed any light on the value of alpha angulation as a predictor of outcome for EVAR, 
fEVAR or OR patients. The vast majority of studies don’t analyse or measure it at all and 
primarily focus on beta angulation. The most important study identified in this regard is 
that by Hobo et.al. [67] a large study from the EUROSTAR registry. In that study that 
compared <60 degrees of beta angulation with >60, they found that greater neck 
angulation was associated with an increased risk of migration perioperatively, type 1a 
endoleak and a predictor of late reintervention. This study therefore suggests the 
importance of beta angulation as a marker of clinical outcomes and the importance of 
analysing it as an anatomical variable for research and when evaluating a patient’s anatomy 
for whether a stent-graft should be placed or not.  
Standardised measurement of angulation as described in this study or that by Van Keulen 
et.al. is important for future research into the question of whether angulation as an 
individual characteristic is an important predictor of poor outcomes for NSA patients when 
comparing different treatment options. Although Hobo et.al. showed worse outcomes for 
>60 degrees compared to <60 degrees undergoing standard EVAR the question still remains 
whether the outcomes for patients with angulation outside the IFU translate to worse 
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clinical outcomes for fEVAR, EVAR and OR patients equally. Furthermore, it is the 
recommendation of this author that in all future studies alpha angulation should be 
measured, recorded and analysed when evaluating the impact of anatomical factors on 
clinical outcomes as the data with regards to this variable is lacking within the literature 
and it would be important to know the role that angulation at this level plays in outcomes 
for these three treatment options. This is especially because fEVAR potentially is the most 
negatively affected by alpha angulation as it is the one treatment of the three that requires 
accurate placement, manipulation and deployment within this area of the aorta.  
10.2.7. Consideration of Number of IFU Violations per case 
Patients who received standard EVAR had less IFU violations pertaining to their aneurysm 
when compared with the other two groups (median of 2 vs 3). In fact, 43% of patients who 
received standard EVAR in this study had only one IFU violation, compared with 7% and 
16% for fEVAR and OR respectively. Therefore, those patients who underwent EVAR 
exhibited ‘simpler’ aneurysm morphology compared to those that underwent fEVAR or OR, 
they had; longer necks with a smaller maximum neck diameter, and although they 
exhibited slightly more thrombus there were fewer IFU violations per patient. This revealed 
that those patients with more complex aneurysms were selected for either OR or fEVAR 
preferentially which is unsurprising given the reported advantages of these types of repair 
over EVAR in these patients. These results suggest there is in fact two groups of patients 
being studied here and that future research should clarify this point in more detail before 
comparisons can be drawn. One group comprises patients with ‘simpler’ aneurysms that 
are borderline in terms of suitability for EVAR and that the other group of patients with 
distinctly more ‘complex’ aneurysms. These results suggest, importantly, that although 
patients who receive EVAR exhibit ‘simpler’ aneurysms overall, they still tended to have 
worse clinical outcomes. Therefore, it seems that the fine line of EVAR suitability is one that 
should be adhered to as, even with simpler aneurysms, they still had worse outcomes. If 
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aneurysms that are more complex have more favourable outcomes with fEVAR and OR it 
stands to reason that the simpler aneurysms would also have more favourable outcomes, 
potentially to an even greater degree. This therefore informs us that if an aneurysm is 
outside the IFU for standard EVAR they probably should not receive standard EVAR if 
possible. Unfortunately, however the current distinction still does not answer the question 
of whether these patients are better served with fEVAR or OR. 
10.2.8. Expected Clamp Site 
There was no statistically significant difference when comparing the level of expected 
clamp site across the three repair groups in terms of survival. Furthermore, there was no 
statistical difference across the three groups in terms of where the expected clamp site was 
according to pre-operative CT imaging. There were differences in the complexity of 
aneurysms treated across the three groups and therefore expected clamp site seems to be 
an insensitive predictor of aneurysm complexity.  
Overall, the subjective assessment of where a clamp would be placed intraoperatively by 
reviewing the pre-operative CT scan has poor correlation with where the clamp was placed. 
Expected clamp site neither predicts outcome in terms of survival nor accurately reflects 
where a clamp would be placed were the patient to undergo an open repair. Therefore, 
there is little value in recording or assessing this variable in future research in an effort to 
try to compare patients who undergo OR with a specific level of clamp with those 
undergoing endovascular repairs. This highlights the difficulties when comparing these two, 
distinct treatment options and their inherent differences. It must be accepted that patients 
who undergo open repair may require any level of clamp intraoperatively regardless of 
what is assessed at the pre-operative CT scan. This should be borne in mind by the surgeon 
proposing OR to an individual patient, especially as higher levels of clamp site are 
associated with poorer outcomes[86], and the level of clamp site does not appear to be 
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able to be accurately predicted. Furthermore, it is suggested that clamp site as a definition 
of juxtarenal/suprarenal/non-standard aneurysms not be used in future research. The 
anatomical measurements described above should be used instead. The majority of studies 
identified within the systematic review evaluating open repair for NSA patients used a 
clamp placed above the renal arteries as a marker for juxtarenal aneurysm. However, in 
this study the definition of non-standard aneurysms identified a cohort of open repair 
patients in whom only 30% received an intraoperative clamp above one renal artery. 
Therefore, there is an important cohort of patients, identified by this research, that has so 
far been neglected within the medical literature. That is, patients undergoing open repair 
who are not suitable for standard EVAR but still can have an infrarenal clamp placed. This is 
an extremely important comparison to make as detailed in the design of this study. It also 
importantly limits the comparison that can be made from the systematic review presented 
in this thesis on open repair with the patients studied in the retrospective cohort studies as 
they seem to be anatomically distinct. 
10.3. Operative data 
All cases in this cohort were performed in theatre under general anaesthetic. There is 
description, in the literature, of endovascular procedures being performed under regional 
or local anaesthetic as well.[201, 202] In this study the use of the operating theatre with 
general anaesthetic reflects local practice and resources specific to the centres studied 
rather than a distinct preference for these techniques over alternatives. It was impossible 
therefore to comment on the role these varying techniques may play in influencing the 
outcome from any given operation. This fact however is important to recognise; variation 
in the use of anaesthetic techniques or operating environment was not present in this 
study thereby reducing the number of potential confounding factors and allowing a more 
meaningful analysis with regard to the specific operation type alone. It is also possible to 
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perform OR through different operative approaches, namely either transperitoneal access 
(midline or transverse) or retroperitoneal access from an incision centred on the flank. 
There is some evidence that the retroperitoneal approach can improve outcomes for 
selected patients and may reduce pulmonary complications [203] but no patients in this 
study received OR via this approach and were all done transperitoneally, again reducing the 
risk of bias secondary to approach. From an endovascular point of view, it is also possible 
to access the arterial system percutaneously or via an open ‘cut down’ to the access artery. 
The proponents of the percutaneous approach suggest that it can reduce morbidity by 
reducing the invasiveness of the groin incision used and can reduce wound complications 
and recovery time; however, there has been little evidence of high quality in this area so far 
to show a true benefit with percutaneous EVAR [204]. All endovascular cases in this study 
received an open cut-down to access the arterial system with formal closure at the end. In 
two cases, a Rutherford-Morrison incision was used instead but these were for specific 
anatomical reasons identified pre-operatively. This again therefore eliminates potential 
bias that would have been invoked by differing approaches to arterial access. In fact, within 
the base site now all endovascular cases, including fEVAR are performed preferentially by 
percutaneous means. 
The operation time was longer in the fEVAR group compared with both other groups with a 
median time of just over 5 hours compared with 3 ½ hours for EVAR and 4 hours for OR. 
This approached but did not reach statistical significance. The method used to estimate the 
operative time was open to potential inaccuracies, so the median time stated above may 
not be an accurate reflection of the true operative time; however, the same method was 
used regardless of the operation type so at least each group would be subject to the same 
inaccuracy. In order to estimate the operation time, the anaesthetic chart for the operation 
in question was scrutinised and the total time was estimated from that. The detail of 
recording on anaesthetic charts is variable and subject to differences between individual 
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anaesthetists who actually record the data. Occasionally but not often, the actual start of 
the operation or ‘knife to skin’ time would be recorded. When this was the case, this was 
taken as the true start time. On any anaesthetic chart there is inevitably a period of time 
where observations are recorded but the operation has not yet started. This is variable for 
each patient and operation type. Often this period of pre-operative recording is longer with 
OR simply because the anaesthetist will often place more invasive monitoring equipment 
such as arterial and central venous lines as well as cardiac output monitoring. This period of 
placing lines is not actually part of the true operation but will be monitored and recorded 
by the anaesthetist nonetheless. Despite this variable ‘pre-operative’ recording time, it is 
often possible to estimate the start of the operation as the patient’s physiological 
parameters will often noticeably change at the start of the invasive surgical procedure and 
the intensiveness of the monitoring by the anaesthetist will increase and usually be duly 
recorded. This potential inaccuracy would generally lead to a longer operation time to be 
recorded than was actually performed for OR. Since the operation time was still found to 
be less than that for fEVAR this inaccuracy is unlikely to have significant consequences for 
these results. In essence we can be certain that fEVAR operations genuinely took the 
longest amount of time out of the three types of repairs despite inherent inaccuracies in 
recording data in a retrospective manner.  
It is unsurprising that the operating time was found to be longest for fEVAR due to the 
complexities of that operation over EVAR and OR. It inevitably takes more time to 
accurately place and deploy a fenestrated stent-graft system due to the multiple target 
vessels that need to be identified, cannulated and secured with target vessel stents. It is 
interesting to note though that despite the burden of prolonged operating this does not 
seem to translate into worse outcomes in terms of immediate or delayed complications, 
prolonged hospital stay or increased use of blood transfusion. Although cost implications 
were not considered in this study the fact that fEVAR took longer to perform would 
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inevitably influence the cost to the healthcare system of this type of operation over the 
other two. fEVAR is already more expensive than either of the other two operations in 
terms of the cost of the ‘consumables’ used within the operation, namely the device itself, 
costing approximately £16,700 on average (range £12,000 - £30,000; The unit cost per 
device varies in line with the complexity of the bespoke stent-graft). This is in comparison 
with £6000 for a standard device and £100 for an OR graft. These lengthy operations 
therefore will only add to this high cost as operating theatre time is one of the most 
expensive periods of a patients care. Further research should take into consideration the 
cost of different types of operations, including the length of operations and even the total 
time spent in the operating theatre and not just the actual operation. As it is this value that 
will affect the overall total cost of an operation for an individual patient. 
Unfortunately, a high proportion (65%) of patients did not have an estimate of 
intraoperative blood loss recorded. This proportion was higher in both the endovascular 
repair groups compared with the OR group. This is most likely due to: 
1) It is not routine to record intraoperative blood loss within the clinical case notes. 
This is especially true when the procedure in question proceeded as expected with 
acceptable or minimum levels of blood loss as determined by the anaesthetic and 
surgical teams.  
2) Endovascular operations typically do not result in the same level of blood loss as 
the more traditional open operation as one would expect. Therefore, the 
anaesthetic and surgical team may not feel it necessary to document the estimated 
blood loss when it was a minimal amount, for example <100mls.  
For any given case, the lack of a recording of the intraoperative blood loss would indicate 
that for that particular patient there probably was a minimal amount of blood loss. This 
may not be true in every case but is a reasonable supposition. It is somewhat unsurprising 
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that OR patients received the highest volume of blood transfusion both autologous and 
homologous as the inherent invasive nature of this operation would inevitably result in a 
higher volume of blood loss. There was at least one patient within the open repair group 
who suffered significant morbidity and potentially mortality related to their significant 
blood loss, which could have potentially been avoided if they were able to undergo 
endovascular repair. The patient in question was estimated to have lost 3000ml of blood 
intraoperative and was transfused 1500mls of autologous blood and 500mls of homologous 
blood. During the first postoperative day their clotting profile was noted to be severely 
deranged with a concomitant anaemia. They died within the first 24 hours after the 
operation. This specific patient however was deemed not suitable for either endovascular 
approach due to angulation and tortuosity within the aneurysm neck as well as the fact 
that the target vessels did not have enough separation to allow satisfactory placement of a 
fenestrated device. It is possible that this degree of anatomical complexity is what lead to 
the difficulties and high blood loss. This case highlights the potential risk undertaken with 
open operation but also that in some circumstances this is the only therapeutic approach 
available to the surgeon and the patient. It also raises an interesting point with regards to 
the validity of this current research; the aim, as stated earlier, was to compare a group of 
anatomically homogenous patients to see which operation gave the best clinical outcomes. 
The idea was simple in that if by defining the patient cohort using anatomy derived from 
IFU then a group of patients that could potentially have undergone any of the three 
operations would be compared. This patient highlights the flaw in that design.  
By using the criteria of IFU anatomy the inclusion of patients is limited to those out with 
IFU but does not limit solely to those with anatomy suitable for endovascular repair. This 
gives rise to the situation, as alluded to earlier, where we are comparing patients who 
underwent open repair (and it was either unfeasible or even technically impossible to place 
an endovascular device) with patients in whom received an endovascular device. Further 
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research should focus to determine outcomes for patients who would be suitable for all 
three repair types. Although this research gives an important insight into outcomes for 
these operations for all comers and indeed it seems to suggest that standard EVAR may not 
be the most suitable the question of whether open repair or fEVAR provides the best 
clinical outcomes is still to be resolved. There are different ways that future research could 
provide this answer and attention should be paid to the design of any future study with this 
problem in mind.  
10.4. Stent Graft Configuration 
In all cases of fenestrated EVAR the Zenith Fenestrated (Cook Inc. Bloomington, Indiana) 
platform was used. In the EVAR group, all patients received a stent-graft from the Zenith 
Flex (Cook Inc. Bloomington, Indiana) platform. During the period studied there was only 
one commercially available fenestrated device available, explaining why all the patients 
received this device. Regarding standard EVAR there were more devices available and in 
use during the study period, and all but one identified by this study was the Zenith flex 
device. The other being an aorfix stent graft. This patient was initially included as was the 
original design and intention of the study but after analysis and further statistical advice it 
was decided that excluding this one outlier in terms of manufacturer would give greater 
reliability to the results when assessing outcomes for Zenith devices. This is in 
acknowledgment that there is potential statistical bias invoked by the change of 
methodology after the beginning of data collection and analysis. It should be noted that 
initial analyses did not demonstrate different results in terms of primary and secondary 
outcome measures because of the fact that the aorfix patient was taken out of analysis. 
The fact that all of the patients received the Zenith flex device represents physician 
preference for this device overall.  Using the institutional database for the Royal Liverpool 
University Hospital (the largest contributor of patients into this study) 143 patients 
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received standard EVAR over the period studied. Of these, 127 (89%) received a Zenith flex 
device, ten patients received a Gore Excluder device, two received an Aorfix device and in 
four no device was recorded on the database. All patients included in the retrospective 
multicentre and single centre studies above were identified from the above database. 
Simply put the physicians using these devices were more familiar with the Zenith flex and 
tended to place this device in all patients more frequently, as a consequence of this when 
faced with a patient with particularly difficult anatomy they would be more inclined to use 
a device that was familiar to them. Furthermore, the Zenith flex device has a perceived 
advantage over the Gore Excluder device especially in the setting of patients with complex 
neck anatomy - it possesses suprarenal fixation (uncovered metal barbs that extend 
beyond the upper part of the fabric) with the intention of providing extra fixation in the 
aorta adjacent to and above the renal arteries. The Gore device also has active fixation 
properties, but these are at the top of the fabric and hence are intended to act upon the 
infrarenal aorta.  
10.4.1. Standard EVAR 
When planning and deploying standard EVAR the manufacturers of all stent graft devices 
recommend that the proximal body diameter of the stent-graft be ‘oversized’ with respect 
to the neck diameter by 10 – 20%. There is evidence to suggest the radial force of the stent 
graft providing the effective seal is increased as the oversize is increased to 20%.[205]  This 
is to provide additional radial force within the sealing zone of the stent graft within the 
infrarenal neck. Too small an oversize theoretically increases the chance of device failure by 
either promoting migration of the stent-graft caudally or by providing insufficient seal so 
that graft related endoleaks (Type 1a) occur. Too much oversizing can result in inadequate 
seal leading to type 1a endoleaks. This occurs because when the device is deployed from a 
constrained fashion to its full extent (as determined by the metallic stent) the fabric may 
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not fully expand as it cannot reach its full diameter, limited by the aortic wall. This leaves 
‘gutters’ round its circumference through which an endoleak can occur. (See figure 10.1) 
Figure 10.1 Schematic Representation of Deployment of Oversized Stent-graft 
 
Analysing the data for EVAR patients within this study shows that a significant proportion 
of patients were out with this ‘ideal’ zone of 10-20% oversizing. When comparing the 
maximum neck diameter recorded for the infrarenal neck with the proximal main graft 
body diameter the following table details the oversizing used for the patients in the EVAR 
group (there was one patient in which the proximal body diameter was not available) (See 
table 10.4). 
Table 10.4. Amount of Oversizing in EVAR Patients 
Amount of oversizing Number of patients (%) 
<0% 2 (7%) 
0 -10% 10 (37%) 
10 – 20% 12 (44%) 
>20% 3 (11%) 
As can be seen from the table there were actually two patients in whom the proximal body 
diameter was less than that of the maximal neck diameter. The first case of ‘under sizing’ 
was in a patient with a maximum neck diameter of 34mm in whom a proximal main body of 
30mm was implanted. In this patient, the neck diameter only dilated to 34mm at 15mm 
Figure 10.1 a and b. Schematic representation of cross section of aorta (Red circle) 
and stent graft (Black), before deployment (Figure 1a) and after deployment (Figure 
1b) if stent graft oversized too much. Gutters (Yellow shaded area) can act as 
channel for blood flow 
Figure 10.1 
b 
Figure 10.1 b 
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from the lowest renal artery origin (LRAO). Above this, the neck diameter was 23mm at 
5mm and 29mm at 10mm from the LRAO. Obviously, this constitutes quite severe 
conicality in this neck and presumably the intention was to try and provide seal within the 
upper portion of the neck albeit in hostile neck anatomy. In the other patient that was 
‘undersized’ a stent graft with a proximal body diameter of 28mm was placed in a neck 
with a maximal diameter of 30mm. Again, the maximal neck diameter was only reached 
15mm below the LRAO. Above this the neck diameter immediately below, 5mm and 10mm 
from the LRAO was 26mm. This again explains the choice of a 28mm diameter main body 
diameter; the purpose undoubtedly would have been to seal within the first 10mm of neck. 
Regarding the 10 patients who exhibited oversizing of between 0 and 10% all followed the 
same pattern as described above with the maximal neck diameter being reached 15mm 
from the LRAO. Of the three patients who had oversizing of >20%; one patient was 
oversized 21% and one 23%. These parameters fall within the realms of interobserver 
measurement error between the initial planning physician and the researcher within this 
study. Furthermore, it is unlikely that such a small amount of oversizing over the 
recommended threshold would have deleterious clinical consequences. There was 
however, one patient in whom the main stent-graft body used was 28mm representing a 
33% oversize. This patient had a long (25mm) neck that was conical enlarging from 17mm 
proximally to 21mm at 15mm distal from the LRAO. There is no obvious explanation why 
this size of stent-graft was selected over a smaller one from the data collected, but there 
are many factors that may promote a clinician to choose a larger stent graft.  
Although the above is interesting it is important to note whether any of the sizing 
discrepancies resulted in poorer outcomes for the patients. This was not specifically 
investigated during this study. As mentioned, there was one patient in whom no 
information was available regarding the size of the stent graft but in the remaining 27 
patients there were 10 cases of clinical failure; 8 due to migration (with or without 
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subsequent open conversion) and two patients who died during their index admission. Of 
those eight patients with migration; five had oversizing <10% and three had oversizing of 
10 – 20%. Both patients who were ‘undersized’ exhibited migration during follow up. 
Although the numbers are small in this study and no firm conclusions can be made 
regarding the amount of oversizing and the resultant clinical outcomes the results do 
suggest that it may play a role. The fact that a significant proportion of patients undergoing 
EVAR had stent grafts oversized <10% or >20% suggests that in this group of patients, those 
outside of IFU for EVAR pose a particular problem during the planning of the repair. 
Although the anatomy seen in this group is somewhat less severe than that seen for either 
the OR or fEVAR groups this is nonetheless an area in which fEVAR and OR have an 
immediate advantage as planning the amount of oversizing within a diseased infrarenal 
neck is not even done for fEVAR or OR as it is not necessary. This highlights the difficulties 
in providing this form of repair for patients who are outside IFU for standard EVAR and 
potentially represents another mode of failure for patients that would not be present if 
they undergo one of the other two types of repair. 
10.5. Post-operative Outcomes 
A significant reduction was seen in the length of critical care stay and hospital stay overall 
for those patients who underwent repair by one of the two endovascular methods. This is 
unsurprising given the less invasive nature and lower inpatient complication rate seen in 
both these types of repair. This fact has obvious implications with regard to overall cost of 
the inpatient episode, but also will undoubtedly have an impact on the wider costs to the 
community and society once the patient leaves hospital. It is reasonable to assume that 
those patients who have a shorter in hospital stay with less complication will be more likely 
to return to full functional capacity similar to their pre-operative status and furthermore 
will be quicker to return to maximum functional capacity once they leave the hospital. This 
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means that the burden on community health and social services will be reduced in this 
population when compared with those undergoing OR. What is uncertain is whether this 
cost benefit does truly exist and if so, is it significant enough to make a difference to the 
overall cost. Previous studies have shown standard EVAR to be more expensive when 
compared with OR with the UK EVAR 1 Trial showing an estimated increased cost of EVAR 
in the region of £1000 for the inpatient episode and £3500 over the lifetime of the 
patient.[64] However, this analysis is over a decade old now, and compares standard EVAR 
with OR for patients with standard aneurysms, the applicability of these estimates to 
current practice with regards to non-standard aneurysms is therefore limited. 
Although not possible to assess in this retrospective study another important consideration 
for any patient deciding about which operation to have would be the quality of life they can 
expect after the operation. This has been considered in randomised controlled trials 
comparing standard EVAR with OR and they found that scores for quality of life 
questionnaires are worse for OR within the first month after operation but return to pre-
operative levels with either no difference or a slight benefit for those having undergone OR 
after 12 months. [64, 88] 
10.6. Comparison of Standard with Non-Standard Aneurysms 
 
As standard aneurysms by definition did not undergo fEVAR comparison was only possible 
for EVAR and OR patients. This comparison was also limited by small numbers of patients 
identified especially for open repair. This makes meaningful comparison between these 
groups difficult. This should be borne in mind when analysing those results. The fact that 
the standard aneurysm patients were only identified from a single centre contributed to 
the confounding factors affecting the comparison of these groups. The differing nature of 
the open operation between standard and non-standard aneurysms is also a confounding 
factor – the fact that no patients received a clamp above the renal arteries in the standard 
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OR group compared to 30% of the non-standard group is an important point for note when 
comparing the outcomes. Very limited information can be drawn from the comparison 
between standard and non-standard patients because of the above considerations. 
Furthermore, the groups were heterogenous in terms of gender make up with more males 
predominating in the standard aneurysm patients. The standard anatomy patients were 
also significantly more likely to have a preoperative diagnosis of ischaemic heart disease 
and conversely non-standard patients had a significantly worse preoperative fEV1. 
Furthermore, and by definition the anatomical characteristics of the groups differed with 
significant differences in terms of neck length, diameter, alpha and beta angulation. 
Importantly however AAA diameter was similar between the two groups. Furthermore, the 
only significant difference found was that of primary technical success for open repair – 
meaning that open repair was more likely be technically successful regardless of whether 
the aneurysm was non-standard or not. This means that technical success across these 
three repair groups is primarily affected by whether it is repaired by open surgery or not - 
regardless of whether it is a non-standard aneurysm or not. It was also not possible to 
investigate the outcomes of mid-term survival and clinical success by the prescribed 
methods set out prior to analysis. This again highlights the need for statistical input prior to 
constructing a study design and methodology to enable this issue to be highlighted early so 
a solution can be found to it. 
The rationale for the above comparison was to try and ascertain whether the distinction of 
anatomy between standard and non-standard was an important determinant of outcome 
however it is not possible, from the results presented to definitively state this one way or 
the other. From the systematic review conducted into outcomes for patients undergoing 
EVAR for NSA it appears, as stated, that the outcomes are worse. However, it could be 
argued that it is irrelevant whether the outcome for non-standard aneurysms are inferior 
to those of standard aneurysms. The anatomy of a patient is predetermined and non-
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modifiable and therefore it is less important whether these patients have different 
outcomes compared to each other but what is important is whether a patient with a 
specific anatomy has different outcomes based on the treatment options available to them.  
10.7. Summary of Discussion 
This study has failed to prove or disprove the hypothesis as set out in the beginning and the 
prime reasons for its failure to do so will be discussed in the next chapter. It has however 
revealed some important aspects regarding the treatment of patients with non-standard 
aneurysms. Firstly, EVAR has a lower rate of immediate technical success than either of the 
other two treatment options and over the longer-term patients have an increased rate of 
clinical failure compared to their fenestrated and open repair counterparts. This is all in the 
context of ‘simpler’ aneurysms anatomically. However, it should be noted that the findings 
of a statistical difference for technical success in this study are independent of whether the 
aneurysm is standard or non-standard and seem to be related to whether a patient has 
open repair or not. As discussed, this is likely due to the peculiarity of the definition of 
primary technical success in the reporting standards. These findings suggest that placing 
standard EVAR outside IFU is a ‘bridge too far’ for this technology and that where possible 
this method of treatment should be avoided. Patients who underwent OR showed an 
increased length of critical care and total hospital stay. Finally, fEVAR demonstrated the 
lowest rate of adverse clinical events (ACE) during follow up. The evidence does not state 
that fEVAR is the best treatment option for non-standard aneurysms but does suggest that 
it may be the least inferior option. Further study is needed to ascertain the true difference 
between these treatment strategies. 
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11. CHAPTER 11 - Discussion on Limitations and Design of 
Study 
The design of any research study involves many aspects so that the study can proceed with 
a sound methodological and ethical grounding. One aspect of good study design should 
consider the practical issues of conducting the research with the resources available. 
Included in this is the time available to conduct and complete the research.  
At the beginning of any research and central to all that follows should be the research 
question. This should be a clearly defined question from which a hypothesis can be drawn, 
and should be so from before the beginning of the research. After this a significant amount 
of groundwork needs to be done before the research actually begins and unfortunately this 
can often take a significant amount of time, putting pressure on an already constrained 
timeframe. Once the research question has been defined there are three important aspects 
that need to be satisfied before data collection and analysis can begin.  
The first domain is with regards to methodology of the proposed study and its design. The 
most appropriate study design (i.e. randomised-controlled trial, case-control cohort study 
etc) should be chosen with clear reasons as to why this design was chosen over others. The 
selected design of study should then be interrogated intellectually to ensure it will provide 
a robust enough framework to enable the researcher to try and answer the question at 
hand with acceptable certainty. Ideally someone with expertise in the design of studies 
should be involved at this stage.   
The second domain relates to the statistics used within a study.   Ideally a statistician 
experienced in the area of research should be involved from the beginning and included 
when deciding on the study design itself. The type of statistical analysis to be used in the 
study should be set out from the beginning with the study question in clear focus at all 
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times. To enable meaningful statistical analysis consideration should be given to the 
number of subjects to be included in the research to minimise the possibility of error 
during statistical analysis. 
The third domain relates to governance and ethics. All studies require an appropriate 
governance framework and within medical research those involving patients certainly 
require consideration of the ethics pertaining to the study and require ethical approval at a 
local, regional or national level, possibly all. 
Supplementary to the above considerations the practicalities of how a study will be 
conducted also need careful thought and planning prior to the commencement of a study. 
These practicalities may also influence the above considerations – for example it may not 
be possible to conduct a randomised controlled trial to answer a particular question given 
the resources available.  
This research was conducted as part of a higher degree by the chief investigator within a 
tertiary vascular unit at a teaching hospital (Royal Liverpool University Hospital) and was 
affiliated to the local university (University of Liverpool). There were no additional 
resources available such as research personnel. During the course of the research valuable 
lessons were learned about study design and the design of research projects within the 
above context. The chief investigator began the research post immediately following a 
clinical post and was a relative novice to the world of academia. There was a clear research 
question at the beginning which allowed the research process to begin in earnest. From 
there discussion and thought was given to the methodology of the proposed research and 
it was decided early on that the study would need to be in the form of a retrospective 
observational study. It was recognised that a prospective longitudinal study could most 
likely answer the question more accurately of whether fEVAR has the best clinical outcome 
as a treatment strategy for non-standard AAAs. However, there were important aspects 
390 
 
that were unknown about fEVAR, the alternative treatment strategies and more so non-
standard AAAs that meant a retrospective analysis would give important insight and 
information that would help the design of a future prospective study. Furthermore, it was 
clear that it would not be possible to complete a prospective research project within the 
confines of a higher degree, mainly because the clinical outcomes that are of interest can 
take years to manifest and therefore a long follow up time would be needed. At this point 
the process of application for ethics approval and registering of the research study with 
local and national governance bodies began. It was decided that to obtain sufficient 
numbers of patients and to improve the validity of the research patients from other 
hospitals within the local region would be included. To lawfully obtain access to their 
health records approval needed to be sought to allow breach of confidentiality for research 
purposes. At the time this meant a further application to the National Information 
Governance Board (NIGB) for section 251 approval. The whole process of application and 
registration took approximately 6 - 9 months before final approval was granted to allow 
data collection to proceed. 
With regard to the first domain mentioned above of design and methodology this study 
began strongly with a clear research question in focus and a defined set of outcome 
measures identified. This design and methodology were interrogated to some degree but 
then the study proceeded without logical analysis of the potential pitfalls. If the researcher 
had taken more time and consideration over these potential pitfalls it may have been 
improved. For example, if the study was designed to allow more flexibility then the 
methodology could have been optimised near the beginning when it became apparent 
there were fewer patients available for analysis than expected. In retrospect, a relatively 
likely complication that could have been foreseen. With regards to the statistical aspects of 
the study a statistician was involved in the final analysis of data however a statistician was 
not involved from the beginning and had no input at the design stage of the study. With 
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regards to the governance and ethical aspects within the study all requirements were 
fulfilled as early as practically possible but without adequately assessing the impact of 
trying to collect data from other centres it is likely that a large proportion of time spent on 
this area (gaining NIGB section 251 approval) was wasted as very little benefit in terms of 
numbers of patients was derived from this effort. 
11.1. Limitation in Number of Patients 
The main limitation in this research was the final number of patients studied. The design of 
the study tried to mitigate this potential problem in two ways – to include patients 
operated on over a two-year period rather than one and to include patients treated at 
different hospitals within the local region. Initially it was decided to include patients 
operated on over the period of one year, but it became apparent that this would not return 
enough patients, so the time period was extended to two years. It was felt that to study 
more than two years would result in too onerous a task in terms of reviewing all CT scans 
and therefore two years was chosen as the appropriate compromise in this area. The 
researcher was mindful that a long follow up time would be needed to try and detect 
important clinical outcomes which occur over the longer term, this limited the most recent 
date a patient could have undergone their operation to 2008 (giving, at the beginning of 
the research project, a 4-5 year follow up time for the most recent patients). It was also 
noted that the introduction of the electronic storage of radiological images on the picture 
archive and communication system (PACS) began in 2006 and therefore it would be more 
difficult to obtain pre-operative CT scans prior to this time. As the introduction of PACS 
began in 2006 it was likely that there would be some difficulty in obtaining pre-operative 
images during this year, but it was felt the number would be relatively small. 
Unfortunately, it was not foreseen that there were significant difficulties in obtaining pre-
operative CT scans performed during 2006 and the research was well underway by the time 
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this was identified. This unfortunately limited the number of patients with an available CT 
scan to scrutinise to identify if the patient could be included or not – 167 patients out of an 
initial number of 497 (34%) did not have a CT scan available for review. Although it is 
unlikely that all of these 167 patients would have met the inclusion criteria a significant 
proportion may have merited inclusion. Of those with a CT scan that was reviewed 59% had 
a non-standard aneurysm. Therefore, if the same proportion of patients with no CT scan 
met the inclusion criteria this would have brought the total number of patients studied to 
180, more than doubling the number of studied patients. In retrospect it would have been 
prudent to assess the availability of CT scans prior to the main data collection so that a 
decision could have been taken at the time whether to shift the time period of interest one 
year later, with the acknowledgment this would sacrifice one year of follow up. This was a 
complication that could have potentially been avoided with careful thought and 
preliminary investigation into the practicalities of obtaining CT scans. 
In order to increase the number of patients available for study and to widen the scope of 
the study to a multicentre trial it was decided to include patients operated on at different 
sites across the region of Cheshire and Merseyside. The decision to include patients 
operated on at other sites was deliberately made to try and increase the number of 
patients but also to try and improve the validity of the results when applying them to a 
general vascular population with AAA. This is because the Royal Liverpool University 
Hospital, the base site where the research was carried out, is a tertiary referral centre 
specialising in complex aneurysm repair including fEVAR. The valid concern was that the 
population being studied would represent an unusually complex group of patients and 
therefore the results would only be applicable to a similar group of complex patients. The 
decision was made to include patients from other centres and this therefore necessitated 
the application to NIGB to seek section 251 approval. This application process was lengthy 
as already stated – meaning that data collection from the other sites to be included in the 
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study began months after data collection from the base site. Out of the original 7 sites 
planned to be included in the study no patients could be identified from four of the sites. In 
each case, initial contact was made through coding departments, theatre departments or 
individual vascular surgeons. In each case the problem was either that relevant CT scans 
could not be transferred as there was no longer a copy of the preoperative CT scan 
available or a list of patients was unable to be provided. This latter problem was despite 
the researcher and supervisor contacting the personnel at each hospital and visiting the 
sites to meet with relevant personnel. Simply put: requests were made for lists of patients 
for potential inclusion into the study but there was no response to the request. After more 
than a year of trying to obtain lists of patients it was decided to abandon trying to get 
patients from these centres as the researcher was nearing the end of his time in a 
dedicated research position and the data collection had almost been completed with the 
already included patients. The pragmatic decision was taken to complete the research with 
the limited number of patients already obtained. During the period of research, the 
vascular services within the Cheshire and Merseyside were undergoing major 
reconfiguration as part of a national programme of service reconfiguration within vascular 
surgery. One of the sites traditionally part of the Cheshire and Merseyside region merged 
with a vascular centre in another region. Three sites (Arrowe Park Hospital, Countess of 
Chester Hospital and Warrington Hospital) were in the process of merging during the 
research period. The other three sites (Royal Liverpool University Hospital, Aintree 
University Hospital and Southport Hospital) became fully integrated during the period of 
research. Due to the relocation of vascular services from some hospitals there was no 
permanent vascular presence at the majority of the sites left and this undoubtedly made 
lines of communication more difficult. There was no permanent staff member who could 
help to take things forward ‘on the ground’ when there were issues. Furthermore, 
individual surgeons who had initially agreed to help with data collection inevitably became 
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busy with the agenda of reorganisation and therefore were unable to devote time to help 
with the research project. In total, 11 patients were identified from other centres that were 
finally included for analysis. One patient was from Southport hospital and the other 10 
from Aintree hospital, from both these hospitals there were no significant delays or 
difficulties in obtaining a list of patients for potential inclusion into the study. Therefore, 
the final result of trying to include patients from sites additional to these two lead to over a 
year delay in the finishing of data collection and analysis with no additional patients finally 
included. It is difficult to see how one could have envisaged the degree of difficulty 
encountered in this area at the outset, however some preliminary background work may 
have helped. It would have been possible to use two or three sites as test sites and if initial 
lines of enquiry received no response or revealed that only small numbers of patients 
would be accessible to review then it could have been decided to abandon this plan. With 
the realisation that trying to include patients from other sites would have been too costly 
in terms of time utilised with very little benefit in terms of numbers of patients. The time 
saved in this aspect could potentially have been used to extend the base hospital search to 
three years instead of two for example. Although this problem encountered is specific to 
this research it does highlight the difficulties of carrying out research across multiple sites 
from one centre with no dedicated research personnel or even ‘points of contact’ at spoke 
sites. For future study into this area it would be recommended to conduct a multicentre 
trial – but recruit research personnel at each site to help drive forward data collection and 
potentially even analysis. A collaborative effort would greatly increase the productivity of 
such a study. Furthermore, it would be beneficial to choose at least one other site that also 
perform complex aneurysm repair and fEVAR as well as at least two other sites that 
perform OR and EVAR. This would ensure sufficient numbers of patients studied that 
underwent fEVAR as well as maintaining the generalisability of the results to all 
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Given the poor yield of patients from hospitals in the surrounding region as was the original 
intention of the study it is important to characterise and define the patient population that 
was captured. Of the final 80 patients that were included: All 15 patients who underwent 
fEVAR were from the Royal Liverpool University Hospital, all 28 patients who underwent 
EVAR were from the Royal Liverpool University Hospital and the majority of patients (26 
patients) undergoing open repair were treated at the Royal Liverpool University Hospital. 
Ten patients undergoing open repair were treated at Aintree University Hospital and one 
was treated at Southport hospital. Therefore, the majority of these patients and all of the 
endovascular cohort were from a single centre. Although this study was multicentre region 
wide in its design, in actual fact after patient capture it essentially was a single centre 
retrospective study. It should be noted that the Royal Liverpool University Hospital is a 
tertiary or quaternary referral centre and receives referrals and operates on patients that 
are referred from other regions. Aintree University Hospital is a similarly sized teaching 
hospital within Liverpool (5 miles apart) and therefore it is reasonable to assume that the 
patient populations captured by both hospitals are similar in terms of demographic detail. 
This fact therefore limits the applicability of the results to a wider population of patients 
presenting to a district general hospital for example, or in a different part of the country. 
This is unfortunate as the original intention within the design of the study was to enable 
comparison of results with most other unselected populations including patients 
presenting to a district general hospital. 
It is also noteworthy that of the final 137 CT scans reviewed more patients were deemed 
non-standard (81) than standard (54) – in 2 patients there was disagreement between 
reviewers. This result suggests a potential sampling bias inherent in the design of the study 
as it would normally be assumed that the majority of patients treated for aneurysmal 
disease are within the IFU for standard EVAR. As stated above this probably reflects the fact 
that the majority of patients were identified from the Royal Liverpool University Hospital 
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which as an expert referral centre will inevitably receive a disproportionate number of non-
standard aneurysms. This was an important reason that the initial study design aimed to 
capture a region wide population to try and mitigate this type of sampling bias. 
Furthermore, it is possible that within the large proportion of patients without a CT scan 
(167) there would have been a significant number of standard aneurysms that have been 
missed by this study. Numerous studies from the systematic review into outcomes after 
EVAR for non-standard aneurysms (Chapter 5) however did show that in their patient 
populations more patients had a non-standard aneurysm compared with standard. Of 
course, these studies will be limited and biased by the same factors mentioned above but it 
is noteworthy that a similar discrepancy is seen among other studies. Ten studies 
specifically compared outcomes between non-standard and standard aneurysms and of 
those four reported a larger number of non-standard aneurysms than standard in their 
study [95, 96, 102, 106, 116]. In fact, from all ten studies the number of non-standard 
patients was 1377 (46%) and standard patient was 1634 (54%). Therefore, it may not be 
that there was a significant sampling bias at all, but that assumptions that the vast majority 
of aneurysms treated have standard anatomy is wrong. Of course, as stated this may just 
be true for tertiary referral expert centres but nonetheless would be an important area for 
future research – to determine the proportion of nonstandard aneurysms treated (by any 
method) within a population of aneurysm patients. 
11.2. Limitation with Definition of Non-Standard 
Another limitation with the study was that by using the inclusion criteria of ‘outside IFU for 
standard EVAR’ led to a number of patients being included that were not suitable for either 
fEVAR or EVAR. This means that the population being studied is not as homogenous as one 
would desire. In order to address this problem, there are many ways in which a study could 
be designed. The first and probably most obvious is to design a randomised controlled trial. 
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This would allow prospective analysis of all cases and only those that were felt suitable for 
an endovascular repair would inherently be included into the study. The other obvious 
advantage of an RCT would be to eliminate selection bias as was present in the current 
study. The disadvantage of this design of trial is that it would be both expensive and time 
consuming. Furthermore, there is some evidence to suggest there is a perioperative 
mortality benefit in patients undergoing fEVAR compared with OR [170] which raises an 
ethical question of whether it would be appropriate to propose a trial where patients 
would be randomly allocated to an operation which may in fact incur a greater 
perioperative mortality. In fact, with the removal of selection bias the perioperative 
mortality rate for those undergoing OR that would be seen may be even higher. It would of 
course be possible to design an RCT where patients in whom there was clinical equipoise as 
to the ‘best’ treatment option would be randomised to a treatment and in those in whom 
there was no equipoise they would go on to receive the prescribed treatment but under 
the auspices and follow up of the ongoing trial. In practice however such a trial may be 
difficult to implement in a standardised way as inevitably there would have to be a 
subjective assessment at some point by an individual as to whether a case represented 
equipoise or not. To circumvent the ethical dilemma offered by an RCT a well-designed 
prospective study in which patients were assessed at the outset and only included if they 
were technically suitable to undergo either fEVAR or OR would answer the question 
adequately. The surgical team, along with the patient, would retain the right to make an 
informed choice of which operation to have and with appropriate pre-operative 
assessment of the patients the selection bias could at least be quantified and taken into 
consideration within the analysis. 
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11.3. Comparison of Literature with Studies 
Three systematic reviews were carried out as part of this thesis to give a background and to 
try and inform and help the discussion regarding outcomes for non-standard aneurysms. 
The first point of note is the significant heterogeneity between studies within each of the 
systematic reviews makes comparisons between those studies and the completed research 
potentially flawed. The majority of the literature also documents a time frame when 
significant technology advances were and still are being made. In endovascular surgery 
there appears to constantly be new innovation and at the time of writing there are 
currently devices available, with ancillary equipment, that can treat aneurysms with an 
infrarenal neck of 4mm or longer within IFU. Although this limits the applicability of results 
from this, past and similar studies for the future the majority of aneurysms treated are still 
within the anatomical variables defined within this study. More importantly the question of 
those patients who are ‘borderline’ for standard EVAR still present themselves in everyday 
clinical practice. The conclusions of the systematic reviews detail that patients with NSA 
who undergo standard EVAR experience an increased rate of type 1a endoleak both within 
30 days from the index procedure and beyond when compared with SA patients. They also 
experience an increased risk of secondary intervention, usually to maintain proximal seal. 
There was however insufficient evidence to suggest whether these findings equate to 
significantly worse outcomes for NSA patients in terms of all cause or aneurysm related 
mortality beyond 30 days. With regard to NSA patients undergoing open repair the 
systematic review could only draw very limited  conclusions due to the poor 
methodological quality of the studies and the heterogeneity evident between them. The 
systematic review of fEVAR for NSA patients identified that it has acceptable clinical 
outcomes both in the short and longer term. Again, there was however heterogeneity 
between studies published and especially when concerning comparative studies making 
valid comparison difficult.  
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Overall within the limitations of the literature and the above studies the clinical outcomes 
of the three treatment options are similar for non-standard aneurysms. The systematic 
reviews also highlight areas for recommendation with regard to reporting and further 
research: Long term data (beyond 5 years) is lacking for NSA patients undergoing standard 
EVAR and represents an area ripe for further research. It is recommended that future 
reports should analyse patients defined by anatomy relating to the IFU for the device 
implanted to allow comparisons of patients across a time period which has seen significant 
advances and evolution in technology. There is also a need for adherence to already 
published reporting standards for open aneurysm repair. At the least adherence to 
definitions regarding juxtarenal aneurysms should be adhered to, ideally future reports 
would adopt the definition of non-standard aneurysms as outlined in this thesis to allow 
meaningful comparisons of an anatomically homogenous population. Bearing in mind that 
clamp position in itself is not the sole definition of what makes an aneurysm non-standard. 
Furthermore, specific anatomical data should be published when reporting outcomes for 
fEVAR patients. It is important to know the potentially relevant role different anatomical 
characteristics play in the outcomes of patients undergoing one of these treatment 
options. 
In order to ascertain if there was significant sampling bias invoked by the lack of patients 
identified for this study important demographic information was compared with the 
published literature presented in the systematic reviews also. This is especially because the 
vast majority of patients were treated at one centre, contrary to the intention and design 
of the study. Compared with the literature, NSA patients undergoing EVAR in this study 
tended to be older, but a similar proportion were male and for the studies in the literature 
that reported ASA grades the rates were similar. 81% ASA grade 3 or 4 in the current study, 
rates of between 50-100% in the literature. Pulmonary disease was poorly reported within 
the literature and the relative rates cannot be commented upon. Furthermore, baseline 
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size of aneurysm between the literature and the current study is similar. The fact that there 
is an increased perioperative mortality rate and poorer long-term survival rate within the 
study above compared with the literature for NSA patients undergoing EVAR is difficult to 
explain purely based on the comparison of demographic information. The most likely 
reason for these observed differences is that the current study is inaccurate due to the 
small number of patients included. This suggests limited information can be drawn from 
these results and therefore conclusion about comparisons to fEVAR and OR are further 
limited.  
Regarding the fEVAR patients within the current study the age, AAA size and proportion of 
male patients was similar to the reported literature. Furthermore, with a mean of 3 target 
vessels per patient the complexity and demographic details were very similar to the 
reported literature. The main difference was that the ASA grade of patients in the current 
study was more commonly 3 or 4 (80%) compared with the literature which was less than 
70% in the majority of studies that reported ASA. Despite these differences the principal 
outcomes were similar between the literature and the current study though again 
inference of treatment effect is limited due to the small number of patients in the current 
study, and for the reasons stated above comparisons with the EVAR cohort should be made 
only with caution. For open repair patients the most significant difference is that all 
patients within the literature identified had a clamp placed above at least one renal artery 
compared to 30% within the current study. This suggests a different anatomical cohort and 
as this study is primarily assessing outcomes and comparing them based on anatomical 
criteria comparison of results with the literature is likely to be flawed.  
For the above reasons and the fact that the vast majority of patients identified were 
treated at one site the generalisability of the results of the above study to a wider 
population are impossible to make. It may be reasonable to compare the outcomes with 
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other tertiary referral centres with a similarly complex case mix, but this would need to 
take into account the specific definition of non-standard aneurysm.  
11.4. Limitation in Study Design/Methodology 
The common thread to the major difficulties encountered during this research study, 
outlined above, relate to a lack of forward planning/pilot research. In retrospect, initial 
investigation with a limited pilot study to determine numbers of patients available for 
review may have been beneficial. This should have been done prior to designing and 
planning the main study and may have led to not only greater efficiency but a larger 
number of subjects included within the study. This pilot study could even feasibly have 
been performed prior to the dedicated period of research further increasing the time 
available to the researcher to plan, design, and conduct the study. The pilot study could 
also have been engineered to collate data on simple, important outcome measures – such 
as mortality - this would have made sample size and power calculations possible in the 
design phase of the study. This, in turn, may have been able to influence decisions such as 
prolonging the study period to three years to try and capture more patients.  
A statistician was not involved in the design of the study from the beginning and was only 
included after the commencement of data collection. In the beginning the statistics to be 
used were simple and mostly descriptive in nature, therefore it was felt that statistician 
involvement was not strictly necessary. As the study progressed more complex ideas of 
what may be possible with the collected data emerged – such as the possibility of 
generating models to predict risk in similar patient populations with non-standard 
aneurysms. At this point it became clear that for help with more sophisticated statistical 
techniques statistician involvement would be necessary. At that point data collection was 
well underway. Ideally a statistician would have been involved from the start, for several 
reasons. Firstly, statistician input would have been extremely helpful during the design 
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phase of the study and with their experience in study methodology, they may have been 
able to improve upon what had been planned. In this study there was no change to the way 
the data was analysed as set out prior to statistician involvement but agreeing upon 
statistical methods to analyse data at the start is important to avoid the possibility that 
analysis techniques are changed to better fit collected data. 
In summary, this research could have been conducted more efficiently and potentially 
included more patients if the following things had been done differently: 
 Once the research question had been identified and an outline of the main study 
design and methodology had been decided categorisation of potential problems 
and pitfalls would have been useful. Categorisation into methodological, statistical 
and governance issues would be useful. In addition to this a category of practical 
issues – such as whether CT scans would be available, whether patients will be able 
to be identified from other centres or not – may have improved this study. 
 Once the relevant, main issues had been identified a focussed pilot study with 
strictly defined aims would have been extremely helpful. The aim of such a pilot 
study would be to address each of the problems outlined in the above phase and 
should therefore be strictly time limited to avoid it partially replacing the main 
study.  
 Statistician involvement from the beginning – even at the stage of setting the pilot 
study. 
 The process of governance and registration with various institutions (University, 
ethics committee, research department) to begin as soon as possible, potentially 
even before the beginning of the research post. 
For future research it would be important to adhere to the above principles when 
beginning and conducting the research as much as possible. For any future prospective 
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study into this area the lessons learned within this study and detailed in this chapter could 
be considered as part of a pilot study and should help to inform the design of such a study. 
 
11.5. Suggestion for Reporting Standards 
 
It is the recommendation of this thesis that the definition of non-standard 
aneurysm/anatomy used in this thesis should be adopted within the reporting standards. 
The term juxtarenal aneurysm should no longer be used. Suprarenal and thoracoabdominal 
aneurysms remain as acceptable definitions. Furthermore, all studies that report on 
aneurysm repair of any type should specifically state the proportion of aneurysms that are 
treated as NSA or SA and report their outcomes separately. This would allow true 
comparison of patients across studies and help the community to understand the possible 
inferior outcomes when treatment is out with the IFU for standard EVAR. To define non-
standard as any aneurysm with anatomy outside the IFU for the stent-graft implanted. 
Anatomical detail should be given for the cohort about the proportions of patients that are 
out with the IFU for each anatomical characteristic, an overall number of IFU violations and 
a mean (+/- standard deviation) of IFU violations for the patient cohort to allow better 
comparisons. When a patient has not yet undergone standard EVAR or is due to undergo 
another method of repair non-standard aneurysm is defined as an aneurysm that is out 
with IFU for any standard device without ancillary equipment such as endoanchors. It is 
appreciated that ancillary equipment recognises a special circumstance and these patients 
should be analysed separately and as a separate treatment modality from standard EVAR. A 
‘standard’ device is one that does not maintain flow to any visceral vessel by deliberate 
augmentation of manufacture of the device in a special way to create branches, 
fenestrations or scallops to maintain such flow. It is intended that the seal zone of the 
device is entirely below the visceral vessels. Chimney endovascular repair again is a 
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separate entity and should be analysed as such. Specific anatomic criteria are not defined 
to characterise a non-standard aneurysm primarily because it is envisaged that the IFU of 
standard stent-grafts may and will evolve with technological development and therefore 
setting a limit of 10mm for neck length, as an example, may potentially include people as 
non-standard now that in the future may be treated within IFU. Of course, analysis and 
review of any new device with different technology that proposes to treat anatomies 
currently outside of IFU is important to determine whether outcomes truly are no more 
inferior. However, if a device were to be introduced with similar outcomes and differing IFU 
an important advantage of the definition of non-standard, as stated, is that it takes this 
future development into account.  
With regards to measurement of aneurysms a validated protocol such as that proposed by 
St Georges institute should be followed to provide reproducibility with the added caveat 
that the top of the aneurysm be clearly defined. In this study the definition used was that 
when the neck diameter increased by 10% from the lowest renal artery this was said to be 
the point at which the aneurysm began. However, it may be more appropriate to define 
the top of the aneurysm as the first point of infrarenal aorta that reaches 30mm in 
diameter regardless of what happens below that and even if it is 30mm at the level of the 
renal arteries. Furthermore, any aneurysm neck with a diameter of 36mm should be 
excluded and described as a type 4 or other thoracoabdominal aneurysm to separate these 
aneurysms from non-standard aneurysms, the anatomy of interest. 
Non-standard aneurysms could be classed as either severe or less severe anatomy 
representing those patients with more severe IFU violations and those with less, however 
further work needs to be done to define which anatomical criteria play a greater and lesser 
role before deciding on such cut offs. 
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With regards to the measurement of renal function and its deterioration or lack thereof 
there are two points of note. Firstly, perioperative renal dysfunction (that seen within the 
first 30 days after the index operation should be defined as anyone suffering an acute 
kidney injury as per the definitions set out in the KDIGO definition. Furthermore, the stage 
of acute kidney injury (1,2 or 3) should be reported with the proportion of patients 
suffering no AKI, AKI stage 1, 2 and 3 in the results. In practice this will require 
measurement of the serum creatinine in the acute hospital stay. Furthermore, any patient 
requiring dialysis as an inpatient should be reported and whether this dialysis continued 
beyond discharge and was either a) permanent or b) was discontinued because of an 
improvement in native renal function. If dialysis was later stopped because of 
transplantation, then this should be made clear in the reporting of this outcome. Regarding 
chronic kidney disease measurement over the period of follow up it is recommended that 
eGFR be used as the surrogate marker for chronic kidney disease and comparison with pre-
operative values is important. Again, the KDIGO definition and reporting of the category of 
chronic kidney disease is recommended. When presenting the proportion of renal 
deterioration over follow up the proportions of patients moving ‘down’ a category should 
be stated and whether anyone eventually requires dialysis for renal dysfunction. The use of 
these definitions for both acute kidney injury and chronic kidney disease are recommended 
by The Renal Association in the UK. 
Regarding primary technical success it is recommended that future studies clearly state 
primary technical success as defined in the reporting standards. With specific attention 
paid to the fact that a graft related endoleak present on completion angiogram disqualifies 
the use of the term primary technical success. It is recognised that the majority of these 
endoleaks seal spontaneously and do not cause further deleterious sequelae and the term 
adjusted primary technical success can be used for such patients in whom the endoleak 
seals spontaneously without adjunctive manoeuvres. Authors should clearly state the 
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primary technical success and adjusted primary technical success rate, so it can be clearly 
seen that this factor has been investigated and taken into consideration. 
Another suggestion is for the inclusion of a term “Adjusted clinical success” this could be 
used to identify those patients detailed as a clinical failure, appropriately by the reporting 
standards, that then ‘regain’ clinical success. This of course is a retrospective definition and 
can only be determined once a patient has completed follow up but nonetheless is an 
important factor to determine the clinical impact of certain modes of failure that are 
believed to lead to serious consequences. It is proposed that this is not always the case and 
the definition of adjusted clinical success helps to identify  cohort of patients that don’t 
appear to have deleterious effects from clinical failure. 
11.6. Future Study Design 
The specific lessons learned from this study that could be applied when designing any 
future prospective study into this area are outlined below: 
1) Inclusion criteria – Pre-operative assessment by CTA would be mandatory. Only if a 
patient was out with the IFU for standard EVAR then should they be included. 
Furthermore, an assessment should be made to ascertain if a patient would be able 
to have fEVAR either within IFU or out with it. If so then the patient should be 
included.  
2) Anatomical classification - A system of classifying the anatomical complexity would 
be more useful and should be more detailed and robust than the existing definition 
based on anatomy (Infrarenal, pararenal, juxtarenal). It should include important 
parameters such as neck length, diameter and conicality. As well as alpha angle 
measurements. Thrombus load and beta angle measurements should be made and 
recorded although it should be recognised these probably play a less important 
role than the variables mentioned above. In the current study only four patients 
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were outside the IFU solely related to thrombus load and one patient solely related 
to beta angle. The degree of calcification within the neck should not be included in 
any scoring system of anatomical complexity as calcification is a subjective 
measurement with no pre-defined criteria for its severity and furthermore as seen 
in this study never solely contributed to an aneurysm being considered outside of 
IFU. There are therefore four important domains of neck characteristic that would 
need to be included into any anatomical scoring system: 1) neck length and 
diameter 2) neck shape (conical or not) 3) Angulation 4) presence of thrombus. A 
formal assessment of iliac anatomy would be useful to ascertain whether there 
truly are patients that are turned down for endovascular repair solely due to 
unfavourable iliac anatomy or not. This anatomical scoring system could be used to 
help define or delineate what constitutes ‘simple’ non-standard AAA anatomy and 
what constitutes ‘complex’ non-standard anatomy. 
3) Complications – The thresholds for what constitute a major complication should be 
rationalised and should reflect clinical practice. Furthermore, as experience with 
endovascular repair has grown a more mature understanding of the failure modes 
and mechanisms of stent-grafts has developed and this should be borne in mind 
when designing any study and particularly what data points should be captured to 
accurately reflect the incidence of adverse clinical events related to the aneurysm 
repair. 
4) Technical success – particular attention should be paid to the recording and 
reporting of technical success, especially with regards to the evolution of the idea 
that some proximal endoleaks may seal spontaneously without adverse event and 
therefore do they truly represent technical failure? 
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5) Cost – As broad an interrogation of costs of differing treatments as is practically 
possible would be desirable. This would include not only inpatient costs but also 
costs when people are discharged from hospital 
6) Quality of life measures – Further research should aim to clarify the position of 
previous studies, and confirm they hold true for patients with nonstandard 
aneurysms, that quality of life following open repair or endovascular repair is 
similar in the long term. 
7) Choice of repair – Recording of reasons why a specific type of repair was chosen by 
surgeon and/or patient would be helpful to give a clearer picture as to the clinical 
context for each case. 
8) Contrast use – as stated it would be important to record diligently variables which 
may explain some of the significant outcomes seen in this study – such as contrast 
use. 
9) Pre-operative aneurysm related deaths – it would be important to identify any 
cases of aneurysm rupture while waiting for eventual repair to ascertain whether 
this plays an important role. 
As stated within the results section the majority of patients included and all of the 
endovascular cohort were from a single centre. This was despite the fact the design of the 
study was such with the intention of capturing patients from an entire region and patients 
treated at district general hospitals as well as teaching hospitals. As stated, the applicability 
of the results to a wider population of patients presenting to a district general hospital for 
example, or in a different part of the country are limited. This is unfortunate as the original 
intention within the design of the study was to enable comparison of results with most 
other unselected populations including patients presenting to a district general hospital. 
However, the population of patients captured within the study is that presenting to an 
experienced high-volume centre treating these patients. Furthermore, many of the patients 
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were referred from locoregional hospitals and further afield. It is therefore reasonable to 
suggest that results seen for these patients would be applicable to another high-volume 
experienced centre receiving referrals from their own locoregional health care community. 
With the progression of reorganisation of vascular service within the United Kingdom to 
fewer, high volume centres the results from this research therefore become applicable to 
those centres routinely carrying out open or endovascular surgery for non-standard 
aneurysms. The original design to include district general hospitals may not be applicable 
anymore. 
Further research would be useful however to ensure that the results seen in this study are 
not particular to the Cheshire and Merseyside Region. Local collaboration with expert units 
in other parts of the country would be needed to answer this problem and control for that 
particular confounding factor. In the first instance it would be relatively straight forward to 
set up a research partnership with similarly sized hospitals in the Greater Manchester 
region especially since these units already have close professional links. The other 
significant advantage of including hospitals further afield (i.e. Manchester) rather than just 
the one region would mean that patients treated by fEVAR would not be from one hospital 
and therefore applicability of results to the wider national population would be possible. 
Furthermore, numbers of complex endovascular cases would be greater allowing for more 
meaningful analysis. 
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12. CHAPTER 12 - Conclusion 
Although the hypothesis from this study cannot be accepted on the evidence presented by 
its findings it does give credence to the suggestion that fEVAR may indeed be the method 
of repair with the best clinical outcomes for non-standard aneurysms. However, with 
regards to the cohort being studied, patients who underwent standard EVAR have a 
significantly worse outcome after their aneurysm repair, as determined primarily by rates 
of clinical failure. This is despite the fact that the morphological features of aneurysms who 
went on to have standard EVAR tended to be less ‘severe’ than the anatomy of those 
patients that went to have OR or fEVAR. It can therefore be recommended from this study 
that where possible placement of standard EVAR devices out with IFU should be avoided in 
preference for an advanced stent-graft technique or open repair. Further study needs to 
ascertain the magnitude of any differences in clinical outcomes between OR and fEVAR. 
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Appendix 1 – Full Search Strategy for Systematic Review of 
Clinical Outcomes Following Placement of Standard EVAR stent 
Graft in Non-Standard Anatomy 
1 Medline exp "AORTIC ANEURYSM, ABDOMINAL"/ 17045 
2 Medline (juxtarenal OR pararenal).ti,ab 1201 
3 Medline (aneurysm*).ti,ab 108834 
4 Medline (2 AND 3) 632 
5 Medline (1 OR 4) 17265 
6 Medline (Fenestrate* OR Endovascular*).ti,ab 43664 
7 Medline (Repair* OR Procedure* OR Intervention*).ti,ab 1964743 
8 Medline (6 AND 7) 25247 
9 Medline (fEVAR OR EVAR).ti,ab 3299 
10 Medline (8 OR 9) 25501 
11 Medline (Infrarenal OR hostile OR inadequate OR short OR IFU OR "instruction* for use" 
OR "Indication* for use" OR angulation OR diameter OR length).ti,ab 1470741 
12 Medline (neck*).ti,ab 188240 
13 Medline (11 AND 12) 18036 
14 Medline (5 AND 10 AND 13) 650 
15 Medline 14 [DT 1998-2018] [Languages English] [Humans] 596 
16 EMBASE exp "AORTIC ANEURYSM, ABDOMINAL"/ 1743 
17 EMBASE (juxtarenal OR pararenal).ti,ab 1510 
18 EMBASE (aneurysm*).ti,ab 135056 
19 EMBASE (17 AND 18) 862 
20 EMBASE (16 OR 19) 0 
21 EMBASE (Fenestrate* OR Endovascular*).ti,ab 63576 
22 EMBASE (Repair* OR Procedure* OR Intervention*).ti,ab 2638437 
23 EMBASE (21 AND 22) 37614 
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24 EMBASE (fEVAR OR EVAR).ti,ab 4975 
25 EMBASE (23 OR 24) 38205 
26 EMBASE 
(Infrarenal OR hostile OR inadequate OR short OR IFU OR "instruction* for use" OR 
"Indication* for use" OR angulation OR diameter OR length).ti,ab 1868886 
27 EMBASE (neck*).ti,ab 260695 
28 EMBASE (26 AND 27) 26734 
29 EMBASE (20 AND 25 AND 28) 207 
30 EMBASE (16 OR 19) 2544 
31 EMBASE (25 AND 28 AND 30) 207 
32 EMBASE 31 [DT 1998-2018] [Languages English] [Humans] 185 
  
424 
 
Appendix 2 – Full Search Strategy for Systematic Review of 
Clinical Outcomes Following Open Surgical Repair in Non-
Standard Aneurysms 
 
# Database Search term Results 
2 Medline (juxtarenal OR pararenal).ti,ab 1211 
3 Medline ((aneurysm* NOT intracrani*) 
NOT TEVAR).ti,ab 
99935 
4 Medline (2 AND 3) 637 
6 Medline (Open).ti,ab 433206 
7 Medline (Repair* OR Procedure* OR 
Intervention* OR Surgery*).ti,ab 
2712908 
8 Medline (6 AND 7) 113731 
9 Medline (4 AND 8) 252 
10 Medline 9  [DT 1998-2018] [Languages 
English] [Humans] 
221 
11 EMBASE (juxtarenal OR pararenal).ti,ab 1538 
12 EMBASE ((aneurysm* NOT intracrani*) 
NOT TEVAR).ti,ab 
117984 
13 EMBASE (11 AND 12) 865 
14 EMBASE (Open).ti,ab 554822 
15 EMBASE (Repair* OR Procedure* OR 
Intervention* OR Surgery*).ti,ab 
3661613 
16 EMBASE (14 AND 15) 164665 
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17 EMBASE (13 AND 16) 361 
18 EMBASE 17  [DT 1998-2018] [Languages 
English] [Humans] 
313 
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Appendix 3 – Full Search Strategy for Systematic Review of 
Clinical outcomes Following Fenestrated Endovascular 
Aneurysm Repair fEVAR Systematic Review 
 
# Database Search term Results 
1 Medline exp "AORTIC ANEURYSM, 
ABDOMINAL"/ 
17221 
2 Medline (juxtarenal OR pararenal).ti,ab 1209 
3 Medline ((aneurysm* NOT intracrani*) NOT 
TEVAR).ti,ab 
99694 
4 Medline (2 OR 3) 100267 
5 Medline (1 OR 4) 102605 
6 Medline (Fenestrate*).ti,ab 3562 
7 Medline (Repair* OR Procedure* OR 
Intervention*).ti,ab 
1979206 
8 Medline (6 AND 7) 1279 
9 Medline (fEVAR).ti,ab 120 
10 Medline (8 OR 9) 1286 
11 Medline (5 AND 10) 756 
13 Medline 11 [DT 1998-2018] [Languages 
English] [Humans] 
592 
14 EMBASE exp "AORTIC ANEURYSM, 
ABDOMINAL"/ 
1930 
15 EMBASE (juxtarenal OR pararenal).ti,ab 1521 
16 EMBASE (aneurysm* NOT intracrani*) NOT 
(TEVAR).ti,ab 
155728 
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17 EMBASE (15 OR 16) 156373 
18 EMBASE (14 OR 17) 156398 
19 EMBASE (Fenestrate*).ti,ab 4587 
20 EMBASE (Repair* OR Procedure* OR 
Intervention*).ti,ab 
2660137 
21 EMBASE (19 AND 20) 1916 
22 EMBASE (fEVAR).ti,ab 173 
23 EMBASE (21 OR 22) 1928 
24 EMBASE (18 AND 23) 1104 
25 EMBASE 24 [DT 1998-2018] [Languages 
English] [Humans] 
973 
 
 
